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Abstract 
Abstract 
Mono-ADP-ribosylation is a reversible post-translational modification that is 
catalysed by either bacterial pathogenic toxins or endogenous cellular ADP- 
ribosyltransferases (ARTs), and that can modulate the functions of target proteins. 
This latter aspect has only recently emerged as an important mechanism in 
mammalian cells for the control of a vast array of cellular processes. Some of the 
members of the poly-ADP-ribosyl-polymerase (PARP) family are among the 
mammalian enzymes that can catalyse mono-ADP-ribosylation. Here, based on 
biochemical data, I provide evidence that the PARP family member PARP12 is a 
mono-ART (mART) that can modify acidic amino acid residues. Using an affinity 
purification method based on a protein module that recognises ADP-ribosylated 
proteins (the macro domain), together with liquid chromatography coupled to tandem 
mass spectrometry, I have identified 25 putative PARP12 substrates that are involved 
in different cellular processes. The identification of this range of substrates suggests 
that PARP12 is involved in multiple cellular functions, ranging from regulation of 
small-GTPases to the control of newly synthesized RNA. To determine its biological 
role, I analysed its intracellular localisation. Data reported here show that PARP 12 is a 
mART that is localised to the Golgi complex, where it can use the NAD+ pool present 
on this organelle to modify Golgi-localised proteins. In line with these findings, 
among the PARP12 substrates, I identified Rab l A, a small GTPase that controls both 
transport from the endoplasmic reticulum to the Golgi complex, and the structure of 
the Golgi itself. My data suggest a role for PARP12 in maintenance of Golgi structure, 
potentially through ADP-ribosylation of Rab l A. A further aspect I have analysed is 
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Abstract 
the ADP-ribosylation of the dual function protein C-terminal binding protein 1/ BFA- 
dependent ADP-ribosylated substrate (CtBP1BARS) as a mechanism of action of the 
toxin brefeldin A (BFA). BFA-induced ADP-ribosylation of CtBP1BARS occurs 
through a novel mechanism that comprises two steps: (i) synthesis of a BFA-ADP- 
ribose conjugate (BAC); and (ii) covalent binding of the BAC into the NAD+-binding 
pocket of CtBP1BARS. Here, I demonstrate that this reaction requires the 
involvement of ADP-ribosyl-cyclases, such as CD38. Importantly, this modification 
abolishes CtBP1BARS fissioning activity, while it increases CtBP1BARS co- 
repressor activity, in a promoter-dependent context. As with sumoylation and 
phosphorylation, ADP-ribosylation thus represents a new mechanism for the 
regulation of the functions of CtBPI/BARS. 
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RNA Ribonucleic acid 
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SH2 Src Homology domain 2 
SH3 Src Homology domain 3 
Sir2 Silent information regulator 2 
siRNA Short-interfering RNA 
SIRT Sirtuin 
SSBs Single strand breaks 
STAT1/6 Signal transducer and activator of transcription 1/6 
SUMO Small ubiquitin-like modifier 
TAE Tris/acetic acid/EDTA 
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TBA 
TBE 
TCA 
TCDD 
TE 
TEMED 
TEP1 
TFF1 
TGN 
TLE 
TNFa 
TRF 1 
TRIS 
VIP2 
Vmax 
tetrabutylammonium 
Tris/boric acid/EDTA 
Trichloroacetic acid 
2,3,7,8-tetrachlorodibenzo-p-dioxin 
Tris/EDTA 
N, N, N', N'-tetramethylethylenediamine 
Telomerase-associated protein I 
Trefoil factor I 
trans-Golgi network 
Trasducin-like enhancer 
Tumour necrosis factor a 
Telomeric repeat binding factor 1 
Tris-[hydroxymethyl]-aminomethane 
Vegetative insecticidal protein 
Maximal velocity of an enzymatic reaction at saturating substrate 
concentration 
VTCs Vesicular tubular clusters 
X-Gal 5-bromo-4-chloro-3-indolyl-D-galactoside 
YFP Yellow fluorescent protein 
ZAP Zinc-finger CCCH-type antiviral protein 
ZEB Zinc finger E-box-binding homeobox 
Znf217 Zinc finger protein 217 
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CHAPTER 1. Introduction 
1.1 Post-translational modifications: regulators of protein function 
and signal integration 
The complex physiology of eukaryotic cells is regulated by a number of 
multilayered and interconnected mechanisms. Transcription of new mRNA, 
alternative RNA splicing, and translation into a protein, which can then be 
followed by post-translational modifications (PTMs) of a protein, create a 
continuously fine-tuned regulatory network. Of the various regulatory 
mechanisms available to the cell, PTMs serve a particular purpose, as they are 
both highly dynamic and largely reversible. As a result of improved detection 
technologies, the list of protein modifications in the literature has risen to well 
over 200 (Mann and Jensen, 2003). This extensive array that includes many 
reversible PTMs creates signalling diversity and is particularly suitable for 
relaying rapid messages in the cell. Some PTMs, including glycosylation, 
lipidation and disulphide bridge formation, are stable and are important for 
maturation and correct folding of newly synthesized proteins. Others, such as 
phosphorylation, are more transient, and thus have essential roles in 
intracellular signalling. A crucial aspect of signalling through PTMs is the 
presence of modular protein domains that recognise particular types of PTMs 
located on specific amino-acid residues. This coupling of PTMs with PTM- 
recognition domains creates an attractive `decoding' mechanism for monitoring 
and responding to alterations in the cellular microenvironment (Sims and 
Reinberg, 2008). 
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The classical example of PTMs is phosphorylation, which involves the 
transfer of the y-phosphate group from ATP to specific amino acids. The first 
protein kinase activity was reported in 1954 for the phosphorylation of casein 
(Burnett and Kennedy, 1954). Over the next few decades, a rapidly growing 
body of evidence revealed the importance of reversible phosphorylation as a 
versatile tool to regulate protein function. Phosphatases removing the 
phosphate group from modified residues were also discovered, and were shown 
to have specificity towards individual phosphorylated residues (Barford et al., 
1998). To date, besides phosphorylation, a variety of further important PTMs 
have been identified and are under study, including in particular, methylation, 
ubiquitination and acetylation, to name just a few. ADP-ribosylation is another 
PTM, which is the focus of the present thesis. 
The ADP-ribosylation reaction 
The modification of proteins by ADP-ribosylation is a phylogenetically ancient 
mechanism (Corda and Di Girolamo, 2003). It involves the transfer of ADP- 
ribose (ADPR) from NAD+ to target proteins, and it is accompanied by the 
release of nicotinamide (Figure 1.1). As with phosphorylation, this reaction is 
reversible and thus the extent of protein modification by ADP-ribosylation 
depends on the activity of cellular ADP-ribosylhydrolases that reverse the 
reaction by hydrolysing the protein ADP-ribose linkage (Figure 1.1) (Corda 
and Di Girolamo, 2003). The consumption of NAD+ by ADP-ribosylating 
enzymes connects them not only to energy metabolism, but also to other 
NAD+-consuming enzymes, including the histone deacetylases (HDACs) of the 
Sirtuin family and ADP-ribosyl cyclases (Ying, 2006) (see sections 1.3.1 
1.3.3). 
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Figure 1.1: The ADP-ribosylation reaction 
A schematic representation of the reversible mono-ADP-ribosylation reaction. An 
arginine-specific mono-ADP-ribosyltransferase catalyses the transfer of an ADP-ribose 
moiety from NAD' to an arginine residue of an acceptor protein, with the simultaneous 
release of nicotinamide. Specific ADP-ribosylhydrolase can reverse the reaction, by 
hydrolysing the N-glycoside linkage between ADP-ribose and the arginine residue. 
Other amino-acid residues that can be modified by this reaction are cysteine, glutamic 
acid, diphthamide and asparagine. From (Di Girolamo et al., 2005). 
ADPribosylhydrolase 
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NAD+ has a cytosolic concentration of about 500 µM, with a half-life of about 
1-2 h (Rechsteiner et al., 1976; Williams et al., 1985). Its reduced form, 
NADH, acts as a coenzyme in numerous redox reactions, and has pivotal roles 
in many fundamental cellular processes, including mitochondrial oxidative 
phosphorylation, where it acts as a co-factor for three rate-limiting enzymes of 
the tricarboxylic-acid cycle. In addition, NAD+ has been implicated in cell 
death, in regulation of calcium homeostasis, and in controlling gene expression 
(Ying, 2006). Thus, the consumption of NAD+ by NAD+-consuming enzymes 
has to be tightly controlled. Poly-ADPR-polymerase enzymes constitute one of 
the major family of NAD+-consuming enzymes, catalysing the transfer of 
multiple ADP-ribose moieties to form long and branched chains of poly- 
ADPR. The presence of poly-ADPR was first described by Chambon and co- 
workers in 1963 (Chambon et al., 1963), and a few years later its structure was 
solved (Reeder et al., 1967; Sugimura et al., 1967). The gene encoding the 
enzyme responsible for poly-ADPR formation is known as a poly-ADPR 
polymerase (PARP), which was isolated some 20 years later, in the late 1980's 
(Alkhatib et al., 1987; Kurosaki et al., 1987; Uchida et al., 1993). In the 
meantime, another ADP-ribosylation reaction was discovered during the 
analysis of bacterial toxins (Gill et al., 1969; Honjo et al., 1968). While PARP 
enzymes catalyse poly-ADP-ribosylation of proteins, these newly discovered 
toxins were shown to mono-ADP-ribosylate proteins. Consequently, the 
presence of mammalian mono-ADP-ribosyltransferases (mARTs) was 
suggested, and ecto-enzymes with mART activity were discovered, although 
the molecular identities of postulated intracellular mARTs are only at the 
beginning of their elucidation (Corda and Di Girolamo, 2003; Hassa et al., 
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2006; Okazaki and Moss, 1999; Seman et al., 2004). The present study is 
aimed at adding new and specific depths to the study of intracellular mARTs, 
and to investigate a new ADP-ribosylation mechanism that is catalysed by the 
fungal toxin brefeldin A (BFA). The two main aspects analysed in the present 
thesis can be summarised as follows: 
1. Study of the BFA-dependent ADP-ribosylation reaction of CtBP1BARS 
and its effects on CtBP1BARS functions; 
2. Study of intracellular mono-ADP-ribosylation, with specific interest 
focussed on PARP12 as a mono-ADP-ribosyltransferase. 
Thus, in the next sections I will give an overview on the ADP- 
ribosylation reactions catalysed by toxins, and on the different eukaryotic 
NAD+-consuming enzymes (mARTs, ADP-ribosyl cyclases, Sirtuins and 
PARPs). The description of PARP enzymes is covered in more details, since a 
part of my PhD project focused on PARP12. The last part of the introduction is 
dedicated to the description of a specific case of ADP-ribosylation (the BFA- 
dependent ADP-ribosylation of CtBP1BARS) and of the cellular functions of 
the target of this reaction, CtBP1BARS. 
1.2 ADP-ribosylation by toxins 
Bacterial pathogens invade and then damage their host through the actions of 
their toxins. 
ADP-ribosylation was the first covalent modification shown for a 
bacterial toxin, in which diphtheria toxin (DTX) transfers the ADPR moiety of 
NAD+ to the R-group of a post-translationally modified histidine of elongation 
factor-2 (EF-2) (Collier, 1975). Since then, several toxins have been identified 
as catalysing ADP-ribosylation of host target proteins. The ADP-ribosylating 
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toxins (ADPRTs) form a large family of deleterious and potentially lethal 
toxins. Examples of these toxins can be found in a diverse range of bacterial 
pathogens, and they are the main active agents in many diseases, including 
cholera, whooping cough and diphtheria (Krueger and Barbieri, 1995). 
Table 1.1 provides a representative list of the members of the ADP- 
ribosylating toxins. Each of these toxins has a unique property, including the 
host protein that is targeted for ADP-ribosylation, the amino acid that is 
modified, and the outcome of ADP-ribosylation on the modified protein. The 
majority of the modified targets are key regulators of cellular functions, and as 
the modification interferes with their activity, this leads to dysregulation of key 
cellular processes, and eventually to cell death (Krueger and Barbieri, 1995). 
The structural organisation of toxins and the targets they modify are 
described in the next section (1.2.1). Particular emphasis is then given to the 
exotoxin ExoS from Pseudomonas aeruginosa, because it targets some of the 
Rabs (small GTPases that control intracellular trafficking), proteins that I have 
also covered in this study. 
1.2.1 Structural organisation ofADPRTs 
The bacterial ADPRT family can be split into four groups on the basis of their 
domain organisation and the nature of their targets. In describing the toxin 
structure, it is commonly accepted to refer to the A and B domains. The A 
domain encodes the catalytic domain, and the B domain comprises a 
translocation (T) domain that facilitates translocation of the A domain into the 
cytoplasm of the host cells, and a receptor binding (R) domain that binds the 
toxin to host cell-surface receptors (Figure 1.2). The A and B domains can be 
structured as a single protein (AB), a complex of non-covalently bound 
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Table 1.1: Representative ADP-ribosyltransferase toxins 
The bacterial ADPRTs. Note that each ADPRT has a unique property, including its 
targets, the amino acid residue modified, and the outcome of ADP-ribosylation on the 
modified protein. 
Toxin Target (residue) Physiological response 
Diphtheria toxin, Pseudomonas ETA EF-2 (diphatamide, His*) Inhibition of protein synthesis 
Cholera toxin, E. coli LT G45 (Arg) Inhibition of GTPase activity of G. 
Pertussis toxin Gai (Cys) Uncoupled Gi protein-mediated 
signal transduction 
C. botullnum C2, iota toxin Actin (Arg) Prevention of actin polymerisation 
ETA: exotoxin A; LT: heat labile enterotoxin; Gos: a subunit of stimulatory heterotrimeric G-protein 
Gay: a subunit of inhibitory heterotrimeric G-proteln. His*: posttranslationally modified histidine. 
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Figure 1.2: Schematic representation of bacterial toxin structure 
The bacterial toxin structure can be schematically represented as the A and B 
domains. The A domain encodes the catalytic domain; the B domain comprises a 
translocation domain that facilitates translocation of the A domain into the cytoplasm 
of the host cells. The receptor-binding domain binds the toxin to the host cell-surface 
receptors. The structure shown is of diphtheria toxin. 
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proteins (A5B), or as two different proteins that encode the A and B domains 
(A-B). In this last case (A-B), the two proteins are independently synthesised 
and secreted from the bacterium, and they can associate only when the B 
domain binds to the surface receptors of sensitive cells (Deng and Barbieri, 
2008b). 
The most well known toxins, cholera toxin (CTX), produced by Vibrio 
cholerae, pertussis toxin (PTX), produced by Bordetella pertussi, and 
Escherichia coli heat-labile enterotoxin (LTX) are members of the A5B family, 
which targets small regulatory G-proteins (see table 1.1). Here, the 
enzymatically active A subunit is situated on a scaffold made of a pentamer of 
B subunits (Deng and Barbieri, 2008b; Gill, 1976; Streatfield et al., 1992; 
Zhang et al., 1995). 
The second group of toxins comprises DTX and Pseudomonas exotoxin 
A (ExoA), whih can ADP-ribosylate a diphthamide residue on EF-2 (see table 
1.1). The structure here can be schematised as AB toxins; both toxins are large 
multidomain proteins with receptor binding, transmembrane targeting, and 
protease-resistant catalytic domains (Allured et al., 1986; Collier, 1975). 
The third group of toxins comprises the actin-targeting AB binary 
toxins. Unlike the more common A5B binary toxins, these are composed of 
two domains: an active catalytic domain and a cell-binding domain. This group 
includes a wide range of clostridial toxins including C2 toxin from Clostridium 
botulinum, Clostridium perfringens Iota toxin (see table 1.1), Clostridium 
spiroforme toxin, Clostridium difflicile toxin and the vegetative insecticidal 
protein (VIP2) from Bacillus cereus (Aktories et al., 2011; Krueger and 
Barbieri, 1995). 
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The final group of toxins are the small single domain C3 exoenzymes, 
which are proteins with molecular mass of 20-25 kDa, that comprise an A 
domain but lack either aT or R domain. In this case, the bacterial secretion 
systems deliver A-domain-containing toxins from the cytoplasm of the 
bacterium to the intracellular environment of the host cell, thus allowing for the 
absence of both the T and R domains. Some examples here are represented by 
Cabot from C. botulinum, and toxins from Clostridium limosum, B. cereus and 
Staphylococcus aureus (Krueger and Barbieri, 1995). 
1.2.2 Cellular properties ofADPRTs 
The bacterial ADPRTs are all thought to have important roles in bacterial 
pathogenesis, through acting as key virulence factors in many diseases. The 
effects caused by the ADPRTs all rely on ADP-ribosylation of key regulatory 
proteins in host cells, which leads to impairment of cell signalling. The A5B 
proteins, including PTX, LTX and CTX, all ADP-ribosylate a subset of 
heterotrimeric GTP-binding proteins. For all three of these toxins, the A 
catalytic domain sits on a `doughnut-shaped' pentamer of binding domains that 
comprise the cell binding and translocation apparatus (Sixma et al., 1991; Stein 
et al., 1994; Zhang et al., 1995). In the bacterial cell, this hetero-hexamer is 
assembled in the bacterium before being transported across the membrane via 
the type II secretion apparatus (Sandkvist et al., 2000). Once secreted, the B- 
pentamer recognises GM1 ganglioside on the host cell surface, through which 
it induces its endocytosis and translocation into the cytosol. For the toxin to 
become active, however, the catalytic domain must undergo proteolytic 
cleavage of the disulphide linked Al -A2 domain (Kassis et al., 1982). This also 
results in the Al domain being released from the A2-B5 complex. Even at this 
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stage, these toxins are not fully functional, because they also require activation 
by host-cell proteins to become fully active. In the case of CTX, these ADP- 
ribosylation activation factors (ARFs) come from the host. ARFs are small 
GTPases that bind CTX in their GTP-bound state. Disease results from both 
CTX and LTX co-opting molecular machineries of the host cell: the toxins 
enter by endocytosis of the toxin-receptor complexes, move to the Golgi 
cisternae or to the endoplasmic reticulum (ER) via retrograde transport, and 
finally translocate to the site of their action on the inner surface of the plasma 
membrane (Lencer et al., 1999). Both CTX and LTX target Gga, the a subunit 
of the stimulatory G-protein of the adenylyl cyclase system. ADP-ribosylation 
of this subunit causes the G-protein to be maintained in its activated GTP- 
bound state, and leads to massive up-regulation of adenylyl cyclase, and the 
subsequent increase in the amount of cytosolic cyclic AMP (cAMP). This 
eventually leads to a major loss of fluid and ions from the intestinal cells that 
are affected, and gives rise to the severe diarrhoea and fluid loss that are 
associated with both cholera and enterotoxigenic E. coli pathogenesis (Gill and 
Richardson 1980). 
PTX is produced by Bordetella pertussis, the major causative agent of 
whooping cough. PTX ADP-ribosylates an exposed cysteine residue on several 
small heteromeric G proteins (such as Gia and Gta). Unlike CTX, PTX- 
catalysed mono-ADP-ribosylation occurs when G. is associated with the (}y- 
dimer, thus generating a modified G protein that cannot transduce signals 
(Collier, 1975; Krueger and Barbieri, 1995). This results in the uncoupling of 
the G-proteins from their effectors, and in an unregulated increase in adenylyl 
cyclase activity, and the consequent increase in cAMP. 
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Figure 1.3: Uncoupling of G-protein-coupled receptors from G proteins by PTX- 
catalysed ADP-ribosylation of Ga. 
The cycle for G-protein activation by ligand binding to G-protein-coupled receptors. 
Receptors (line traversing the plasma membrane) are composed of seven 
transmembrane strands. G proteins are localised to the cytosolic face of the plasma 
membrane through fatty acid acylation, as indicated. (A) In the absence of ligand for the 
receptor, there is no association between the receptor and G protein, which is in its 
inactive GDP-bound state. (B) In the presence of ligand, the G protein associates with 
the receptor and GTP is exchanged for GDP, thereby activating the G protein. (C) The a 
subunit containing bound GTP dissociates from the 13y dimer, and each can influence the 
appropriate effector systems. (D) The a subunit has an intrinsic GTPase activity. Upon 
hydrolysis of GTP to GDP, the a subunit is inactivated. (E) Two models for the 
physiological effect of ADP-ribosylation of G proteins by PTX that conform to the 
experimental data: the ADP-ribosylated G protein associates with the receptor, but the 
interaction is not functional (right); or the ADP-ribosylated G protein no longer interacts 
with the receptor (left). From Krueger and Barbieri (1995). 
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DTX is an example of a eukaryotic EF-2 (eEF-2) ribosylating toxin 
(Moynihan and Pappenheimer, 1981). It is secreted by Corynebacterium 
diphtheriae as a single protein, encompassing the three A-T-R domains. DTX 
binds to the heparin binding epidermal growth factor-like growth factor 
precursor (HB-EGF), and it is cleaved on the cell surface by furin or furin-like 
proteases, to produce a di-chain protein that is linked by a disulphide bond. 
Receptor binding triggers the entry of DTX into the lumen of a developing 
endosome by receptor-mediated endocytosis. Upon acidification, the T domain 
facilitates the translocation of the A domain across the endosomal membrane 
into the host-cell cytoplasm, where the A domain catalyses ADP-ribosylation 
of eEF-2 on an exposed histidine that is modified by the addition of a 
diphthamide side-group. The ADP-ribosylation interrupts the function of eEF-2 
in the host cell, which in turn interfers with protein synthesis, and results in 
profound physiological changes and ultimately cell death (Krueger and 
Barbieri, 1995). 
A further well-known target of ADP-ribosylation by toxins is actin. Iota 
toxin, from Clostridium perfringens, and VIP2 from Bacillus cereus are both 
actin ADPRTs, and each of these can ADP-ribosylate actin at an exposed 
arginine, Arg 177. This ADP-ribosylation prevents actin polymerisation by 
capping the exposed ends of the actin filaments, which leads to cell rounding 
and eventual cell death, as the actin cytoskeleton breaks down (Aktories and 
Wegner, 1989). This class of actin modifying binary toxin also includes C. 
botulinum C2 toxin, C. spiroforme toxin and C. diJcile toxin components 
cdtA and cdtB. The toxins do not bind cells as complete A-B units. Instead 
proteolytically activated B monomers bind to cell-surface receptors as homo- 
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heptamers. These homo-heptamers then bind the A domains and are taken into 
the cell via endocytosis. Once inside the acidic endosomes, the low pH 
activates the translocation function of the B domain heptamers, and they 
translocate the catalytic A domains across the endosomal membrane into the 
cytoplasm, where they can act to ADP-ribosylate actin and bring about cell 
death (Barth et al., 2004). 
The C3 exoenzymes are characterised by C3bot from C. botulinum, and 
also includes representatives from Clostridium limosum (C31im), B. cereus 
(C3cer) and S. aureus (C3EDIN, C3Stau2). This family of ADPRTs selectively 
ADP-ribosylates the small GTPases RhoA, B and C at an exposed arginine 
residue (Arg4l). This prevents Rho moving into its active GTP-bound state and 
leads to a loss of control in the downstream pathways controlled by the Rho 
GTPases, thus resulting in loss of control of the cell cytoskeleton and eventual 
cell death (Wilde and Aktories, 2001). Although these effects are seen in vitro, 
the roles of C3bot and its related ADPRTs in pathogenesis are not yet known, 
as they lack any cell translocation or binding domains. 
- Pseudomonas aeruginosa ExoS and ExoT exotoxins 
P. aeruginosa is an opportunistic human pathogen that is associated with multi- 
drug-resistant nosocomial infections (Obritsch et al., 2005). 
P. aeruginosa produces ExoA that, similarly to DTX, ADP-ribosylates 
EF-2, and it also produces the Type III cytotoxins ExoS, ExoT, ExoU and 
ExoY, which create an environment that favours bacterial survival and 
dissemination. These exotoxins are delivered across the bacterial cell 
membrane and cell wall into a mammalian cell through a secretion apparatus 
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that is composed of 20-30 proteins. Among the above-mentioned Type III 
cytotoxins, only ExoS and ExoT function as mARTs. They are bi-functional 
toxins that comprise a Rho GTPase activating protein (RhoGAP) domain and 
an ART domain (Deng and Barbieri, 2008b). 
ExoS- and ExoT-RhoGAPs inactivate small Rho GTPases, including 
RhoA, Racl, and Cdc42, which disrupts the host-cell cytoskeleton (Deng and 
Barbieri, 2008b). While the RhoGAP activity is similar for both of these, ExoS 
and ExoT are still distinct, in that they ADP-ribosylate unique host substrates 
(Barbieri and Sun, 2004). 
ExoT was originally thought to be an inactive precursor of ExoS, but 
later studies implicated a role for the ART domain in eliciting cell rounding. 
Indeed, ExoT was determined to ADP-ribosylate CTI0-regulator of kinase 
(Crk) (Sun and Barbieri, 2003). Crk proteins are SH2-SH3-domain-containing 
adaptor proteins that are components of the integrin signaling pathway leading 
to Rad 1 and Rap l activation, required for the integrin-mediated phagocytosis 
and formation of focal adhesions. Mass spectroscopic analysis identified Arg20 
as the site of ADP-ribosylation of Crk by ExoT. Arg20 is a conserved residue 
located within the SH2 domain that is required for interactions with upstream 
signaling molecules such as paxillin and p130cas. ADP-ribosylated Crk-I failed 
to bind p130cas or paxillin. This indicates that ADP-ribosylation inhibited the 
direct interaction of Crk with these focal adhesion proteins, thus leading to cell 
rounding (Deng et al., 2005). 
In contrast to the restricted group of substrates of ExoT, ExoS ADP- 
ribosylates numerous substrates. Several small monomeric GTPases have been 
identified as cellular targets of ExoS (Coburn et al., 1989). ExoS was shown to 
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ADP-ribosylate Ras at Arg41, which is adjacent to the switch region of the 
GTPase (Ganesan et al., 1998), and subsequent studies showed that ADP- 
ribosylation inhibited guanine nucleotide exchange factor (GEF)-catalysed 
nucleotide exchange, which uncoupled Ras signal transduction (Ganesan et al., 
1998). 
Other targets of ExoS include the Ezrin/Radixin/Moesin (ERM) family 
proteins (Maresso et al., 2004), which are regulators of the actin network. The 
Rab proteins are also targets of ExoS. Rab GTPases have essential roles in 
host-cell vesicle trafficking, including endocytosis, receptor recycling, vesicle 
maturation and trafficking to the Golgi complex and lysosomes (van der Bliek, 
2005). It has been demonstrated that ExoS localises to Rab-positive vesicles 
and that it ADP-ribosylates Rab5, Rab7, Rab8 and Rab11, both in vitro and in 
vivo (Fraylick et al., 2002). 
The effects and mechanism of the ADP-ribosylating activity of ExoS 
were investigated by Barbieri and co-workers. These authors demonstrated that 
ExoS ADP-ribosylation influences the intracellular trafficking of the EGF 
receptor (EGFR), as well fluid phase endocytosis, through inhibition of Rab5 
activity (Deng and Barbieri, 2008a). 
It is well recognized that the binding of EGF to the extracellular domain 
of EGFR leads to the activation of EGFR as well as to the internalisation of the 
EGF-EGFR complex via the canonical clathrin-mediated endocytic pathway, 
through early and late endosomes, for degradation in lysosomes (Ceresa, 
2006). Endocytic trafficking of the EGFR is necessary for the correct temporal 
and spatial regulation of EGF signalling. Several G proteins have been 
implicated in EGFR endocytic trafficking. While dynamin drives EGFR 
37 
Introduction 
endocytosis, Rab5 mediates entry of the EGFR into early endosomes, Rab7 is 
required for degradation of the EGF-EGFR complex by the lysosomes, and 
Rab II facilitates EGFR recycling to the plasma membrane (Ceresa, 2006). 
In cells treated with ExoS, upon EGF activation, the EGFR still 
internalises to clathrin-coated vesicles, but it does not mature to the Rab5- 
positive early endosomes (Deng and Barbieri, 2008a). The observation that a 
constitutively active Rab5 protein can reverse ExoS inhibition of EGF- 
activated EGFR trafficking out of clathrin-coated vesicles suggests that ADP- 
ribosylation catalysed by ExoS inhibits Rab5 activity in cells. The uncoupling 
of Rab signalling might enable P. aeruginosa to evade trafficking to 
perinuclear vacuoles, while endowing P. aeruginosa with the capacity for 
intracellular replication. 
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1.3 Eukaryotic NAD+-consuming enzymes 
NAD+ was identified a century ago as a cofactor and coenzyme, and it has 
attracted attention for its versatile function in relation to energy metabolism 
(Houtkooper et al., 2010). 
NAD+-consuming ecto-enzymes are primarily represented by the 
CD38/CD157 system and by the family of ecto-mARTs. In contrast, the 
PARPs and sirtuins operate within the cell. Currently, 22 human genes 
encoding proteins with an ART activity are known, and these can be divided in 
ecto-mARTs and PARPs. Recently, a unified nomenclature referring to this 
family of proteins as ARTs was proposed, sub-dividing the ARTs according to 
structural criteria of their catalytic domains, into ART DTX-like (ARTD) and 
ART CTX-like (ARTC) proteins (Hottiger et al., 2010). Table 1.2 shows the 
new nomenclature, in comparison with the old one, and the 
postulated/demonstrated enzymatic activity for each member of the PARP 
family. 
In the following sections I will describe each of these NAD+-consuming 
enzyme families, starting from ADP-ribosylcyclases, going through mART, 
and sirtuins. Particular emphasis is then given to the PARP family members. In 
this regard, I will refer to the different enzymes using the old nomenclature. 
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Table 1.2: Nomenclature and enzymatic activity of PARP family members 
Comparison of the PARP catalytic core motifs and described/ postulated enzymatic 
activities of the PARP family members. The new proposed nomenclature is also 
given. Asterisks indicate that experimental evidence has demonstrated the mART 
activity. Light purple, pART; green, mART; light blue, inactive enzymes. Even 
though PARP3 shows structural features similar to the classical PARPs, it has been 
demonstrated to function as a mART (Loseva et al., 2010). Note that only PARPs 3, 
10 and 14 have been demonstrated to function as mARTs. For all of the other 
members, mART activity has only been postulated. 
Protein name New nomenclature Gene symbol Catalytic core motif ADP-ribosylation 
activity 
PARPI ARTD I PARPI HYE Poly 
PARP2 ARTD2 PARP2 HYE Poly 
PARP3 ARTD3 PARP3 HYE Mono 
PARP4 (vPARP) ARTD4 PARP4 HYE Poly 
PARP5a(TNKSI) ARTD5 TNKS HYE Poly 
PARP5b (TNKS2) ARTD6 TNKS2 HYE Poly 
PARP6 ARTD17 PARP6 HYI Mono 
PARP7 ARTDI4 TiPARP HY1 Mono 
PARP8 ARTD16 PARP8 HYI Mono 
PARP9 (BALI) ARTD9 PARP9 QYT Inactive 
PARPIO ARTIO PARPIO HYI Mono * 
PARPII ARTDII PARPII HYI Mono 
PARP12 
(ZC3HDC I) 
ARTD12 PARP12 HYI Mono 
PARP13 
(ZC3HAV 1 /ZAP) 
ARTDI3 ZC3HAVI YYV Inactive 
PARPI4 (BAL2) ARTD8 PARP8 HYL Mono 
PARPI5 (BAL3) ARTD7 P4RPI5 HYL Mono 
PARP16 ARTD15 PARP16 HYY Mono 
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1.3.1 The ADP-ribosylcyclase CD38/CD157 family 
ADP-ribosylcyclase (ADPRC) from A. californica was the first enzyme shown 
to have this cyclase function (Lee and Aarhus, 1991). Based on sequence 
homology (States et al., 1992), two human antigens, CD38 and CD157, were 
shown to also have the cyclase activity (Hirata et al., 1994; Howard et al., 
1993). The following sections describe the current knowledge concerning the 
structures and enzymatic functions of both CD38 and CD157. 
1.3.1.1 CD38 structure 
Human CD38 is a type II surface glycoprotein that is characterised by a large 
extracellular domain (257 amino acids), a single transmembrane domain (23 
amino acids), and a short cytoplasmic tail (20 amino acids) (Alessio et al., 
1990). Within the human immune system, CD38 is expressed by immature 
haematopoietic cells, down-regulated by mature lymphocytes and re-expressed 
at high levels by activated T and B cells and dendritic and natural killer cells. It 
represents the main mammalian member of the ADPRC family of enzymes and 
it appears to be ubiquitous in eukaryotic cells (Malavasi et al., 2008). 
The protein encoded by the CD38 gene has a molecular weight of 45 kDa. 
The overall structure of the CD38 molecule is `L' shaped, and it can be divided 
into two separate domains: the NH2-terminal domain (residues 45-118 and 144- 
200) and the COOH-terminal domain (residues 119-143 and 201-300), which 
are connected by a hinge region that is composed of three peptide chains. A 
disulphide bond that is unique to CD38 (Cys-1 19-Cys-201), plus five other 
pairs of disulphide bonds that are conserved in ADPRC family members, 
further stabilise the relative conformations of the two domains by linking 
peptides 118-119 with 200-201 (Liu et al., 2005) (Figure 1.4). 
41 
Introduction 
As well as the membrane form of CD38, a soluble form was identified 
in cell-culture supernatants of activated T lymphocytes, in several tumour cell 
lines, and in vivo under normal and pathological conditions (Funaro et al., 
1996). 
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Figure 1.4: Crystal structure of CD38 
The `L' shaped structure of CD38 is divided into two separate domains. The C- 
terminal domain consists of four ß-sheets surrounded by two long (a8 and a9) and 
two short (a4 and a7) a-helices. The N-terminal domain is formed by a bundle of a- 
helices and two ß-strands. These two domains are connected by a hinge region that 
is composed of three peptides. From Malavasi et at. (2008). 
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1.3.1.2 CD 157 structure 
Human CD 157 is a glycosylated single chain of 42-45 kDa that is anchored to 
the membrane via a glycosylphosphatidylinositol (GPI) tail (Itoh et al., 1994). 
Similar to CD38, the CD157 molecule is divided into two domains, known as 
the N-domain and the C-domain, which are connected by a hinge region of 
three peptides. All 10 cysteine residues that are conserved among the cyclase 
family form disulphide bonds, as seen in the structure of the Aplysia cyclase 
(Yamamoto-Katayama et al., 2002). Each subunit of the CD 157 dimer contains 
a substrate-binding cleft, which is covered mainly by hydrophobic and acidic 
residues, and which is important for its catalytic function. The three key 
residues, Trp-77, Trp-140 and Glu-178, are invariant among the sequences of 
CD157, CD38 and the Aplysia cyclase, which share a common substrate- 
recognition mode and catalytic scheme (Yamamoto-Katayama et al., 2002) 
(Figure 1.5). 
1.3.1.3 Enzymatic activities controlled by CD38 
The identification of sequence similarity between the human lymphocyte 
antigen CD38 and the Aplysia ADPRC (States et al., 1992) marked the 
beginning of long-term investigations into the enzymatic properties of CD38 
and into its role in human physiology and pathology. 
CD38 is a multifunctional ecto-enzyme that is involved in the 
catabolism of NAD+ and NADP+, the two main substrates of CD38 thus far 
identified. This reaction leads to the generation of potent intracellular Ca2+- 
mobillising compounds: cADPR, nicotinic acid adenine dinucleotide phosphate 
(NAADP) and ADPR. 
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Figure 1.5: Crystal structure of CD157 complexed with etheno-NAD 
CD157 forms a homodimer of two symmetrical subunits. Each subunit is divided into 
two domains, termed the N domain (green-light green) and the C domain (red-light 
red), which are connected by a hinge region of three peptide chains. Each subunit of 
the CD 157 dimer contains a substrate-binding cleft, formed by the N and C domains. 
This large cleft is surrounded by a4, a5, a6, a7, and ßl, and is mainly covered by 
hydrophobic and acidic residues. Adapted from Yamamoto-Katayama et a!. (2002). 
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The enzymatic properties of CD38 were formally demonstrated after analysing 
a purified recombinant soluble form of CD38 (sCD38). When added to NAD+, 
sCD38 catalysed the formation and hydrolysis of cADPR (Howard et al., 
1993). Similar results were obtained using solubilised human erythrocyte 
membranes: the three ecto-enzyme activities, i. e., NADase, ADPRC, and 
cADPR hydrolase, could be purified to homogeneity using an anti-CD38 
monoclonal antibody (Zocchi et al., 1993). These results were also confirmed 
in human T-cell models, where the NAD-hydrolysing enzymatic activity was 
shown to correlate with the amount of CD38 on the cell surface. Moreover, 
CD38 immunoprecipitated from thymocytes behaved as an authentic NADase 
enzyme, by transforming NAD+ stoichiometrically into nicotinamide and 
ADPR (Gelman et al., 1993). As above-mentioned, the human cyclase family 
of enzymes has A. californica as its founding member. Even if the human 
version of ADPRC retains high homology with its Aplysian ancestor, its 
functional activities have evolved significantly. Indeed, while the Aplysia 
enzyme functions mainly as a cyclase, the human CD38 is mainly a NAD+ 
glycohydrolase that leads to the generation of ADPR and nicotinamide as 
products, accounting for >90% of all NAD+ase activity in humans (Liu et al., 
2009). The cyclase function is present, but its activity is approximately 100- 
fold lower than that of the hydrolase. The structural determinants critical for 
the catalytic characteristics of ADPRC and CD38 were described by Liu and 
co-workers, by comparing the crystal structures of the complexes of ADPRC 
and CD38 bound with various catalytically revealing substrates and products 
(Liu et al., 2009). The results identify residues Phe-174 in the cyclase and Thr- 
221 in CD38 as the main determinants for the cyclase and hydrolysis activities 
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of these enzymes. Indeed, a point mutation of Phe-174 to glycine can turn 
ADPRC from a cyclase towards a NADase. The equivalent residue in CD38, 
Thr-221, is shown not to favour the cyclising folding of the substrate, which 
results in NADase being the dominant activity. 
Being the major NADase enzyme in cells, CD38 has an important role 
in controlling NAD+ levels, both in the extracellular and intracellular space 
(Aksoy, White et al. 2006). This last aspect was examined by the Chini group. 
These authors postulated that CD38 is the major NADase in mammalian cells 
and that it regulates intracellular NAD+ levels (Aksoy, White et al. 2006), 
modulating the activity of the sirtuins, which are NAD+-dependent 
deacetylases that are implicated in ageing, cell protection, and energy 
metabolism in mammalian cells (see section 1.3.3). This regulation occurs 
inside the nucleus and is mediated by CD38 expressed by the inner nuclear 
membrane (Aksoy et al., 2006). 
A separate enzymatic activity that has been attributed to CD38 involves 
catalytic exchange of the nicotinamide group of NADP+ with nicotinic acid 
(NA). The product is nicotinic acid adenine dinucleotide phosphate (NAADP), 
a potent Cat+-mobilising metabolite (Aarhus et al., 1995). This activity occurs 
selectively at an acidic pH; the acidic dependence of NAADP metabolism, 
coupled with its biological function in targeting the acidic Ca2+ stores in cells, 
suggests that NAADP serves as a specific Ca2+ messenger for the acidic 
organelles of the endocytic pathway in cells (Santella, 2005). Moreover, it has 
also been shown that NAADP can release Ca 2+ from the ER (Gerasimenko et 
al., 2006). Thus, in addition to inositol 1,4,5-trisphosphate, internal Ca2+ stores 
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can be mobilised by at least two other molecules, cADPR and NAADP, which 
target separate Ca2+ stores and are bound by distinct receptors. 
1.3.1.4 Enzymatic activities controlled by CD 157 
Similar to the Aplysia enzyme and to CD38, soluble CD157 incubated with 
NAD+ produces cADPR, and subsequently ADPR, which indicates that CD 157 
has both ADPRC and cADPR hydrolase activities. However, the catalytic 
efficiency of CD 157 is several-hundred-fold lower than that of CD38 (Ortolan 
et al., 2002). 
1.3.1.5 Receptor activities of CD3 8/CD 157 
The most radical change in the evolutionary path of CD38 was the acquisition 
of a membrane anchor, which made it possible to interact laterally and frontally 
with molecules other than its substrate. Indeed, CD38 forms supra-molecular 
complexes that generally include other receptors, adhesion molecules and 
structural proteins (Malavasi et al., 2008). The receptor aspect of CD38/CD157 
has been reviewed in details by Malavasi and co-workers (Malavasi et al., 
2008; Vaisitti et al., 2011). I will not describe this aspect, since it does not fall 
within the main topic of the introduction to my thesis (1.3.1), which has the 
aim to describe the NAD'-linked functions of the different enzyme families. 
1.3.2 The mammalian ecto-ADP-ribosyltransferases 
After the discovery of the bacterial ARTs, similar enzymatic activities were 
sought in eukaryotic cells. However, the enzymes responsible for these 
activities eluded molecular cloning until the groups of Moss and Shimoyama 
succeeded in purifying and sequencing proteins with ADP-ribosylating 
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activities from rabbit skeletal muscle and chicken bone-marrow cells (Tsuchiya 
et al., 1991; Zolkiewska et al., 1992). These findings constituted the starting 
point for further characterisation of other enzymes of this type (Koch-Nolte 
and Haag, 1997). 
The knowledge acquired to date allows us to group the mammalian 
ecto-mARTs into a single family of structurally and functionally related genes. 
This family comprises five members, ART 1-5. They are all ecto-enzymes, 
which are anchored to the outer leaflet of the plasma membrane via a GPI tail, 
with the exception of ARTS, which is secreted into the extracellular space 
(Okazaki and Moss, 1998). Among these five ARTs, only ART 1, ART2 and 
ARTS show enzymatic activity, whereas ART3 and ART4 appear to have lost 
their catalytic function (Glowacki et al., 2002). In humans, the presence of a 
art2 pseudogene that carries three premature stop signals limits the number of 
ART enzymes to four. Conversely, the duplication of the art2 gene in mouse 
increases the number of enzymes to six (Glowacki et al., 2002). 
This family of enzymes shares very limited amino-acid sequence 
identity, with 20% to 30% seen among the ART paralogue members within any 
species. The exception here is mouse ART2.1 and ART2.2, where their 
sequence identity (85%) indicates recent evolutionary duplication of the mouse 
art2 gene (Braren et al., 1998). 
The ART2 enzymes have also been cloned from rat, and in this case the 
two isoforms are alternative splicing variants of the two alleles known as 
ART2. a and ART2. b (Bortell et al., 1999). These two allelic variants show 
sequence variation of only 10 amino acids, which is associated with a change 
in the enzymatic activity between ART2. a and ART2. b; indeed, while both 
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isoforms can catalyse the hydrolysis of NAD+ to ADPR and nicotinamide, only 
ART2. b can undergo auto-ADP-ribosylation (Haag et al., 1995). 
As the human and mouse genome sequences have been completely 
determined, all of the recognisable members of these ARTs have been 
identified for these two species, with an amino acid sequence identity between 
orthologues ranging from 75% to 85%. As an example, the deduced amino- 
acid sequence of mouse ART 1, which was the first cloned and characterised 
mammalian arginine-specific ART, is 77% and 73% identical to human and 
rabbit ART 1, respectively (Braren et al., 1998; Okazaki and Moss, 1998) 
As expected by the sequence similarity, there are common structural 
features that characterise the family of mammalian ecto-ARTs (Domenighini et 
al., 1994; Domenighini and Rappuoli, 1996). The catalytic domain of these 
enzymes is completely coded for by a single exon in all of the ARTs, and it 
contains a conserved glutamate residue that has been demonstrated to be 
crucial for catalytic activity, as demonstrated by site-specific mutagenesis for 
the ART! and ART2 murine and rat isoforms (Hara et al., 1996; Takada et al., 
1995). In addition, mutational analysis performed on the ART1 from rabbit 
show that besides the classical glutamate, the neighbouring glutamic residue 
(E238) has an important role for ADPR transfer (Hara et al., 1996; Takada et 
al., 1995). Indeed, in several of the ARTs, the replacement of this second 
glutamate abolishes the ability of the transferases to use arginine as acceptor, 
thus further supporting the hypothesis that this region is involved in substrate 
recognition (Han and Tainer, 2002). According to the structural model 
proposed by Rappuoli and colleagues (Domenighini and Rappuoli, 1996), the 
catalytic domain is composed of 70-100 amino acids and consists of three 
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regions. Region 1 is near the N-terminal portion of the protein and is 
characterised either by a conserved histidine (as in DTX, ART3 and the 
PARPs) or by a conserved arginine (as in PTX, CTX, the LTX and the other 
ARTs). Region 2 is characterised either by hydrophobic amino acids that are 
involved in NAD+ binding or by a serine-x-serine motif (where x represents 
threonine, serine or alanine). Region 3 is highly acidic and is characterised by 
the conserved glutamate residue. The arginine-serine-glutamate-x-glutamate 
motif (R-S-E-Q-E; which spans regions 1-2-3, respectively) is present in CTX 
and in ART 1, ART2 and ARTS, and it is typical of the arginine-specific ARTs. 
This motif is missing in ART3 and ART4 (Koch-Nolte et al., 1997). Through a 
comparative analysis of crystallographic structures, Han and Tainer (Han and 
Tainer, 2002) extended the significance of the region 3 sequences by 
identifying an ADP-ribosylating turn-turn (ARTT) motif that they have 
implicated in substrate recognition. Consistent with the relevance of the ARTT 
motif, it has been shown that the auto-ADP-ribosylation of ART2. b is 
abolished by mutations of its R204, which is part of the ARTT motif. 
Similarly, if the Y204 of ART2. a is mutated to an arginine (Y204R), it is 
possible to promote ART2. a auto-ADP-ribosylation (Stevens et al., 2003). 
The other common structural features of the ARTs include an a-helix- 
rich N-terminal region, which represents a signal sequence for extracellular 
proteins, and a C-terminal region folded into ß-sheets, which is characteristic 
of GPI-anchored membrane proteins (Bazan and Koch-Nolte, 1997). As 
mammalian (human and mouse) ARTS does not contain this hydrophobic C- 
terminal signal sequence, it is a secreted protein (Glowacki et al., 2001). 
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Finally, there are four cysteines involved in disulphide bridge formation that 
are conserved among all of the ART isoforms. 
The identification of this class of enzymes gave new impetus to studies 
of the physiological significance of the ADP-ribosylation reaction. Thus, in the 
next section, I report the current knowledge concerning the specific targets that 
are known to be modified by ecto-ARTs, and how the modifications affect 
their substrate functions. 
1.3.2.1 Ecto-ART substrates as functions of their distribution 
Although substantial progress has been made with regard to the molecular 
characterisation of ARTs, identification of their physiological target proteins 
has been difficult. In the identification of the substrates, and thus their 
functions, it is important to remember that ecto-ART-encoding genes show 
tissue-specific expression. Northern blotting and RT-PCR with human and 
animal tissues have revealed relatively broad distributions of ART3 and ART4, 
and rather specific expression of ARTI in heart and skeletal muscle in both 
species. ART5 is mainly expressed in testis, while ART2, which is absent in 
man, has been detected in mouse peripheral and rat lymphoid tissues (Seman et 
al., 2004). 
In addition to these different distributions, the patterns of ART 
expression in some cases are related to cell differentiation and/or activation 
states. In human polymorphonuclear neutrophils, for example, translocation of 
ARTI to the cell surface depends on the presence of activating ligands, such as 
interleukin (IL)-8 or platelet-activating factor (Kefalas et al., 1999). Similarly, 
the rate of ART3-transcription is increased upon exposure of human monocytes 
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to lipopolysaccharide, which also induces expression of ART4 mRNA 
(Grahnert et al., 2002). Another typical example is ART2 expression on murine 
T cells. ART2 is expressed only on a small subpopulation of mature 
thymocytes, and thus appears to be developmentally regulated (Koch-Nolte et 
al., 1999). Moreover, whereas ecto-ART expression increases with human 
polymorphonuclear-leukocyte or monocyte activation, ART2 is shed from the 
membrane upon T-cell activation (Kahl et at., 2000). 
The following sections describe the known substrates modified by ecto- 
ARTs in relation to their expression. 
ART I 
ART I was identified as the first mammalian ART after its purification from 
skeletal muscle and cDNA cloning from rabbit (Zolkiewska et al., 1992), 
human skeletal muscle (Okazaki et al., 1994) and mouse lymphoma cells 
(Okazaki et al., 1996). In search of proteins that can be ADP-ribosylated by 
ARTI, a7-integrin was identified as a key protein (Zolkiewska and Moss, 
1997). a7-Integrin is expressed specifically in skeletal and cardiac muscle, and 
it forms a dimer with 01-integrin, and binds to laminin, an extra-cellular matrix 
(ECM) protein. ADP-ribosylation enhances the interaction between a7/ßl- 
integrin and its ligand, laminin (Zolkiewska and Moss, 1997). This effect might 
represent a mechanism of up-regulation of a7/ßl-integrin function in situations 
where more efficient interactions are required, such as muscle injuries or 
diseases (Zolkiewska, 2005). Interestingly in mouse skeletal muscle cells, the 
expression of ARTI correlates with the transition from non-differentiated 
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mononucleated myoblasts to multinucleated non-replicating myotubes 
(Zolkiewska and Moss, 1993). 
Another well-known substrate for ART1 is the human defensin HPN-1 
(Paone et al., 2002). Defensins are small cationic arginine-rich peptides (2 kDa 
to 6 kDa) that act as protein mediators of innate immunity and are produced by 
inflammatory cells, such as neutrophils, and epithelial cells lining the airways. 
As components of adaptive immunity, HPN1-3 can also be produced by human 
natural killer cells and T and B lymphocytes stimulated with cytokines. 
Defensins induce cytokine production, and modulate cell proliferation (Ganz, 
2003). 
In vitro studies performed by Paone and colleagues demonstrated that 
ART1 specifically modifies a synthetic HNP-1 on Arg14, with a secondary site 
on Arg24. The reaction is almost specific for ARTI, since other arginine- 
specific ARTs show minor, if any, activity towards this HNP-1 (Paone et at., 
2006). In its ADP-ribosylated form, the peptide reduces both its antimicrobial 
and cytotoxic activities, while enhancing its promotion of release IL-8 from 
epithelial cells. Conversely, the chemotactic activities evaluated for the 
recruitment of T lymphocytes are not affected by ADP-ribosylation. The 
concept here is that once modified, HNP-1 acquires properties that result in the 
recruitment of neutrophils (by the release of IL-8) and in the modulation of its 
own antimicrobial and cytotoxic activities. 
Importantly, high concentrations of HNP-1 are likely to be present in 
sites of inflammation and these can inhibit the transferase activity of ART 1 and 
thus the formation of reduced modified HNP-1. This might represent a 
regulatory mechanism. The same inhibitory effect has been demonstrated for 
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ART5 activity, although it does not modify HNP-1 (Paone et al., 2006). 
Additional substrates of ART1 have been identified in various cell lines over- 
expressing ART 1, as demonstrated for the basic fibroblast growth factor 
(FGF)-2 in ART 1-transfected rat adenocarcinoma cells. FGF-2 binds its 
specific extracellular receptor (FGFR), as well as heparin, with high affinity. It 
can thus be sequestered by the heparan sulphates on the cell surface and in the 
ECM. Heparin inhibits the ADP-ribosylation reaction, implying that the 
heparin binding of FGF-2 and its ADP-ribosylation are mutually exclusive 
reactions. Furthermore, the ADP-ribosylated site of FGF-2 is in its receptor- 
binding domain, and so it is possible that ADP-ribosylation modulates the 
binding of FGF-2 to its receptor and to heparin, thus regulating its availability 
to the cell (Jones and Baird, 1997). 
ART1 can also ADP-ribosylate another growth factor, i. e. the specific 
BB isoform of platelet-derived growth factor (PDGF-BB), as demonstrated in 
ART1-transfected Chinese hamster lung fibroblasts. Here, the role of ADP- 
ribosylation is to inhibit PDGF-BB stimulation of mitogenic and chemotactic 
responses in human pulmonary smooth muscle cells, as well to reduce PDGF 
binding to its receptors as demonstrated in competition-binding assays (Saxty 
et al., 2001). Similar to the effects of ADP-ribosylation of FGF-2, in this case 
also ADP-ribosylation has an inhibitory effect on PDGF-BB, thus negatively 
regulating its signalling at the cell surface. 
ART2 
ART2 is expressed in immune system cells, such as resting T cells and natural 
killer cells, where it should have an immunomodulatory activity. Indeed, in 
different animal models, autoimmune disorders, such as juvenile diabetes and 
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systemic lupus, have been found to coincide with defects in the structure and 
function of ART2 (Koch-Nolte et al., 1995). In rat, susceptibility and resistance 
to diabetes correlate with the absence and presence, respectively, of ART2- 
expressing T cells (Fowell and Mason, 1993). Nolte and co-workers (Seman et 
al., 2003) uncovered an intriguing function of ART2: activation of the P2X7 
purinoceptor as a consequence of ADP-ribosylation. P2X7 is a member of the 
P2X family of ATP-gated ion channels, and it is widely expressed in several 
types of blood cells. The presence of ATP at millimolar concentration activates 
this purinoreceptor, thus inducing the formation of large membrane pores that 
trigger calcium fluxes and phosphatidylserine exposure, typical features of the 
apoptotic process (Di Virgilio et al., 2001). 
Similar to ATP, micromolar concentrations of NAD+ have the same 
effects, through ADP-ribosylation catalysed by ART2 (Seman et al., 2003). 
These data provide an excellent explanation for the rapid apoptosis induced by 
extracellular NAD (NAD-induced cell death) in naive T cells (Scheuplein et 
al., 2003). The molecular mechanism that explains how ADP-ribosylation can 
activate the channel is still not clear. However, it might be that ADPR 
functions as a ligand for the adenosine-binding site on the P2X7 receptor, or 
could activate P2X7 by an allosteric conformational change, independent of the 
ligand-binding site. Identification of the ADP-ribosylated arginine residues will 
help to solve this question. 
The regulation of the P2X7 channel constitutes an interesting signalling 
pathway that is regulated by ADP-ribosylation. As mentioned above, ART2 is 
not present in humans and so far is not known if such a mechanism is catalysed 
by another enzyme. Trying to answer this question constitutes an interesting 
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point of investigation. Nevertheless, a common role for ART1 and ART2 can 
still be defined, that of the regulation of the immune response. 
ART3, ART4 and ART5 
The biological roles of ART3, ART4 and ART5 remain almost completely 
obscure. Looking at their sequences, they show conspicuous substitutions of 
key residues that line the catalytic site. It is therefore conceivable that ART3 
and ART4 have acquired novel target specificities or that they have lost ART 
enzyme activity, as has happened for some members of the PARP family 
(Koch-Nolte et al., 2008) (explained in section 1.3.4). 
1.3.3 Sirtuins 
Sirtuins comprise an ancient family of NAD+-dependent protein deacetylases 
that have been evolutionarily conserved from bacteria to eukaryotes (Michan 
and Sinclair, 2007). The founding member of the sirtuin family, yeast Sir2 
(silent information regulator 2) was originally isolated in a screening for 
silencing factors, and later shown to regulate the lifespan in lower organisms 
(Kennedy et al., 1995; Rine et al., 1979). Subsequent analysis revealed that 
Sir2 functioned biochemically as a HDAC, in a unique reaction that required 
the energetic intermediate NAD+ as a co-factor (Imai et al., 2000). The 
requirement of NAD+ as part of their enzymatic action suggested a mechanistic 
link between sirtuin activity and intracellular energetics. Based on these 
observations, there have been efforts to understand if there is a similar role for 
sirtuins in mammals; here indeed sirtuins have been connected to an ever 
widening circle of activities, which encompasses cellular stress resistance, 
genomic stability, tumorigenesis, and energy metabolism (Finkel et al., 2009). 
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In the next sections, I will mainly describe the enzymatic features of the 
mammalian enzymes and their localisation, while giving a brief report on some 
of the pathways in which they are involved as mART. Since the sirtuins are not 
specifically part of my study and to date are best recognised as deacetylases 
more than ARTs, I will not describe their roles as deacetylase. 
1.3.3.1 Enzymatic mechanism 
Mammals have seven sirtuins, SIRTI-7, which are characterised by their 
highly conserved central NAD+-binding and catalytic domain, termed the 
sirtuin core domain (Haigis and Guarente, 2006). Although sirtuin sequences 
are relatively conserved, their N and C termini differ, and they are likely to 
have highly divergent biological functions owing to (a) different enzymatic 
activities, (b) unique binding partners and substrates, and (c) distinct 
subcellular localisation and expression pattern (reviewed in section 1.3.3.2). 
The predominant reaction catalysed by the sirtuins is NAD+-dependent 
lysine deacetylation (Figure 1.6), via a unique enzymatic mechanism that 
requires NAD+ cleavage for each reaction cycle (Landry et al., 2000; Tanner et 
al., 2000). Unlike other HDACs that hydrolyse acetyl-lysine residues, sirtuin 
activity is intimately tied to the metabolic state of the cell. The mechanistic 
basis for deacetylation by sirtuins is both elegant and peculiar. The 
deacetylation reaction begins with amide cleavage of NAD+ and formation of 
nicotinamide and a covalent ADPR peptide-imidate intermediate. The 
intermediate is resolved to form O-acetyl-ADPR (AADPR), and the 
deacetylated substrate is released (Sauve et al., 2001). Although some details 
remain to be resolved, it is thought that peptide binding facilitates an allosteric 
change in sirtuin structure that enables the reaction of NAD+ with a nucleophile 
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Figure 1.6: Deacetylation reaction catalysed by the sirtuins 
The sirtuins are NAD+-dependent deacetylases that regulate a wide array of 
proteins that are involved in metabolism and cell survival. The s-acetyl lysine 
residues of the target protein serve as substrates for sirtuin deacetylation, which 
generates 2'-OAADPr as a by-product. 2'-OAADPr: 2'-O-acetyl ADP-ribose; 
NAM, nicotinamide. From Michan and Sinclair (2007). 
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from the sirtuin to generate the enzyme-stabilised ADPR intermediate (Sauve 
et al., 2006). Deacetylase activity is not the only activity associated to the 
sirtuins, even if the most prominent. An mART activity has been clearly 
associated to SIRT4, while for SIRT6 the mART activity is still under debate. 
Regarding SIRT4, it has been demonstrated that it ADP-ribosylates the 
glutamate dehydrogenase GDH. This event leads to down-regulation of 
mitochondrial glutamate dehydrogenase (GDH) in pancreatic 0-cells, thereby 
down-regulating insulin secretion in response to amino acids (Haigis et al., 
2006) and, thus, regulating glucose homeostasis (Haigis et al., 2006). 
SIRT6 represents an interesting case. Recently, Denu and co-workers 
(Pan et al., 2011) reported the first quantitative assessment of SIRT6 activity, 
providing direct evidence that OAADPR is formed as a product of the 
deacetylase reaction; importantly, the rate of nicotinamide cleavage is similar 
to the rate of OAADPR formation, suggesting that SIRT6 functions as a 
NAD+-dependent deacetylase rather than as an ART. 
However, a general consensus on a clear role for SIRT6 is still lacking. 
Indeed, recently it has been demonstrated that under stress conditions, SIRT6- 
catalysed mono-ADP-ribosylation promotes DNA repair by activating PARP 1. 
In this case, the poly-ADP-ribosylation activity of PARP1 is stimulated by its 
ADP-ribosylation on lysine 521 that is catalysed by SIRT6. This enhances 
DSB repair by both homologous recombination (HR) and non-homologous 
end joining (NHEJ), and thus suggests a new role for SIRT6 in DNA repair, by 
integrating the DNA repair and stress signalling pathways (Mao et al., 2011). 
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1.3.3.2 Subcellular localisation 
The seven mammalian sirtuins are found in numerous compartments within the 
cell (Figure 1.7). SIRTI, SIRT6, and SIRT7 are found predominantly in the 
nucleus; SIRT3, SIRT4 and SIRT5 reside in the mitochondria; and SIRT2 is 
primarily cytoplasmic. Their localisation can be dictated by their sequences as 
well by cell status (Michishita et al., 2005). 
Each sirtuin contains primary amino-acid signal sequences that 
contribute to their intracellular localisation. For example, the nuclear 
localisation of SIRT1, SIRT6, and SIRT7 is largely attributed to their nuclear 
localisation signals. In addition to having two nuclear localisation signal 
regions, SIRTI contains two nuclear export signals (Tanno et al., 2007). Thus, 
the exposure of nuclear localisation signals versus nuclear export signals might 
dictate the nuclear versus cytosolic localisation of SIRT1, respectively. 
SIRT3, SIRT4 and SIRT5 contain N-terminal mitochondrial targeting 
sequences, and they are widely believed to localise to the matrix of the 
mitochondria (Michishita et al., 2005). However, studies have not conclusively 
ruled out localisation for these proteins to other compartments. The localisation 
of SIRT3 has been controversial (Hallows et al., 2008). Initial reports found 
that overexpressed SIRT3 was localised exclusively to the mitochondria 
(Schwer et al., 2002). However, subsequent studies using a Sirt3 antibody that 
recognises the endogenous protein demonstrated that SIRT3 localises to the 
nucleus and that it can translocate from the nucleus to the mitochondria during 
cell stress (Scher et al., 2007). These authors demonstrated that the human 
protein goes to the nucleus, where it functions as a histone deacetylase, and 
that here it can be cleaved at the N-terminus (region required for the nuclear 
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localisation); only this processed protein travels to the mitochondria, where it 
can target other substrates (Jin et al., 2009; Scher et al., 2007). For example, 
SIRT3 deacetylates and activates acetyl-CoA synthetase 2 in mitochondria, 
both in vitro and in vivo, thus directly modulating the activity of a metabolic 
enzyme (Schwer et al., 2006). Strictly associated with this aspect is the idea 
that the different distributions of the sirtuins among multiple compartments is a 
dynamic process, which depends on tissue/ cell type and physiological 
conditions. 
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Figure 1.7: sub-cellular localisation of sirtuins 
Mammalian sirtuins show different sub-cellular localisations. SIRTI, SIRT6 and SIRT7 
are predominately in the nucleus. In the nucleus a large fraction of SIRTI is associated 
with euchromatin, whereas SIRT6 associates with heterochromatin and SIRT7 is found in 
the nucleolus. The sirtuin that resides most prominently in the cytoplasm is SIRT2. 
SIRT3, SIRT4 and SIRT5 have been described as mitochondrial sirtuins. 
Adapted from Michishita et al., 2005. Mol Biol Cell, 16: 4623-4635. 
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1.3.4 The PARP-superfamily of ADP-ribosylating enzymes 
As mentioned in section 1.1, NAD+/NADH is among the most versatile of 
biomolecules, as it can be used not only as a coenzyme for a large number of 
oxidoreduction reactions, but in its oxidised version, it can also serve as 
substrate for different ADP-ribosylation reactions, the main theme of my 
thesis. So far, I have described how NAD+ can be used by toxins to modify host 
targets, by ADP-ribosyl cyclases to generate second messengers that modulate 
calcium homeostasis, by ecto-mARTs to modulate protein functions, and in the 
deacetylation reaction catalysed by the sirtuins. 
The PARPs are major players in the consumption of NAD+. They are 
an ancient family of enzymes that are encoded in humans by a set of 18 
different genes. Sequence and structure analysis of the PARPs has 
demonstrated that while PARP 1-PARP6 show a conserved HYE triad in the 
catalytic domain, the other 11 members have the glutamic residue that is 
indispensable for polymerase activity replaced, by different residues (I-L-Y) 
(Otto et al., 2005). Moreover, two members of the family (PARP9 and 
PARP13) also show changes in the first histidine residue of the triad that is 
involved in NAD+ binding, and for this reason they have been classified as 
inactive enzymes (Otto et al., 2005). Together, these features suggest that the 
PARP family is not homogenous regarding its catalytic activity, and indeed, 
the new members have been indicated to function as mARTs, with 
experimental evidence for PARP10 (Kleine et al., 2008) and PARP14 (Goenka 
et al., 2007) now available (see Table 1.2). 
In the following sections, I describe the current understanding of the 
roles of the different PARPs, starting with PARP 1, the founding member of the 
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family. Figure 1.8 shows the domain organisation for all the different PARPs, 
organized into subgroups based on the presence of specific domains. 
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Figure 1.8: The PARP superfamily 
The domain architecture of the human PARP family members. Within each putative PARP 
domain, the region that is homologous to residues 859-908 of PARPI (the PARP signature) 
is indicated by the darker green. BRCT, SAM, UIM, MVP-BD, VWA and ANK are protein- 
interaction modules. ANK, ankyrin; BRCT, BRCAI-carboxy-terminus; HPS, 
homopolymeric runs of His, Pro and Ser; macro, the macro domain that is involved in ADP- 
ribose and poly(ADP-ribose) binding; MVP-BD, MVP-binding domain; NES, nuclear 
export signal; N(o)LS, nuclear (nucleolar) localisation signal; PARP, poly(ADP-ribose) 
polymerase; PARP_Reg, putative regulatory domain; RRM, RNA-binding motif; SAM, 
sterile a-motif; TiPARP, 2,3,7,8-tetrachlorodibenzo-p-dioxin-inducible poly(ADP-ribose) 
polymerase; UIM, ubiquitin-interacting motif; VIT, vault inter-a-trypsin; vPARP, vault 
poly(ADP-ribose) polymerase, vWA, von Willebrand factor type A; WGR, conserved W, G 
and R residues; WWE, conserved W, W and E residues; ZnF, DNA or RNA binding zinc 
fingers (except PARP1 ZnFIII, which coordinates DNA-dependent enzyme activation). 
From Hakme et al. (2008). 
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1.3.4.1 PARP 1 
PARP 1 structure 
PARP 1 was identified almost five decades ago by Chambon, Weill and Mandel 
(Chambon et al., 1963), which gave rise to an interesting and intriguing field of 
research. PARPI is a highly conserved and abundant nuclear protein, which is 
catalytically active as a dimer and is the major acceptor protein of poly-ADPR 
in intact cells, via the so-called auto-modification reaction (D'Amours et al., 
1999). PARP1 has a modular structure that comprises multiple independently 
folded domains (Figure 1.8). The major functional units of PARP1 are an 
amino-terminal DNA-binding domain (DBD), a central auto-modification 
domain (AMD), and a carboxy-terminal catalytic domain (CD), which can be 
further broken down into modules that have specific functions (Figure 1.8). 
The DBD contains two zinc fingers (FI/Znl and FII/Zn2) that mediate binding 
to DNA, a newly discovered third zinc finger domain (FIII/Zn3) that is 
responsible for DNA-dependent enzyme activation (Langelier et al., 2010; 
Langelier et al., 2008), a nuclear localisation signal (NLS), and a caspase-3 
cleavage site (Hakme et al., 2008; Schreiber et al., 2006). In the central AMD, 
specific glutamate and lysine residues serve as acceptors of ADPR moieties, 
thereby allowing the enzyme to ADP-ribosylate itself (Tao et al., 2009). 
Interestingly, this domain also comprises a BRCA1 carboxy-terminal (BRCT) 
repeat motif, and a protein-protein interaction domain found in other members 
of the DNA-damage response pathway (Schreiber et al., 2006). Finally, the CD 
domain, which is the most conserved domain across the PARP family, contains 
a PARP signature motif, which binds NAD+, as well as a `WGR' motif, which 
is named after the most conserved amino-acid sequence in the motif (Trp, Gly, 
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Arg) and which has an unknown function. Together, the structural and 
functional domains of PARP 1 confer the activities required for the broad range 
of functions of PARP 1 in the nucleus (Schreiber et al., 2006). 
At steady state, PARP1 has a very low basal enzymatic activity that 
increases up to 500-fold after DNA damagle (Alvarez-Gonzalez and Althaus, 
1989). However, its auto-modification can also be triggered by alternative 
activation mechanisms that are independent of DNA strand breakage. Indeed, 
PARPI can recognise distortions in the DNA helical backbone, such as DNA 
hairpins, cruciforms and stably unpaired regions (Lonskaya et al., 2005). 
Following its activation, PARP 1 modifies many nuclear proteins, including 
histones, DNA repair enzymes, transcription factors, and even itself. It is this 
diversity of modified substrates that accounts for the vast array of functions in 
which PARP1 is involved, an issue covered in the next section. 
PARPI function 
PARP1 contributes in many unique ways to the molecular biology of nuclear 
processes, with key roles in DNA damage signalling pathways, chromatin 
modification and transcriptional regulation (Krishnakumar and Kraus, 2010a). 
In the next section, I provide an overview on the different functions in 
which PARP 1 is involved. 
PARP1 in DNA damage and cell death 
The earliest functions ascribed to PARP1 were related to DNA repair and the 
maintenance of genomic integrity (D'Amours et al., 1999). As mentioned 
above, PARP 1 binds to and is activated by DNA damage, leading to an 
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immediate (15 s to 30 s after damage) and dramatic PARP 1-dependent poly- 
ADP-ribosylation response, which targets a variety of nuclear proteins 
(Alvarez-Gonzalez and Althaus, 1989). Owing to the size and large negative 
charge of poly-ADPR, its addition to proteins such as histones, topoisomerase I 
and DNA protein kinase (DNA-PK) interferes with their functions (D'Amours 
et al., 1999). However, the bulk of poly-ADPR is attached to PARP 1 itself. 
Notably, this polymer can recruit hundreds of other proteins, typified by 
XRCCI, a scaffolding protein of the DNA base excision repair (BER) 
machinery (EI-Khamisy et al., 2003; Masson et al., 1998). Some of these 
proteins bind directly to poly-ADPR through specific domains (see paragraph 
1.4), while others are indirectly recruited because they interact with poly- 
ADPR-binding proteins. At the same time, formation of poly-ADPR reduces 
the affinity of PARP1 and histones for DNA, providing a mechanism for 
removing PARP 1 from damaged DNA and for the local modulation of 
chromatin compaction (Poirier et al., 1982; Timinszky et al., 2009). Indeed, in 
vitro studies have demonstrated that removal of PARP1 allows the access of 
repair proteins and suppresses further poly-ADPR synthesis (Satoh and 
Lindahl, 1992). ADPR hydrolases and poly-ADPR-glycohydrolases (PARG) 
remove the poly-ADPR, which contributes to the switching off of the signal 
(Oka et al., 2006). 
As well as its role in the BER pathway, growing evidence suggests that 
PARP1 is also involved in alternative DSB repair pathways, by both 
homologous recombination and non-homologous end joining. DSBs are 
routinely repaired via the NHEJ pathway, which involves the coordinated 
action of DNA-PK and the XRCC4-DNA ligase IV complex. In addition to this 
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`classical mechanism', the BER components PARP1, XRCC1 and DNA ligase 
III can also repair DSBs, which provides a back-up pathway for the classical 
NHEJ mechanism (Audebert et al., 2004; Audebert et al., 2008; Audebert et al., 
2006). Moreover, it has been shown that poly-ADPR synthesis is required to 
recruit two important components of the homologous recombination system, 
namely mitotic recombination 11 and ataxia telengiectasia-mutated (ATM), 
which suggests that PARPI has an additional role in this process (Haince et al., 
2007; Haince et al., 2008). Consistent with the involvement of PARP 1 in all of 
these DNA-damage responses, Parp l "'' mice are more sensitive to DNA- 
damaging agents, such as alkylating agents and ionising radiation (Shall and de 
Murcia, 2000). 
Although poly-ADPR has a half-life of seconds to minutes, the 
consequences of poly-ADPR metabolism on cellular homeostasis can persist 
long after PARP 1 and the hydrolases have acted. Polymer synthesis consumes 
substantial amounts of NAD+ and poly-ADPR cleavage generates large 
amounts of AMP, leading to the activation of the bioenergetic sensor AMP- 
activated protein kinase (AMPK), which can induce an authophagic state 
(Huang et al., 2009). Moreover, long and branched polymers can directly 
trigger specific cell death, known as parthanatos. Parthanatos specifically 
indicates a type of cell death triggered by PAR (indeed this word refers to 
PAR, poly-ADP-ribose, and thanatos, the greek personifition of death and 
mortality) (Andrabi et al., 2006; David et at., 2009). Thus, the various 
consequences of PARP 1 activation reflect the collective effects of poly-ADPR 
synthesis on PARP1 substrates, binding of various proteins to poly-ADPR, 
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changes in cellular NAD+ (and ATP) levels during poly-ADPR synthesis and 
changes in AMP levels through poly-ADPR degradation. 
In summary, DNA-damage-dependent poly-ADPR production has three 
main purposes: 
- first, poly-ADP-ribosylated histones and/or PARP 1 itself cause relaxation of 
chromatin, which increases the access of other proteins to the site of the DNA 
lesions; 
- second, it mediates the fast recruitment of SSBs/BER factors (such as 
XRCC1 and DNA ligase III) to the sites of lesions; 
- third, it signals the extent of damage, so that the cell can response 
appropriately, according to the damage (DNA repair or cell death). 
Based on the important roles of PARP 1 in the maintenance of genomic 
stability and regulation of cell death, several clinical studies are using PARP 1 
inhibitors to treat cancers that are associated with defects in DNA repair 
machines. These studies are based on the concept that PARP 1 is a potential 
synthetic lethal therapeutic target for the treatment of cancers that carry 
specific DNA-repair defects. An example here is the familial form of breast 
cancer, which is caused by an inherited defect and subsequent loss of 
heterozygosity in one of the BRCA1 or BRAC2 alleles, both of which have 
important roles in the repair of DNA DSBs by homologous recombination 
(Venkitaraman, 2002). Of interest, Fong and colleagues (Fong et al., 2009) 
conduced a phase I clinical trial using an oral PARP 1 inhibitor, oloparib, and 
showed that it has few side effects and has antitumour activity in cancer 
associated to BRCAI or BRCA2 mutations. Spontaneously occurring SSBs 
cannot be repaired in the absence of PARPI activity, which in this case is 
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achieved by chemical inhibition of PARP1, and which results in the collapse of 
replication forks. BRCA proficient cells can repair these profound lesions via 
homologous recombination, while in BRCA-deficient cells these lesions are 
either repaired by error-prone pathways, leading to further genetic instability, 
or are directly lethal to cells (Helleday et al., 2005). 
Defects in homologous-recombination repair can also be caused by loss 
of function of proteins other than BRCA1 and BRCA2, including ATM and the 
checkpoint kinases CHK1 and CHK2. Such defects in homologous- 
recombination repair may be relatively common in some sporadic cancers, 
including breast cancer and ovarian cancer, making this therapeutic strategy 
more widely useful as an anticancer treatment (Peng and Lin, 2011). 
PARP 1 and transcniptional regulation 
- Regulation of chromatin structure 
Although historically PARP 1 has been mainly related to DNA damage, later 
studies revealed its important role in transcriptional regulation (Kraus and Lis, 
2003). It is now evident that PARP1 carries out this role by participating to 
different processes, such as modulation of chromatin structure, regulation of 
transcription factors, and regulation of methylation pattern (Kraus, 2008). 
PARP1 disruption of chromatin through the modification of histones 
was one of the first functional effects identified for PARP1 (Poirier et al., 
1982). Under steady-state conditions, PARP 1 is associated with chromatin, 
where it binds core histone proteins (MA, H2B, H3 and H4) in the 
nucleosome. Atomic force microscopy shows that this binding promotes the 
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compaction of nucleosomes into higher order structures that are refractory to 
transcription (Wacker et al., 2007). As soon as PARPI is activated, the highly 
charged poly-ADPR reduces the affinity of PARP1 for its associated proteins, 
which leads to a loosening of the chromatin structure and restoration of 
transcription (Kim et al., 2004; Wacker et al., 2007). At first glance, this would 
appear to be at odds with genomic studies that demonstrate that PARP 1 is 
associated to actively transcribed genes (Krishnakumar et al., 2008), which 
would suggest that it has a role in promoting the formation of chromatin 
structures that are permissive to transcription. It is therefore important to 
consider the specific NAD+ concentration: in the absence of NAD+ (non- 
physiological conditions) PARPI favours a closed chromatin structure, 
whereas at physiological nuclear NAD+ concentrations, PARP1 does the 
opposite, acting both on PARP 1 itself and on chromatin-associated factors. 
Indeed, in this regard, PARP1 and histone H1, a nucleosome binding protein 
that is associated to gene repression (Happel and Doenecke, 2009), show 
reciprocal patterns of chromatin binding at many RNA polymerase II 
transcribed promoters (Krishnakumar et al., 2008). Recently, Krishnakumar 
and co-workers (Krishnakumar and Kraus, 2010b) demonstrated that PARP I 
establishes a permissive chromatin environment at the promoters of its 
regulated genes by preventing demethylation of histone H3, through ADP- 
ribosylation of the specific histone H3 demethylase KDM5B, while promoting 
the exclusion of histone H 1. The permissive chromatin environment is required 
for the efficient loading of the polymerase II transcription machinery and 
subsequent transcription. Moreover, the authors showed that while the histone 
H3 demethylation is necessary to reduce gene expression, it is not sufficient, 
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and that the PARP 1 protein must be physically removed from the promoter to 
allow histone H1 binding and subsequent changes in chromatin structure. In 
this mechanism, PARP1 catalytic activity is only required for the regulation of 
KDM5B activity, while it is dispensable for displacing histone H1. 
Furthermore, during oestrogen-induced transcription of the TFFI gene, 
PARPI not only promotes the removal of histone Hl, but also recruits 
HMGB 1, thus enhancing transcription (Ju et al., 2006). Along the same line of 
evidence, PARP1 can also modify another repressive chromatin-associated 
protein, known as DEK, thus promoting its release from chromatin (Gamble 
and Fisher, 2007). 
Moreover, as well as its modulation of chromatin structure through 
regulation of its composition, PARP 1 can regulate transcription by functioning 
as a classical co-regulator and regulating the methylation state of DNA. 
- PARP 1 as co-regulator 
In a `co-regulator' mode, PARPI can be recruited to target promoters as a 
functional endpoint of signalling pathways, to regulate components of the 
transcription complex assembled at the promoter. In some cases, the enzymatic 
activity of PARP 1 is required (e. g., with HES 1 and Elk I) (Cohen-Armon et al., 
2007; Ju et al., 2004), while in others it is not (e. g., NF-kB and RAR) (Hassa et 
al., 2001; Pavri et al., 2005). When acting as a co-regulator during signal- 
regulated transcriptional responses, PARP 1 can function as a promoter-specific 
exchange factor that promotes the release of inhibitory factors and the 
recruitment of stimulatory factors. 
In the context of NF-kB-dependent gene activation, for example, 
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PARPI can physically interact with the co-activator complex Mediator and the 
histone acetyl transferase (HAT) p300, as well as with HDAC 1-3. Acetylation 
of several lysine residues in PARP1 by p300/CBP results in an enhanced 
interaction with p50 (a subunit of Nf-kB) and subsequent activation of NF-kB- 
dependent gene expression in response to inflammatory stimuli, which suggests 
stimulus-dependent induction of PARP 1-dependent NF-kB activation in 
concert with further transcriptional co-activators (Hassa et al., 2005). 
Interplay between PARPI and Mediator was also observed when 
studying the essential factors for retinoic acid receptor (RAR)-mediated 
transcription from the RARß2 promoter (Pavri et al., 2005). PARP1 occupies 
RAR-responsive promoters continuously, along with the Mediator complex 
and other factors, as confirmed by ChIP experiments. After ligand-dependent 
induction of gene expression, PARP 1 is indispensable for converting Mediator 
from its inactive state (Cdk8+) to its active state (Cdk8-), through the release of 
the repressing Cdk8 module (Pavri et al., 2005). Interestingly, PARP1 directly 
binds Cdk8 via its N-terminal region, and the interaction is weakened after 
TNFa stimulation, which precedes acetylation of PARP 1 and the subsequent 
NF-kB activation (Hassa et al., 2005). A similar situation was observed in 
neural differentiating stem cells: PARPI is a component of the groucho/TLE 
co-repressor complex that mediates the release of this complex upon PDGF 
stimulation and after PDGF-triggered activation of calcium/calmodulin 
dependent protein kinase II, which allows for the recruitment of co-activators 
and subsequent promoter activation (Ju et al., 2004). The PARP 1 catalytic 
activity is essential for this function, and several components of the 
groucho/TLE complex, including TLE1, the DNA topoisomerase Topollß and 
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Nucleolin, are ADP-ribosylated by PARPI (Ju et al., 2004). These authors 
extended their model by a further study that provided evidence that the signal- 
dependent activation of transcription requires the transient formation of 
dsDNA breaks by Topollß and concomitant PARP I activation, with the latter 
inducing a nucleosome-specific exchange of histone H1 against the high- 
mobility group (HMG) B protein and local changes in chromatin structure (Ju 
and Rosenfeld, 2006). 
- PARP 1 and DNA methylation 
Studies over the past decade have begun to link PARP 1-dependent poly-ADP- 
ribosylation to DNA methylation, a stable epigenetic mark that can be passed 
to daughter cells upon cell division and is associated with the repression of 
gene expression (Caiafa and Zampieri, 2005). One of the ways in which 
PARP1 affects DNA methylation is by regulating the expression and activity of 
the DNA methyltransferase Dnmtl (Zampieri et al., 2009; Zlatanova and 
Caiafa, 2009). PARP1 binds to the promoter of the Dnmtl gene and protects it 
from DNA-methylation-induced silencing in a poly-ADPR-dependent manner 
(Zampieri et al., 2009). In this regard, overexpression of poly-ADPR- 
glycohydrolase (PARG), an enzyme that degrades poly-ADPR, leads to 
aberrant methylation of a CpG island in the promoter of the Dnmtl gene in 
mouse fibroblasts, which in turn inhibits Dnmtl transcription. The loss of 
Dnmtl expression leads to widespread passive hypomethylation of genomic 
DNA (Zampieri et al., 2009). 
In addition, PARP1 has been shown to interact with Dnmt 1 in a 
complex that contains poly-ADPR (Reale et al., 2005). The non-covalent 
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binding of poly-ADPR polymers by Dnmtl within the complex inhibits the 
Dnmtl DNA methyltransferase activity, probably through a steric inhibitory 
mechanism (Reale et al., 2005). Interestingly, the effects of PARP1 on DNA 
methylation are modulated by the protein CTCF, which might promote PARP 1 
auto-modification, and thus CTCF poly-ADP-ribosylation and accumulation of 
poly-ADPR polymers, which ultimately inhibits Dnmt 1 DNA 
methyltransferase activity (Guastafierro et al., 2008). Future studies will be 
required to determine the extent to which PARP 1 has a role in the dynamic 
regulation of DNA methylation under different physiological and pathological 
states. 
1.3.4.2 PARP2 
PARP2 was discovered in the late 1990s and it is the only other known PARP 
that contributes to the formation of ADPR polymers in response to DNA 
damage. This enzyme bears the strongest similarity to PARPI; nevertheless, 
the N-terminal DNA-binding domain is very different to PARPI and consists 
of only 64 amino acids. PARP2 has high homology (62%) with the C-terminus 
of PARP1, which bears the catalytic domain (Ame et al., 1999). As expected, 
its catalytic properties strongly resemble those of PARP1, with the synthesis of 
long ADPR polymers being dependent on the binding to and activation by 
nicked DNA (Arne et al., 1999). However, the differences in their DBD might 
account for differential substrate recognition: for instance, PARP2 cannot 
modify histones, which are instead the prototypical PARP 1 substrates (Messner 
et al., 2010; Nguewa et al., 2005). 
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PARP2 shares many functions with PARP 1 in DNA repair processes: it 
interacts with the same components of the BER pathway, its enzymatic activity 
is required for efficient BER of DNA lesions, it can hetero-dimerise with 
PARPI within the same regions, being responsible for its homo-dimerisation, 
and PARP I and PARP2 can poly-ADP-ribosylate each other in a trans-ADP- 
ribosylation reaction (Nguewa et al., 2005). In addition, Parp2"'- mice are 
hypersensitive to DNA-damaging agents, similar to Parp 1''' mice, and the 
double mutant Parpl'1' Parp2''' mice are embryonic lethal, demonstrating their 
essential roles in early embryogenesis and underlining their at least partial 
functional redundancy in maintaining genome integrity (Menissier de Murcia 
et al., 2003). Further similarities between PARP2 and PARP1 include their 
roles in the maintenance of telomere integrity through binding to telomeric- 
repeat binding factor 2 (TRF2) (Dantzer et al., 2004; Gomez et al., 2006). 
Additionally, the cleavage of PARP2 and PARP 1 during caspase-dependent 
apoptosis, mediated by caspase-8 and caspase-3, respectively (Benchoua et al., 
2002; Kaufmann et al., 1993), and their localisation to centromeres, where they 
interact with centromeric proteins and poly-ADP-ribosylate them after DNA 
damage, thus modulating the compact chromatin structure of the centromeres 
(Saxena et al., 2002). 
1.3.4.3 PARP3 
PARP3 was initially discovered in an expressed sequence tag (EST) library 
screening using the catalytic domain of human PARP1 (Johansson, 1999). The 
human PARP3 gene has two splicing variants, which gives rise to two proteins 
that differ by seven amino acids at the N-terminus. The full-length protein is a 
core component of the centrosome, and it resides preferentially in the daughter 
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centriole throughout the cell cycle; the shorter splice variant accumulates 
within the nucleus (Augustin et al., 2003). As for PARP1 and PARP2, PARP3 
can undergo auto-ADP-ribosylation and can activate PARP1 in the absence of 
DNA damage (Loseva et al., 2010). Overexpression of PARP3 or its N- 
terminal domain interferes with the G1/S phase of cell-cycle progression, 
without inducing centrosomal amplification (Augustin et al., 2003). Moreover, 
it has been demonstrated that PARP3 associates with the polycomb group 
proteins that are involved in transcriptional silencing and with DNA repair 
networks, including SSB/BER and NHEJ, thus suggesting a role for PARP3 in 
the maintenance of genomic integrity (Rouleau et al., 2007). In this study of 
Rouleau et al. (2007), PARP3 was identified as part of the DNA repair protein 
complexes by a proteomic approach, which revealed an association with 
PARP 1 and the DNA ligases III and IV. Thus, PARP3 might be involved in the 
maintenance of transcriptional repression and might be linked to the DNA 
repair machinery. 
A recent study by Dantzer and co-workers (Boehler et al., 2011) 
provided evidence for a synergistic role of PARP3 and PARP1 in cellular 
responses to DSBs, with PARP3 acting to accelerate the repair response. 
Additionally, these authors identify PARP3 as a key component of a protein 
complex containing NuMa and tankyrasel; in this complex, PARP3 stimulates 
NuMa ADP-ribosylation by tankyrase1, which facilitates the formation and 
maintenance of the mitotic spindle and genomic integrity. Both of these 
findings open promising prospects for targeting PARP3 in cancer therapy. 
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1.3.4.4 PARP4 
PARP4 (also known as vault-PARP) was originally identified as a component 
of the mammalian ribonucleoprotein (RNP) complexes known as vaults 
(Kickhoefer et al., 1999) and shown to share 28% identity with the catalytic 
domain of PARPI; as for PARP1, the PARP4 catalytic domain can undergo 
auto-modification. Additionally, it can modify one of the major components of 
vaults, the major vault protein (MVP), and it has been shown that ADP- 
ribosylation is retained into the vault complexes (Kickhoefer et al., 1999). 
However, further studies demonstrated that even though ADP-ribosylation at 
vault complexes leads to a more stable association between PARP4 and MVP, 
PARP4 incorporation in this structure was not dependent on PARP4 catalytic 
activity: indeed, PARP4 association to vaults depends only on the PARP4 C- 
terminal domain, which lacks the catalytic activity (Zheng et al., 2005). 
Besides this structural role, PARP4 has been found at other cellular 
locations, such as the nucleus and mitotic spindle, which indicates that it might 
have multiple roles in vivo (Kickhoefer et al., 1999). Interestingly, PARP4 
interacts with telomerase-associated protein 1 (TEP I ), suggesting that PARP4 
and TEP I might have roles in both cytoplasmic and nuclear RNP complexes. 
However, an analysis of Parp4"1" mice revealed that these mice are viable and 
fertile without any apparent defects in telomere length or function, or in the 
structure of the vault particles (Liu et al., 2004), and indicated that PARP4 is 
therefore dispensable for the function of vaults as well as for maintaining 
telomere function. The only phenotype observed so far for Parp4"" mice is an 
increased susceptibility to carcinogen-induced colon tumorigenesis (Raval- 
Fernandes et al., 2005). 
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1.3.4.5 PARP5a and PARP5b (Tankyrase I and 2) 
PARP5a and PARP5b, also known as tankyrasel and tankyrase2 (hereafter 
indicated as PARP5a and PARP5b), are two closely related members of the 
PARP superfamily and were identified as components of a telomeric complex 
(Kaminker et al., 2001; Smith and de Lange, 1999). They share 85% identity 
and differ in the N-terminal HPS domain, which is missing in PARP5b (see 
figure 1.8). They can form homo- and hetero(oligo)mers through their sterile- 
alpha motif domains (Hsiao and Smith, 2008). Their functions have mainly 
been connected to telomeres, although additional roles in mitosis and vesicular 
trafficking have been proposed (Hsiao and Smith, 2008) 
PARPSa was identified in a yeast two-hybrid screen as an interaction 
partner for telomeric repeat binding factor 1 (TRF 1), with binding to TRF 1 
being mediated through its ankyrin repeats (Smith et al., 1998). PARP5a can 
auto-modify itself, as well as poly-ADP-ribosylate TRF1, with which it co- 
localises at telomeric DNA (Smith et al., 1998). A careful analysis of the 
PARP5a ADP-ribosylation capacity revealed that PARP5a can synthesise poly- 
ADPR with an average chain length of 20 units, but lacks the ability to form 
branched polymers, as has been described for PARPI and PARP2 (Rippmann 
et al., 2002). In addition to its telomeric localisation, PARP5a shows multiple 
subcellular localisation, related to the cell-cycle; at mitosis, PARP5a is located 
around the pericentriolar matrix of mitotic centrosomes, while during 
interphase I is on the cytoplasmic side of the nuclear envelope and partially in 
the Golgi complex (Chi and Lodish, 2000; Smith and de Lange, 1999). 
The role for PARP5a in telomere elongation is associated with ADP- 
ribosylation of TRF l; indeed, once modified, TRF I is released from telomeres, 
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allowing access of telomerase to the telomeres (Cook et al., 2002; Smith and de 
Lange, 2000). This release might be regulated by a second TRF 1-interacting 
factor, TIN2 (Ye and de Lange, 2004). In contrast to this model, a mutant 
PARP5a that cannot ADP-ribosylate TRF1 appeared to be sufficient to loosen 
the telomeric heterochromatin and to promote telomere elongation (Muramatsu 
et al., 2008). 
As well as its function in telomere elongation, the catalytic activity of 
PARPSa has a fundamental role in mitosis (Chang et al., 2005; Dynek and 
Smith, 2004). Of note, poly-ADPR has been shown to be required for spindle 
assembly (Chang et al., 2004), and knockdown of PARPSa results in pre- 
anaphase mitotic arrest. Taking these findings together, they support the idea 
that PARP5a activity is necessary for correct spindle formation. Accordingly, 
the spindle protein NuMA was demonstrated to be a substrate for PARP5a- 
mediated poly-ADP-ribosylation during mitosis, which results in the regulation 
of some NuMa functions. These authors demonstrated that even the 
knockdown of PARP5a does not cause displacement of NuMa from the spindle 
poles, it migh have a role in ensuring the correct spindle number. Knockdown 
of NuMA completely abolished the localisation of PARP5a to the spindles 
during mitosis, indicating an essential role for NuMA in the recruitment of 
PARP5a (Chang et al., 2005). 
As mentioned above, a fraction of PARP5a is also associated with the 
Golgi complex. Here, PARP5a interacts with the insulin-responsive amino 
peptidase that probably recruits it to GLUT4 storage vesicles in adipocytes 
(Chi and Lodish, 2000). Later studies demonstrated that the catalytic activity of 
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PARPSa is required to regulate GLUT4 storage-vesicle trafficking (Yeh et at., 
2007). 
The gene encoding PARPSb, at that time designated as the TNKL gene, 
was cloned in 2001 (Kuimov et al., 2001). Almost simultaneously, the PARPSb 
protein was identified as an interaction partner of the adaptor protein Grbl4, 
and both proteins were shown to be enriched in a subcellular fraction 
containing Golgi vesicles and endosomes (Lyons et al., 2001). Similar to 
PARPSa, PARPSb interacts with and can modify TRF1, which indicates a 
potentially redundant role for PARPSa and PARPSb in telomere regulation 
(Cook et al., 2002). Considering the high homology of PARP5a and PARP5b, 
these observations were not surprising. Indeed, the discovery of a tankyrase- 
binding motif in several of the interaction partners shared between both 
tankyrases, and their reciprocal ability to associate and to co-localise (Sbodio 
and Chi, 2002), suggested a high redundancy in terms of physiological 
function, a situation resembling the close connection between PARP 1 and 
PARP2. 
1.3.4.6 The 11 members of mono-ADP-ribosyltransferases of the PARP family 
The following sections focus on the current knowledge of the 11 putative 
mARTs of the PARP family. As mentioned in section 1.3.4, sequence 
alignment analysis performed by Koch-Nolte and co-workers identify two 
main groups of PARPs: one containing six bona-fide PARPs (PARP1-PARP6) 
and a second group composed of the other 11 members, which are believed to 
function as mono-ADP-ribosyl-transferases (Table 1.2). These 11 members are 
characterised by a conserved catalytic domain (the PARP domain) that is 
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associated - in a Lego-like fashion - with a broad spectrum of known protein 
domains (see Figure 1.8). These different domains allow a further division of 
the PARP super-family into subgroups that share specific domains. I will use 
this criterion to describe the 11 members. 
The Macro PARPs: PARP9, PARP14 and PARP15 
PARP9 (also known as BALI), PARP14 (also known as BAL2/CoaSt6) and 
PARP15 (also known as BAL3) belong to the subfamily of macro-PARPs, 
which link 1-3 macro domains to a PARP domain. 
The gene encoding PARP9 was originally identified as the BALI (B-aggressive 
lymphoma 1) gene in a screen for risk-related genes in diffuse large B-cell 
lymphoma (DLBCL) and mapped to chromosome 3g21 (Aguiar et al., 2000). It 
encodes a nuclear protein of 88 kDa with an N-terminal duplicated macro 
domain, a protein motif that is involved in the detection of different forms of 
ADPR and in transcriptional repression (discussed in section 1.4). The 
overexpression of PARP9 in B-cell lymphoma cells stimulated their migration 
in transwell assays, which indicated a tumour-promoting role for PARP9 in 
malignant B cells (Aguiar et al., 2000). Interestingly, PARP9 interacts with the 
ubiquitin E3 ligase Deltex-3 (Takeyama et al., 2003). Deltex-3 regulates the 
subcellular localization of PARP9, and PARP9 overexpression in DLBCL cell 
lines resulted in an increase in the expression of multiple interferon-stimulated 
genes, suggesting an important role for PARP9 in inflammatory processes 
(Juszczynski et al., 2006). Although PARP9 contains a C-terminal PARP 
domain, it lacks catalytic activity due to the absence of the conserved residues 
that are essential for catalysis, although it can repress transcription in general 
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via its macro domains, as assessed by reporter gene assays (Aguiar et al., 
2005). 
A database search identified two genes related to BAL 1, which 
consequently were named BAL2 and BAL3. Both of these genes were mapped 
to chromosome 3q21, arranged in tandem with the previously identified BALI. 
The encoded proteins, PARP14 and PARP15, like PARP9, have N-terminal 
macro domains and a C-terminal PARP domain, but in contrast to PARP9, the 
C-terminal regions of both PARP14 and PARP15 are subject to auto-ADP- 
ribosylation, which indicates an intact catalytic activity (Aguiar et al., 2005). 
PARP15 was reported to have a transcriptionally repressive function, which is 
not as pronounced as for PARP9, but which is also mediated by its macro 
domains. Since its PARP domain alone slightly stimulated transcription, it was 
suggested that the intrinsic PARP activity of PARP15 might counteract the 
repressive effect of the macro domains (Aguiar et al., 2005). 
PARP14 was identified in a yeast two-hybrid screen as an interaction 
partner of STAT6, and so it was named collaborator of STAT6 (CoaSt6) 
(Goenka and Boothby, 2006). In spite of its three macro domains, and in 
contrast to the repressive effect of the related PARP9 and PARP15 proteins, 
PARP14 was described as having a potentiating effect on the IL-4-induced 
transcriptional activation by STAT6 that is mediated mainly by its macro 
domains. Importantly, PARP14 appears to be a specific co-activator for 
STAT6-mediated transcription, since it did not stimulate the interferon-? - 
induced gene expression by STAT1 (Goenka and Boothby, 2006). These 
authors proposed a model in which PARP14 ADP-ribosylates p 100, a STAT6 
co-activator, which enhances the interaction of STAT6 with the basal 
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transcription machinery, thereby mediating a stimulatory effect on STAT6- 
driven gene expression (Goenka et al., 2007). More recently, the same group 
described the molecular mechanism responsible for this effect, defining 
PARP14 as a transcriptional switch for STATE-dependent gene activation. In 
particular, these authors demonstrated that under non-stimulating conditions 
(i. e., in the absence of IL4), PARP14 recruits HDAC2 and HDAC3 to IL-4- 
responsive promoters, thus blocking transcription. Upon IL-4 stimulation, Stat6 
is activated and binds to its promoter element, inducing PARP 14 enzymatic 
activity, so that it can modify itself on the N terminus and HDAC2 and 
HDAC3 in the complex. This results in the dissociation of PARP14 and the 
HDACs from the promoter, while allowing access to coactivators, such as 
HATs like CBP/p300, to activate transcription (Mehrotra et al., 2011). 
PARP 10 
PARP 10 has a unique domain composition among the PARP family members, 
combining potential DNA/RNA binding motifs and ubiquitin-interacting 
motifs with the catalytic PARP domain (see Figure 1.8). PARP 10 can ADP- 
ribosylates itself as well as core histones (Chou et al., 2006). 
PARP10 was initially identified as an interaction partner of the 
oncoprotein MYC (Yu et al., 2005). It was reported to localise preferentially in 
the cytoplasm and to shuttle between the cytoplasm and the nucleus through its 
functional nuclear-export sequence (NES). Importantly, PARP 10 can impair 
the c-MYC/H-RAS-driven transformation of rat embryo fibroblasts in a dose- 
dependent manner, a feature that is abrogated in a PARP10 mutant carrying a 
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non-functional NES, but is not dependent on the PARP10 catalytic activity (Yu 
et al., 2005). 
Subsequent work by Lusher and co-workers (Kleine et al., 2008) clearly 
defined the catalytic activity of PARP 10 in more detail, and found that 
PARP 10 functions as a mART, thereby defining a new class of intracellular 
mARTs. Interestingly, they proposed the mechanism of substrate-assisted 
catalysis for the automodification. According to this model, PARP 10 uses a 
substrate glutamate and possibly an aspartate for catalysis, thus allowing for 
the absence of the glutamic residue found in the `classical' PARPs. 
However, a physiological role for PARP 10 has not been elucidated yet. 
CCCH-PARPs: PARP7-PARP12 and PARP13 
The CCCH-type PARP subfamily contains three members (PARP7, PARP12 
and PARP 13) that share a similar domain organization, comprising PARP 
catalytic domain, a WWE domain (protein-protein interaction domain) and 
CX8CX5CX3-like zinc fingers. These zinc finger domains are known to 
recognise RNA and thus are different from PARP1 zinc forger domain 
involved in DNA recognition. 
PARP7 
PARP7 was identified as a gene that is up-regulated by treatment of mouse 
hepatoma cells with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototype 
substance from the class of dioxins that cause pleiotropic harmful effects in 
mammalian species through modulation of gene expression. PARP7 is broadly 
expressed in murine tissues and is likely to have enzymatic ADP-ribosylation 
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ability, although it was not been determined whether it undergoes auto-ADP- 
ribosylation (Ma et al., 2001). 
To date, there is no available information about a role for PARP7. 
PARP 12 
Figure 1.9 shows the structure of PARP12, which includes five zinc-finger 
domains, two WWE domains, and a catalytic domain at its C-terminus. The 
function of PARP 12 is still not known, and indeed, the study of PARP12 and 
its cellular function constitute a part of my PhD project. 
PARP13 
PARP13 is also known as ZAP (zinc-finger CCCH-type antiviral protein 1) 
and it was identified during a search for genes that prevent viral infection. Its 
antiviral property has been linked to its specific binding and degradation of 
viral mRNAs in the cytoplasm (Gao et al., 2002), with this binding shown to be 
mediated by the four CCCH zinc finger motifs in ZAP (Guo et al., 2007). 
Degradation of viral mRNAs involves recruitment of the RNA processing 
exosome through an interaction of ZAP and the exosome component hRrp46p 
(Guo et al., 2007). Interestingly, expression of the murine ZAP gene is induced 
by interferon-y and interferon-ß stimulation, and its protein product inhibits 
Sindbis virus replication, thereby linking the ZAP protein to interferon- 
mediated antiviral activities (Zhang et al., 2007). The human ZAP gene can be 
expressed as two alternatively spliced isoforms. While the short isoform 
ZAP(S) does not code for a PARP domain, the longer isoform ZAP(L) encodes 
a protein containing a C-terminal PARP domain in addition to the CCCH zinc 
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finger motifs, the TiPARP homology domain and a WWE domain (Kerns et 
al., 2008). 
According to analysis by Koch-Nolte and co-workers (Otto et al., 
2005), PARP13 is enzymatically inactive, as it lacks the important residues for 
NAD+ binding, and therefore its anti-viral functions cannot be associated with 
an intrinsic ADP-ribosylation activity. Further studies are required to cast more 
light upon this aspect. 
To date, there are no available data on PARP6, PARP8, PARP 11 and 
PARP 16, which remain to be fully characterised. The structure of these PARPs 
is shown in Figure 1.8. 
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CCCH-Zn Finger domain w. ^V` PARP domain 
Figure 1.9: Domain architecture of human PARP12 
PARP12 belongs to the CCCH-Zinc Finger PARPs. It has five Zn-finger domains, 
as found in proteins involved in RNA binding, two WWW domains (named after 
three of its conserved residues), which are predicted to mediate protein-protein 
interactions, and a PARP catalytic domain. The darker colour in the PARP domain 
indicates the homologous residues to PARP 1. 
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1.4 How to read ADP-ribosylation: the ADP-ribose binding modules 
In the previous sections, I indicated the different functions in which ADP- 
ribosylation is involved, ranging from the action of bacterial toxins to a role for 
ADP-ribosylation in DNA repair, maintenance of genomic stability, and 
regulation of mitosis. Despite these important roles of ADP-ribosylation, 
progress in understanding how these PTMs are `read' by other proteins has 
been made only recently. Work by three different groups (Abel et al., 2009; 
Gottschalk et al., 2009; Timinszky et al., 2009) have provided insights into the 
actions of an ADPR interaction domain, known as the macro-domain, in the 
process of DNA repair. 
The first macro domain to be described was that of Afl521, a protein 
from the thermophilic organism Archaeoglobus fulgidus, which was shown to 
bind ADPR with high affinity (KD in the range of 120 nM) (Karras et al., 
2005). The crystal structure of Afl521 bound to ADPR provided a clear 
explanation for this high affinity, showing that ADPR is bound in an L-shaped 
cleft on the protein surface, with the adenine moiety residing in a deep 
hydrophobic pocket, where the distal ribose can form several H-bonds that are 
not present in the ADP-bound structure of Afl 521 (Karras et al., 2005). 
The three research groups mentioned above demonstrated that macro 
domains interact with poly-ADPR in living cells. To show this, the authors use 
a laser-microirradiation procedure to introduce DNA breaks at discrete 
locations and to stimulate PARP 1 activity. The local synthesis of poly-ADPR 
was recognised by fluorescently tagged macrodomains from different proteins 
overexpressed in the cell system (Timinszky et al., 2009). Among the proteins 
recruited to the site of damage, there were the histone variant macroH2A 1.1 
92 
Introduction 
and the oncoprotein ALC 1 (amplified in liver cancer 1), a member of the 
SWF2 ATPase superfamily of remodelling proteins, both of which are 
involved in the alteration of chromatin structure. Furthermore, ALC 1 interacts 
with other DNA repair proteins, including XRCC1, and these interactions are 
also dependent on poly-ADPR formation (Ahel et al., 2009). Thus, macro 
domains can be used by proteins `to read the message encoded by ADPR'. 
According to databases, only 10 human proteins containing macro domains 
have been reported. This low number suggests that other domains that bind 
ADPR will exist. Nature has invented other `tools' to recognise ADPR, and so 
far at least two additional motifs have been identified. 
Indeed, in addition to macro domains, several groups have defined 
poly-ADPR-interacting proteins and derived potential consensus sequences for 
proteins with this capacity; the most refined of these is an eight amino acid 
motif, which is found in many proteins linked to DNA repair and chromatin 
regulation (Gagne et al., 2008). Accordingly, the first indication for an ADPR 
binding motif was published in the late 1990's by Malanga et al., which 
showed that three regions within the tumour suppressor protein p53 can bind 
poly-ADPR, either free or attached on PARP1, through strong non-covalent 
interactions, thus interfering with p53 binding to DNA (Malanga et al., 1998). 
The following studies led to the discovery of a poly-ADPR-binding motif that 
is composed of a cluster that is rich in basic amino acids and a pattern of 
hydrophobic amino acids interspersed with basic residues (Pleschke et al., 
2000). However, it is not certain whether the binding of poly-ADPR is indeed a 
specific feature of the proteins with the `eight amino acid motif, or whether 
the preponderance of basic residues reflects their general affinity for the ADPR 
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polymer. Another characterised motif is the poly-ADPR-binding zinc finger 
(PBZ), which is also associated with DNA repair proteins (Ahel et at., 2008). 
In summary, three different protein motifs have been identified that 
specify interaction with ADPR (Figure 1.10). The functional differences 
among these three motifs are unclear, and require further studies. 
1.5 A specific case: ADP-ribosylation and CtBP1/BARS 
The predominant topic of this thesis is my study of ADP-ribosylation. As 
explained in the previous sections, this post-translational modification is `used' 
by toxins and cellular enzymes to modulate cell functions. I explored both 
aspects of these modifications. In particular, on the one side, my project was 
focused on the study of the ADP-ribosylation reaction that is dependent on the 
toxin brefeldin A (BFA), to understand how it affects C-terminal binding 
protein 1 (CtBP1) functions, as described in Chapter 3. On the other side, I 
analysed intracellular ADP-ribosylation, with particular focus on the enzyme 
PARP 12, as described in Chapter 4. 
Thus, after this general introduction to ADP-ribosylation, I will now 
introduce the current knowledge on BFA-dependent ADP-ribosylation and the 
target of this modification: CtBPI, or BFA-dependent ADP-ribosylated 
substrate (CtBP1/BARS). This introduction will be instrumental to the 
understanding of the results I describe in Chapter 3. 
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Figure 1.10: ADP-ribose binding modules 
Summary of the three poly-ADP-ribose-binding domains that have been described. 
Additional domains might exist that can read the modifications. See text for details. 
PAR, poly-ADP-ribose; PBZ, poly-ADP-ribose- binding zinc finger. 
Adapted from Kleine et al. (2009). 
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1.5.1 Brefeldin A 
BFA is a macrocyclic lactone that is synthesised from palmitate by a variety of 
fungi, and its structure is shown in Figure 1.11. BFA induces a rapid and 
reversible block of secretion (Fujiwara et al., 1988), and for this reason it has 
been widely used to analyse the mechanisms of membrane transport. The best 
known effects of BFA are a dramatic morphological reorganisation of the 
Golgi complex and redistribution of both resident and cargo proteins from the 
Golgi complex to the endoplasmic reticulum (ER) (Doms et al., 1989; Fujiwara 
et al., 1988; Lippincott-Schwartz et al., 1989; Sciaky et al., 1997). However, 
BFA also affects the morphology and function of the endosomal/ lysosomal 
compartments (Lippincott-Schwartz et al., 1991). The redistribution of the 
Golgi proteins induced by BFA is very rapid, occurring in a few minutes, and it 
is completely reversible (Doms et al., 1989). The effects of BFA are caused, at 
least in part, by the release of a set of proteins from the Golgi complex, which 
includes two major non-clathrin coat proteins, ß-COP, a component of the 
cytosolic protein complex coatomer, and ADP-ribosylation factor (ARF; a 
small Ras-like GTPase) (Donaldson et al., 1991; Donaldson et al., 1990). As 
with the other small GTPases in the cell, the regulatory activity of ARF is 
through its continuous switching between its GTP-bound and GDP-bound 
forms. In its GTP-bound state, ARF is active and membrane bound, and it 
mediates the assembly of the coats on membranes. In its GDP-bound state, 
ARF is inactive, and dissociates from membranes, and thus these membrane 
coats are disassembled. The activity of ARF is in turn regulated by two factors 
that determine the rate of guanine nucleotide exchange (guanine nucleotide 
exchange factors; GEFs) and the rate of hydrolysis of GTP 
96 
Introduction 
OH 
HO u" BFA 
Figure 1.11: Structure of brefeldin A 
BFA is a macrolide antibiotic that is produced by fungal organisms such as 
Eupenicillium brefeldianum. It is a potent inhibitor of membrane trafficking and 
vesicular transport. It induces disassembly of the Golgi complex and retrograde 
transport of Golgi proteins back to the endoplasmic reticulum, thereby blocking 
transport and secretion. 
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(GTPase activating proteins; GAPs) (Barlowe, 2000; Donaldson and Jackson, 
2000). All of the GEFs share a conserved 200-amino-acid domain, known as 
the Sec7 domain, which catalyses the GTP/GDP exchange on ARF (Peyroche 
et al., 1999). 
As demonstrated by Payroche and co-workers, BFA acts as an 
uncompetitive inhibitor for the ARF GEF; thus, rather than binding to the Sec7 
domain of the GEF for ARF, BFA binds to the transient ternary complex 
formed by ARF, GDP and the Sec7 domain, and it stabilises this complex. 
Therefore, BFA forms a stable abortive complex with ARF and its exchange 
factor, which will also remove exchange factor molecules from exchange 
reactions with other ARF molecules, i. e. BFA makes endogenous ARF-GDP 
behave as a `dominant negative' (Peyroche et at., 1999). 
BFA has also been described as a toxin that can affect the ADP- 
ribosylation of endogenous eukaryotic proteins (De Matteis et al., 1994): 
GAPDH and a protein of 50 kDa, that in his context was named as BARS 
(BFA-ADP-ribosylated substrate). This BARS was later identified as a member 
of CtBP family: CtBPI-S (short-form) (Spano et al., 1999). To date, this BFA- 
dependent ADP-ribosylation mechanism has not yet been fully characterized, 
and indeed, it constitutes a part of my findings. 
A more detailed description of the CtBP protein family is reported in 
the next sections. 
1.5.2 The CtBP family 
The CtBP family of proteins are modulators of several essential cellular 
processes. Invertebrate and plant genomes contain only a single copy of the 
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Figure 1.12: The CtBP family proteins 
Schematic representation of the sequences of the CtBP family of proteins. CtBPI-L 
and CtBP I -S/BARS are the alternative splice variants of the CtBP 1 gene; CtBP2-L, 
CtBP2-S and Ribeye are alternative splice variants of the CtBP2 gene. The region 
conserved in all of the CtBPs is shown in dark blue; this includes a dehydrogenase 
homology region (D2-HDH) that has a weak but significant similarity to the 
D-stereoisomer-specific 2-hydroxyacid NAD-dependent dehydrogenases (Nardini et 
al., 2003). CtBP2-L is the only isoform of the CtBPs that has a nuclear localisation 
signal (NLS, green) (Verger et al., 2006). 
441 
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CtBP gene (Folkers et al., 2002; Nibu et al., 1998), which code for different 
isoforms as a result of its RNA processing (Mani-Telang and Arnosti, 2007). In 
contrast, vertebrates have two CtBP-encoding genes, CtBP1 and CtBP2. As a 
result of alternative RNA splicing, the CtBP1 gene gives rise to two protein 
isoforms: CtBPI-L (long) and CtBPI-S (short) (Chinnadurai, 2003; Corda et 
al., 2006), which differ only in their first 11 N-terminal amino acids (Figure 
1.12). CtBP1-L was identified as a protein that binds the C-terminal region of 
the adenovirus E1A oncoprotein (Boyd et al., 1993; Schaeper et al., 1995), 
which contains the PLDLS amino acid sequence and subsequently 
characterised as a transcriptional co-repressor in Drosophila (dCtBP) (Nibu et 
al., 1998). Later, the short isoform of CtBP1 was first identified as a substrate 
of the ADP-ribosylation induced by the fungal toxin BFA, and hence it was 
named as BARS (De Matteis et al., 1994). Soon after, BARS was shown to be 
a member of CtBP family, and to have important roles in membrane fission 
(Weigert et al., 1999). However, the observation that CtBPI-L behaves 
similarly to CtBPI-SEARS in different intracellular transport assays (Corda et 
al., 2006; Liberali et al., 2008) indicates that their functions are very likely to 
overlap, also because most of the tools used in different assays do not 
discriminate between these two isoforms (Valente et al., 2005). Moreover, 
since the identity between the two CtBPI isoforms is very high and the role of 
the 11 amino acids at the N-terminus of CtBPI-L has not been characterised, I 
will refer to both proteins collectively as CtBP1BARS. 
The CtBP2 gene codes for three protein isoforms: CtBP2-L (Katsanis 
and Fisher, 1998) and CtBP2-S (Verger et al., 2006), which share 80% identity 
with the CtBPI isoforms, and RIBEYE (Schmitz et al., 2000). CtBP2-S lacks 
100 
Introduction 
the N-terminal nuclear localisation signal (NLS) of CtBP2-L (Verger et al., 
2006). RIBEYE has a different organisation, as it contains a large N-terminal 
domain that is otherwise unrelated to the CtBPs. This is linked to a form of 
CtBP2 that is devoid of the 20 N-terminal amino acids (Schmitz et al., 2000). 
Therefore, CtBP2-L is the only CtBP isoform that contains a NLS (Figure 
1.12). 
The major splice variants of both CtBP 1 and CtBP2 (i. e. CtBP 1-L and 
CtBP2-L) function as transcriptional co-repressors, while CtBP I -SEARS and 
RIBEYE have cytosolic functions, controlling different aspects: CtBP1BARS 
has a role in membrane fissioning events, while RYBEYE has a role in 
synaptic function (Corda et al., 2006). 
The two different functions of CtBP1BARS are tightly regulated by 
post-translational modifications as well by the presence of co-factors, and these 
mechanisms are strictly related to its structure. In the following sections, I will 
describe the structure of CtBPIBARS, and thence its regulation, and finally 
the functions in which it is involved (the co-repressor functions and the 
fissioning functions). As to date there is no direct evidence that CtBP1 and 
CtBP2 have different functions in the nucleus, for the description of the co- 
repressor activity I will refer to both of these proteins as CtBP. 
1.5.2.1 CtBP 1 BARS structure 
To delineate the structural basis of the transcriptional co-repressor and/or 
fissioning activities shown by CtBPI/BARS, the truncated form of the rat 
protein (devoid of the 80, mostly hydrophobic, C-terminal residues) was 
crystallised with NAD(H) (Nardini et al., 2003). Its structure is very similar to 
those of the D-stereoisomer-specific-2-hydroxyacid NAD-dehydrogenases 
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(Kumar et al., 2002), with which CtBP1BARS shares <20% sequence identity 
(Nardini et al., 2003). The CtBP1/BARS: NAD(H) binary complex forms an 
elongated homodimer in which each CtBP1BARS monomer consists of two 
compact domains that are separated by a deep cleft. In accordance with the 
literature on enzymes with similar structures (Kumar et at., 2002), the two 
domains are referred as the nucleotide-binding domain (NBD; residues 113- 
308) and the substrate-binding domain (SBD; residues 1-112 and 309- 350). 
NBD contains all of the residues for NAD+ binding, while SBD contains the 
binding cleft for the PxDLS sequence (Nardini et al., 2003). The central core of 
the dimer is built around two NBDs, whereas the two SBDs are at opposite 
poles of the assembled dimer (Figure 1.13). 
Structural modelling and binding studies have shown that CtBP1BARS 
can bind NAD(H) and long-chain acyl-CoAs through the same site. This 
structural analysis suggested that NAD(H) binding promotes a `closed 
conformation/ dimerisation' of CtBP1BARS, whereas acyl-CoA binding 
induces an `open conformation/ monomerisation' (Nardini et al., 2003; Nardini 
et al., 2009). This mechanism might represent a functional molecular switch 
between the transcriptional activity and fissioning activity of the CtBP1BARS 
proteins. Indeed, the activity of CtBP1BARS in transcription and in membrane 
fissioning is regulated in different ways, and one of these is through the 
presence of different co-factors. 
The description of the various mechanisms mediating the functional 
switch of the CtBPs is reported in the next section. 
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Figure 1.13: The structure of CtBPI-S/BARS 
Ribbon diagram of a truncated form of CtBPI-S/BARS (lacking the C-terminal 
segment; t-CtBPI-S/BARS) as a dimer bound in its interdomain cleft to NAD(H) 
(shown in black). Light/dark green, substrate binding domain (SBD); orange/red, 
nucleotide binding domain (NBD). The light/dark colouring illustrates the 
individual CtBP 1-S/BARS molecules. 
From Nardini et al. (2003). 
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1.5.2.2 Mechanisms of the CtBP1BARS functional switch 
Proteins that show switches between two roles are often connected to changes 
in intracellular localisation, oligomerisation state, binding to different ligands 
and/or proteins, or post-translational modifications (Jeffery, 2004). CtBP also 
shows similar behaviour, as it appears to shuttle between the nucleus and the 
cytoplasm, and it is probably the regulation of this movement that controls the 
functions of this protein (Figure 1.14). This regulation is assured by post- 
translational modifications, as well by co-factor binding and protein-protein 
interactions, an issue analysed in the next sections. 
CtBPI/BARS regulation by co-factors 
As mentioned above, structural and biochemical analyses indicate that 
CtBP1BARS binds both acyl-CoAs and NAD(H) in the same pocket (Nardini 
et al., 2003) and that this event can induce a structural change that appears 
connected to the change in CtBP1BARS functions. Accordingly, it has been 
suggested that the CtBP1 conformational changes upon NAD(H) binding are 
propagated to the N-terminus, and that this event promotes binding to PxDLS- 
containing proteins. Therefore, NAD(H) stabilises the dimer, and the 
interaction with PxDLS-containing proteins is increased. At the same time, the 
effect of NAD(H) is also to decrease the interaction between some non- 
PxDLS-containing proteins and the CtBP1BARS (Mimezami et al., 2003). 
Therefore, it has been suggested that the structural changes induced by elevated 
levels of NADH have opposing effects on the interactions of PxDLS- 
containing and non-PxDLS-containing proteins with CtBP1/BARS (Mirnezami 
et al., 2003). These results suggest that NAD(H) can 
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Figure 1.14: Regulation of the nuclear/ cytoplasmic activities of CtBP1 
CtBP 1 is a multitasking protein that is involved in several cellular functions that depend on 
its cellular localisation. In the nucleus, where SUMOylated CtBPI is found, CtBP1 can act 
as a transcriptional corepressor. Here, CtBP I can form oligomers and regulate the assembly 
of multiprotein complexes that are involved in the regulation of transcription. The 
oligomerisation of CtBPI is also stabilised by NAD(H) binding, which in turn enhances the 
CtBPI-mediated repression of some genes (e. g. E-cadherin). With its nuclear localisation 
signal, CtBP2 binding by CtBP1 can direct CtBPI to the nucleus as well, implying that a 
mechanism for nuclear localisation of CtBPI might depend on its heterodimerisation with 
CtBP2. In the nucleus, CtBP I is also phosphorylated by PKA. This phosphorylation results 
in dimerisation of CtBPI, reducing its corepressor function. In the cytoplasm, where CtBP1 
that has been phosphorylated by PAKI is found, CtBPI can act in membrane fission and is 
involved in several dynamin- independent membrane- fissioning steps: fragmentation of the 
Golgi complex (GC) membranes during mitosis; transport of the cargo reporter VSVG from 
the TGN to the basolateral plasma membrane in epithelial cells; fluid-phase endocytosis; 
macropinocytosis and COPI-vesicle-mediated retrograde transport of the KDEL receptor. 
Like PAKI, PAK6 phosphorylates CtBPI, which inhibits its dimerisation and thus blocks its 
corepressor activities. AcylCoA binding is required for CtBPI-dependent membrane 
fissioning, while nNOS binding to the CtBP I PDZ domain can regulate the cytosolic CtBPI 
localisation. ER, endoplasmic reticulum; N, nucleus; P, phosphorylation. 
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modulate protein-protein interactions through its regulation of the 
oligomerisation state of CtBPI. Interestingly, the interactions between 
CtBPI/BARS and PxDLS-containing cellular repressors appear to be enhanced 
in the presence of NAD(H) more than in the presence of NAD+ (Zhang et al., 
2002), thus suggesting a role for CtBPl/BARS as a sensor linking cellular 
metabolic status to transcriptional regulation (Fjeld et al., 2003). Accordingly, 
experimental conditions that increase the NAD(H)/NAD+ ratio, such as 
hypoxia or hypoxia-mimicking environments, enhance the CtBP 1-mediated 
repression of E-cadherin as a result of increased interactions with cellular 
repressors such as ZEB (Zhang et al., 2002). Consistent with results on E- 
cadherin repression, hypoxia has been reported to increase tumour-cell 
migration due to decreased E-cadherin expression (Zhang et al., 2006). 
From the opposite site, NAD(H) binding to CtBPl/BARS inhibits its 
membrane fission function (Yang et al., 2005). Indeed, the role for 
CtBPl/BARS in COPI-coated vesicle formation requires its interaction with 
ARFGAPI, which is in turn oppositely regulated by acyl-CoAs and NAD(H). 
Acyl-CoAs, the other co-factors in the regulation of CtBP/BARS function, 
favours the interactions between CtBPl/BARS and ARFGAPI, which 
promotes membrane fissioning, while NAD(H) inhibits this interaction, and 
thus negatively modulates the CtBPl/BARS activity during the fissioning of 
COPI vesicles (Yang et al., 2005). Structural and biochemical analyses indicate 
that CtBPl/BARS binds acyl-CoAs in the same pocket where NAD(H) is 
bound, with an affinity in the low pM range, and both NAD(H) and NAD+ are 
competitors of this binding (Nardini et al., 2003). Additionally, CtBP 1 BARS- 
dependent membrane fission is inhibited more potently in the presence of 
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NADH than in the presence of NAD+ (Victor Hsu, personal communication), 
and similar to what has been proposed for the co-repressor activity, this effect 
would link the metabolic status of the cell not only to transcriptional 
regulation, but also to membrane trafficking. 
CtBP 1 BARS regulation by protein-protein interactions 
The cytoplasmic and nuclear localisation of CtBP1BARS can also be 
regulated by its interactions with other proteins, including CtBP2 and neuronal 
nitric-oxide synthase (nNOS). It has been shown that CtBP 1 and CtBP2 can 
homodimerise and heterodimerise, and indeed they can be co-purified in the 
same transcriptional co-repressor complex (Shi et al., 2003). As indicated 
above, CtBP2 has a unique first coding exon (absent in CtBP 1-SBARS) that 
contains a NLS (Figure 1.12). However, CtBP2 not only localises to the 
nucleus, but it can also shuttle between the nucleus and the cytoplasm. 
Interestingly, expression of CtBP2 can direct CtBP I BARS to the nucleus: this 
implies that the mechanism for nuclear localisation of CtBPI might depend on 
its heterodimerisation with CtBP2 (Verger et al., 2006). 
Conversely, CtBPI/BARS can also interact with nNOS, through the 
PDZ domain of nNOS. Interestingly, when CtBP1BARS and nNOS are co- 
overexpressed in epithelial cells, their distributions are mainly cytosolic. These 
data suggest a function for nNOS as a regulator of the nuclear/ cytosolic 
localisation of CtBPI/BARS (Riefler and Firestein, 2001). 
CtBP 1BARS regulation bypost-translational modifications 
The shuttling of CtBP 1 between the nucleus and the cytoplasm is also 
controlled by post-translational modifications (Figure 1.14), namely 
phosphorylation and sumoylation. CtBP can be phopshorylated by p21- 
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activated kinase 1 (PAK1), an ubiquitous kinase that is involved in several 
cellular functions, including signalling, regulation of cytoskeletal dynamics, 
and membrane trafficking. PAK1 phosphorylates CtBP1-L at Ser158 and 
CtBPl-SBARS at Ser147 (Barnes et al., 2003; Liberali et al., 2008). 
PAK1-mediated CtBPl/BARS phosphorylation can trigger the change 
in the CtBP1 cellular localisation, from the nucleus to the cytoplasm. A 
phospho-mimetic CtBPl/BARS mutant localises mostly to the cytosol, 
whereas a phospho-depleted mutant localises predominantly to the nucleus 
(Barnes et al., 2003; Liberali et al., 2008). Moreover, phosphorylation blocks 
CtBPl/BARS co-repressor activity (Barnes et al., 2003). Molecular dynamics 
simulation studies have suggested that PAK1-dependent phosphorylation on 
the serine 147 could change the oligomerisation status of CtBP 1 BARS, 
shifting it towards the monomeric state (Liberali et al., 2008). In addition to 
PAK1, PAK6 can also phosphorylate CtBP1-L at SerlOO (Ser89 on CtBPl- 
SEARS). As with PAK1-dependent phosphorylation, this phosphorylation is 
predicted to sterically interfere with CtBPl/BARS dimerisation, blocking the 
co-repressor activities (Dammer and Sewer, 2008). The phosphorylation of 
CtBPl/BARS by PAK1 might provide a mechanistic link between the two 
activities of CtBP1BARS: PAKI switches CtBP1BARS on for membrane 
fissioning, and at the same time it turns it off as a co-repressor. Indeed, the 
findings of Liberali and co-workers suggested the following model for 
membrane fission driven by CtBP1BARS: membrane-associated 
CtBPl/BARS is phosphorylated by PAK1, and through this phosphorylation, 
the stability of the dimeric conformation is reduced in favour of the monomeric 
state. The same dimer-monomer shift is believed to be induced by binding to 
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CtBP1BARS of the acyl-CoA co-factor, which is involved in fissioning of 
COPI-coated vesicles (Nardini et al., 2003; Yang et at, 2005). Thus, PAK1- 
dependent phosphorylation and acyl-CoA binding potentially act 
synergistically to promote the monomeric form of CtBP1BARS. These 
monomers might facilitate fissioning by either binding new protein partners in 
the forming fission complex, or by exposing hydrophobic residues that can 
then participate directly in the final destabilisation (Liberali et al., 2008). 
The other modification is the SUMOylation of CtBP. This is essential 
for the localisation of CtBP 1 in the nucleus and for its co-repressor activity 
(Lin et al., 2003). CtBP1-LBARS is SUMOylated at a single Lys residue, 
Lys428 (Lys418 in CtBP 1-SEARS); indeed mutation of Lys428 into Arg 
(K428R) shifts CtBP1-L from the nucleus to the cytoplasm, while it has little 
effect on its interaction with PxDLS-containing proteins. Consistent with a 
change in localisation, this K428R mutation abolishes CtBP1 repression of E- 
cadherin expression. Notably, the PDZ domain of nNOS inhibits SUMOylation 
of the CtBP1s, which correlates with the known inhibitory effects of nNOS on 
nuclear accumulation of the CtBP1s (Lin et al., 2003). This study identifies 
SUMOylation as a regulatory mechanism underlying CtBP1BARS-dependent 
transcriptional repression. 
1.5.2.3 The dual role of CtBP 
CtBP as a co-repressor 
A large number of specific DNA-binding transcriptional repressors mediate 
their activity through the recruitment of CtBP. An exception is the case of the 
C. elegans homologue that binds directly to promoter regions via its N-terminal 
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domain (Liew et at., 2007). The various DNA-binding repressors recruit CtBP 
through motifs related to the CtBP-binding sequence motif (PLDLS) that was 
originally identified in the adenovirus E1A protein, which is generally referred 
to as the PxDLS motif (Schaeper et at., 1995). In addition to the PxDLS motif, 
certain transcription factors use a different domain to interact with CtBP, the 
RRT motif (Quinlan et at., 2006a). Importantly, most of the known RRT-motif- 
containing proteins also contain PxDLS motifs, and thus it is possible that the 
RRT motif has a role in stabilising PxDLS-mediated interactions (Quinlan et 
at., 2006a; Quinlan et al., 2006b). 
Structural analyses have shown that CtBPs can oligomerise (Kumar et 
at., 2002; Nardini et at., 2003; Nardini et al., 2006) and that this is crucial for 
their co-repressor activity (Kumar et al., 2002; Shi et al., 2003). Thus, each 
CtBP oligomer contains multiple PxDLS-binding and RRT-binding motifs, 
which would allow CtBP to bridge two (or more) PxDLS-motif-containing 
partners. However, a number of CtBP partners, including some histone- 
modifying enzymes, do not have PxDLS motifs and probably bind to a 
different surface of CtBP (Shi et at., 2003). An example here is the neuronal 
repressor NRSF/REST, which does not contain any of these motifs, but which 
still binds CtBP to repress transcription of neuronal genes (Garriga-Canut et 
at., 2006). 
Thus, as a general scheme, it can be envisaged that CtBP functions in 
the assembly of a multi-protein repressor complexes involved in the 
modulation of gene expression. Indeed, an analysis of a CtBP1BARS nuclear 
protein complex purified by tandem affinity purification combined to mass 
spectrometry has revealed the presence of various histone-modifying 
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enzymatic constituents as well as DNA-binding transcription factors (Shi et al., 
2003), such as ZEB 1 /2, RREB-1 and Znf217, all of which are implicated in 
direct binding to promoter elements. All of these DNA-binding factors appear 
to directly interact with CtBP through the PxDLS motif (ZEB1/2 and RREB-1) 
or through PxDLS/RRT motifs (Znf217). Additionally, the complex contained 
enzymes involved in the modulation of chromatin structure, such as HDAC 1/2, 
histone lysine methyl transferases (HMTases G9a and GLP) and histone lysine- 
specific demethylase (LSD1). The class I HDACs do not have apparent CtBP- 
binding motifs and have been reported to bind indirectly to CtBP through the 
presence of other co-repressors, including CoREST. In contrast to class I 
HDACs, class II HDACs are directly recruited through the PxDLS motif 
(Zhang et al., 2001). The involvement of HDACs, however, is not the only 
route of action of CtBP; indeed, CtBP in vertebrates can also function in an 
HDAC-independent manner, depending on the different promoter contexts. In 
this regard, different studies have identified several factors of the RNA 
polymerase II transcription machinery as potential PxDLS-motif-containing 
proteins. These include various bromodomain-containing HAT coactivators, 
such as p300/CBP, GCN5 and P/CAF, as well as TAFII and TAFII-250. Kim 
and co-workers (Kim et al., 2005) demonstrated that CtBP1BARS directly 
associates to p300 by binding the PxDLS motif found in the p300 
bromodomain. P300 is a member of the HAT family of transcriptional 
coactivators, and it is required for gene activation through its acetylation of 
histones in the promoter regions of target genes. The authors demonstrated that 
the binding of CtBP1BARS to p300 leads to repression of p300-mediated 
general transactivation, since CtBP1 competes with the binding of p300 to 
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acetylated histones (the PxDLS motif is found in the bromodomain of p300, a 
domain that is important for the binding to acetylated histones), thus impairing 
transcription. 
Additionally, the SUMO moiety attached to CtBP might serve as a 
potential binding site for class II HDACs (Hay, 2005). Sumoylation might also 
regulate interactions between CtBP and its interacting proteins. For example, it 
has been demonstrated that ZEB1/2 are SUMOylated near the PxDLS motif, 
thus interfering with CtBP binding. Thus, SUMOylation might serve as a 
mechanism in the regulation of the subunit composition of the CtBP repression 
complex. 
CtBP in onco enesis 
A comprehensive gene expression profiling study using CtBP-null mouse 
embryo fibroblasts (MEFs) and CtBPI-rescued MEFs revealed co-repression 
of several epithelial genes and pro-apoptotic genes by CtBP, including PERP 
(p53-effector related to pmp-22), p21, BAX and NOXA (Grooteclaes et al., 
2003). Additionally, PTEN, a phosphatase and a negative regulator of the 
survival kinase Akt, was also identified as a CtBP repression target. Consistent 
with these results, the CtBP-null MEFs were found to be hypersensitive to 
anoikis (a form of apoptosis mediated by the loss of contact from the ECM) 
and apoptotic stimuli, such as Fas ligand and UV. These results show that by 
repressing expression of epithelial cell adhesion molecules (such as E-cadherin, 
desmoglein-2 and plakoglobin) and pro-apoptotic genes, CtBP contributes to 
epithelial-to-mesenchymal transition (EMT). This represents a step that 
contributes to the malignant property of tumour cells, due to the loss of 
intercellular adhesion in tumours, acquisition of motile and invasive 
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phenotypes, and resistance to apoptosis. The role of CtBP in EMT may be 
particularly critical in cancers that overexpress Zebl (e. g., breast, colon, and 
endometrial). Indeed, Zeb 1 overexpression with concomitant E-cadherin 
repression has been reported in several human cancers. Studies with colon 
carcinomas have revealed that high levels of Zeb 1 and CtBP were correlated 
with low levels of E-cadherin (Pena et al., 2006). 
CtBP-mediated transcriptional repression of E-cadherin appears to be 
regulated by the hypoxic environment seen in solid tumours with poor 
vascularisation and high metabolic activity. According to the regulation of 
CtBP by co-factors, it has been shown that hypoxic conditions, by increasing 
free NADH levels (Zhang et al., 2002), enhance recruitment of CtBP to the E- 
cadherin promoter; this leads to enhanced motility of tumour cells (Zhang et 
al., 2006). Cell motility can be reduced by siRNA-mediated depletion of CtBP, 
which suggests that this effect is independent of HIF-1 or other E-cadherin 
repressors. CtBP also modulates the expression and activities of the Ink4 
family tumour suppressors. The Ink4 region codes for three different cell-cycle 
inhibitors, pl61nk4a, Ink4a/Arf and pl5lnk4b. Rocco and colleagues (Mroz et 
al., 2008) have reported that expression of E1A in primary human fibroblasts 
and keratinocytes resulted in a substantial increase in pl61nk4a expression. The 
effect of ElA on p161nk4a expression was lost in cells that expressed a mutant 
of E1A that lacked the CtBP-binding motif, or in cells depleted of CtBP, 
suggesting that interactions of ElA with CtBP were responsible for this 
activity. 
Moreover, three different groups have reported on strong interactions 
between CtBP and another tumour suppressor, adenomatous polyposis coli 
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(APC) (Hamada and Bienz, 2004; Nadauld et al., 2006; Sierra et al., 2006). 
One of these reports (Nadauld et al., 2006) provided compelling evidence that 
APC can function as a platform for proteasome-dependent degradation of 
CtBP1, in addition to regulating the stability of ß-catenin. This view was 
supported by the observation that adenomas from patients with familial 
adenomatous polyposis contained high levels of CtBP 1 compared to healthy 
samples. Furthermore, reintroduction of APC in colon carcinoma cell lines also 
resulted in degradation of CtBP 1. These results received strong support from a 
zebrafish model harbouring a mutant form of APC and expressing high levels 
of CtBP 1 (whereas CtBP 1 mRNA levels remained unchanged). These data are 
consistent with a model in which APC targets both ß-catenin and CtBP 1 
simultaneously, to inhibit expression of Wnt target genes and to relieve 
repression of CtBP target genes that are involved in intestinal cell 
differentiation. 
CtBP1BARS in membrane fission 
The study of CtBP 1 BARS in membrane fission in vivo have revealed that this 
protein is an essential component of dynamin-independent trafficking steps. 
Indeed CtBP1BARS has been shown to have a role in different fissioning 
steps of various trafficking processes: transport from the Golgi complex to the 
basolateral membrane in epithelial cells (Bonazzi et al., 2005), (Valente et al., 
in press), fluid phase endocytosis, retrograde transport of the KDEL receptor to 
the endoplasmic reticulum by COPI-coated vesicles (Yang et al., 2005) and 
macropinocytosis (Liberali et al., 2008). These transport events do not require 
dynamin, and indeed several dynamin-dependent transport processes, like 
apical transport to the plasma membrane and receptor-mediated endocytosis, 
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do not require CtBP 1 BARS. This indicates that dynamin and CtBP 1 BARS 
drive non-overlapping fissioning machineries. Moreover, CtBP1BARS 
fissioning also regulates Golgi fragmentation during mitosis (Colanzi et al., 
2007; Hidalgo Carcedo et al., 2004). A brief description for each processe is 
provided as follows. 
Post-Golgi carrier formation 
During the trafficking of cargo from the trans-Golgi network (TGN) to the 
basolateral plasma membrane, large pleiomorphic tubular carriers elongate out 
of the Golgi complex along microtubules, before detaching and moving to the 
plasma membrane. When CtBP1/BARS function is inhibited, these tubules do 
not detach from the Golgi complex, but continue to elongate out and retract 
back into the Golgi complex. Thus, under these conditions, the fissioning step 
of post-Golgi carrier formation is inhibited (Bonazzi et al., 2005). Recently, the 
function of the fissioning protein CtBP1BARS in post-Golgi carrier formation 
has been elucidated (Valente et al., in press). Using CtBP1BARS as bait in 
affinity purification approaches, followed by mass spectrometry, Valente and 
co-workers described a protein complex that contains both budding and 
fissioning molecules already known to have crucial roles in carrier formation, 
as well as novel players, such as the adaptor protein 14-3-3y. The authors 
demonstrated that 14-3-3y dimers bridge the fission-inducing protein 
CtBP1BARS and ARF- activated PI4KIIIP (the probable initiator of the 
transport process). This complex is stabilised by reversible phosphorylation, 
which is mediated by two of the other CtBP1BARS complex components 
identified: protein kinase D and p21-activated kinase (PAK) kinases, which 
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phosphorylate Ser294 in PI4KIIIß and Ser147 in CtBPIBARS, respectively, 
thus enabling carrier fission. Disrupting this complex inhibits fissioning of 
elongating carrier precursors, indicating that the complex couples budding with 
fission. The regulated assembly of this complex provides new insights into the 
mechanisms of action of CtBP1BARS and the molecular organisation required 
for the formation of large pleiomorphic carriers. 
COPI-coated vesicle formation 
COPI-coated vesicles mediate retrograde transport of the KDEL-receptor from 
the Golgi complex to the ER. When CtBP1BARS function is inhibited, COPI- 
coated vesicles bud, but do not detach from the Golgi cisternae in vivo and 
from Golgi membranes in vitro (Yang et al., 2005). This role of CtBP1BARS 
requires its interaction with ARFGAPI, which is in turn regulated oppositely 
by acyl-CoAs and NAD(H). 
Fluidphase-endocytosis 
This is the least-well-characterized CtBPI/BARS-dependent fissioning event. 
Constitutive fluid-phase endocytosis monitored by dextran uptake is inhibited 
by CtBPI/BARS impairment (Bonazzi et al., 2005). 
Macropinocytosis 
This form of endocytosis (bulk uptake of fluid and solid cargo) results in the 
formation of large endocytic vesicles, called macropinosomes, which originate 
from actin ruffles at the plasma membrane. This ruffling is followed by 
invagination of the plasma membrane and formation of the macropinocytic 
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cup, which then undergoes fissioning of its junction with the plasma membrane 
(Swanson and Watts, 1995). Inhibition of CtBP1/BARS, e. g., by injection or 
expression of a dominant-negative mutant, did not affect macropinocytic cup 
formation, which formed normally, but this did inhibit the membrane fission 
that was required for macropinosome closure, again underlining the specific 
CtBPI-SEARS role in membrane fissioning (Liberali et al., 2008). 
Golgi fragmentation duringmitosis 
During the G2-mitosis transition, the Golgi ribbon is first fragmented into 
isolated stacks of cisternae, and then further fragmented into tubulo-vesicular 
elements. These elements are separated into the two main pools that constitute 
the new Golgi complexes in the daughter cells. CtBP1BARS is necessary for 
the first stage of this fragmentation. Inhibition of CtBPl/BARS by 
microinjection of a blocking antibody results in inhibition of mitotic Golgi 
partitioning and arrest of the cell cycle at the G2 stage (Colanzi et al., 2007; 
Hidalgo Carcedo et al., 2004). 
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1.6 My findings 
In the previous sections I have described what ADP-ribosylation is and its `use' 
by toxins and by cellular enzymes, for the modulation of cell functions. I have 
explored both of these aspects (as described in Chapters 3 and 4). In particular, 
on the one hand, my project was focused on the study of the BFA-dependent 
ADP-ribosylation reaction, to understand how this affects CtBPI functions, 
thus describing a novel mechanism in CtBP1/BARS regulation; on the other 
hand, I have analysed intracellular ADP-ribosylation, focusing on the enzyme 
PARP12. My results demonstrate that PARP12 is a novel mART, and through 
the identification of its substrates, this suggests new roles for ADP-ribosylation 
in the regulation of cellular functions. 
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CHAPTER 2: Materials and Methods 
2.1 Materials 
DL-dithiothreitol (DTT), bovine serum albumin (BSA), saponin, Tris- 
[hydroxymethyl]-aminomethane (iris), ethylene glycolbis(beta- 
aminoethylether)-N, N, N', N'-tetraacetic acid (EGTA), 
ethylenediaminetetraacetic acid (EDTA), H2PO4, Na2HPO4, KH2PO4, sucrose, 
brefeldin A (BFA), reduced L-glutathione, Igepal, and sodium deoxycholate 
were all from Sigma-Aldrich (WI, USA). NaCl, HC1, NaOH, KOH, 
dimethylsulphoxide (DMSO), acetone, ethanol, methanol, chloroform, xylene 
cyanol, and bromophenol blue were all from Carlo Erba (Italy). 4-(2-Hydroxy- 
ethyl)-piperazine-l-ethane-sulfonic acid (HEPES), glycerol, KCI, HgC12, and 
MgC12 were all from Merck (Germany). C-mercaptoethanol was from Fluka- 
Analytical (Switzerland). Mowiol was from Calbiochem (CA, USA). 
Paraformaldehyde (16% in H2O) was from Electron Microscopy Sciences (PA, 
USA). The sources of the other materials used will be specified for each 
procedure. 
2.2. Solutions 
Phosphate-buffered saline (PBS): 1.5 mM KH2PO4,8 mM Na2HPO4,2.7 mM 
KCI, 137 mM NaCl, pH 7.4. 
Paraformaldehyde (16%, v/v) was diluted in PBS, pH 7.4, to the appropriate 
concentrations (as indicated), and stored at 4 °C. 
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The blocking solution for immunofluorescence experiments was prepared as 
follows: 0.5% (w/v) BSA, 50 mM NH4CI in PBS, pH 7.4. Saponin was added 
to the preparation to 0.05% (w/v). Aliquots of this blocking solution were 
stored at -20 °C. 
2.3 Subcloning and mutation of DNA 
2.3.1 Materials 
Restriction enzymes were from New England Biolabs (USA), T4 DNA ligase 
and DNA molecular size standards were from Gibco/BRL (NY, USA), 
oligonucleotides and Pfu Turbo DNA Polymerase were from Stratagene (CA, 
USA); pcDNA3. I /myc-His vector was from Invitrogen (Carlsbad, CA, USA), 
untagged full-length PARP12 cDNA cloned into pCMV6-XL5 was from 
Origene (Rockville, MD, USA). Sequencing was performed by BMR 
Genomics (Italy). 
`QlAquick PCR Purification kits', `QIAprep Spin Miniprep kits', 
`QIAGEN Plasmid Maxi kits' were from Qiagen (CA, USA). Tryptone 
peptone, yeast extract, and agar were from Difco, Becton Dickinson (MD, 
USA). 
2.3.2 Solutions and media 
Lysogeny broth (LB): 1% (w/v) tryptone peptone, 0.5% (w/v) yeast extract, 1% 
(w/v) NaCl; autoclaved 15 min at 121 °C. 
LB-agar: LB plus 1.5% (w/v) agar: autoclaved 15 min at 121 °C. 
TE (Tris/EDTA) buffer: 10 mM Tris-HCI, 1 mM EDTA, pH 8. 
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TAE (Tris/acetic acid/EDTA) buffer (50x, 1.0 1): 242 g TRIZMA base, 57.1 ml 
glacial acetic acid, 100 ml 500 mM EDTA. 
2.3.3 DNA agarose gels 
Agarose gels were prepared by dissolving agarose (Bio-Rad Laboratories, UK) 
in TAE buffer and heating in a microwave oven. Ethidium bromide was added 
(to 0.5 µg/ml), and the gels were poured and run on an agarose gel apparatus 
from Bio-Rad Laboratories (UK). DNA standards (0.5 µg) were loaded and 
used as the reference for approximate estimations of the amounts of DNA in 
the samples. 
2.3.4 DNA constructs 
GFP-tagged Rab 1A was kindly provided by Prof. Bruno Goud, Curie Institute 
(Paris, France). 
The pYFP-CtBP1BARS and its point mutant pYFP-CtBP1BARS (H304A) 
vectors were provided by Claudia Cericola, in the Laboratory of Daniela Corda 
(previously of the Departemnt of Cell Biology and Oncology [DCBO], 
Consorzio Mario Negri Sud [CMNS], Santa Maria Imbaro, Italy). Untagged 
full-length PARP12 cDNA cloned into the pCMV6-XL5 vector was purchased 
from Origene (Rockville, MD, USA). 
Myc-His-tagged PARP12 was generated by subcloning PARP12 cDNA from 
the pCMV6-XL5 vector into a C-terminal tagged pcDNA3.1/myc-His vector. 
The primers used for the PCR reactions were: 
forward primer: 5'- GTACGTAAGCTTATGGCCCAGGCCGGCGTCGT - 3' 
reverse primer: 5'- GTACGTCTCGAGCTGTCGGCTGCTGAACAGGG - 3' 
PCR reactions were performed as follows: 1 min at 95 °C, followed by 30 
cycles of 95 °C for 30 s, 65 °C for 60 s, 72 °C for 180 s, and a final extension 
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at 72 °C for 10 min. The PCR product was purified using a PCR purification 
kit, digested with HindIII/XhoI restriction enzymes and subcloned (as 
described in sections 2.3.5,2.3.6) in the HindlIl/XhoI linearised 
pcDNA3.1/myc-His vector and processed for automatic sequencing. 
The His-Myc PARP 12 vector was used to generate the PARP12 mutants (see 
section 2.3.7). 
His-tagged PARP12 and GST-tagged PARP12 were generated using Gateway 
technology (see sections 2.4.2,2.4.3). 
2.3.5 PCR amplification of DNA inserts 
To amplify specific regions of DNA inserts, PCR was performed by incubating 
10 ng DNA plasmid as a template in 50 µl20 mM Tris-HCI, pH 8.8,10 mM 
KCI, 2 mM MgSO4,10 mM (NH4)SO4,0.1% Triton X-100,0.1 mg/ml 
nuclease-free BSA, 200 nM each oligonucleotide, 200 gM each dNTP, 2.5 U 
Pfu Turbo DNA Polymerase. The PCR reaction mixtures were subjected to 25- 
30 temperature cycles in a programmable thermal cycler (MJ Research Inc., 
Massachussets, USA). The melting, annealing and elongation temperatures 
were adjusted according to the features of the templates and primers. To 
facilitate the subsequent subcloning of the PCR products, the forward and the 
reverse primers were provided with restriction sites at their 5' ends. 
2.3.6 Restriction and ligation 
DNA (vectors and inserts) was cut with 5 U/µg of the appropriate restriction 
enzymes in the buffer supplied with each enzyme. After restriction, the 
reaction mixture was loaded onto 1.0% (w/v) agarose gels; the bands of interest 
were cut from the gels with a sterile scalpel, and the DNA was extracted from 
these gel samples with the Qiaex II extraction kit (Qiagen, CA, USA), 
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according to the manufacturer instructions. The DNA was eluted in water. To 
ligate the vector and the insert, -100 ng of the vector and an -3-fold molar 
amount of the insert were incubated with 1U T4 DNA ligase in T4-DNA- 
ligase buffer (Gibco/BRL, UK), for 1-3 h at room temperature (RT). 
2.3.7 DNA mutagenesis 
The DNA (10 ng myc-His tagged PARP 12) was amplified by PCR using 2.5 U 
Pfu Turbo DNA Polymerase and 150 ng of the two synthetic oligonucleotide 
primers containing the desired mutations, as follows: 1 min at 95 °C, followed 
by 14 cycles of 95 °C for 30 s, 55 °C for 1 min, 68 °C for 16 min, and a final 
extension at 65 °C for 15 min. The melting, annealing, and elongation 
temperatures were adjusted according to the features of the template and the 
primers. After the reactions, DpnI endonuclease was added to the mixture for 1 
h at 37 °C, to digest the parental non-mutated DNA template. The products 
were checked on agarose gels and the mutations were verified by DNA 
sequencing (BMR Genomics, CRIBI, Padova, Italy). 
The primers used to generate each mutation are listed below. For each 
mutation, the forward (fw) and reverse (rev) primer names and sequences are 
reported in Table 2.1. 
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Table 2.1: Primers used for PARP12 mutagenesis. 
Stock concentrations is 100 µM. 
Oligo name Oligo sequence 
P 12-H564A-fw CGAGCGGCAGCTGTTCGCCGGCACCAGCGCCATTTTT 
P12-H564A-rev AAAAATGGCGCTGGTGCCGGCGAACAGCTGCCGCTCG 
P12-H564Q-fw CGAGCGGCAGCTGTTCCAAGGCACCAGCGCCATTTTT 
P 12-H564Q-rev AAAAATGGCGCTGGTGCCTTGGAACAGCTGCCGCTCG 
P12-1660A-fw GAACAGTGTGTCCGACCCCTCCGCCTTTGTGATCTTTGAGAAA 
P 12-I660A-rev TTTCTCAAAGATCACAAAGGCGGAGGGGTCGGACACACTGTTC 
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2.3.8 Transformation of bacteria 
The DNA plasmid of interest (10 ng of uncut plasmid, or half of a ligation 
reaction) was added to competent bacteria. After gentle mixing, the cells were 
left on ice for 30 min, and then heat shocked for 45 s at 42 °C. After the 
addition of 800 gl LB, the bacteria were incubated under continuous shaking 
(200 rpm) at 37 °C for 60 min. The bacteria were plated onto LB agar 
containing the appropriate selective antibiotic, and incubated overnight (0/N), 
at 37 °C. The next day, isolated bacterial colonies were picked and used to 
inoculate 2 ml LB containing the appropriate antibiotic. The culture was 
incubated O/N at 37 °C. Sterile glycerol (300 µl) was added to 700 gl of the 
bacterial culture, which was then stored at -80 °C. 
Unless otherwise specified, the preparation of heat-shock 
transformation-competent bacteria was carried out by Michele Santoro and 
Giuseppe Di Tullio (previously of DCBO, CMNS, Italy). 
2.3.9 Small-scale preparation ofplasmid DNA (minipreps) 
The clones obtained after the transformation of the ligation reaction were 
usually screened using minipreps and subsequent restriction analysis. Isolated 
bacterial colonies were picked and inoculated into 5 ml LB containing the 
appropriate antibiotic. After O/N growth at 37 °C under continuous shaking 
(200 rpm), 700 µl of the cultures was mixed with 300 µl 50% (v/v) sterile 
glycerol and stored at -80 °C; the rest of each culture was chilled on ice and 
centrifuged 10 min at 4,000x g. The DNA was extracted using 'QlAprep Spin 
Miniprep kits' (Qiagen, CA, USA), according to the manufacturer instructions, 
and analysed by restriction analysis and separation on agarose gels. 
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2.3.10 Large-scale preparation ofplasmid DNA (maxipreps) 
A small amount of the bacteria transformed with the plasmid of interest was 
scraped from the glycerol stock, inoculated into 2 ml LB containing the 
appropriate selective antibiotic, and grown at 37 °C under continuous shaking 
(200 rpm) for 4-6 h. This pre-culture was used to inoculate 250 ml LB 
containing the selective antibiotic. After an O/N incubation, the bacteria were 
collected by centrifugation at 6,000 rpm in a JA14 rotor (4,000x g) for 10 min 
at 4 °C and processed according to the maxi-plasmid purification protocol of 
`Qiagen Plasmid Maxi kits'. The DNA obtained was resuspended in water, 
checked on agarose gel, quantified, and stored at -20 °C. 
2.4 Gateway cloning 
The Gateway technology is a universal cloning method based on the site- 
specific recombination properties of bacteriophage lambda. It allows for the 
rapid and efficient movement of DNA sequences into multiple vector systems. 
First, the desired target DNA is amplified by PCR using primers containing 
four nucleotides (CACC) that base pair with the overhang sequence (GTGG) of 
each pENTR TOPO vector. Second, the overhang in the pENTR vector invades 
the 5' end of the PCR product, anneals to the added bases, and stabilises the 
PCR product in the correct orientation. Finally, this entry vector can be used to 
recombine into the destination vector of interest depending on the intended use. 
Gateway cloning was performed according to the manufacturer 
instructions. However, the main steps are described in the next sections. 
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2.4.1 Materials 
The pENTR vector (pENTR/SD/D-TOPO) was kindly provided by Michele 
Sallese, DCBO, CMNS, Italy. The pDEST vectors were purchased from 
Invitrogen (Carlsbad, CA, USA). The following pDEST vectors were used: 
pDEST26 (cat. no. 11809-019), pDEST15 (cat. no. 11802-014), and pDEST10 
(cat. no. 11806-015). One Shot TOP10 and DHIOBac Chemically Competent 
E. coli, LR Clonase II enzyme mix, Cellfectin II transfection reagent were from 
Invitrogen (Carlsbad, CA, USA). Gentamicin solution was from Gibco. 
Tetracycline, kanamycin and X-Gal (5-bromo-4chloro-3-indolyl-D- 
galactoside) were from Fluka-Analytical (Switzerland). 
2.4.2 Generation of pENTR PARP12 
The primers used to obtain PARP 12 blunt-end PCR products are listed below: 
Forward: CACCGCCCAGGCCGGCGTCGT 
Reverse: TCACTGTCGGCTGCTGAACAG 
For PCR amplification, Pfu polymerase from Stratagene (CA, USA) was used. 
The PCR reaction was performed as follows: I min at 95 °C, followed by 30 
cycles of 95 °C for 30 s, 55 °C for 1 min, 72 °C for 3 min, and a final extension 
at 72 °C for 10 min. The PCR product was analysed by agarose gel 
electrophoresis. The TOPO cloning reaction (to allow the insertion of the PCR 
product into the pENTR vector) was performed for 5 min at RT, according to 
the manufacturer instructions, using a 1: 1 molar ratio of PCR product: TOPO 
vector. Here, 2 gl of TOPO cloning reaction mix were used to transform One 
Shot TOP 10 chemically competent E. coli. To analyse the transformants, six 
colonies were picked, and plasmid DNA was purified and used for PCR 
analysis. PCR reactions were performed using the M13 forward primer 5'- 
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GTAAAACGACGGCCAG-3' (which hybridises onto pENTR vector) and a 
PARP12 specific reverse primer (sequence as reported above), as follows: 1 
min at 95 °C, followed by 30 cycles of 95 °C for 30 s, 55 °C for 1 min, 72 °C 
for 3 min, and a final extension at 72 °C for 10 min. The PCR products were 
visualised by agarose gel electrophoresis. Additionally, the plasmid DNA was 
sequenced. The correct clone was used to make a glycerol stock. 
2.4.3 Generation of pDEST PARPJ2 vectors 
The destination vectors used during this study were: pDEST26 (for mammalian 
expression of recombinant His-tagged PARP12), pDEST10 (for expression of 
recombinant His-tagged PARP12 with the Baculovirus expression system), 
pDEST15 (for expression of recombinant GST-tagged PARP12 in E. coli). 
The recombination reactions were carried out using the amount of 
reagents as recommended (100 ng PARP 12 recombinant pENTR and 1pl 
pDEST vectors, corresponding to 150 ng) diluted in TE buffer (Tris HCl 10 
mM, pH 8,1 mM EDTA) and using 2 pl LR Clonase II enzyme mix. The 
reaction was carried out for 1h at 25 °C. Then 1 µl proteinase K solution was 
added to each reaction, with incubation for 10 min at 37 °C. Then 1 p1 of each 
reaction mix was used to transform DH5a competent cells. Five colonies were 
picked, plasmid DNA was purified and analysed by PCR, using a PARP12 
forward primer and a T7 reverse 5'- TAATACGACTCACTATAGGG- 3' (that 
hybridises on pDEST vectors). The PCR reactions were performed as reported 
above. In the case of GST-PARP12, plasmid DNA was then used to transform 
BL2 I -DE3 cells for the production and purification of the protein. 
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2.5 Bac-to-Bac Baculovirus Expression System 
The Bac-to-Bac Baculovirus Expression System facilitates rapid and efficient 
generation of recombinant baculoviruses (Ciccarone et al., 1998). This method 
takes advantage of the site-specific transposition properties of the Tn7 
transposon to simplify and enhance the process of generating recombinant 
bacmid DNA. 
In the pDEST10 vector used in this study, the expression of the gene of 
interest (His-PARP12) is controlled by the Autographa californica multiple 
nuclear polyhedrosis virus (AcMNPV) polyhedrin (PH) promoter, for high- 
level expression in insect cells. This expression cassette is flanked by the left 
and right arms of Tn7, and also contains a gentamicin resistance gene and an 
SV40 polyadenylation signal, to form a mini Tn7. 
The second major component of the system is the DH10Bac E. coli 
strain that is used as the host for the vector of interest. DH I OBac cells contain a 
baculovirus shuttle vector (bacmid) with a mini-attTn7 target site and a helper 
plasmid. Once the vector containing the gene of interest (PARP12 recombinant 
pDEST10, in this specific case) is transformed into DHIOBac cells, 
transposition occurs between the mini-Tn7 element on the pDEST 10 vector 
and the mini-attTn7 target site on the bacmid, to generate a recombinant 
bacmid. This transposition reaction occurs in the presence of transposition 
proteins supplied by the helper plasmid. Once the transposition reaction has 
been performed, it is possible to isolate the high molecular weight recombinant 
bacmid DNA and transfect the bacmid DNA into insect cells to generate a 
recombinant baculovirus that can be used for preliminary expression 
experiments. 
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2.5.1 Generation of the His-PARP12 recombinant bacmid 
To generate the His-PARP12 bacmid, 1-2 ng plasmid DNA obtained from the 
selected His-PARP12 pDEST10 clone was used to transform 100 µl MAX 
efficiency DH1OBac chemically competent E. coli. The transformation 
conditions were similar to the conditions described in section 2.3.8, with the 
cells left at 37 °C for 4h to allow the recombination to take place. Then 100 µl 
of three 10-fold serial dilutions of the cells were plated on LB agar containing 
50 gg/ml kanamycin, 7 pg/ml gentamicin, 10 pg/ml tetracycline, 100 pg/ml X- 
gal and 40 gg/ml IPTG. The plates were incubated for 48 h at 37 °C. White 
colonies were picked for the analysis. Insertions of the mini-Tn7 into the mini- 
attTn7 attachment site on the bacmid disrupt the expression of the LacZa 
peptide, so colonies containing the recombinant bacmid are white. 
To check for the recombination, 100 ng of recombinant bacmid DNA 
were analysed by PCR using pUC/M 13 forward and reverse primers (that 
hybridise to sites flanking the mini-attTn7 site). A schematic representation is 
reported in Figure 2.1. The PCR reaction was performed as follows: 3 min at 
95 °C, followed by 30 cycles of 94 °C for 45 s, 55 °C for 45 s, 72 °C for 5 min, 
and a final extension at 72 °C for 7 min, as indicated by the Bac-to-Bac 
manufacturer instructures. The selected clone of the recombinant DHIOBac E. 
coli was used to prepare glycerol stocks. The bacmid DNA was also stored at - 
20 °C. The bacmid DNA purification was performed using PureLink HiPure 
Plasmid Maxiprep kits from Invitrogen (Carlsbad, CA, USA). 
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pDEST10 
Bacmid DNA 
Figure 2.1: PCR analysis of the recombinant BAC plasmid 
Schematic representation of PCR analysis of the recombinant BAC plasmid. 
pUC/M 13 forward and reverse primers hybridise to sites flanking the mini-attTn7 site 
of the BAC plasmid, thus allowing the amplification of the region of interest. 
Oligo name: pUC/M 13 Forward 
Sequence: 5'- CCCAGTCACGACGTTGTAAAACG-3' 
Oligo name: pUC/M13 Reverse 
Sequence: 5'-AGCGGATAACAATTTCACACAGG-3' 
Modified from the Bac-to-Bac manual, Invitrogen. 
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2.5.2 Transfection of Sf9 insect cells to generate His-PARP12 Baculovirus 
Recombinant bacmid DNA was used to transfect Sf9 insect cells using a 
Cellfectin II reagent, according to the manufacturer instructions. Briefly, 8 
X 105 Sf9 insect cells were plated for each well of a 6-well format, in 2 ml 
unsupplemented Grace's insect medium (without antibiotics and serum). The 
cells were left to attach for 15 min at RT and then transfected with 1 Rg 
baculovirus DNA, previously mixed with 8 µl Cellfectin. After 5h at 27 °C, 
the transfection mixture was removed and complete growth medium was 
added. The cells were incubated at 27 °C until signs of infection appeared (as 
described in the manual). After 6 days, the media (containing the virus) was 
recovered and stored at 4 °C. This media represented the P1 viral stock. The P1 
viral stock was used to subsequently infect Sf9 insect cells to generate a P2 
viral stock. The P2 viral stock was used at a 1: 30 dilution to infect Sf9 cells for 
His-PARP 12 production. Here, 96 h was chosen as the optimal time for the 
expression of His-PARP12. An aliquote of each viral stock was stored at -80 
°C. Figure 2.2 shows the PARP12 expression levels after 72 h, 96 h and 6 days 
post transfection. The growth conditions for the Sf9 insect cell are described in 
section 2.8.2. 
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72 h 96 h 6 days 
W. b: anti-PARP12 
Ctrl PARP12 Ctrl PARPl2 Ctrl PARP12 
Figure 2.2: His-PARP12 expression in PARP12 baculovirus infected Sf9 insect 
cells 
Sf9 insect cells were infected with PARP 12 recombinant baculovirus and incubated 
at 27 °C for the indicated times. The cells were then lysed and the expression of 
His-PARP12 was monitored by western blotting using an anti-PARP12 antibody. 
Non-infected Sf9 cells represent control of the procedure (ctrl). PARP 12 expression 
was started after 72 h incubation. 96 h were chosen as the optimal time for protein 
production. Even the protein was still present after 6 days post-infection, 
degradation products were visible and thus this time was not considered as 
appropriate for protein production. 
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2.6 Real-time qRT-PCR 
2.6.1 Materials 
Plates and SYBR green mixture were from Roche (Basel, Switzerland). RNA 
extraction kits and QuantiTect Reverse Transcription kits were from Qiagen 
(CA, USA). Primers used for the real-time RT-PCR were from Sigma-Aldrich 
(WI, USA). 
2.6.2 RNA extraction and the RT-PCR reaction 
Total RNA was isolated from control and CD38+1+ HeLa cells using RNAeasy 
Qiagen (CA, USA) kits, according to the manufacturer instructions. The 
quality of the RNA was checked on agarose gel. 
For each experiment, I gg total RNA was converted to cDNA using 
QuantiTect Reverse Transcription kits (Qiagen, CA, USA), according to the 
manufacturer instructions. The procedure comprised two main steps: 
elimination of genomic DNA, and reverse transcription. Briefly, the purified 
RNA samples were incubated in gDNA Wipeout Buffer at 42 °C for 2 min, to 
effectively remove contaminating genomic DNA. After this step, the RNA 
sample was used for reverse transcription using a master mix prepared from 
Quantiscript Reverse Transcriptase, Quantiscript RT Buffer, and RT Primer 
Mix. The entire reaction was performed at 42 °C and then inactivated at 95 °C. 
2.6.3 Preparation of samples for real-time qRT-PCR analysis 
Here, 20 µl of a mix containing 100 ng cDNA, 200 nM of each primer and 
SYBR Green master mix (Roche, Basel, Switzerland) were used for real-time 
PCR. Real-time PCR measurements were performed using a Light Cycler 480 
Real-Time PCR System (Roche, Basel, Switzerland). Each sample was 
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measured in duplicate and the data were analysed using the MMCT method (2' 
DDCT) for comparing relative expression results. Resting cells were considered 
the reference sample, and Homo sapiens hypoxanthine 
phosphoribosyltransferase 1 (HPRT1) served as the house-keeping gene. 
Statistical analysis were performed using a GraphPad Prism Software. The list 
of primers used is given in Table 2.2. 
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Table 2.2: Primers used for real-time qRT-PCR 
Name Sequence (5'-3') Company Stock conc. (KM) 
HPRT1 forward tgctgacctgctggattaca Sigma-Aldrich 
HPRT1 reverse cctgaccaaggaaagcaaag Sigma-Aldrich 
E-cadherin forward cgacccaacccaagaatcta Sigma-Aldrich 
E-cadherin reverse 
Bax forward 
Bax reverse 
p21 forward 
p21 reverse 
Noxa forward 
Noxa reverse 
gctggctcaagtcaaagtcc Sigma-Aldrich 
ggggacgaactggacagtaa Sigma-Aldrich 
ctgtaatcccagctccttgg Sigma-Aldrich 
gacaccactggagggtgact Sigma-Aldrich 
ggcgtttggagtggtagaaa Sigma-Aldrich 
agctggaagtcgagtgtgct Sigma-Aldrich 
ttcctgagcagaagagtttgg Sigma-Aldrich 
100 
100 
100 
100 
100 
100 
100 
100 
100 
100 
136 
Materials and Methods 
2.7 Luciferase assay 
2.7.1 Materials 
The Dual-Luciferase Reporter 1000 assay system was purchased from Promega 
(Madison, WI, USA). Plates were from Roche (Basel, Switzerland). The pGL2 
vector containing the firefly luciferase gene under the control of the E-cadherin 
promoter was kindly provided by Eric Fearon, Division of Medical Genetics 
(University of Michigan, USA). pLA/S 5Kb-WT vector containing the firefly 
luciferase gene under the control of the B66 promoter was kindly provided by 
Dr. Riccardo Dalla-Favera, Institute for Cancer Genetics (Columbia 
University). These vectors are referred to as reporter I. The control vector 
containing the Renilla luciferase gene (referred reporter II) was kindly 
provided by Dr. Fulvio Chiacchiera, CMNS. 
2.7.2 Procedure 
Control and CD38+1+ HeLa cells (60,000) were plated for each well of a 24- 
well format and co-transfected with 500 ng Reporter I and 10 ng Reporter II 
using the TranslT-LT1 transfection Reagent (according to the method 
described in section 2.8.3). After 12 h, the cells were stimulated with 40 . tg/ml 
BFA in DMEM in the presence of exogenously added 5 mM NAD+. After 12 h 
treatment, the cells were lysed using 100 µl of freshly prepared Passive Lysis 
Buffer (PLB) of the Dual-Luciferase Reporter assay system, according to the 
manufacturer instructions. Then 20 .d 
PLB cell lysate was used to measure the 
luciferase activity. To measure the firefly luciferase activity, 100 µl of 
Luciferase Assay Reagent II (LARII) was added to each sample to generate a 
stabilised luminescent signal. After quantifying the firefly luminescence, the 
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Renilla luciferase reaction was initiated by adding 100 µl Stop & Glo Reagent 
to the same sample. The Stop & Glo Reagent also produces a stabilised signal 
from the Renilla luciferase, which decays slowly over the course of the 
measurement. The luminescence measurements were performed using a plate- 
reading luminometer in Dr. Antonio Moschetta's Laboratory (CMNS), with the 
help of Dr. Giuseppe Lo Sasso. The values obtained were analysed as ratios 
between RepI/RepII* 10000. Statistical analyses were performed using 
GraphPad Prism Software. 
2.8 Work with eukaryotic cell lines 
2.8.1 Materials 
HeLa cells and Sf9 insect cells were purchased from the European Collection 
of Cell Culture (ECACC). CD38+1+ and control HeLa cells were kindly 
provided by Prof. Antonio De Flora (Advanced Biotechnology Centre, 
University of Genoa, Italy). Dulbecco's Modified Eagle's Medium (DMEM), 
Minimum Essential Medium (MEM), foetal bovine serum (FBS), penicillin, 
streptomycin, trypsin-EDTA, L-glutamine and MEM Non-Essential Amino 
Acids Solution were all from Gibco/BRL (NY, USA). Grace's Insect medium 
(supplemented and unsupplemented) was from Invitrogen (Carlsbad, CA, 
USA). All of the plastic cell culture materials were from Corning (NY, USA). 
Filters 0.2 gm were from Amicon (MA, USA). 
2.8.2 Cell-growth conditions 
Control and CD38+1+ HeLa cells were grown in DMEM supplemented with 2 
mM L-glutamine, 50 U/ml penicillin and 50 gg/ml streptomycin, and 10% 
(v/v) FBS. HeLa cells were grown in MEM supplemented with 2 mM L- 
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glutamine, 50 U/ml penicillin and 50 µg/ml streptomycin, 10% (v/v) FBS and 
100 µM MEM Non-Essential Amino Acids Solution containing glycine, L- 
alanine, L-asparagine, L-aspartic acid, L-glutamic acid, L-proline and L-serine. 
Sf9 insect cells were grown in Grace's Insect medium supplemented with 2 
mM L-glutamine, 50 U/ml penicillin and 50 pg/ml streptomycin, 10% (v/v) 
FBS. Complete growth media were prepared by diluting stock solutions in 
MEM, DMEM or Grace's medium, and filtering the resulting media through 
0.2 µm filters. 
Cells were grown in flasks under a controlled atmosphere in the 
presence of 95% air/ 5% CO2 at 37 °C, until they reached 90% confluence. For 
propagation, the medium was removed, the cells were washed with sterile PBS, 
and 0.25% (v/v) trypsin solution was added for 2 min to 5 min. The medium 
was then added back to block the protease action of the trypsin, and the cells 
were collected in a plastic tube. After centrifugation for 5 min at 300x g, the 
cell pellet was resuspended in fresh medium. Sf9 insect cells were grown in 
flasks at 27 °C, in absence of 5% CO2. For propagation, cells were resuspended 
in old medium by dislodging the cells by pipetting, centrifuged at 500x g for 5 
min and resuspended in fresh complete growth medium. 
2.8.3 DNA transient transfection 
2.8.3.1 Materials 
DNA constructs used for transient transfection are reporetd in section 2.3.4. 
TranslT-LTI-Reagent was from Mirus Bio LLC (Madison, WI, USA). 
OptiMEM was from from Invitrogen/Gibco (Carlsbad, CA, USA). 
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2.8.3.2 TranslT-LT 1-Reagent-based cell transfection 
HeLa cells were plated onto glass coverslips in 24-well plates or in 10-cm petri 
dishes in complete culture medium in the absence of antibiotics at a 
concentration suitable to have 50% to 70% confluence for transfection. The 
day after, a transfection mixture was prepared by diluting the TranslT-LT 1 
Reagent in OptiMEM medium and incubated it at RT for 5 min. The cDNA 
(0.5 µg for a 24-well format, or 6 . tg for a 10-cm petri dish) was then added to 
the transfection mixture, which was then gently shaken, and kept at RT for 
another 20 min, to allow the DNA-TranslT-LT 1 Reagent complex to form. The 
cells were then incubated prior to the assays with the transfection mixture for 
24 h at 37 °C, in complete medium without antibiotics, as reported for each 
experiment. For control and CD38+1+ HeLa cells, 2x 106 cells were plated in a 
10-cm petri-dish, and soon after, the transfection mixtures (prepared as 
described above) were directly added to the cells. The cells were then 
incubated for 24 h at 37 °C, in complete medium without antibiotics. 
2.8.4 siRNA transfection 
2.8.4.1 Materials 
SiRNAs were from Dharmacon (CO, USA): ON-TARGET plus SMARTpool 
L-013740-00-0020, Human PARP 12, NM022750,20 nmol (stock 20 µM); 
non-targeting siRNA pool, D-001206-13-20 (siRNAs; stock 20 µM). 
OptiMEM culture medium and Lipofectamine 2000 were from 
Invitrogen/Gibco (Carlsbad, CA, USA). RablA specific siRNAs were kindly 
provided by Dr. Rossella Venditti, of the Dr. De Matteis Laboratory, TIGEM, 
Naples, Italy. 
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2.8.4.2 Procedure 
HeLa cells were plated onto glass coverslips in 24-well plates in normal culture 
medium (in the absence of antibiotics) at a concentration suitable to have 30% 
confluence for transfection (for HeLa cells, 20,000 cells were usually plated 
the day before transfection). One day later, a transfection mixture was prepared 
by diluting the siRNA smart pool in OptiMEM medium, and Lipofectamine 
2000 with the same medium in a separate tube, according to the manufacturer 
instructions. The tubes were gently shaken and incubated for 5 min at RT; after 
this, the diluted siRNAs smart pool was mixed with the diluted Lipofectamine 
2000 and incubated further for 20 min at RT, to allow the siRNAs- 
Lipofectamine complex to form. The transfection mixture thus included the 
specific concentration of siRNA sequences or the non-targeting siRNA was 
added to the cells in complete medium without antibiotics, with an incubation 
for an additional 72 h prior to assay. For the PARP12 knock-down 
experiments, 100 nM PARP12 specific siRNA was transfected for 72 h. For 
RablA knock-down experiments, 50 nM specific siRNA were transfected for 
72 h. The efficiency of interference was assessed by Western blotting. 
2.9 Cell-cycle synchronisation of HeLa cells 
HeLa cells were grown on fibronectin-coated glass coverslips. Once they were 
attached to the coverslips, they were incubated in growth medium plus 9 . tM 
RO-3306, a CdKI inhibitor (from Calbiochem, CA, USA), for 20 h, to 
accumulate the cells in G2 phase. Then the cells were immediately fixed (in G2 
phase) or washed in complete growth medium and incubated in complete 
growth medium for 1h (causing the cells to accumulate in M phase) (Vassilev 
et al., 2006). For accumulation of cells in Go phase, they were maintained in 
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starvation medium (MEM without serum) for 24 h. At the end of each 
experimental condition, the cells were fixed and stained with Hoechst to 
visualise DNA organisation, and with anti-phosphorylated-histone H3 
antibodies as a marker for the cell-cycle phase. 
2.10 Immunofluorescence procedures 
2.10.1. Materials 
The Alexa 488- and Alexa 546-conjugated donkey anti-rabbit, anti-mouse and 
anti-goat antibodies were from Molecular Probes (OR, USA). 
2.10.2 Sample preparation 
Cells were fixed in 4% paraformaldehyde for 10 min at RT, washed three times 
in PBS, and incubated for 40 min at RT in blocking solution with saponin. The 
cells were subsequently incubated with the specified antibodies diluted in 
blocking solution (see Table 2.3 for the antibodies and the dilutions used) for 2 
h at RT or O/N at 4 °C. After incubation with the primary antibody, the cells 
were washed three times in PBS and incubated with a fluorescent-probe- 
conjugated secondary antibody directed against the constant region of the 
primary IgG molecule, for 45 min at RT. Commonly, Alexa 488- or Alexa 546- 
conjugated anti-rabbit, anti-mouse or anti-goat donkey antibodies were used at 
a dilution of 1: 400 in blocking solution. After immuno-staining, the cells were 
washed three times in PBS and twice in sterile water, to remove salts. The 
coverslips were then mounted on glass microscope slides (Carlo Erba, Italy) 
with Mowiol (20 mg mowiol dissolved in 80 ml PBS, stirred O/N and 
centrifuged for 30 min at 12,000x g). 
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Table 2.3: Antibodies used in immunofluorescence experiments. 
Antibody target Dilution Animal source Company/ source 
Giantin 1: 500 Mouse, monoclonal 
PARP 12 1: 100 Goat, polyclonal 
Phospho S10 
histone H3 
Dr H. P. Hauri (University of 
Basel, Switzerland) 
Abcam 
1: 100 Rabbit, polyclonal Upstate 
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2.11 Expression and purification of recombinant proteins from E. 
coli 
2.11.1 Materials 
Ampicillin, chloramphenicol and serine protease inhibitor Pefabloc (4-(2- 
aminoethyl)benzenesulfonyl fluoride hydrochloride, AEBSF) were from Fluka 
Analytical (Switzerland). Lysozyme, isopropyl-C-D-1 thiogalactopyranoside 
(IPTG), imidazole, reduced glutathione, sodium borate and triethanolamine 
were from Sigma-Aldrich (WI, USA). Triton X-100 was from Bio-Rad 
Laboratories (UK). All of the other enzymes used were from Roche (Basel, 
Switzerland). Dimethylpimelidate (DMP) was from Pierce (IL, USA). 
Glutathione Sepharose 4B matrix and glutathione were from Amersham 
Pharmacia Biotech (NJ, USA). 
2.11.2 Expression and purification of GST-tagged proteins 
(These procedures were carried out entirely by Claudia Cericola, in the Corda 
Laboratory, DCBO, CMNS) 
GST-EIA, GST-14-3-3y and GST-PAK1 were purified as previously described 
for recombinant GST-BARS (Valente et al., 2005). The following procedures 
led to 4-5 mg of these recombinant GST-tagged proteins. The bacteria 
transformed with the empty vector, pGEX4T1, were usually processed in 
parallel, which led to the production of about 10 mg GST. A small amount of 
the bacteria were scraped from the glycerol stocks, inoculated into 2 ml LB 
containing 60 µg/ml ampicillin, and grown at 37 °C under continuous shaking 
(200 rpm) for 6-8 h. Two ml of these cultures were inoculated into 100 ml of 
the same medium and grown ON under the same conditions. These cultures 
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were then diluted 1: 20 in 1.0 1 of the same medium, and the optical density at 
600 nm (OD600) was monitored until it reached 0.4. The bacteria were then 
induced with the addition of 0.1 mM IPTG for 2 h, at 37 °C. After this, the 
cultures were chilled on ice and centrifuged at 6,000 rpm in a JA10 rotor 
(4,000x g) for 10 min at 4 °C. After discarding the supernatant, the pellets were 
resuspended in 50 ml GST lysis buffer containing a protease inhibitor cocktail, 
and lysozyme and Triton X-100 were added to final concentrations of 1 mg/ml 
and 1% (w/v), respectively. The suspensions were incubated with gentle 
agitation at 4 °C for 30 min, sonicated on ice 8 times for 15 s, and centrifuged 
at 18,000 rpm in a JA20 rotor (20,000x g) for 20 min at 4 °C. The supernatants 
were recovered and added to 2 ml glutathione Sepharose 4B matrix 
(Amersham Pharmacia Biotech, NJ, USA) that had been previously 
equilibrated in GST lysis buffer. The suspension was incubated with gentle 
agitation at 4 °C for 30 min and then centrifuged at 700x g for 5 min, to 
sediment the matrix. Each matrix was washed 5 times with 50 ml PBS 
(centrifuging as above). After washing, each matrix was packed into a 10 ml 
chromatography column (Bio-Rad Laboratories, UK), drained, and the bottom 
cap of the column was replaced. The protein was eluted by adding 2 ml GST 
elution buffer, incubating for 10 min at room temperature, removing the 
bottom cap, and collecting the eluate. The elution and collection steps were 
repeated at least 5 times. The protein usually peaked in the first or second 
fraction. The fractions containing the greater amounts of protein (at least 0.2 
mg/ml) were pooled, dialysed twice against 1,000x volumes of PBS, and 
stored in aliquots at -80 °C. 
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2.11.3 Expression and purification of His-tagged proteins 
(These procedures were carried out entirely by Claudia Cericola, in the Corda 
Laboratory, DCBO, CMNS). 
His-CtBP1/BARS was purified as described previously (Valente et al., 2005). 
The following procedure led to about 2 mg of recombinant His-tagged proteins. 
A small amount of bacteria were scraped from the glycerol stocks, inoculated 
into 5 ml LB containing 60 µg/ml ampicillin and 10 µg/ml chloramphenicol, 
and grown ON at 37 °C under continuous shaking (200 rpm). The cultures 
were then diluted 1: 20 in 80 ml of the same medium, and the OD600 was 
monitored until it reached 0.6. The bacteria were then induced with the 
addition of IPTG to 0.4 mM for 2 h, at 37 °C. After this, the cultures were 
chilled on ice and centrifuged at 8,000 rpm in a JA14 rotor (5,000x g) for 10 
min at 4 °C. After discarding the supernatants, the pellets were resuspended in 
4 ml His lysis buffer containing a protease inhibitor cocktail, and frozen by 
immersion in liquid nitrogen. The lysates were stored at -80 °C ON, or for up 
to a few days. Each suspension was thawed by transferring it to a4 °C 
waterbath, protease inhibitor cocktail was added again, and lysozyme was 
added to a final concentration of 1 mg/ml. Each lysate was incubated with 
gentle agitation at 4 °C for 30 min and sonicated on ice 8 times for 15 s. Then 
MgCl2 (to 10 mM) and DNAse I (to 10 gg/ml) were added, and each lysate was 
incubated for 15 min on ice, and then centrifuged at 18,000 rpm in a JA20 rotor 
(20,000x g) for 20 min at 4 °C. Each supernatant was recovered and added to 
0.5 ml Ni-NTA beads (Qiagen, CA, USA) that had been previously 
equilibrated in His lysis buffer. Each suspension was incubated with gentle 
agitation at 4 °C for 1 h, and then packed into a 10 ml chromatography column 
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(Bio-Rad Laboratories, UK). The columns were washed 5 times with 10 ml His 
wash buffer, and the protein was eluted by adding aliquots of 0.5 ml His 
elution buffer, with each eluate collected in a clean tube. The elution and 
collection steps were repeated at least 5 times. The protein usually peaked in 
the first fraction. The fractions containing the greater amounts of protein (at 
least 0.2 mg/ml) were pooled, dialysed twice against 1,000x volume of PBS, 
and stored in aliquots at -80 °C. 
2.11.4 Preparation of cross linked GST-tagged macro-domain resins 
2.11.4.1 Materials 
Vectors coding for full-length Af1521 wild-type and its G42E mutant macro 
domains were provided by Dr. Andreas Ladurner (EMBL, Heidelberg) and 
sub-cloned into the pGEX4T1 vector by Dr. Annalisa Stilla, in the Corda and 
Di Girolamo Laboratories, DCBO, CMNS. 
STE buffer: 150 mM NaCl, 20 mM Tris HCI, pH 8,1 mM EDTA. 
Washing buffer: PBS, 1 mM EDTA, 1 mM DTT, 0.5 mM pefabloc. 
2.11.4.2 Procedure 
A small amount of BL21-DE3 cells was scraped from the glycerol stocks, 
inoculated into 50 ml LB containing 100 µg/ml ampicillin, and grown ON at 
37 °C under continuous shaking (200 rpm). The cultures were then diluted 1: 10 
in 500 ml of the same medium, and the OD600 was monitored until it reached 
0.6. The bacteria were then induced with the addition of 0.2 mm IPTG for 3.5 
h at 20 °C. After this, the cultures were chilled on ice and centrifuged at 6,000 
rpm in a JA14 rotor (5,000x g) for 10 min at 4 °C. After discarding the 
supernatants, the pellets were resuspended in 4 ml STE buffer containing 
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protease inhibitor cocktail, 1 mM DTT and 0.5 mg/ml lysozyme, and incubated 
with gentle shaking for 30 min on ice; after this step, suspensions were frozen 
by immersion in liquid nitrogen and stored at -80 °C O/N, or for up to a few 
days. Each suspension was thawed by transferring it to a 20 °C waterbath, and 
1% (w/v) Triton X-100, protease inhibitor cocktail and 1 mM DTT were added. 
Lysates were incubated with gentle agitation at 4 °C for 20 min and sonicated 
on ice 3 times for 30 s. The lysates were clarified by centrifuging at 15,000 
rpm in a JA20 rotor (20,000x g) for 15 min at 4 °C. Ten µI of lysates were 
saved as inputs to monitor the purification procedure. Each supernatant was 
recovered and incubated with 0.5 ml glutathione sepharose matrix, (previously 
equilibrated in washing buffer) for 1-2 h on a rotating wheel at 4 °C. Each 
suspension was then washed 6 times with 12 ml washing buffer. Ten µl of each 
suspension were saved to monitor the cross-linking procedure. The resin was 
then treated with the cross-linker DMP, as follows. First, the resin was washed 
twice with 10 ml 0.2 M sodium borate, pH 8.6, and centrifuged at 1,000x g for 
5 min at RT. All of the further centrifugation steps were performed under the 
same conditions. After, the suspensions were incubated with 600 ttl of 0.2 M 
tris-ethanolamine, pH 8.3, added with 20 mM of the cross-linker DMP, on a 
rocker for 30 min at RT. Ten µl of the suspension was removed, for monitoring 
of the efficiency of cross-linking. At the end of this incubation, the suspension 
was centrifuged, and the supernatant removed. The reaction was stopped by 
washing the beads once with 14 ml 0.2 M ethanolamine, pH 8.2, and then 
incubating in the same buffer (10 ml) for 1h at RT on a rocker. At the end of 
this incubation, 10 tl were removed (as above), and after centrifugation and 
removal of the buffer, the beads were washed three times in PBS, three times 
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with 20 mM GSH, in 20 mM Tris HCI, pH 8, once again in PBS, and finally 
with 100 mM glycine, pH 2.5, to remove material not covalently bound to the 
resin. Finally, the cross- linked matrices were washed twice with PBS and 
stored in PBS with 0.02% (w/v) sodium azide at 4 °C. The efficiency of cross- 
linking was monitored by boiling samples removed at each step (before adding 
DMP, after incubation with DMP, after washing with PBS) in SDS sample 
buffer, running on a 10% SDS-PAGE gel, and revealing of the protein by silver 
staining. Before use for the pull-down assay, the resins were monitored using 
NarE as a positive control, a toxin from Neisseria meningitidis that shows auto- 
ADP-ribosyltransferase activity (Koehler et al., 2011). The ADP-ribosylation 
reaction was carried out as follows: 3µg purified NarE were incubated for 1h 
at 37 °C in ADP-ribosylation buffer (50 mM Tris-HCI, pH 7.4,500 µM MgCl2, 
4 mM DTT, 100 µM total NAD+, 5 µCi [32P]-NAD+). At the end of incubation, 
equal amounts of the reaction mixture were diluted in 450 µ1 RIPA buffer and 
incubated with 15 µl resin cross-linked with the wild-type or mutated GST- 
macro-domain, at 4 °C. After an O/N incubation, the samples were centrifuged 
for 5 min at 500x g, washed tree times in RIPA buffer, analysed on a 12% 
SDS-PAGE, and transferred onto nitrocellulose. The amount of [32P]-ADP- 
ribose incorporeted was visualised by autoradiography. Figure 2.3 shows the 
ADP-ribosylated NarE bound to the GST-macro-domain cross-linked resins. 
These resins were used for the macro-domain pull-down assay for the 
identification of PARP12 substrates (as described in Chapter 4). The 
purification of His-NarE was carried out by Claudia Cericola, DCBO, CMNS, 
as described by Koehler C. et al. (2011). 
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AR [''P] 
Input mut MD wt MD unb mut MD unb wt MD 
Figure 2.3: wild type GST-macro domain cross-linked to resin can recognise 
ADP-ribosylated NarE 
GST-macro-domain cross-linked resins were tested using ADP-ribosylated NarE. 
After the ADP-ribosylation reaction of NarE toxin, GST-tagged mutated and wild- 
type macro domains (mut MD, wt MD) cross-linked to resins were incubated with 
ADP-ribosylated NarE. After an O/N incubation, the protein bound to resins, input 
and unbound materials (unb) were analysed on 12% SDS-PAGE, and transferred 
onto nitrocellulose. The amount of [32P]-ADP-ribose incorporeted was visualysed 
by auto-radiography (AR). 
Note that ADP-ribosylated NarE is recognised by wild-type macro-domain cross- 
linked resin and not by the mutated macro-domain. ADP-ribosylated NarE is 
present in the unbound material from mut MD and only as a small fraction in the 
unbound material from wt MD. 
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2.12 General biochemical procedures 
2.12.1 Materials 
Sodium dodecyl sulphate (SDS), glycine, TRIZMA base, Ponceau red, 
polyoxyethylenesorbitan monolaurate (Tween-20), ammonium persulphate 
(APS), N, N, N', N'-tetramethylethylenediamine (TEMED) and the acrylamide 
stock solution at 40% (w/v) acrylamide: bis-acrylamide (37.5: 1) were from 
Sigma-Aldrich (WI, USA). Acetic acid was from Carlo Erba (Italy). Secondary 
antibodies conjugated with horse-radish peroxidase (HRP) and directed against 
mouse or rabbit IgGs were from Calbiochem (CA, USA). The ECL reagents 
were from Amersham Pharmacia Biotech (NJ, USA). GelCode Blue Stain 
Reagent was from Pierce (IL, USA). 
2.12.2 Solutions 
- Running buffer: 25 mM TRIZMA base, 200 mM glycine, 0.1 % (w/v) SDS. 
- SDS sample buffer: 62.5 mM Tris-HCI, pH 6.8,2% (w/v) SDS, 10% (v/v) 
glycerol, 5% (v/v) C-mercaptoethanol and 0.1% (w/v) bromophenol blue. 
- Transfer buffer: 25 mM TRIZMA base, 200 mM glycine, 20% (v/v) 
methanol. 
- TBS: 150 mM NaCl, 20 mM Tris-HCI, pH 7.5. 
- TTBS (TBS plus Tween 20): TBS + 0.05% (w/v) Tween 20 
- Blocking solution for Western blotting: 1% (w/v) BSA in TTBS. 
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2.12.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS- 
PAGE) 
2.12.3.1 Assembly of polyacrylamide gels 
Two 16 cm x 18 cm plates were used for standard gels. The plates were 
assembled to form a chamber using two 1.5 mm plastic spacers aligned along 
the lateral edges of the plates. The plates were then fixed using two clamps and 
mounted onto a plastic base which sealed the bottom. All of the materials were 
from Hoefer Scientific Instruments (Germany). The `running' polyacrylamide 
gel was prepared by mixing H2O, 40% (w/v) acrylamide: bisacrylamide 
solution, 1.5 M Tris-HC1, pH 8.8,10% (w/v) SDS, to have the selected 
concentration of acrylamide in 375 mM Tris-HC1,0.1% (w/v) SDS. Then, 
0.06% (w/v) APS and 0.06% (v/v) TEMED were added; the solution was 
mixed and poured into the gap between the plates, leaving -5 cm for the 
stacking gel. Soon after pouring, the gel was covered with a layer of H2O and 
left at RT for -1 h. The H2O layer was then removed (by aspiration). The 
`stacking' polyacrylamide gel was prepared by mixing H2O, 40% (w/v) 
acrylamide: bisacrylamide solution, 500 mM Tris-HCI, pH 6.8,10% (w/v) 
SDS, to have 4% (w/v) acrylamide, at a final concentration of 125 mM Tris- 
HCI, 0.1% (w/v) SDS. Then, 0.1% (w/v) APS and 0.07% (v/v) TEMED were 
added, and the solution was mixed and poured onto the `running' gel. 
Immediately, a 10-well comb was inserted between the glass sheets and the 
apparatus was left for Ih at RT. 
2.12.3.2. Evaluation of protein concentrations 
Protein concentrations were evaluated using a commercially available protein 
assay kit (Bio-Rad Laboratories, UK). This assay is based on the colour change 
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of Coomassie brilliant blue G-250 dye in response to various protein 
concentrations. 1-5 µl of samples were diluted in 800 ml H2O and mixed with 
200 ml reagent. After 5 min, a blue colour developed, the adsorbance of which 
(wave-length, OD 595 nm) was measured using a spectrophotometer. The 
protein concentrations were obtained by extrapolation from standard curves 
using known concentrations of BSA. 
2.12.3.3. Sample preparation and running 
Samples were prepared by adding SDS sample buffer, incubating at 100 °C for 
5-10 min in a multi-block heater (Lab-Line, IL, USA), cooling to RT, briefly 
centrifuging and finally loading onto the gel. One well was loaded with 5 Al 
Rainbow recombinant protein molecular weight markers (Amersham 
Pharmacia Biotech, NJ, USA) or with 5 µg Low Molecular Weight Standards 
(Bio-Rad Laboratories, UK). The gel was then transferred into the 
electrophoresis apparatus (Hoefer Scientific Instruments, NJ, USA), and the 
electrophoresis was carried out under a constant current of 8 mA (for O/N 
runs) or 40 mA (for - 4-h runs). 
2.12.3.4 Gel staining with GelCode Blue Stain Reagent 
The GelCode Blue Stain Reagent uses the colloidal properties of the 
Coomassie G-250 dye for protein staining on polyacrylamide gels. After 
electrophoresis, the gels were placed in a clean tray and rinsed 3x5 min with 
200 ml ultrapure water and for 30 min with 50% (v/v) methanol and 7% (v/v) 
acetic acid solution, with gentle shaking. After this step, 50 ml of GelCode 
Blue Stain Reagent were added for a 16 x 20 cm gel and incubated at room 
temperature for 3-4 h with gently shaking, to allow protein band development. 
To destain gels, the Stain Reagent was replaced with ultrapure water and the 
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water was changed several times over 1-2 h. The gel was then left in water at 4 
°C before LC-MS/MS analysis. 
2.12.4 Western blotting 
2.12.4.1. Protein transfer onto nitrocellulose 
The polyacrylamide gels were soaked for 15 min in transfer buffer, placed on a 
sheet of 3MM paper (Whatman, NJ, USA) and covered with a nitrocellulose 
filter (Schleicher & Schuell, Germany). The filter was covered with a second 
sheet of 3MM paper, to form a `sandwich', which was subsequently assembled 
into the blotting apparatus (Hoefer Scientific Instruments, NJ, USA). The 
protein transfer was carried out at 400 mA for 5h or at 125 mA for 16 h. At the 
end of the run, the sandwich was disassembled, and the nitrocellulose filter was 
soaked in 0.2% (w/v) Ponceau red (Sigma-Aldrich, WI, USA) and 5% (v/v) 
acetic acid for ca. 5 min, to appropriately visualise the protein bands, and then 
rinsed with 5% acetic acid to remove excess unbound dye. 
2.12.4.2. Probing the nitrocellulose with specific antibodies 
The nitrocellulose filters were cut into strips with a razor blade. The strips 
containing the proteins of interest were incubated in the blocking solution for 
Western blotting plus 1% (w/v) BSA or 5% (w/v) milk powder for 1h at RT, 
and then with the primary antibody diluted to its working concentration in the 
blocking solution for Western blotting (see Table 2.3 for the antibodies used in 
the Western blotting experiments). After a 2-4 h incubation at RT, or an ON 
incubation at 4 °C, the antibody was removed and the strips were washed twice 
in TTBS, for 10 min each. The strips were next incubated for 1h with the 
appropriate HRP-conjugated secondary antibody diluted in the blocking 
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solution for Western blotting (anti-rabbit: 1: 10,000; anti-mouse: 1: 5,000) and 
washed twice in TTBS, for 10 min each, and once in TBS for 5 min. After 
washing, the strips were incubated with the ECL reagents, according to the 
manufacturer instructions, and protein signals were detect by autoradiography 
using Kodak film. 
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Table 2.4: Antibodies used in immunoprecipitation and Western blotting 
experiments 
Antibody target Dilution Animal source 
BFA 
Biotin 1: 10000 Rabbit, polyclonal 
CtBPI/BARS 
(BC3) 
CtBP1BARS 
1: 500 Rabbit, polyclonal 
1: 100 
1.5 tg/mg total Rahhit nnlvclnnal 
Company/ source 
Kindly provided by 
Prof. Ignazio 
Sandoval, 
University of 
Madrid 
Bethyl Laboratory, 
Inc. 
Mouse, monoclonal 
Piccini D. 
(IFOM-IEO, Milan) 
(P502) lysate . _...,., --, r---, 
GAPDH 1: 80000 Mouse, monoclonal 
GFP 1: 1000 Rabbit, polyclonal 
GFP (for I. P. ) 1.0 gg/mg total Mouse, monoclonal 
GST 
iysate 
1: 10000 Rabbit, polyclonal 
Myc (for I. P. ) 1.0 
ysate 
µg/mg total Mouse, monoclonal l 
PARP 12 1: 2000 Rabbit, polyclonal 
Rab 1A1: 1000 Rabbit, polyclonal 
Our laboratory 
(Corda D., IBP, 
Naples) 
Sigma-Aldrich 
Abcam 
Abcam 
Di Tullio G. and 
Santoro M. (De 
Matteis Laboratory) 
Invitrogen 
Sigma-Prestige 
Antibodies 
Santa Cruz 
Biotechnology, Inc. 
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2.13 Immunoprecipitation experiments 
2.13.1 Preparation of cell lysates 
2.13.1.1 Lysis buffers 
1% Triton lysis buffer: 50 mM Tris HCI, pH 7.4,150 mM NaCI, 5 MM M902, 
I mM DTT, 5 mM EGTA, 1% (w/v) Triton X-100, supplemented with 
protease inhibitor cocktail (Complete Mini EDTA-free, Roche, Basel, 
Switzerland) RIPA Buffer: 100 mM Tris pH 7.4,150 mM NaCl, 0.1% SDS, 
1% (w/v) Igepal, 0.1% (w/v) sodium deoxycholate, supplemented with 
protease inhibitor cocktail (Complete Mini EDTA-free, Roche, Basel, 
Switzerland). 
2.13.1.2 Procedure 
Cells maintained in the appropriate growth medium were washed three times 
with ice-cold PBS and directly scraped in the specific lysis buffer on ice. Cell 
lysates were kept on a turning wheel for 30 min at 4 °C. The lysates were then 
clarified by centrifugation at 13,000x g for 10 min. The supernatants obtained 
from the centrifugation were recovered and the protein concentrations 
evaluated according to the method described in section 2.10.3.2. 
2.13.2 CtBPI/BARS immunoprecipitation procedure 
CD38+/+ HeLa cells (12 x106) plated in six 10-cm petri dishes were transiently 
transfected with cDNAs coding for YFP-CtBPI/BARS WT or its point mutant 
H304A (6 µg cDNA were used for each petri) using TranslT-LT I (see section 
2.8.3). Twenty-four hours after transfection, three 10-cm petri dishes for each 
condition (WT and H304A mutant) were treated with BFA (80 µg/ml) or 
vehicle alone as a control (DMSO), in DMEM for 4h at 37°C. After 4 h, the 
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media were removed and the cells were washed three times in ice-cold PBS. 
All of the following steps were performed on ice and using ice-cold solutions. 
Cells were lysed using 1% Triton lysis buffer (see section 2.11.1) and 3 mg of 
total lysates for each condition were incubated with 5 p. g of an anti- 
CtBP1BARS antibody. After an O/N incubation, 25 µl Protein-A Sepharose 
beads (Amersham) were added, with an incubation for an additional 1h at 4 
°C. The suspensions were then centrifuged for 5 min at 500x g, and the 
supernatants were recovered. The matrices were washed 4 times, each time by 
adding 1 ml lysis buffer and two times with lysis buffer without Triton X-100, 
inverting the tubes several times and centrifuging as before. The bound 
proteins were eluted by boiling the samples for 10 min in 80 gl SDS sample 
buffer. The immunoprecipitated proteins were separated on 10% SDS-PAGE 
gels and transferred onto nitrocellulose. Western blotting with anti-BFA 
antibodies was performed to reveal the ADP-ribosylated CtBP1BARS. 
2.13.3 Myc-tagged PARP12 immunoprecipitation procedure 
HeLa cells (8 X 106) were plated in four 10-cm petri dishes and transiently 
transfected with cDNAs coding for Myc-tagged PARP12 or the Myc empty 
vector (6 µg cDNA were used for each petri) using TranslT-LTI (see section 
2.8.3). Twenty-four hours after transfection, the growth media were removed 
and the cells were washed three times in ice-cold PBS. All of the following 
steps were performed on ice and using ice-cold solutions. The cells were lysed 
using RIPA buffer (see section 2.11.1.1), and 4 mg total lysates for each 
condition were incubated with 4 gg of an anti-Myc antibody (for dilution see 
Table 2.4). After 3h incubation at 4 °C on a rotating wheel, 25 gl Protein-G 
Sepharose beads (Amersham) previously equilibrated in RIPA buffer were 
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added, with an incubation for an additional 1h at 4 °C. The suspensions were 
then centrifuged for 5 min at 500x g, and the supernatants recovered (referred 
to as the unbound materials). The matrices were washed 4 times, each time by 
adding 1 ml lysis buffer with ice-cold RIPA buffer and two times with the 
same buffer without detergents, inverting the tubes several times and 
centrifuging as before. The bound proteins were eluted by boiling the samples 
for 10 min in 80 µl SDS sample buffer. The immunoprecipitated proteins and 
30 gg of the input and unbound materails were separated on 12% SDS-PAGE 
gels and transferred onto nitrocellulose. Western blotting was performed to 
reveal the immunoprecipitated proteins. 
2.14 Preparation of total membrane fractions 
Confluent HeLa cells (3 x 106 cells for each 10-cm petri dish) were washed 
three times with ice-cold PBS, and mechanically detached in 800 pl HEPES 
buffer (20 mM HEPES pH 7.4,1 mM EDTA, 250 mM sucrose) using a cell 
scraper. The cells were recovered and then sonicated on ice three times for 15 
s; unbroken cells were removed by centrifugation at 500x g for 5 min. The 
resultant supernatants were ultra-centrifuged for 1h at 100,000x g; with the 
supernatants representing the cytosolic fraction and the pellets the total 
membrane fraction. The total membrane fractions were then resuspended in 20 
mM HEPES, pH 7.4, containing 1 mM EDTA and protease inhibitors, and 
stored at -80 °C. A few microliters were lysed in IM NaOH and the protein 
concentration was evaluated by the method described in section 2.10.3.2. 
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2.15 Macro-domain-based pull-down assay 
For MS analysis, the pull-down assay was performed using solubilised total 
membranes (previously ADP-ribosylated as described in section 2.18), while 
for routine experiments, the protein amounts used were lower (as described 
later). Total membrane fractions were prepared as described above, starting 
from 30 10-cm petri dishes with cells that had not been transfected or had been 
transiently transfected with untagged PARP 12. Eight mg total membranes were 
ADP-ribosylated for 8 h, as described in section 2.18, washed once with PBS 
to remove unbound NAD+, and then recovered by centrifugation at 100,000x g 
for 60 min at 4 °C. The pellet was solubilised in 4.5 ml RIPA buffer (100 mM 
Tris HCI, pH 7.5,150 mM NaCl, 1% Igepal, 0.1% deoxycholate, 0.1% SDS, 
and protease inhibitors), under constant rotation for 30 min at 4 °C. The 
mixtures were clarified by centrifugation at 13,000x g for 10 min at 4 °C. The 
supernatants were incubated with 100 µl 10 µg/µl GST cross-linked mutated 
macro-domain resin for 8h at 4 °C, on a rotating wheel. After the incubation, 
the mixtures were centrifuged at 500x g for 5 min to recover the proteins 
bound to the mutated macro domain, and the supernatants were incubated for a 
further 8h with the same amount of GST cross-linked wild-type macro-domain 
resin. The resins were previously equilibrated with RIPA buffer. After 8h 
incubation, the samples were centrifuged at 500x g for 5 min. Both of the 
resins were then washed 8 times with RIPA buffer and another 8 times in the 
same buffer without detergents. Each time, the samples were centrifuged at 
500x g for 5 min. At the end of the washing steps, the resins were resuspended 
in 100 µl SDS sample buffer, boiled and analysed by 10% SDS/PAGE. The 
gels were then stained with GelCode Blue Stain Reagent (as described in 
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section 2.11.3.4). The bands were analysed by LC-MS/MS, which was 
performed by Dr. Maria Monti, CEINGE Institute, Naples, Italy. 
For routine experiments, 2 mg total lysates was used, and incubated with 25 µl 
GST-macro-domain cross-linked resins. The samples were processed as 
described above, analysed by SDS-PAGE, and transferred onto nitrocellulose 
for Western blotting. 
2.16 BAC purification 
(The BAC purification was carried out entirely by Claudia Cericola, in the 
Corda Laboratory, DCBO, CMNS. This method is described by Colanzi A. et 
al. (manuscript in preparation). 
2.16.1 BAC synthesis 
Salt-washed rat brain membranes (1.5 mg/ml), BFA (80 µg/ml), NAD+ (5 mM) 
were incubated under agitation in metabolite buffer (20 mM Tris, pH 7.0,50 
mM NaC1), for 2h at 37 °C. At the end of the incubation, the sample was 
centrifuged at 18,000 rpm in a JA 20.1 Beckman rotor, for 45 min. The pellet 
(representing the total membrane fraction) was discarded. 
The supernatant was recovered and filtered using an Amicon pressure 
apparatus (10,000 molecular-weight cut-off). The filtrate was extracted twice 
in two volumes of McOH/ CHC13 (1: 2), and the aqueous phase was collected 
and lyophilised. 
2.16.2 HPLC methods 
Large scale BAC purification. The lyophilised BAC preparation was 
resuspended in 1 ml buffer A (10 mM KH2PO4,2.5 mM TBA) and purified 
using a Kontron HPLC Pump 420, equipped with a Reodine injector (2 ml 
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loop), with an ACS UV-Vis detector (model 750/11/AZ) set at 254 Mn; the 
chromatograms were recorded using a Shimadzu C-R60 CHOMATOPAC 
integrator. The peaks were resolved using a semi-preparative C18 reverse 
phase column (Viosfer, 10 µm, 25x250 mm) equilibrated with 2.5 ml/min 
buffer A and eluted with a non-linear gradient of buffer B (40% buffer A, 60% 
methanol), as: time 0,0% buffer B; time 20 min, 50% buffer B; time 30 min, 
100% buffer B; time 35 min, 100% buffer B; time 40 min, 0% buffer. The 
eluate was collected in 2.5 ml fractions that were then analysed in ADP- 
ribosylation assays (as described in section 2.15.2). The fraction containing the 
activity was supplemented with sucrose (final concentration, 10 mM), 
lyophilised, resuspended in 1 ml 20 mM HEPES (pH 7.2), and further purified 
using the same C18 reverse-phase column. The column was equilibrated with 
water and eluted with a gradient of buffer C (80% methanol) (time 0, buffer C 
0%; time 60 min, buffer C 100%). All the % values used here refer to v/v. 
Using this procedure, it was possible to purify to homogeneity the molecule 
that eluted at 26 min, with this fraction supplemented with 10 mM sucrose, 
lyophilised, and resuspended in 20 mM Hepes, pH 7.2 (final BAC 
concentration, 100 µM). The BAC solution was then aliquoted and stored at - 
20 °C for up to several months. 
2.17 GST pull-down assays 
2.17.1. Solutions 
GST incubation buffer: 20 mM Tris, pH 8.0,100 mM KCI, 1 mM EDTA, 0.2% 
(w/v) Triton X- 100 and protease inhibitor cocktail (Complete Mini EDTA-free, 
Roche, Basel, Switzerland). 
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GST elution buffer: 100 mM Tris, pH 8.0,20 mM reduced glutathione, 5 mM 
DTT. 
2.17.2 CtBPJ/BARS ADP-ribosylation using purified BAC 
Twenty Vg His-CtBP1BARS were incubated for 3h at 37 °C with 8 tl HPLC- 
purified BAC (120 µM) or with 8 µl buffer alone (20 mM Tris, 10 mM 
sucrose), to allow binding of BAC to the His-CtBP1BARS. The reaction 
mixture was then stopped on ice, split in four samples, and used for the GST 
pull-down assays (see next section). 
2.17.3 Procedure 
All of the following steps were performed on ice or at 4 °C using ice-cold 
solutions, unless otherwise indicated. Equimolar amounts of GST-PAKI (120 
kDa, corresponding to 11 µg ), GST-14-3-3y (55 kDa, corresponding to 5.5 
µg), GST-E1A or GST (30 kDa, corresponding to 2.5 µg) were incubated with 
5 gg His-CtBP1BARS or CtBP1BARS bound to BAC (50 kDa), in GST 
incubation buffer for 2h with gentle agitation. After this step, 25 µl glutathione 
sepharose 4B matrix (previously equilibated in GST incubation buffer) was 
added to each sample, which were then further incubated for Ih at 4 °C. The 
suspensions were then centrifuged at 500x g for 5 min, to sediment the matrix. 
The matrix was washed 6 times with GST incubation buffer (centrifuging as 
above). The interacting proteins were eluted by adding GST elution buffer, 
incubating for 10 min at 4 °C, centrifuging as before, and collecting the 
supernatants in tubes. The eluted fractions were examined by SDS-PAGE and 
Western blotting. The experimental procedure is schematised in Figure 2.4. 
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GST Pull-down assay 
5 µg His-BARS 
w/o BAC with BAC 
" Incubation for 3h at 37 °C; 
" incubation with GST, GST E1A, GST 14/3/3y or GST- 
PAK1 for 3h at 37 °C (buffer: 20 mM Tris HCI, 1 mM EDTA, 
0,2% Triton, 100 mM KCI); 
" incubation with giutathione resin for ih at 4 °C; 
"6 washes in the same buffer; 
" elution with 100 mM Tris HCl, pH 8,20 mM giutathione, 5 mM DTI. 
Figure 2.4: GST in vitro pull-down assay 
Schematic representation on the GST pull-down assay. For a detailed description see text. 
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2.18 ADP-ribosylation assay 
2.18.1 Materials 
ß-NAD+, 3-aminobenzamide (3-AB), PJ-34 hydrochloride hydrate, vitamin- 
K1, and meta-iodobenzylguanidine (MIBG) were from Sigma-Aldrich (WI, 
USA). [32P]-ß-NAD+ was from PerkinElmer. 3-AB was dissolved in DMSO, 
MIBG was dissolved in methanol, PJ-34 was dissolved in water. Biotinylated- 
NAD+ was from Trevigen. Biotin was from Sigma-Aldrich (WI, USA). 
2.18.2 Procedure 
The ADP-ribosyltransferase activity was measured by following the 
incorporation of [32P]-ADP-ribose into membrane proteins. Samples were 
incubated in 50 µl ADP-ribosylation buffer (50 mM Tris-HC1 pH 7.4,4 mM 
DTT, 500 µM MgC12,50 µM total NAD) at 25 °C for 30 min (standard 
conditions), unless otherwise specified. 500 ng of His-PARP 12 from total 
membrane fraction of Sf9 insect cells were routinely used. His-PARP12 
concentration was determined by comparing the PARP 12 band intensity with 
the intensities of known concentrations of a His-tagged protein. Alternatively, 
50 µg of total membrane fractions from HeLa were usually used in ADP- 
ribosylation assays, unless otherwise specified. 
For chemical treatments or experiments with ADP-ribosylation inhibitors, the 
assays were performed as described above in presence of the specific 
compounds. Control experiments (0 µM) were performed with the highest 
concentrations of solvent used for the compounds. The reactions were stopped 
by the addition of SDS sample buffer; the samples were subjected to SDS- 
PAGE and transferred onto nitrocellulose. For the quantification of the 
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incorporated label, an Instant Imager was used or the radioactive bands were 
cut out and their activities were measured by Cerenkov counting. For the 
determination of kinetic parameters, ADP-ribosylation reactions were 
performed with a fixed amount of [32P]-NAD+ and increasing concentrations of 
total NAD+ for 30 min at 25°C. Reactions were stopped by the addition of 500 
ttl BSA (100 µg/ml) and 530 µl ice-cold TCA; the precipitated material was 
washed twice with diethyl ether, once with acetone, air-dried and measured by 
Cerenkov counting. Data were analysed by Lineweaver-Burk plot. 
For the ADP-ribosylation experiments using biotinylated NAD+, the 
ADP-ribosylation assays were performed as described above, with the ADP- 
ribosylation mixtures contained 10 µM biotinylated NAD+ (or biotin alone, as 
control) and 40 µM unlabelled NAD+. For these experiments, 200 µg of total 
membranes from HeLa cells were used. The reactions were carried out at 25 
T. After 1 h, the membranes were solubilised with RIPA buffer, and the 
solubilised proteins were incubated with 30 pl streptavidin resin (previously 
equilibrated in RIPA buffer) at 4 T. After an O/N incubation, the samples 
were centrifuged for 5 min at 500x g, washed three times in RIPA buffer and 
another three times with the same buffer without detergents. The resins were 
then resuspended in 80 µl SDS sample buffer and analysed by SDS-PAGE and 
Western blotting (using an anti-biotin antibody), to visualise the ADP- 
ribosylated proteins. 
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2.19 Analysis of ADP-ribosylation reaction products 
2.19.1 Materials 
Phosphodiesterase I was from USB Corp. (Cleveland, OH, USA). 
Acrylamide: bis-acrylamide (19: 1) and urea were from Sigma-Aldrich (WI, 
USA). Trichloroacetic acid was from Carlo Erba (Italy). 
2.19.2 Procedure 
Analysis of the ADP-ribose polymer length was carried out as described by 
(Panzeter and Althaus, 1990; Shah et al., 1995). Briefly, after the ADP- 
ribosylation assay (as described in section 2.18), the proteins were TCA 
precipitated, washed twice with diethyl ether and acetone, and [32P]-labeled 
reaction products were detached from proteins by incubating at 60°C for 3h 
with 10 mM Tris, 1 mM EDTA, pH 12. At the end of incubation, the samples 
were mixed with 1/3 vol of 4x loading buffer [25 mM NaCl, 4 mM EDTA, pH 
7,5,0.02% (w/v) xylene cyanol 0.02% (w/v) bromophenol blue], to which an 
equal volume of 100% urea has been added. After pre-electrophoresis for 1h at 
300 V, samples were loaded onto a 20% (w/v) polyacrylamide gel. 
Electrophoresis at 300 V was carried out until the bromophenol blue dye had 
migrated over about three-quarters of the entire gel length. The gel was then 
exposed to X-ray film at -80 °C. 
2.20 Analysis of ADP-ribosylated residue 
The ADP-ribosylation reaction was performed as described in section 2.18, 
using His-PARP12 from baculovirus-infected Sf9 insect cells. At the end of the 
incubation, the samples were treated with 1M NaOH or 1 mM HgCl2 for 2h at 
25 °C. Control samples were treated with 1M NaCl. Alternatively, the 
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reactions were performed in the presence of the different MIBG concentrations 
(5 µM, 50 µM, 500 µM); as controls, the reaction was performed in the 
presence of the maximum concentration of MIBG solvent. The reactions were 
stopped by the addition of SDS sample buffer, and then the protein separated 
by SDS-PAGE and transferred onto nitrocellulose. The radioactivity 
incorporated was analysed using an Instant Imager (from PerkinElmer). 
For identification of the ADP-ribosylated residue by MS, the total 
membrane fraction from His-PARP12 baculovirus infected Sf9 insect cells was 
used in the ADP-ribosylation assay in the absence of radiolabel NAD+ (see 
section 2.18). After a3h incubation at 25 °C, the membranes were TCA 
precipitated, washed with diethyl ether and acetone, and then resuspended in 
phosphodiesterase-I-containing buffer. The phosphodiesterase reaction was 
carried out at 37 °C. After 2h incubation, the reactions were stopped by the 
addition of SDS sample buffer and processed for MS for the identification of 
the residue, as run by Angela Amoresano, at the CEINGE Institute (Naples, 
Italy). Briefly, the samples were loaded onto 8% SDS-PAGE. The gels were 
then washed several times with water to remove the SDS, and then stained with 
colloidal Coomassie and destained with repeated washes in water. The band 
corresponding to PARP 12 was excised from gel and processed for the MS 
analysis. 
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RESULTS 
Preface 
Chapters 3 and 4 are dedicated to the description of the results that I obtained 
during my PhD project. In the first chapter dedicated to the description of 
results (Chapter 3-Results I), I describe the novel BFA-dependent ADP- 
ribosylation mechanism of CtBP1/BARS (Results I), while in the second part 
(Chapter 4-Results II), I deal with the characterisation of PARP 12 as a new 
mono-ADP-ribosytransferase and the identification of its potential substrates, 
with particular emphasis on Rab 1A (Results II). 
Note that throughout these Results sections I use the generic term of 
CtBP1/BARS to refer collectively to CtBP1-L and CtBP1-S/BARS. 
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CHAPTER 3. Results I 
A novel ADP-ribosylation mechanism regulates CtBP1BARS 
function 
3.1 Introduction 
CtBP1BARS is a multitasking protein that is involved in several cellular 
functions that depend on its cellular localisation. CtBP1BARS is regulated by 
two different post-translational modifications and protein interactions that 
affect its localisation and functions. In section 1.5.2.2, I described how 
phosphorylation of CtBP1BARS by PAK1 induces its translocation from the 
nucleus to the cytoplasm, along with inhibition of its transcriptional activity. 
Sumoylation of CtBP1BARS has the opposite effects. BFA-induced ADP- 
ribosylation represents another post-translational modification that might 
regulate these CtBP1/BARS activities. 
Previous studies in our laboratory have demonstrated that BFA- 
dependent ADP-ribosylation of CtBP1BARS is a non-classical reaction that 
comprises two distinct steps (Figure 3.1). The first step is the synthesis of a 
BFA-ADP-ribose conjugate (hereafter referred as BAC), which is catalysed by 
a membrane-bound enzyme that starts from NAD+. This NAD-derivative, 
BAC, can be purified by HPLC. The second step is the covalent binding of 
BAC into the CtBP1BARS NAD+-binding pocket. Through mass- 
spectrometry analysis and mutagenesis experiments, it has been shown that the 
entire BAC binds covalently to CtBPI/BARS through histidine 304 of 
CtBP1BARS (Figure 3.2). 
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Figure 3.1: Molecular mechanism of BAC synthesis 
The ADP-ribosyl cyclases convert NAD' to cyclic ADP-ribose and/or ADP-ribose through 
cleavage of the nicotinamide-ribose bond (1) and formation of an enzyme-stabilised ADP- 
ribosyl oxocarbenium ion intermediate (2). This intermediate is a good nucleophile acceptor 
that can react with the intra-molecular adenine (3) or water (4), to give cyclic ADP-ribose or 
ADP-ribose, respectively. Since BFA has two hydroxyl groups, it can act as a nucleophile 
and form a conjugate with the oxocarbenium ion intermediate (5), thus leading to the 
formation of the BFA and ADP-ribose conjugate (BAC). 
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Figure 3.2: BAC binding occurs on histidine 304 of CtBPI/BARS 
Histidine 304 as the residue involved in BAC binding was identified by mass 
spectrometry. To confirm the involvement of this amino-acid residue in the formation 
of the covalent bond between BAC and CtBPI/BARS, different point mutants of the 
CtBP 1 /BARS protein were generated and tested in in vitro ADP-ribosylation assays, 
using recombinant His-CtBPI/BARS proteins and brain total membranes as the 
enzyme source. Only the mutant protein in which histidine 304 was replaced by 
alanine (H304A) did not show BAC binding. Mutation of the other residues shown 
did not affect BAC binding. 
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In this context, my study was aimed at: 
1. Identification of the enzyme that catalyses the first step of this reaction 
(section 3.2); 
2. Providing an understanding of how this post-translational modification 
affects CtBPI/BARS functions (section 3.3). 
I analysed the first point by evaluating the involvement of the ADP- 
ribosyl cyclase CD38 in this BFA-dependent mono-ADP-ribosylation, both in 
vitro and in intact cells, showing that CD38 can indeed support this reaction. 
Subsequently, I analysed the effects of this modification on CtBP1BARS 
activities, i. e. its fissioning activity and its co-repressor activity. The 
experiments described demonstrate that BFA-dependent mono-ADP- 
ribosylation is important in modulating CtBPI/BARS functions. 
3.2 The enzyme involved in the BFA-dependent mono-ADP- 
ribosylation of CtBP1/BARS 
3.2.1 CD38 can catalyse the BFA-ADP-ribose conjugate synthesis both in vitro 
and in intact cells 
An important point in the search for the enzyme that catalyses the BFA- 
dependent ADP-ribosylation reaction came from the HPLC analysis of the 
purified NAD+-metabolite BAC synthesised in vitro, which showed that its 
synthesis is supported by NAD+, NADP+ and cyclic-ADP-ribose, but not by 
ADP-ribose (Colanzi, A. et al., manuscript in preparation). These data are 
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consistent with the involvement of an ADP-ribosyl cyclase in the synthesis of 
this NAD derivative. 
To test the hypothesis that BAC is synthesised by an ADP-ribosyl 
cyclase, I focused on the mammalian membrane-bound ADP-ribosyl cyclase 
CD38. To this end, I performed in vitro ADP-ribosylation assays (according to 
the method described in section 2.18) using total membranes prepared both 
from control HeLa cells, which do not express CD38, and from CD38 stably 
transfected HeLa cells (kindly provided by Prof. Antonio De Flora, University 
of Genoa, Italy). The total membrane fractions were incubated with 
recombinant His-CtBP1BARS in [32P]-NAD+-containing ADP-ribosylation 
buffer for 2h at 37 °C, in the absence and presence of 80 µg/ml BFA. At the 
end of the incubation, the samples were analysed by SDS-PAGE and 
autoradiography. As shown in Figure 3.3, only the total membrane fraction 
obtained from CD38+1+ HeLa cells supported ADP-ribosylation of 
CtBP1BARS. This thus demonstrated that CD38, the main mammalian ADP- 
ribosyl cyclase, is the enzyme responsible for the synthesis of the NAD- 
derivative BAC in this cell model. 
To further analyse this result, I also examined the features of BAC 
formation and its binding to CtBP1BARS in intact living cells. Here, CD38+i+ 
HeLa cells were transfected with YFP-CtBP1/BARS or its point mutant on the 
histidine 304, H304A (the CtBP1BARS residue involved in BAC binding). 
After 24 h, the cells were incubated at 37 °C for 4h in the absence and 
presence of 80 gg/ml BFA and with 5 mM NAD+ added to the growth medium. 
At the end of the incubation, the cells were lysed, then YFP-CtBP1/BARS was 
immunoprecipitated with an anti-CtBP1BARS antibody, and the various 
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samples were subjected to SDS-PAGE and immunoblotting with antibodies 
against BFA. Strikingly, the over-expressed YFP-CtBPI/BARS protein in the 
CD38+1+ Hela cells showed binding to BAC. As a control, the YFP- 
CtBPI/BARS H340A point mutant (the residue for the ADP-ribosylation) was 
not modified (Figure 3.4). No signal was detected in the absence of BFA. 
In the experiments described above, I added 5 mM NAD+ to the growth 
medium that results in a hugely increased production of BAC by CD38. This 
concentration is not physiological, since the extracellular NAD+ concentration 
is in the nanomolar range. For this reason, I performed the same experiments 
also in the absence of exogenously added NAD+. Control HeLa cells (which do 
not express CD38) and CD38 stably transfected HeLa cells were transiently 
transfected with YFP-CtBP I BARS. After 24 h, the cells were incubated for 1 
h and 4h in the presence and absence of 80 . tg/ml BFA and without and with 5 
mM NAD+ in the medium. At the end of the incubation, the cells were lysed, 
then YFP-CtBPI/BARS was immunoprecipitated, and the various samples 
were subjected to SDS-PAGE and immunoblotting with antibodies against 
BFA. Again, the YFP-CtBPI/BARS expressed in CD38+i+ Hela cells incubated 
with BFA and NAD+ for 1h or 4h showed BAC binding. Importantly, the 
fraction of modified protein was substantial, albeit lower, also in cells 
incubated with BFA without the addition of NAD+ to the medium (Figure 3.5). 
Moreover, the modification is completely reversible, indicating that an enzyme 
that can remove BAC should also exist. 
Altogether, these results show that CD38 can catalyse the formation of 
the NAD+ metabolite, BAC, also in intact cells and under physiological NAD+ 
conditions. 
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Figure 3.3: CD38 can support BAC synthesis in in vitro ADP-ribosylation 
assays 
In vitro ADP-ribosylation assay. Ten tg total membrane fractions from control 
(CD38--) and CD38+i+ HeLa cells were incubated for 2h at 37 °C with 0.5 pg 
recombinant His-CtBPI/BARS and 30 tM total NAD` (labelled with 5 µCi [32P]- 
NAD'), in the absence and presence of BFA (80 tg/ml). At the end of the 
incubation, the samples were analysed by SDS-PAGE and transferred onto 
nitrocellulose. Autoradiography (AR [32P]) shows the modified CtBPI/BARS; 
CtBPI/BARS total levels were been analysed by Western blotting (W. b). 
Note that BAC binding was observed only in presence of CD38 and BFA, which 
indicates that CD38 can catalyse the formation of BAC. 
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Figure 3.4: CD38 can support BAC synthesis in intact cells 
CD38+" HeLa cells were transfected with YFP-CtBP1/BARS wild-type (WT) and its 
point mutant on histidine 304 (H304A). After 24 h, the cells were treated with 80 
µg/ml BFA for 4h at 37 °C, in the presence of 5 mM extracellular NAD`. YFP- 
CtBPI/BARS was immunoprecipitated from the total lysates using an anti- 
CtBP1/BARS antibody, and the ADP-ribosylated protein was revealed using an anti- 
BFA antibody. Total CtBP1/BARS levels are shown in the bottom panel. 
BAC binding also occurs in intact cells, and no binding is observed when the H304A 
CtBP1/BARS mutant is over-expressed. 
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Figure 3.5: BAC is also formed in the absence of exogenously added NAD+ 
CD38+" HeLa cells were transfected with YFP-CtBPI/BARS. After 24 h, the cells were 
treated with 80 tg/ml BFA for 4h at 37 °C, in the presence or absence of exogenously 
added 5 mM NAD+. BFA wash-out was performed in BFA-free complete medium for a 
further 3 h. YFP-CtBPI/BARS was immunoprecipitated from total lysates using an 
anti-CtBPI/BARS antibody, and the ADP-ribosylated protein was revealed using an 
anti-BFA antibody. Total CtBP 1 /BARS levels are shown in the bottom panel. 
BAC binding occurs also in the absence of exogenously added NAD', and it becomes 
evident after 4h of BFA treatment. The lack of BAC binding after BFA wash-out 
suggests that the reaction is completely reversible. 
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3.2.2 CD38 acts as a transporter for the entrance of the metabolite BAC 
As described in the Introduction (section 1.3.1.1), CD38 is an ectoenzyme, 
with its catalytic domain facing the extracellular space, whereas CtBP1BARS 
is an intracellular protein. This `topological paradox' can be explained 
assuming that the metabolite BAC is produced in the extracellular space, and 
then it reaches its substrate intracellularly. 
If BAC is produced in the extracellular space, I reasoned that the 
culture medium should represent a source of BAC, and thus can be used to 
induce the in vitro ADP-ribosylation of recombinant CtBP1/BARS (the second 
step of the reaction described in Figure 3.1). To demonstrate this point, I 
stimulated control and CD38+i+ HeLa cells with BFA in the presence of 
exogenously added NAD+, for 4h at 37 T. After the incubation, I collected 
the different media to perform the second step of the BFA-dependent ADP- 
ribosylation reaction. Figure 3.6 shows that CtBPI/BARS immuno-reacts with 
the specific BFA antibody only when the supernatant of CD38+i+ HeLa cells 
was used, thus demonstrating that it is produced in the extracellular space, 
according to the initial hypothesis. Moreover, it is clear that BAC binding is 
specific, since no labelling is present when using the supernatant of control 
HeLa cells stimulated with BFA. 
To clarify whether CD38 also has a role in the intracellular transport of 
the metabolite BAC I performed the following experiment. CD38+i+ and control 
Hela cells were transfected with YFP-CtBPIBARS. After 24 h, the cells were 
stimulated for 4h without and with 80 µglml BFA, in the presence of 5 mM 
NAD+ added to the growth medium. To compensate for the absence of CD38 
in the control HeLa cells, and thus for the production of BAC, I added 
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recombinant CD38 to the growth medium of one sample of the control Hela 
cells. At the end of the incubation, the cells were lysed, then YFP- 
CtBP 1 BARS was immunoprecipitated with an anti-CtBP 1 BARS antibody, 
and the various samples were subjected to SDS-PAGE and immunoblotting 
with antibodies against BFA. To check for the correct formation of BAC, I also 
saved all of the supernatants and I used them to induce the ADP-ribosylation of 
recombinant His-CtBP1BARS in an in vitro assays. According to the previous 
results, Figure 3.7A shows that in intact cells, YFP-CtBP1BARS is ADP- 
ribosylated only in CD38+i+ HeLa cells stimulated with BFA, and so not in 
control HeLa cells. Importantly, despite the presence of recombinant CD38 in 
the medium, YFP-CtBP1BARS was not modified in intact control HeLa cells 
stimulated with BFA (Figure 3.7A), while the supernatant of this sample 
(containing BAC produced by the added recombinant CD38), still ADP- 
ribosylated recombinant His-CtBPI/BARS in vitro (Figure 3.7B). 
These data suggest that not only is CD38 involved in the production of 
the metabolite BAC, but it can have a role in the translocation of BAC itself 
into the cytoplasm, where CtBP1BARS is located. 
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Figure 3.6: BAC is produced by CD38 in the extracellular space 
Control (CD38-'-) and CD38-" HeLa cells were treated with BFA (80 µg/ml) at 37 °C. 
After 4h treatment, the supernatants (SN) were recovered and incubated with 
recombinant His-CtBPI/BARS for 2h at 37 °C. The samples were analysed by SDS- 
PAGE and transferred onto nitrocellulose. The modified CtBPI/BARS was analysed 
using an anti-BFA antibody. Total levels of CtBPI/BARS are shown in the bottom 
panel. 
CtBPI/BARS shows BAC binding only when incubated with the supernatant of BFA- 
treated CD38+'' HeLa cells. 
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Figure 3.7: CD38 is required for BAC entrance into the intracellular space 
Control (CD38-'") and CD38_'` HeLa cells were transiently transfected with YFP- 
CtBP1/BARS. After 24 h of over-expression, the cells were treated for 4h with BFA (80 
µg /ml) at 37 °C. To compensate for the absence of CD38, the recombinant CD38 enzyme 
(rec CD38) was added to the extracellular medium for the treatment time. All of the 
supernatants (SN) were saved and used to check for the presence of BAC. (A) At the end 
of the incubation, the cells were lysed and CtBP1/BARS was immunoprecipitated. The 
samples were resolved on SDS-PAGE and transferred onto nitrocellulose. Modified 
CtBP1/BARS was analysed using an anti-BFA antibody. Total levels of CtBPI/BARS are 
shown in the bottom panel. (B) Recombinant His-CtBPI/BARS was incubated with the 
supernatants (SN) for 2h at 37 °C, to induce BAC binding in-vitro. An anti-BFA antibody 
was used to check for modified CtBP1/BARS. BAC produced by both recombinant CD38 
and by the membrane fraction of CD38'" HeLa cells can bind to recombinant His- 
CtBP1/BARS. Note that despite the presence of BAC produced by the recombinant CD38 
(B), intracellular CtBPI/BARS was not modified in control HeLa cells (A), indicating that 
BAC did not reach the intracellular space due to the absence of CD38. 
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3.3 BFA-dependent ADP-ribosylation of CtBPI/BARS modulates its 
functions 
3.3.1 BAC modulates the binding of CtBPI/BARS with its interactors 
Next, I investigated whether the ADP-ribosylation mediated by BFA can affect 
CtBP1BARS functions. Previous studies in our laboratory have demonstrated 
that, indeed, BFA-induced ADP-ribosylation of CtBP1BARS inhibits its 
fissiogenic activity (Spano et al., 1999; Weigert et al., 1999). As reported in 
Chapter 1 (see section 1.5.2.3), the fissioning protein CtBP1BARS is an 
essential component of Golgi complex fragmentation during mitosis. This 
process can be followed by using an assay that reconstitutes the fragmentation 
process in permeabilised normal rat kidney (NRK) cells incubated with mitotic 
cytosol. The mitotic cytosol induces the break-up of the Golgi ribbon into 
tubulovesicular clusters, which then disperse throughout the cell, similar to the 
Golgi clusters that are characteristic of prometaphase in intact cells (Warren et 
al., 1995). 
The effects of BAC binding on the fissiogenic activity of CtBP1BARS was 
evaluated by an analysis of Golgi complex fragmentation during mitosis 
(experiments performed by Prisca Liberali). These results showed that BAC 
addition to the mitotic cytosol in the Golgi fragmentation assay induced a 
strong inhibition of Golgi fragmentation. This finding was in agreement with 
other previous data showing that BFA-dependent ADP-ribosylation inhibits 
CtBP1BARS fissiogenic activity. 
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Based on these data, I investigated whether once modified, 
CtBP1BARS still binds to known partners involved in both co-repressor and 
fissioning activities. To this end, I performed in vitro GST-pull-down assays 
using recombinant His-CtBPIBARS and some known GST-tagged interactors, 
i. e. the viral repressor E1A, as an interactor for the co-repression function, and 
14/3/3y and PAK1 as interactors for the fissioning activity. First, I induced 
CtBP1BARS modification by incubating purified BAC and His-CtBP1BARS 
(for 3h at 37 °C), and then I incubated the modified CtBP1BARS protein with 
GST-tagged interactors (as described in section 2.17). Figure 3.8 shows that 
BAC strongly impaired the CtBP1BARS binding to GST-tagged 14/3/3y and 
GST-tagged PAK1, which are two essential CtBP1BARS interactors in post- 
Golgi trafficking (Valente, C. et al., submitted manuscript) and 
macropinocytosis (Liberali et al., 2008), respectively. No binding was observed 
using GST alone as the control. The interaction with EIA, a viral repressor that 
contains a specific CtBP-binding motif (PLDLS), was not affected by BAC 
binding to CtBP1BARS. 
In addition, previous data from gel-filtration analysis of ADP- 
ribosylated CtBP 1 BARS demonstrated that the modified CtBP 1 BARS protein 
forms a tetramer, while the non-ADP-ribosylated CtBP1BARS remains 
monomer (Colanzi et al., manuscript in preparation). 
Taken together, these results suggest that the covalent binding of BAC 
to CtBP1BARS can `lock' CtBP1BARS in a closed, tetrameric conformation, 
which is not available for binding to proteins involved in membrane fission. 
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Figure 3.8: CtBPI/BARS interactions with its fission partners is affected by BAC 
binding 
In-vitro GST pull-down assay. His-CtBP1/BARS was pre-incubated with BAC at 37 °C 
to induce BAC binding. After 3 h, equimolar amounts of GST, GST-E1A, GST-14/3/3y 
or GST-PAKI were added to the mixture, which was then incubated for a further 2h at 
4 °C. The GST-tagged proteins were recovered using glutathione resin, and eluted with 
a 20 mM glutathione-containing buffer. The samples were subjected to SDS-PAGE and 
immuno-blotted (W. b. ) with antibodies directed against GST and CtBPI/BARS. 
Note that the interaction between CtBPI/BARS and GST-14/3/3y or GST-PAKI is 
affected when BAC is bound to CtBP1/BARS (bottom panel). 
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According to the literature, the closed conformation of CtBP1BARS is 
required for the transcriptional activity of CtBP1BARS (Nardini et al., 2009). 
For this reason, even though the results from the in vitro pull-down assays 
showed that the binding between CtBP 1 BARS and the viral repressor EIA 
was not affected, I decided to investigate this aspect further, by evaluating the 
effects of CtBPiBARS ADP-ribosylation on the transcription levels of 
specific target genes. 
3.3.2 Effects of BA C binding on CtBP transcriptional activity 
As reported in the Introduction (1.5.2.2), it is known that NAD(H) promotes 
the dimeric/ tetrameric conformation of CtBPIBARS and enhances the 
binding of CtBPIBARS to cellular and viral transcriptional repressors; 
conversely, binding of palmitoyl-coenzyme A to CtBPIBARS promotes the 
monomeric conformation of CtBPIBARS and its interaction with ARF-GAP 
(a component of COPI-coated vesicles), thus promoting vesicle fission. In a 
similar manner, the CtBPIBARS conformation is influenced by covalent 
binding to BAC, which locks CtBPIBARS in a closed, dimeric/ tetrameric 
conformation (Colanzi et al., manuscript in preparation); i. e., according to data 
reported in the literature, the conformation required for CtBPIBARS to act as 
a transcription co-repressor. 
For this reason, I tested the effects of BFA-dependent ADP- 
ribosylation on the expression levels of genes under the control of 
CtBPIBARS. As described in Chapter I (section 1.5.2.3), CtBP1/BARS 
transcriptional co-repressor activity has been shown to have important 
regulatory roles in cell development and transformation, through the regulation 
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of the expression of adhesion molecules (such as E-cadherin) and pro-apoptotic 
genes (such as P21, BAX and NOXA). Thus, I tested the effects of BFA- 
induced ADP-ribosylation on the transcriptional activity of CtBP1BARS, by 
making use of two different approaches, a luciferase assay and real-time RT- 
PCR (for methods see sections 2.6,2.7). 
The dual-luciferase reporter assay is a genetic reporter system that is 
widely used to study eukaryotic gene expression. Dual reporters are commonly 
used to improve experimental accuracy. The term `dual reporter' refers to the 
simultaneous expression and measurement of two individual reporter enzymes 
within a single system. Typically, the `experimental' reporter (called reporter 1) 
is correlated with the effects of specific experimental conditions, while the 
activity of the co-transfected `control' reporter (called reporter II) provides an 
internal control that serves as the baseline response. Normalising the activity of 
the experimental reporter to the activity of the internal control minimises the 
experimental variability caused by differences in cell viability or transfection 
efficiency, as well other sources of variability. 
I analysed the effects of BFA administration on expression levels of 
the luciferase gene under the control of the E-cadherin promoter in both 
CD38+i+ and control HeLa cells. These CD38+1+ and control HeLa cells were 
transfected with 500 ng reporter I (RepI) and 10 ng reporter II_(RepII). After 12 
h, the cells were stimulated with BFA (40 µg/ml) and after a further 12 h, the 
cells were processed as described in section 2.7.2, to evaluate the luciferase 
gene expression levels. 
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Figure 3.9: BFA treatment increases the co-repressor activity of CtBPII/BARS at 
the E-cadherin promoter 
Luciferase assay. CtBPI/BARS-mediated transcriptional repression was monitored 
using an E-cadherin promoter-luciferase reporter (Reporter I). Control (CD38-'-) and 
CD38+'+ HeLa cells were transfected with 500 ng reporter I (Rep I) and 10 ng reporter 
II (Rep II). After 12 h, the cells were treated with BFA (40 µg/ml). After a further 12 
h, the cells were lysed according to the manufacturer instructions of the Dual 
Luciferase assay system (Promega), and luciferase expression levels were determined 
using a luminometer (expressed as the RepI/ReplI ratio, in arbitrary units). 
BFA treatment decreased luciferase expression (29% reduction) in CD38'' HeLa 
cells, as compared to CD38"+ HeLa cells not treated with BFA. This reduction is even 
more evident (52.8%) when the luciferase expression levels are compared to the 
control HeLa cells (CD38-'-) stimulated with BFA, while no differences were seen 
between the two cell lines in the absence of BFA. 
BFA treatment decreased luciferase expression (52.8% reduction) in CD38'` HeLa 
cells, as compared to control (CD38-'-) HeLa cells treated with BFA. 
Data are means ± SEM of three different experiments, each performed in duplicate. 
*, p= 0,0127; **, p=0.0016. 
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As shown in Figure 3.9, BFA-stimulated CD38+1+ HeLa cells showed a 
reduction (29%) in the luciferase expression levels, when compared to the 
control HeLa cells not stimulated with BFA. Interestingly, this reduction is 
even more evident (52.8%) when the luciferase expression levels are compared 
to the control HeLa cells (CD38"l") stimulated with BFA, while no differences 
were seen between the two cell lines in the absence of BFA. 
Based on these first results, I additionally evaluated the effects of BFA- 
dependent ADP-ribosylation in a more physiological way, with an analysis of 
the transcription levels of the E-cadherin, Bax, p21 and Noxa mRNA, using 
real-time qRT-PCR. CD38+i+ and control HeLa cells were stimulated with BFA 
(40 gg/ml). After 12 h, RNA was extracted and the transcription levels of the 
specific genes (CDHJ, BAX, NOXA and P21) were analysed using real-time 
qRT-PCR. The results were normalised to HPRT1 reporter gene (section 2.6.2, 
2.6.3). As shown in Figure 3.11, CD38+1+ HeLa cells display a 45% reduction 
in p21 transcription levels when compared to control HeLa cells stimulated 
with BFA, while there was no difference after BFA stimulation for Bax and 
Noxa mRNA levels between the two cell lines. However, an increase in the 
Noxa mRNA levels was observed, probably due to the toxic effects of BFA per 
se. Unfortunately, the E-cadherin mRNA levels were too low to be analysed in 
a reproducible manner. 
Taken together, these results suggest that BAC binding to 
CtBP1BARS increases its co-repressor activity, in a promoter-specific 
manner. 
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Figure 3.10: BFA treatment increases co-repressor activity of CtBPI/BARS at 
the p21 promoter 
Control (CD38-/-) and CD38'/' HeLa cells were treated with BFA for 12 h. Total RNA 
was extracted and processed to obtain cDNA. The mRNA levels of BAX, NOXA and 
P21 genes were analysed using real-time qRT-PCR. The results were normalised to 
the HPRTI gene. 
Compared to control HeLa cells (CD38-'-), BFA treatment reduces the p2l expression 
levels (45% reduction), while bax and Noxa mRNA levels were not affected. The data 
are means of three different experiments, each performed in duplicate. **, p=0.0023. 
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Interestingly, CtBP1/BARS also acts as a co-repressor for the BCL6 gene 
(Mendez et al., 2008). Bc16 is a transcriptional repressor that regulates B-cell 
differentiation at the germinal centres. It is required for the formation of 
germinal centres and its down-regulation is essential for B-cells to undergo 
further differentiation to memory cells or plasma cells (Ye et al., 1997). Bc16 is 
often expressed constitutively in diffuse large B-cell lymphomas, where it 
blocks the differentiation of B-cells, contributing to the blastic feature of B 
cells (Phan and Dalla-Favera, 2004). I reasoned that in this context, an 
increased co-repressor activity of CtBP1BARS would be useful. Indeed, 
lowering the Bc16 levels, the increased co-repressor activity could favour the 
differentiation of B-cells, thus counteracting the progression of the tumour. 
Based on this assumption, I asked if BFA stimulation can enhance the 
co-repressor activity of CtBP 1BARS at the BCL6 promoter. HeLa cells do not 
express Bcl6, and for this reason I analysed the expression of the luciferase 
gene under the control of the BCL6 promoter in both control and CD38+i+ 
HeLa cells after BFA treatment, at different times. In contrast to the results 
obtained for the expression of the luciferase gene under the control of the E- 
cadherin promoter, BAC binding to CtBP1BARS did not result in reduced 
levels of the luciferase gene under the control of the BCL6 promoter (figure 
3.11), thus ruling out the above-mentioned hypothesis. 
Collectively, these effects support the idea that ADP-ribosylation can 
modulate the co-repressor activity of CtBP1BARS depending on the specific 
promoter context. Moreover, the differential modulation observed after BFA 
treatment for the genes described rules out a non-specific effect due to BFA 
toxicity. 
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Figure 3.11: BFA treatment does not affect CtBPI/BARS co-repression activity at 
the Bc16 promoter 
Luciferase assay. CtBPI-mediated transcriptional co-repression was monitored using a 
BCL6 promoter-luciferase reporter (Reporter I). Control (CD38-'-) (A) and CD38"" (B) 
HeLa cells were transfected with 500 ng reporter I (Rep I) and 10 ng reporter 11 (Rep II). 
After 12 h, the cells were treated with BFA (40 . tg/ml) for the indicated times, and then 
lysed according to the manufacturer instructions of the Dual Luciferase assay system 
(Promega). Luciferase gene expression levels were determined using a luminometer 
(expressed as the Repl/Repll ratio, in arbitrary units). Data are means ± SD from two 
single experiments. 
Note that the luciferase expression levels remain unchanged after BFA treatment, for 
both cell lines. 
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To ensure that the effects of BFA stimulation on the transcription 
levels of the genes analysed were really due to the ADP-ribosylation of CtBPs 
and not to other effects associated with the presence of CD38, I performed the 
same assay in cells silenced for both CtBP1BARS and CtBP2. I obtained a 
good reduction of both of the CtBP1BARS and CtBP2 proteins at 48 h after 
transfection with the siRNAs; however, the double knock-down in combination 
with the BFA treatment was too toxic for the cells. The effect observed for the 
double knock-down of the CtBPs is in agreement with data reported in the 
literature, which showed that the absence of CtBPs favours apoptosis 
(Bergman et al., 2009). This suggests that the stimulation of cells directly with 
purified BAC would help to demonstrate that the effects observed are a 
consequence of the binding of BAC to the CtBPs. Moreover, in collaboration 
with Dr. Nicolosi (University of Catania, Italy), we are synthesising BFA 
analogues, with the aim of separating the `ADP-ribosylating' activity of BFA 
from its effects on Golgi complex morphology and intracellular trafficking. 
3.4 Discussion 
I have shown here that the new mechanism involved in BFA-dependent ADP- 
ribosylation of CtBP1BARS can be catalysed by ADP-ribosyl cyclases, such 
as CD38. ADP-ribosyl cyclases catalyse the conversion of NAD+ to cyclic- 
ADP-ribose and/or ADP-ribose through the cleavage of the nicotinamide- 
ribose bond and formation of an enzyme-stabilised ADP-ribosyl oxocarbenium 
ion intermediate (Figure 3.1), which is a good nucleophile acceptor. This 
intermediate can react with water, to form ADP-ribose, or with the purinic ring 
of the adenine moiety of NAD+, to form cyclic-ADP-ribose (Liu et al., 2008) 
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(Figure 3.1). Similarly, as it has two hydroxyl groups (positions 4 and 7; see 
Figure 3.1), BFA can form a conjugate with the oxocarbenium ion 
intermediate, which leads to the formation of BAC (Colanzi et al., manuscript 
in preparation). Subsequently, BAC binds to CtBP1BARS. An interesting 
point is that the locations of the two proteins (CD38 and CtBP1BARS) are 
different, with CD38 being a type II transmembrane protein and CtBP1BARS 
being an intracellular protein. Thus, I reasoned that the production of BAC 
should occur extracellularly, and then it should reach the cytoplasmic space, 
where it can bind to CtBP1BARS. To clarify this point, I investigated a role 
for CD38 as a transporter for BAC. The results obtained indicate that CD38 not 
only supports the reaction, but can also contribute to the entrance of BAC into 
the intracellular space. 
Here I also provided evidence that BFA-dependent CtBPl/BARS 
ADP-ribosylation affects CtBPl/BARS functions. The results obtained from 
the in vitro pull-down assays clearly show that there is an impairment of the 
binding with partners involved in the CtBPl/BARS fissioning activity, while 
the ability to interact with the viral repressor ElA is not affected. It is well 
known that CtBPl/BARS functions are tightly regulated by post-translational 
modifications and co-factors. In particular, sumoylation, as well as NADH, 
favours the nuclear functions, while phosphorylation, as well as acyl-CoA, 
promotes cytoplasmic localisation (see paragraph 1.5.2.2). These different 
activities reflect different conformational status: the co-repressor activity is 
associated with a closed/ dimeric conformation, while the fissioning activity is 
associated with the monomeric form of CtBPiBARS. In line with these 
findings, data obtained in our laboratory from gel filtration experiments 
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(Colanzi et al., manuscript in preparation), demonstrate that BAC binding to 
CtBPIBARS favours the dimeric/ tetrameric conformation. Altogether, these 
considerations prompted me to further investigate the effects of BFA- 
dependent mono-ADP-ribosylation on CtBPIBARS co-repressor activity. To 
this end, I analysed how the levels of CtBPIBARS-regulated genes were 
changed after BFA treatment, by comparing control HeLa cells with CD38+i+ 
HeLa cells. The results obtained show that the co-repressor activity of modified 
CtBPIBARS is modulated, and in particular, increased, in a promoter- 
dependent manner. Among the genes tested (P21, BAX, NOXA, and luciferase 
gene under the control of the E-cadherin or BCL6 promoters), only the 
expression levels of the luciferase gene under the control of the E-cadherin 
promoter and p21 mRNA levels were decreased after BFA treatment, while the 
transcriptional levels of all of the other genes were unaffected, when compared 
to control HeLa cells (which do not express CD38). Looking at the 
transcription levels of the genes above mentioned in BFA-treated samples, 
compared to their controls, there is an increase in mRNA levels observed for 
the NOXA gene, as well for the luciferase gene under the control of the E- 
cadherin promoter. The increased levels of Noxa mRNA might be connected to 
the toxic action of BFA, while I cannot at this stage explain the increase in the 
luciferase gene under the control of the E-cadherin promoter. The use of 
purified BAC, instead of BFA, should avoid the toxicity effects. 
However, considering that the same toxic effects of BFA are present 
for all of the genes analysed, and considering that I only observed effects on 
p21 and E-cadherin-promoter regulated luciferase expression, it is reasonable 
to suppose that these effects are due to an enhanced co-repressor activity of 
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CtBP 1 BARS bound to BAC, rather than to a toxic effect of BFA per se. 
Moreover, these data allow us to propose that BAC binding to CtBP1BARS 
affects its co-repressor activity depending on the specific promoter context. A 
broader analysis of different genes will better clarify which are the specific 
gene subsets that are regulated by the binding of BAC to the CtBPs. 
The experiments described here did not explore the molecular 
mechanisms underlying these effects, which remain to be fully elucidated. One 
possibility is that the modified CtBP1BARS has an enhanced ability to recruit 
proteins that are important for the repressor activity. In this context, chromatin 
immuno-precipitation experiments would help to clarify this aspect. 
Albeit the fact that from the experiments described in this Chapter do 
not directly demonstrate that the effects on the transcriptional activity of 
CtBP 1 BARS are linked to BFA-dependent ADP-ribosylation of 
CtBP1BARS, the results showing that cells that lack the enzyme catalyse this 
reaction suggest this is this very likely. However, different approaches (as 
already discussed above) will be required to definitely demonstrate this point. 
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CHAPTER 4. Results II 
The new mono-ADP-ribosyltransferase PARP12 
4.1 Introduction 
As described in the Introduction (section 1.3.4), over the past 10 years, 17 
mammalian genes with distant sequence homology to bacterial diphtheria toxin 
(DTX) have been described. The first and best characterised of these proteins is 
poly-ADP-ribose (ADPR) polymerase (PARP)1, the prototypical member of a 
family of mono- and poly-ADP-ribosyltransferases (m/pARTs). The concept 
that some of the PARPs can function as mARTs rather than pARTs came from 
an analysis across all of the PARP sequences that showed the lack of a 
glutamic acid residue, which is essential for elongation of poly-ADPR, in 
PARP7 to PARP16 (Otto et al., 2005). Since then, experimental evidence has 
become available indicating PARP10 and PARP14 as mARTs, with PARP10 
being the `founder member' of this sub-family (Kleine et al., 2008). All of the 
other members of this family remain to be fully characterised. 
In this area my experiments have focused on the PARP family member 
PARP12. In particular, here I describe results that establish that PARP12 is a 
new mART and the identification of its intracellular substrates, thus providing 
new insights into the physiological role of PARP12. The choice of PARP12 
among all of the other new PARPs (PARP7 to PARP16) was based on an 
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initial screening, in which the ADP-ribosylation activity of the different PARPs 
was tested in in vitro ADP-ribosylation assays using lysates from HeLa cells 
transiently transfected with cDNAs coding for each of the different PARPs. 
This first screening showed that PARP12 was among the more active of these 
enzymes, and that similarly to PARP10, it could ADP-ribosylate itself. 
Moreover, because the conserved glutamate residue in the catalytic site that is 
important for the polymerase activity was absent in PARP12, it was 
particularly important to establish if PARP12 is a possible new mART. 
Therefore, the first part of this Chapter describes the experimental evidence 
examining the catalytic properties of PARP12 (sections 4.2,4.3), while the 
second part (sections 4.4-4.8) is focused on the identification of its intracellular 
substrates, providing a possible role for PARP12 in a cellular context. 
4.2 The PARP12-mediated ADP-ribosylation reaction 
4.2.1 Production of the recombinant PARP12 protein 
As mentioned above, the initial screening across all of the PARP isozymes 
showed that the overexpressed PARP12 in HeLa cells could ADP-ribosylate 
itself. To further evaluate the enzymatic properties of PARP12, we sought to 
produce a recombinant GST-tagged full-length PARP 12 in bacteria. The 
purification conditions were set up and performed by Claudia Cericola, a 
technician in our laboratory at the time. Unfortunately, the protein produced in 
this system was present in inclusion bodies and was mostly insoluble. 
Moreover, the small amounts of solubilised protein were inactive when tested 
in ADP-ribosylation assays. As an alternative choice, I decided to produce the 
recombinant PARP12 in SO insect cells. 
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The Sf9 cell/ baculovirus expression system is widely used for high 
levels of protein expression, often with the purpose of purification. 
Importantly, proteins expressed in Sf9 cells contain most of the post- 
translational modifications (PTMs) known for mammalian cells. To express a 
protein of interest, Sf9 cells have to be infected with genetically modified 
baculoviruses, which can be produced using one of the several kits available. 
For my purposes, I used a baculovirus expression system, which uses a special 
E. coli strain that contains modified baculoviral DNA (Ciccarone et al., 1998). 
Recombination of the plasmid (containing the DNA of interest) with the 
baculovirus DNA occurs in the bacteria. The complete modified baculovirus 
DNA is isolated from the bacteria and used for direct transfection of Sf9 cells. 
To achieve this, I first produced the His-PARP12 recombinant 
baculovirus, and then set up the optimal conditions to infect Sf9 insect cells 
(described in sections 2.4,2.5). The His-PARP12 protein produced in this cell 
system was present in the total membrane fraction, where it represented the 
major band. Importantly, the His-PARP12 present in the total membrane 
fraction showed robust auto ADP-ribosylation when tested in the in vitro ADP- 
ribosylation assays. 
Unfortunately the His-PARP12 protein produced by the baculovirus 
system is also insoluble complicating its purification. This part of the study 
was performed in collaboration with Giuliana Catara. Improvements in the 
protocol are still in progress. We have tried different solubilisation conditions, 
but when the protein is solubilised (mainly using denaturing conditions), it 
loses its catalytic activity (checked by following its auto-ADP-ribosylation 
activity). 
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One possible explanation concerning this solubilisation problem is that 
PARP12 forms aggregates through its WWE domains, a protein-protein 
interaction motif. We are still trying to solve this problem: for this reason I 
decided to use the total membrane fraction as an enzyme source to carry out the 
PARP 12 biochemical characterisation. 
4.2.2 PARP12 functions as a mono-ADP-ribosyltransferase 
As mentioned in the introduction to this Chapter, in initial experiments, the 
human PARP12 overexpressed in HeLa cells could ADP-ribosylate itself and 
other substrates. Importantly, no mobility shift could be observed after its auto- 
modification, which suggested that the addition of a single ADP-ribose moiety 
takes place, and thus that PARP12 functions as a mART. In support of this 
observation, PARP12 has an important substitution in the catalytic triad; i. e. 
the presence of an isoleucine instead of the glutamic acid, substitution that is 
responsible for the lack of polymerase activity, as also shown for PARP 10 
(Kleine et al., 2008). 
A structure-based alignment of PARPI, PARP3, PARP12 and the 
PARP10 model has been reported by Lusher and co-workers (Kleine et al., 
2008). PARP1 has PARP activity, while PARP 10 catalyses only mono-ADP- 
ribosylation. To identify the origins of this difference, the authors compared 
the PARP 10 model with that of PARP I. The core secondary structure elements 
are retained, as are the histidine and tyrosine residues involved in NAD+ 
binding, and which constitute the first two amino acids of the highly conserved 
"HYE" triad found throughout the PARP superfamily (Figure 4.1). However, it 
is clear that in PARP 10 an isoleucine (1987) has replaced the catalytic 
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glutamate found in PARP1 (E988) (Figure 4.1). The same is the case for 
PARP12, where isoleucine 660 has replaced the glutamic acid of PARP1. 
Based on these features, I checked the role of these residues in PARP 12 ADP- 
ribosylation activity by generating specific PARP12 mutants. I mutated the 
first histidine (involved in NAD+ binding) to alanine (non-conservative 
mutation) or to glutamine (conservative mutation), as well as isoleucine 660 to 
alanine. As shown in Figure 4.2, my data demonstrate that the substitution of 
these important residues abolishes the PARP12 catalytic activity. Even though 
the expression levels of Myc-tagged PARP 12 mutants were lower compared to 
wild-type PARP12-Myc, this difference cannot explain the abolishing of the 
auto-ADP-ribosylation activity. The absence of the first histidine, which is 
important in NAD+ binding, is a characteristic of inactive PARPs, such as 
PARP9 and PARP13, and indeed the H564A PARP12 mutant and the H564Q 
PARP12 mutant were inactive. Of note, the absence of isoleucine 660 also 
impaired PARP 12 catalytic activity, suggesting that this residue is involved in 
the catalytic mechanism. These results thus reinforce the initial hypothesis that 
PARP12 is a mART. 
To investigate this further, I performed a series of biochemical assays 
that are well described in the literature as experimental tools to analyse protein 
ADP-ribosylation (mono-ADP-ribosylation versus poly-ADP-ribosylation) 
(Hottiger et al., 2010). In all of the experiments described in this section, the 
enzyme source I used was a total membrane fraction of Sf9 insect cells infected 
with His-PARP 12 recombinant baculovirus. 
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Figure 4.1: Sequence alignment of the catalytic domains of PARPs 1,3,10 and 12 
Structure-based sequence alignment of the catalytic domains of PARPs 1,3,10 and 12. 
Yellow shading, structurally conserved regions. *, residues of the conserved "HYE" triad. 
Note that PARP 10 and PARP12 lack the glutamic residue that is important for the 
polymerase activity (red box). 
Modified from Kleine H. et al. (2008). 
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Figure 4.2: PARP12 mutants do not show auto-ADP-ribosylation activity 
Total membrane fractions from HeLa cells transfected with Myc empty vector (e. v. ) 
or cDNAs coding for His-PARP12 wild-type (P12-His WT), Myc-tagged PARP12 
wild-type (P 12Myc-WT) or Myc-tagged PARP 12 mutants (P 12Myc-H564A/P 12Myc- 
H564Q/P 12Myc-I660A), tested in the ADP-ribosylation assay performed at 37 °C for 
1 h, in the presence of 30 pM total NAD- and 4 gCi 32P-NAD+. The reactions were 
stopped by adding sample buffer, and the proteins were separated by SDS-PAGE and 
transferred onto nitrocellulose. The incorporated label was revealed by 
autoradiography (AR [32P]). The total amounts of PARP12 were revealed by Western 
blotting (Wb) using a PARP12 antibody. 
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First of all, I investigated whether His-PARP12 can ADP-ribosylate itself at 
different NAD+ concentrations (Figure 4.3a) and reaction times (Figure 4.3b). 
The rationale of these experiments was based on the data reported by 
Mendoza-Alvarez and co-workers (Mendoza-Alvarez and Alvarez-Gonzalez, 
1993) that demonstrated that at low NAD+ concentrations, PARP 1 functions 
mainly as a mART (200 nM to 2 pM NAD+), while it behaves as a pART at 
high NAD+ concentration (200 pM NAD). Figure 4.3 shows that, unlike 
PARP1, which undergoes a substantial increase in apparent molecular weight 
due to the formation of poly-ADP-ribose polymers (Kleine et al., 2008), 
PARP12 did not show any substantial changes to its mobility, even at high 
substrate (NAD) concentrations and long incubation times, indicating that the 
reaction was mono-ADP-ribosylation. 
The ADPR chains can be detached after alkali treatment. Thus, to 
further characterise the PARP12-catalysed reaction, I analysed the auto- 
modification products after NaOH treatment, by assaying for ADP-ribose 
monomer release (typical of mARTs) or ADP-ribose oligomers (typical of 
pARTs) on a sequencing gel. As shown in Figure 4.4, ADP-ribose monomer 
was the only product obtained in this reaction, indicating that PARP12 
functions as a mART. 
The differences between mono-ADPR versus poly-ADPR formation is 
also reflected in the considerably lower Vmax of PARP12 (Figure 4.5), as 
compared to PARPI (0.5 versus 500 pmol/min/pg, respectively). The K. for 
NAD+ was around 30 pM for PARP12, which is lower than the Km for 
PARP 10 and PARP 1 (roughly 50 µM). 
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Moreover, I also analysed the effects of some PARP 1 inhibitors (PJ34 
and 3-aminobenzamide [3-AB]) on PARP12 activity. The auto-ADP- 
ribosylation of PARP12 was inhibited by PJ34 (Figure 4.6a) and by 3-AB 
(Figure 4.6b), with IC50 values of 5 gM and 55 µM, respectively. These values 
are much higher than those of PARP 1 (0.04 µM and 8 µM, respectively) 
(Loseva et al., 2010). In addition, the PARP 12 activity was not affected by 
vitamin K 1, which specifically inhibits classical mARTs (Figure 4.6c). 
In summary, the experiments described here allowed me to conclude 
that the lack of detectable mobility shift of auto-ADP-ribosylated PARP12, the 
production of monomeric ADP-ribose after alkali treatment, and the kinetic 
parameters, demonstrate that PARP12 is a novel mART. 
In addition to this, and similar to what happens for PARP10, the 
differential sensitivity to known PARP 1 inhibitors, which distinguishes 
PARP 12 from PARP1, and the lack of vitamin K1 inhibition, demonstrate that 
PARP12 belongs to a new class of mARTs. 
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Figure 4.3: PARP12 auto-ADP-ribosylation reaction 
(A) His-PARP 12 from Sf9 insect cells incubated in the presence of a constant amount of 
[322P]-NAD' and increasing concentrations of unlabelled NAD', as indicated, for 30 min 
at 25 °C. The reactions were stopped by adding sample buffer. The proteins were 
separated by SDS-PAGE and transferred onto nitrocellulose. The incorporated label was 
revealed by autoradiography (AR [32P]). The total amount of PARP12 was revealed by 
Western blotting (Wb) using an anti-PARP12 antibody. (B) His-PARP12 from Sf9 
insect cells incubated in the presence of a constant amount of total NAD' and 
[32P]-NAD' at 25 °C, for the indicated times. The reactions were stopped by addition of 
sample buffer. The proteins were separated by SDS-PAGE and transferred onto 
nitrocellulose. The incorporated label was detected by autoradiography (AR [32P]). The 
total amount of PARP12 is indicated by Ponceau red staining. The displayed experiment 
is representative for two independent experiments. 
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Figure 4.4: PARP12 is a mono-ADP-ribosyltransferase 
His-PARP12 was auto-ADP-ribosylated under standard reaction conditions. The 
automodified PARP12 was TCA precipitated and then subjected to alkali treatment. 
The reaction products were analysed on a sequencing gel (see Methods). Marks with 
labels indicate the lengths of the ADP-ribose chains as determined by co-migration of 
bromophenol blue (BBF, 8 ADP-ribose polymers) and xylene cyanol (XC, 20 ADP- 
ribose polymers) (Alvarez-Gonzalez and Jacobson, 1987). The control (Ctrl) indicates 
the NAD' migration. The autoradiography analysis is shown. Note that monomeric 
ADP-ribose is the only product obtained after the alkali treatment. 
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Figure 4.5: Kinetic parameters of the PARP12 auto-ADP-ribosylation reaction 
PARP12 auto-modification reactions were performed with a fixed amount of [32P]- 
NAD+ and increasing concentrations of total NAD*. The incorporated label was 
determined by TCA precipitation and Cerenkov counting, and the data were 
analysed using a Lineweaver-Burk plot. The kinetics shown is from the means of 
two independent experiments. 
Vmax = 0.5 pmol/min/[tg; Km = 30 µM 
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Figure 4.6: Sensitivity of PARP12 auto-ADP-ribosylation to different ADP- 
ribosylation inhibitors 
His-PARP12 from Sf9 insect cells was subjected to the ADP-ribosylation reaction 
using standard conditions (50 µM total NAD' for 30 min at 25 °C) in the absence and 
presence of the indicated concentrations of different ADP-ribosylation inhibitors, as 
indicated. Controls (0 µM) were carried out with the highest concentrations of solvent 
used for the inhibitors. The IC50 values are indicated. All experiments were performed 
twice, with similar outcomes. 
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4.2.3 PARP12 modifies acidic residues 
ADP-ribosylation occurs on different amino acids, including acidic residues, 
arginines and cysteines. Thus, I also studied the residue(s) modified by 
PARP 12 during this reaction. As a first approach I used chemical treatments 
known to affect the different chemical bonds formed between ADP-ribose and 
the target amino acid with distinct sensitivities (Lupi et al., 2000). Auto-ADP- 
ribosylated PARP12 was sensitive to hydroxylamine treatment, which 
indicated an ester bond between the ADP-ribose and acidic residues. It was 
also insensitive to HgC12, which cleaves Cys-ADP-ribose, and meta- 
iodobenzylguanidine (MIBG), an inhibitor of arginine-specific mono-ADP- 
ribosyltransferases (Figure 4.7). Thus, from this first set of experiments, I 
could reasonably assume that cysteines or arginines are not modified by 
PARP 12, while acidic residues are. 
To further validate this point, we decided to identify the specific residue 
involved in this reaction by a different approach; i. e. by mass spectrometry 
(MS) analysis (in collaboration with Prof. Piero Pucci). MS is a versatile and 
indispensable tool in protein chemistry and proteomics. MS determines the 
mass-to-charge ratio (m/z) of peptide and protein ions that are generated by 
electrospray ionisation (EST) or matrix-assisted laser desorption/ ionisation 
(MALDI) sources, and tandem MS (MS/MS) enables the peptides to be 
sequenced and PTMs to be identified and characterised. Thus, MS is ideally 
suited to the determination of PTMs because the covalent addition of a 
chemical moiety to an amino acid leads to an increase in the molecular mass of 
that residue, of the corresponding (tryptic) peptide, and of the intact protein. 
For example, the phosphorylation of a Tyr residue (163 Da) increases its mass 
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Figure 4.7: PARP12 ADP-ribosylates acidic residues 
His-PARPI2 was ADP-ribosylated under standard conditions and then subjected to 
treatment with (A) I mM HgCl2 or (B) IM neutral NH2OH for the indicated times. (C) 
Alternatively, the ADP-ribosylation assay was performed in presence of the indicated 
concentrations of meta- Iodobenzylguanidine (MIBG), an inhibitor of arginine-specific 
mARTs. (D) Control reactions were performed in presence of IM NaCl, for the 
indicated times. Residual radioactivity was determined by autoradiography. Total 
amounts of PARP12 are indicated by red Pounceau staining. Note that NH2OH 
treatment reduces by 60% the ADP-ribosylation signal, while no change is observed 
after other chemical treatments, indicating that acidic residues are modified. 
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to 243 Da by the addition of an HPO3 group (80 Da). Similarly, the addition of 
ADP-ribose is responsible for an increase of 541 Da. 
It has been reported that in MS analysis the linkage between the ADP- 
ribose and the acceptor residue is labile, giving rise to mixed species that are 
linked to the only ribose-phosphate moiety or to the full ADP-ribose moiety 
(Tao et al., 2009). Based on this evidence, we sought to set up a method to 
simplify the moiety to be analysed. In detail, we decided to proceed as follows: 
first, we induced the ADP-ribosylation reaction using the total membrane 
fraction of His-tagged PARP12 from Sf9 cells; and then the total membrane 
fraction was recovered by TCA precipitation and the auto-ADP-ribosylated 
PARP 12 (present in the total membrane fraction) was treated with 
phosphodiesterase (as described in section 2.20), to obtain PARP12 linked to 
the ribose-phosphate, leaving the AMP moiety out. In this way, PARP12 was 
linked to the ribose-phosphate moiety alone (responsible for an increase of 212 
Da), allowing facilitated analysis by MS. In agreement with the chemical 
treatments described above, the described approach led us to identify the 
specific residue involved in the reaction, glutamic acid 39. The coverage 
achieved for PARP12 was 85%. Moreover, the data obtained so far indicate 
that Glu 39 seems to be the only residue modified, in contrast to PARP 1, which 
has been reported to be modified on multiple sites (Tao et al., 2009). This 
aspect should further distinguish PARP12 from PARP1, highlighting a 
completely distinct enzymatic mechanism. 
The preparation of the sample was carried out by Giuliana Catara, a member of 
our group, and the MS analysis by Angela Amoresano at CEINGE Institute, 
Naples. 
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In summary, the results described in this section clearly show that 
PARP12 modifies acidic residue and that the glutamic acid in position 39 
seems to be the only residue modified by PARP12 during its auto-ADP- 
ribosylation. The construction of a specific mutant at this identified residue 
would thus undoubtedly confirm the modification site, and should exclude the 
possibility of a secondary modification sites. 
The data reported here provides the basis for the design of a synthetic 
peptide substrate that would be useful for kinetic analyses, mechanistic 
investigations, substrate specificity determination, and the identification of 
inhibitors specific for PARP12. This last aspect is of great interest, as to date, 
no specific inhibitors for each individual PARP enzyme are available on the 
market. Thus, this area represents a future plan to develop. 
4.3 Discussion I 
The data presented in this chapter demonstrates that PARP 12 is a novel mART. 
Its kinetic parameters and sensitivity towards specific PARP1 inhibitors reveal 
a trend similar to PARP10, a known mART, and also a different chemistry 
specificity compared to the poly-ADP-ribosyl polymerase PARP1. Thus, with 
these results, I have described a new intracellular mART that belongs to the 
PARP superfamily. My data are in agreement with the sequence analysis 
performed by Koch-Nolte and co-workers (Otto et al., 2005), from which they 
suggested the existence of a new family of intracellular mARTs, to which 
PARP12 belongs. In addition, the production of PARP12 mutants allowed me 
to demonstrate the importance of the HYI triad for its catalytic activity. 
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Moreover, these findings support the structure- and sequence-based 
division of the PARP family into three functionally distinct subgroups, one 
with poly-ADP-ribosyl polymerase activity, one with mART activity (to which 
PARP12 belongs) and one that is catalytically inactive, as reported by Lusher 
and co-workers (Kleine et al., 2008) (for summary, see Table 1.2). 
Importantly, the MS analysis reported above permits the identification 
of the specific residue involved in the reaction, i. e. the glutamic acid in position 
39. In addition to the identification of this specific residue, the data reported 
here show that Glu 39 can be a unique site for the modification, different from 
what has been shown for PARP1, which shows multiple auto-modification 
sites. In summary, we can consider the data described in this Chapter 
significant for four reasons, as follows. 
First, I have described a new intracellular enzyme that can catalyse 
mono-ADP-ribosylation reactions, increasing the possibility of understanding 
how this PTM is used intracellularly with respect to its specific pathways. 
Secondly, I have developed a strategy to map the modification sites of the 
PARP12 substrates, permitting the identification of a single ADP-ribosylation 
site on PARP 12. This represents the first verification of the acceptor amino- 
acid residue in PARP12, where the ADP-ribosylation takes place. Thirdly, in 
contrast to PARPI, the data obtained so far suggest that the auto-ADP- 
ribosylation of PARP12 can be limited to a single residue. Finally, using the 
information derived from this study, we should be able to design small peptide 
substrates for PARP 12 that can be used as specific inhibitors, or as PARP 12 
substrates. 
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4.4 Identification of PARP12 substrates using the macro-domain 
pull-down assay 
The first poly-ADPR molecule in mammals was identified in 1963 (Chambon 
et al., 1963) and PARP1, the main enzyme responsible for synthesising poly- 
ADPR in cells was cloned in 1987 (Alkhatib et al., 1987). At present, it is well 
recognised that PARP 1 is the founder member of a larger family of enzymes 
that have distinct enzymatic activities. Nevertheless, to date the physiological 
consequences of ADP-ribosylation are only in part understood. In this context, 
an important aspect of my PhD project has been the study of the physiological 
role of intracellular mono-ADP-ribosylation, with a specific focus on PARP12. 
To link PARP12 activity to a physiological role, we decided to identify its 
substrates. A great limitation to the study of ADP-ribosylated proteins has been 
the lack of ADPR-specific antibodies that can potently recognise ADP- 
ribosylated proteins. In our laboratory, a new method has been described for 
the identification of ADP-ribosylated substrates (Dani et al., 2009). It is based 
on the use of a protein module, the macro domain of the protein Af1521 from 
Archeoglobus fulgidus, a domain that recognises monomeric and polymeric 
ADPR (Karras et al., 2005). Briefly, the method foresees the use of both a 
wild-type macro domain, that binds ADPR, and a mutated macro domain, 
where the point mutation of the glycine in position 42 to glutammic acid 
(G42E) is sufficient to abrogate the ADPR binding to the macro domain and 
thus to ADP-ribosylated proteins. The combined use of these two versions of 
the macro-domain together with MS analysis provides the methodology for the 
identification of ADP-ribosylated proteins. 
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The method reported above was based on the use of a His-tagged macro 
domain. These authors also described a slightly modified method using a GST- 
tagged macro domain cross-linked to Sepharose resin to minimise non-specific 
resin interactions with proteins. Here I have used the procedure with the GST- 
tagged macro domains for the identification of specific PARP12 substrates 
(Figure 4.8). 
4.4.1 Setting up of the ADP-ribosylation conditions used for the macro-domain 
based pull-down assay 
The use of the macro-domain-based pull-down assay represents a good, affinity 
based, method to enrich samples in ADP-ribosylated proteins. In addition to 
this strategy, to increase the amounts of ADP-ribosylated proteins, I increased 
the levels of ADP-ribosylation catalysed by PARP12, by performing an in vitro 
ADP-ribosylation assay before the macro-domain-based pull-down assay. 
To establish the best reaction conditions to obtain high levels of ADP- 
ribosylation, I performed the ADP-ribosylation reaction using total membrane 
fractions of control and PARP 12 transiently transfected HeLa cells at different 
NAD+ concentrations, reaction times and temperatures. First of all, I performed 
the ADP-ribosylation reaction for 2h at 37 °C using different total NAD+ 
concentrations (from 500 gM up to 3.0 mM). Figure 4.9a shows that at 2 mM 
total NAD+, the amount of auto-modified PARP12 was higher compared to 
these other NAD+ concentrations. The efficiency of the reaction was also 
demonstrated by the appearance of an upper band that was recognised by the 
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Figure 4.8: Macro-domain-based pull-down assay 
Schematic representation of the macro-domain-based pull-down assay, as described by 
Dani N. et al. (2009). Solubilised proteins are incubated with the mutated macro domain 
(mAfl52l/G42E; non-specific pull-down) and then with the wild-type macro domain 
(mAf152l; specific pull-down). The proteins bound to the wild-type macro domain are 
eluted and then analysed by LC-MS/MS. 
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PARP12 antibody, corresponding to the ADP-ribosylated PARP12. The 
intensity of this band increased with the increase in total NAD+ concentrations. 
Based on this result, I kept the total NAD+ constant and performed the assay 
while changing the incubation time (1,2,5,8,12 h) as well as the temperature 
(25 °C and 37 °C). Figure 4.9b shows that the greatest amount of modified 
protein was obtained using 8h and 25 °C incubations. 
It is important to note that 2 mM total NAD+ is not a physiological 
condition, but as explained above, the idea was to use strong conditions to 
force the reaction to a maximum level to obtain an extensive modification of 
the substrates by PARP12. Bearing this in mind, I decided to use these 
conditions as described here to perform the ADP-ribosylation assay before the 
identification of PARP12 substrates, using the macro-domain-based pull-down 
assay. 
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Figure 4.9: Setting-up of the ADP-ribosylation conditions 
HeLa cells were transiently transfected with empty vector (e. v. ) or with PARPI2 (P 12) cDNA. (A) 
Fifty pg total membrane fraction were used to perform the ADP-ribosylation assays, using 4 µCi 
[32P]-NAD' and the indicated NAD+ concentrations. The reactions were carried out for 2h at 37 °C, 
and stopped by addition of sample buffer. The proteins were analysed by SDS-PAGE and 
transferred onto nitrocellulose. ADP-ribosylated PARPI2 was followed by autoradiography (AR 
[32p]); total levels of PARP12 were analysed by Western blotting (W. b) using an anti-PARP12 
antibody. (B) Thirty . tg total membrane fraction were used in the ADP-ribosylation assays, 
performed using 2 mM total NAD', labelled with 4 µCi [32P]-NAD'. The reactions were carried out 
at 25 °C or 37 °C, for the indicated times. The samples were processed as described above. 
Quantification of the ADP-ribosylated band at 80 kDa (molecular weight of PARP12) was carried 
out using an Instant Imager and was used to evaluate the trend of the ADP-ribosylation reaction; 
data are means of two independent experiments. Representative images are shown. 
219 
Results-Part II 
4.4.2 Description of the macro-domain-based pull-down assay 
After establishing the best ADP-ribosylation conditions, I performed the ADP- 
ribosylation reaction using 8 mg total membrane fraction from control HeLa 
cells untransfected or transiently transfected with PARP12. The reaction was 
performed using 2 mM total NAD+, for 8 h, at 25 °C. At the end of the 
incubation, the total membrane fraction was separated from the NAD+ mixture 
by centrifugation, washed to remove extra buffer, and solubilised. The 
solubilised proteins were first incubated with the mutated macro domain, as a 
pre-clearing step, and then in sequence with the wild-type macro domain (as 
described in section 2.15). The proteins bound to the resins were eluted using 
sample buffer, and then run on acrylamide gel and stained with coomassie (as 
described in section 2.12.3.4). The gel was analysed by MS as indicated in 
Figure 4.10. 
We decided to analyse only the proteins bound to the wild-type resins 
(from both control and PARP 12-over-expressing samples) and to use the 
proteins identified in the control sample as the background for the procedure. 
In this way, we only considered those proteins that were specific for PARP12. 
Approaching the analysis in this way, we excluded proteins that were certainly 
ADP-ribosylated, but not by PARP12. Indeed, as internal control, we found 
glutamate dehydrogenase (GDH), a known substrate that is mono-ADP- 
ribosylated by SIRT4 (Haigis et al., 2006), or PARPI, a poly-ADP-ribosylated 
protein. Using this described approach, I found 25 specific putative substrates 
for PARP12. All of the identified proteins (from both control and PARP12 
over-expressing HeLa cells) are reported in Table 4.1. 
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Figure 4.10: Bands analysed by MS for identification of PARP12 substrates 
The solubilised proteins from the control (Ctrl) and PARP12 over-expressing HeLa cells 
(PARP12) were first incubated with the mutated macro-domain, as a pre-clearing step, 
and then in sequence with the wild-type macro-domain. The proteins bound to the resins 
were eluted using sample buffer, run on acrylamide gels and stained with Coomassie 
blue. The proteins eluted from the resin cross-linked with the wild-type macro-domain 
were analysed by MS, as shown by the grid drawn on the lanes. In detail, the individual 
protein bands were excised from the gels and subjected to in-gel trypsin digestion and 
MS analysis. The trypsinisation and MS analysis were performed entirely at the 
CEINGE Institute by Dr. Maria Monti. 
221 
Results-Part II 
Table 4.1: list of ADP-ribosylated substrates identified using the macro-domain 
based pull-down assay. The substrates specifically identified in PARP 12 over-expressing 
sample are highlighted in red. 
Substrates from control HeLa cells Substrates from PARP12 overexpressing HeLa 
cells 
Poly [ADP-ribose] polymerase 1 Poly [ADP-ribose] polymerase 1 
SAFE-like, transcription modulator 
Scaffold attachment factor B2-B1, Carbamoyl- Scaffold attachment factor B2-B1, Carbamoyl- 
phosphate synthase phosphate synthase 
Matrin-3; Netrin receptor UNC5A 
N-acetyltransferase 10; Heterogeneous nuclear N-acety ltransferase 10; Heterogeneous nuclear 
ribonucleoprotein U ribonucleoprotein U 
DNA topoisomerase 1 
Splicing factor, proline- and glutamine-rich; Kinesin- Splicing factor, proline- and glutamine-rich; Kinesin- 
like protein KIF20A; Eukaryotic translation initiation like protein KIF20A; Eukaryotic translation initiation 
factor 4 gamma 3 factor 4 gamma 3 
RNA helicase DDX1; DNA helicase; RNA binding protein 
EWS 
ATP-dependent RNA helicase DDX3; Lamin A/C; RNA ATP-dependent RNA helicase DDX3; Laminin A-C; RNA 
binding protein 14 binding protein 14 
Calcium-binding mitochondnal carrier protein Aralar2 
RNA helicase DDX1; RNA helicase DDX3X; ATP- RNA helicase DDX1; RNA helicase DDX3X; ATP- 
dependent DNA helicase 2; Ribophorin-1; Nuclear RNA dependent DNA helicase 2; Ribophorin-1; Nuclear RNA 
export factor 1; p21 Ras GTPase-activating protein export factor 1; p21 Ras GTPase-activating 
associated p62 proteinassociated p62 
RNA helicase DDXS; Laminn A/C; RNA binding protein RNA helicase DDX5; Laminn A/C; RNA binding protein 
FUS; Paraspeckle component 1 FUS; Paraspeckle component 1 
RNA helicase DDX28; Heterogeneous nuclear 
ProteinFAM98A ribonucleoprotein G 
Protei n FA M 98A 
Dihydrolipoyllysine-residue succinyltransferase; RNA 
ATP-synthase subunit alpha; glutamate dehydrogenase helicase DDX5 
(GDH) ATP-synthase subunit alpha; glutamate dehydrogenase 
(GDH) 
Elongation factor 1-alphal 
Non-POU domain-containing octamer-BP; Polymerase Non-POU domain-containing octamer-BP; Polymerase 
delta-interacting protein 3; delta-interacting protein 3; 
Heterogeneous nuclear ribonucleoprotein G; 60S Heterogeneous nuclear ribonucleoprotein G; 60S 
ribosomal protein L4 ribosomal protein L4 
Actin Actin 
HLA class I histoeompatibility antigen 
hTidl hTid 1 
60S ribosomal protein L5; DNA-3-methyladenine 
glycosylase (ADPG); 
Prohibitin-2; Histone H1.2 ; THO complex subunit 4 Heterogeneous nuclear ribonucleoproteins A2/B1-AI 
Prohibitin-2; Histone H1.2 ; THO complex subunit 4 
40S ribosomal protein S3; Histone H1.5 40S ribosomal protein S3; Histone H1.5 
ADP/ATP translocase; 40S ribosomal protein S4 Signal recognition particle receptor subunit beta; 605 
ribosomal protein L7 
ADP/ATP translocase; 40S ribosomal protein S4 
GTP-binding nuclear protein Ran 
UPF0568 protein C14orf166; 40S ribosomal protein UPF0568 protein C14orf166; 40S ribosomal protein 
S8; Rab5A; Probable ribosome S8; Rab5A; Probable ribosome 
biogenesis protein NEP1; 60S ribosomal protein L13- biogenesis protein NEP1; 60S ribosomal protein L13- 
L10a L10a 
Rab-14; 60S ribosomal protein 115-L9; RlbIA, 
Rab7A; Rab2A Transmembrane protein 33 
Rab7A; Rab2A 
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4.4.3 Study of the substrates identified 
The first approach I used to study the substrates identified was to cluster the 
different proteins into subgroups based on their functions, according to the data 
available in the literature. This criterion allowed me to divide the substrates 
identified into five major subgroups, as shown in Figure 4.11. Thirteen of 
identified proteins are involved in RNA processing, three are DNA-binding 
proteins, four are members of the GTPase family, two are mitochondrial 
proteins and three are plasma-membrane receptors. As described in the 
previous section, the macro-domain module functions as the bait to fish out 
ADP-ribosylated proteins. It is reasonable to assume that some of the proteins 
identified would be interactors of ADP-ribosylated substrates rather than 
substrates of ADP-ribosylation. Considering this, validation experiments need 
to be undertaken. 
One common problem in the proteomic approach is how to sort and 
validate all of the identified proteins. I decided to use a "hypothesis-driven 
approach" to start with the validation of the substrates. As a first selection 
criterion, I decided to choose proteins or protein families known already to be 
ADP-ribosylated, including by toxins. I reasoned that, indeed, toxins could use 
mechanisms similar to mammalian endogenous enzymes to regulate protein 
functions. As a proof of principle, the eukaryotic translation elongation factor-2 
is the specific target of ADP-ribosylation by two lethal toxins, DTX and 
Pseudomonas aeruginosa exotoxin A, and it has also been demonstrated to be 
an endogenous mono-ADP-ribosylated protein, following interleukin-lß 
stimulation (Jager et al., 2011). Figure 4.11 shows that small-GTPases are 
among the possible substrates for PARP12. 
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Figure 4.11: Sub-groups of ADP-ribosylated proteins 
The substrates identified by MS (as indicated) were clustered into sub-groups based on 
their functions (as indicated), according to the data available in the literature. Five major 
sub-groups emerged from this analysis. Each of these is highlighted in a different colour. 
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Interestingly, as reported in the introduction (paragraph 1.2.2), Barbieri and co- 
workers showed that RabS and Rab4 are substrates of the ADP-ribosylation 
catalysed by the toxin ExoS from Pseudomonas aeruginosa (Deng and 
Barbieri, 2008a). This finding made the small-GTPases `appealing' substrates 
for my analysis. 
I decided to start with RablA, a small-GTPases localised at the 
intermediate compartment and involved in the control of transport between the 
endoplasmic reticulum (ER) and the Golgi complex, as well as in intra-Golgi 
transport. Of note, as described in section 4.6, PARP12 is a Golgi-localised 
protein. Together, the considerations reported above prompted me to select 
Rab 1A as the first target of my analysis. 
4.5 RablA as a PARP12 substrate: validation experiments 
4.5.1 PARP12 ADP-ribosylates Rab1A 
As described in section 4.4.2, to identify PARP12 substrates, I performed the 
ADP-ribosylation reaction using 2 mM total NAD+ for 8h at 25 °C, conditions 
that are not physiological. For this reason, I checked if the over-expressed 
PARP12 can modify Rab lA also in intact HeLa cells. To this end, PARP 12 
was over-expressed in HeLa cells and, after 18-20 h, cell lysates were used to 
perform the macro-domain-based pull-down assay. After a pre-clearing step to 
remove non-specific binding, the lysates from control HeLa cells and PARP12 
over-expressing HeLa cells were incubated with the wild-type macro domain. 
The bound proteins were eluted with sample buffer, fractionated on SDS- 
PAGE gels and analysed by Western blotting, using antibodies against 
PARP12 and RablA (see section 2.15 for method). Figure 4.12 shows that 
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PARP12 was specifically recognised by the wild-type macro-domain; this 
constituted a positive internal control of the procedure. The antibody that 
recognised RablA showed that there was an enrichment in the amount of 
RablA linked to the wild-type resin when PARP12 was over-expressed 
(compared to control HeLa cells). One can consider the binding of Rab lA to 
the wild type resin observed in control HeLa cells as the amount of Rab lA 
modified by endogenous PARP12. 
Another way I selected to confirm that PARP12 could ADP-ribosylate 
Rab 1A was the use of biotinylated NAD+ in in vitro ADP-ribosylation assays. 
The advantage of this tool is that it is possible to make use of the high affinity 
of the streptavidin resin towards biotin to recover ADP-ribosylated substrates. I 
performed the ADP-ribosylation reactions using total membrane fractions from 
control and PARP12 transiently transfected HeLa cells, using an ADP- 
ribosylation mixture containing biotinylated NAD+ or, as the control, biotin 
alone. After the reaction, the membrane fractions were solubilised and 
incubated with the streptavidin resin. The bound proteins were eluted using 
sample buffer, separated on SDS-PAGE, and transferred onto nitrocellulose 
(see methods, paragraph 2.18.2). 
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Figure 4.12: Macro domain pull-down assay in intact cells 
Total lysates of HeLa cells transfected with empty vector or with Myc-tagged 
PARP12 were subjected to a preclearing step (P. C. ) and then incubated with the wild- 
type macro domain (as indicated), to pull-down ADP-ribosylated proteins. The 
proteins were separated by SDS-PAGE and blotted onto nitrocellulose. Western 
blotting (W. b. ) with anti-PARP12 and anti-RablA antibodies, as indicated. Inputs 
were also monitored, as indicated. Note that there was an enrichment in the amount of 
ADP-ribosylated Rab lA when PARP12 was over-expressed (compare macro domain 
WT lanes). 
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Figure 4.13: ADP-ribosylation reaction using biotinylated NAD` 
HeLa cells were transiently transfected with empty vector (Control) or PARP12 cDNA. 
Total membrane fractions were used to perform in vitro ADP-ribosylation assays, using 
50 µM total NAD+, containing 5 µM biotinylated NAD`. The reactions were carried out 
for 2h at 37 °C. The samples were analysed by SDS-PAGE and transferred onto 
nitrocellulose. ADP-ribosylated proteins were detected using an anti-biotin antibody. 
Upper panel (w. b: anti-biotin) indicates ADP-ribosylated Rab l A. Inputs were also 
analysed using both anti-PARP12 (to monitor the over-expression) and anti-Rab lA 
antibodies (bottom panels). 
Note that there was an enrichment in the amount of ADP-ribosylated Rab lA when 
PARP 12 was over-expressed (upper panel). 
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The modified proteins were revealed using an anti-biotin antibody. Figure 4.13 
(upper panel) shows that the over-expression of PARP 12 led to an increase in 
the amounts of ADP-ribosylated RablA, as compared to the control, while no 
non-specific binding of biotin to Rab lA was observed. The Western blotting 
with anti-RablA (bottom panel) shows that the band of interest was indeed 
RablA. 
To summarise, the two different procedures I have described here 
(macro-domain pull-down assay in intact cells at physiological NAD+ 
concentrations, and in vitro ADP-ribosylation assay using biotinylated NAD) 
are supporting Rab lA as a substrate for the mART PARP12, validating the 
data obtained through MS. However, from these experiments, it is not possible 
to rule-out that Rab lA might be part of a complex and that another protein of 
this complex is instead the direct target of PARP12. However, as also 
described in the next section, the strongly denaturing solubilisation conditions I 
used, should disrupt this putative complex, thus supporting the conclusion that 
Rab lA is a substrate for PARP12. Other experiments, such as an 
immunoprecipitation of RablA after in vitro ADP-ribosylation assays or 
macro-domain-based pull-down assays in cells in which the expression of 
PARP12 is abrogated by RNA interference should directly demonstrate that 
Rab1A is modified by PARP12. 
4.5.2 The PARP12-Rab1A interaction 
An alternative way I considered to validate Rab 1A as a PARP 12 substrate was 
to determine whether these two proteins interact. To address this question, I 
investigated if the over-expression of a myc-tagged PARP12 would allow the 
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detection of an interaction with the endogenous Rab 1 A. Figure 4.14 shows that 
under the conditions of the experiment, there was no interaction. However, it is 
important to note that it is not always possible to validate an interaction 
between two proteins, in particular if we are referring to an enzyme-substrate 
complex. Indeed, in this case, the interaction is transient, since by definition an 
enzyme has to release its substrate after the modification. However the 
interaction can be stabilized using cell lysates from cells that over-express 
PARP12 mutants and the interaction analysed by performing immune- 
precipitation experiments. In this case, since the mutants do not have catalytic 
activity, they should retain the substrates, thus allowing the interaction to be 
seen. The principle for this approach was proposed by Tonks and colleagues 
for the identification of protein phosphatase interactors (Flint et al., 1997). 
Another aspect to consider is that to solubilise PARP 12 strong detergents need 
to be used (described in section 2.13.3), hence using denaturing conditions that 
can interfere with the maintenance of the complex. Therefore, when the data 
described in the previous paragraph is considered, showing that it is not 
possible to follow the interaction biochemically under these experimental 
conditions used, support the conclusion that RablA is indeed a substrate, and 
not an interactor, of PARP 12. 
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Figure 4.14: RablA does not co-immunoprecipitate with PARP12 
HeLa cells were transiently transfected with myc empty vector (Myc-e. v. ) or myc- 
tagged PARP12 (Myc-P12) cDNAs. The cells were lysed, and the over-expressed 
PARP 12 was immunoprecipitated using an anti-Myc antibody. The samples were 
analysed by SDS-PAGE and transferred onto nitrocellulose. Immunoprecipitated 
PARP 12 was analysed using an anti-PARP 12 antibody (upper panel). Western blotting 
(W. b) with an anti-RablA antibody is shown in the bottom panel. Inputs and unbound 
materials were also monitored, as indicated. 
Note that there is no interaction between PARP12 and Rab1A under the experimental 
conditions used. 
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4.5,3 RablA modulates PARP12 activity 
As described in the previous section, RablA is ADP-ribosylated by PARP12. I 
reported in the Introduction (section 1.3.2.1) that the defensin HPN-1 is a 
substrate for ART 1 and that high concentrations of defensin HNP-1 inhibit the 
transferase activity of ART 1, thus representing a regulatory mechanism. I 
sought to investigate whether a similar mechanism could regulate PARP 12, 
and thus I checked if the concomitant over-expression of PARP 12 and Rab 1A 
could affect PARP 12 enzymatic activity. 
To address this point, I transfected HeLa cells with cDNAs coding for 
GFP, PARP 12, or GFP-tagged Rab l A, or co-transfected them with 
GFP/PARP12 and GFP-Rab l A/PARP 12. The total membrane fractions from 
the transfected cells were used to perform in vitro ADP-ribosylation assays 
(method described in section 2.18). As shown in Figure 4.15, the concomitant 
over-expression of GFP-tagged Rab lA and PARP 12 abrogated the ADP- 
ribosylation activity of PARP12, while the incubation of GFP-tagged RablA 
over-expressing total membranes together with PARP 12-over-expressing total 
membranes did not give the same result. These data suggest that PARP12 and 
RablA should be in contact in some way or that the presence of cofactors is 
needed to provide an effect. For these reasons, it is possible that the simple 
incubation of membranes does not allow a correct environment to achieve an 
effect on PARP 12 enzymatic activity. 
I would like to point out that the results I have described here show that 
PARP12 catalytic activity can be modulated by Rab l A. This new finding 
represents the first example of regulation (in this specific case, of inhibition) of 
a member of the new mART family by another protein. It might be possible 
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Figure 4.15: RablA regulates PARP12 ADP-ribosylation activity 
HeLa cells were transiently transfected with cDNAs coding for GFP, PARP12, or GFP- 
tagged Rab 1 A, and co-transfected with GFP/PARP 12 and GFP-Rab 1 A/PARP 12. The 
total membrane fractions (TM) from the transfected cells were used to perform in vitro 
ADP-ribosylation assays. Samples were analysed by SDS-PAGE and transferred onto 
nitrocellulose. The ADP-ribosylated proteins were analysed by autoradiography (AR 
[32P]). Arrow, ADP-ribosylated PARP12. PARP12 and GFP-Rab lA levels were 
analysed using PARP12 and RablA antibodies. Lane 1, TM over-expressing PARPI2; 
lane 2, TM over-expressing GFP-RablA; lane 3, TM over-expressing PARPI2 
incubated with TM over-expressing GFP-RablA; lane 4, TM co-over-expressing 
PARP 12 and GFP-Rab 1 A; lane 5, TM co-over-expressing PARP 12 and GFP. 
Note that PARP 12 catalytic activity is strongly reduced by Rab IA over-expression. 
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that Rab 1A interacts with PARP 12 at the auto-modification site, thus impairing 
its auto-ADP-ribosylation. Further work is required to dissect out the molecular 
mechanisms responsible for this regulatory mechanism and the role in terms of 
PARP12 function. 
4.6 PARP12 localisation 
4.6.1 Endogenous PARP12 is localised to the Golgi complex 
Sub-cellular localisation determines the environments in which proteins 
operate. As such, the sub-cellular localisation influences protein functions by 
controlling access to and availability of all types of molecular interaction 
partners and possibly metabolites. Accordingly, knowledge of protein 
localisation often has a significant role in characterising the cellular function of 
hypothetical and newly discovered proteins. 
To understand the role of PARP12, as well as the identification of its 
substrates, I analysed its subcellular localisation. The cell system I used is 
HeLa cells, a well characterised cell model, and I investigated the localisation 
of endogenous PARP12 in these HeLa cells by immunofluorescence. The 
staining given by the PARP 12 specific antibody clearly indicated that PARP 12 
is localised to the Golgi complex, and to some extent in the nucleus (Figure 
4.16a). Here, I used a generic Golgi marker (giantin) for Golgi localisation. 
The staining of the antibody was specific, as confirmed by the lack of labelling 
after abrogation of PARP 12 expression using RNA interference (Figure 4.16b). 
Interestingly, the Golgi localisation seen by immunofluorescence was 
not as predicted, since any transmembrane domain or specific sequences of 
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Figure 4.16: PARP12 localises to the Golgi complex 
(A) Representative confocal images of non-transfected HeLa cells labelled with an anti- 
PARP12 antibody (green, for endogenous PARP12) and with a monoclonal anti-giantin 
antibody (red, Golgi marker). (B) Endogenous PARP12 expression was abrogated using 
a specific siRNA. The cells were labelled as above. The absence of PARP12 labelling 
indicates that the staining of the antibody is specific. Scale bar 10 µM. 
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PTMs that target proteins to membranes (such as prenylation) would be 
revealed by bioinformatic analysis. One possible explanation of this 
observation is that the presence of PARP12 on the Golgi complex is dependent 
on an interaction with a specific partner. Thus far, I did not evaluate this 
possibility, but it would be of great interest as a future extension of this study, 
also considering recent data that demonstrate that PARP5 (the other PARP 
localised at the Golgi complex) interacts with PARP 12 (Leung et al., 2011). 
4.6.2 PARP12 localisation during cell-cycle progression 
In the previous section, I reported that PARP 12 is a Golgi-localised protein and 
that it is also present to some extent in the nucleus. It is well known that during 
mitosis the Golgi ribbon undergoes extensive fragmentation through a 
multistage process that promotes its correct partitioning and inheritance by 
daughter cells (Sutterlin et al., 2002). Based on these observations, I wondered 
if the two different PARP12 localisations (nucleus/Golgi) might change during 
cell-cycle progression. 
In general, I performed the immunofluorescence experiments on non- 
synchronised HeLa cells, and so across different phases of the cell cycle. To 
obtain a more homogeneous population to analyse, I performed the 
immunofluorescence experiments on synchronised cells (for methods, see 
paragraph 2.9). To achieve this, I took advantage of the use of a specific 
inhibitor of Cdkl (RO-3306) that results in the accumulation of cells in the G2 
phase (Vassilev et al., 2006). This inhibition is reversible, so after inhibitor 
washout, cells can re-enter the cell cycle in a synchronous manner, and they 
reach the mitotic peak within 1h (M phase). In addition, to accumulate cells in 
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the Go phase, the cells were starved for 24 h. To detect the different stages of 
the cell cycle, I used an antibody that recognises phosphorylated serine 10 of 
histone H3. This histone is phosphorylated by the kinase Aurora-B, a crucial 
event for chromosome condensation. During chromosome assembly, global 
phosphorylation of histone H3 occurs in a step-wise and ordered manner. In 
mammalian cells in G2 phase, phosphorylation is first detected in 
pericentromeric heterochromatin, and as mitosis proceeds, it spreads 
throughout the whole of the chromosomes. This global phosphorylation of 
histone H3 is completed in late prophase and maintained through metaphase. 
Dephosphorylation of histone H3 begins in anaphase and ends at early 
telophase (Hans and Dimitrov, 2001), and thus it is not seen in Gl/S and 
quiescent cells. 
Figure 4.17 shows that in cells in Go (no staining of phosphorylated 
histone H3) PARP12 was exclusively localised on the Golgi complex, without 
any nuclear staining. In contrast, PARP12 localisation in the nucleus varied 
according to cell-cycle progression. Indeed, PARP12 showed a nuclear and 
perinuclear staining in G2 cells (characterised by discrete dots of 
phosphorylated histone H3), while it was dispersed throughout the cytosol 
when cells were in M-phase (when phosphorylated H3 co-localises with 
condensed chromosomes). I did not evaluate this observation further, but it 
would be interesting to further study it since one of the substrates identified for 
PARP12 is the small GTPase Ran, a protein that is involved in nuclear-to- 
cytoplasm transport and in the control of the cell cycle (Clarke and Zhang, 
2008). 
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Figure 4.17: PARP12 localisation changes during cell-cycle progression 
HeLa cells were synchronised in different phases of the cell cycle, fixed and labelled 
with the DNA-specific dye Hoechst and with an anti-phospho-histone-H3 antibody 
(PH3), to identify the different cell-cycle phases. An anti-PARP12 antibody was used 
to follow PARP12 localisation during the different phases. Representative images are 
shown. Scale bar 10 [M. Note that PARP12 localisation is exclusively on the Golgi 
complex in quiescent cells, while it starts having a nuclear localisation as cells enter 
the cell cycle. 
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4.6.3 Localisation of over-expressed PARP12 
Different from the endogenous protein, over-expressed PARP12 shows a 
complex localisation. In particular, the protein was present as foci in the 
cytoplasm (Figure 4.18). Of note, I observed that PARP12 over-expression was 
associated with a loss of the classical Golgi-ribbon-like organisation, with the 
Golgi appearing fragmented. Under these conditions, PARP12 did not co- 
localise with the Golgi markers (Figure 4.18). 
Thus, these experiments suggest that PARP12 is involved in the 
maintenance of the structure of the Golgi complex. Interestingly, a role for 
RablA in the control of the structure of this organelle has already been 
reported (Haas et al., 2007; Wilson et al., 1994), and thus it is possible to 
hypothesise that ADP-ribosylation of RablA catalysed by the over-expressed 
PARP12 can alter the RablA functions, and can lead to this fragmented 
phenotype. Based on these assumptions, the abrogation of Rab lA expression 
should have the same effects, on both the structure of the Golgi complex and 
on PARP12 localisation. For this reason, I decided to further investigate this 
aspect, by evaluating the consequences of the modulation of Rab 1A expression 
on PARP12 localisation. 
4.6.4 PARP12 localisation is affected by modulation of Rab1A expression 
To determine whether the modulation of Rab 1A expression affects PARP 12 
localisation, I first silenced RablA in HeLa cells and then analysed the 
localisation of the endogenous PARP12. As shown in Figure 4.19, RablA 
silencing strongly affected PARP12 localisation, which appeared to be 
displaced from the Golgi complex, which itself appeared to be fragmented. The 
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Figure 4.18: PARP12 over-expression results in fragmentation of the Golgi complex 
(A) Representative confocal image of HeLa cells transiently transfected with myc-tagged 
PARP12, labelled with an anti-PARP12 antibody (red) and giantin antibody (green), to 
monitor Golgi morphology. Scale bar 10 [tM. (B) The graph shows the quantification of 
the cells showing a fragmented Golgi, as data from three independent experiments. Note 
that the cells with fragmented Golgi increased by 30% when PARP 12 was over-expressed. 
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Figure 4.19: PARP12 localisation is affected when RablA expression is abrogated 
(A) RablA expression in HeLa cells was abolished by using a specific siRNA. The cells 
were then fixed and stained with an anti-PARP12 antibody (red, endogenous PARPI2) 
and with an anti-giantin antibody (green, Golgi marker). Representative images are 
shown. Scale bar 10 µM. (B) The levels of RablA interference were monitored by 
Western blotting (W. b) using an anti-RablA antibody, and normalised according to the 
GAPDH levels. 
Note that in the absence of Rab l A, PARP 12 is displaced from the Golgi complex, 
which itself appears to be fragmented. 
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over-expression of RablA, instead, did not have any effects on endogenous 
PARP12 localisation, which still localised to the Golgi complex (Figure 4.20). 
The displacement of endogenous PARP12 from the Golgi complex 
after abrogation of RablA expression led me to suppose that RablA is 
important for PARP12 localisation, thus explaining the mis-localisation from 
the Golgi complex of over-expressed PARP 12. For this reason, I checked if the 
concomitant over-expression of RablA-GFP and PARP12 restored the Golgi 
localisation of over-expressed PARP l 2. Figure 4.21 shows that Rab lA over- 
expression is not sufficient to restore the Golgi localisation of over-expressed 
PARP12. This suggests that other proteins are involved in ensuring the 
localisation of PARP 12 to the Golgi complex, or that protein overexpression 
interferes with the localisation process. 
Taken together, these data are in agreement with previous work 
showing that RablA is implicated in the maintenance of the Golgi morphology 
(Haas et al., 2007; Wilson et al., 1994); (Venditti Rossella, personal 
communication) and suggest that PARP 12 localisation on the Golgi complex 
may be dependent on the existence of a protein complex. In this regard, 
recently Chang and co-workers demonstrate that PARP12 interacts with 
PARP5 (Leung et al., 2011), the other PARP localised at the Golgi complex. 
Thus, one can speculate that the Golgi localisation of PARP12 is relying on a 
protein complex; when the equilibrium of this complex is altered (by PARP 12 
over-expression), PARP12 does not localise on the Golgi complex. 
Interestingly, as described in the next section, a role for ADP-ribosylation 
seems to be required for the correct Golgi localisation of PARP 12, thus 
suggesting that PARP5 could indeed play a role in this. 
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Figure 4.20: Rabla over-expression does not affect endogenous PARP12 localisation 
Representative images of HeLa cells transiently transfected with GFP-tagged Rab1A and 
stained with an anti-PARP12 antibody (red, endogenous PARP12). Scale bar 10 µM. 
Note that Rab1A over-expression does not affect the endogenous PARP12 localisation. 
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Figure 4.21: Concomitant over-expression of Rab1A and PARP12 
Representative images of HeLa cells co-transfected with GFP-tagged Rab 1A and myc- 
tagged PARP12, stained with an anti-myc antibody. Note that the concomitant 
overexpression of RablA does not restore the Golgi localisation of over-expressed 
PARP 12 (see text for details). Scale bar 10 µM. 
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1.7 PARP12 has a role in the re-formation of the Golgi structure 
after BFA wash-out 
It is well known that BFA causes a rapid dispersal of Golgi membranes and a 
redistribution of Golgi-resident enzymes to isolated vesicles and to the ER. 
This process is completely reversible, and the Golgi reassembles within 1h of 
addition of BFA-free medium (Lippincott-Schwartz et al., 1989). Considering 
that PARP12 might have a role in the maintenance of the Golgi morphology, I 
investigated whether PARP 12 might also have a role in the reassembly of the 
Golgi structure after BFA was washed out. To this end, I evaluated the re- 
formation of the Golgi structure in cells in which the expression of PARP12 
was abolished using a specific PARP 12-directed siRNA, compared to cells 
transfected with a non-targeting siRNA. The complete disassembly of the 
Golgi structure was achieved by treating the cells with 2.5 µg/ml BFA for 30 
min at 37 °C, and its re-formation was achieved by the removal of the BFA, 
followed by incubation of complete BFA-free medium (Fujiwara et al., 1988; 
Lippincott-Schwartz et al., 1989). Figure 4.22 clearly demonstrates that while 
recovery of the Golgi structure was complete in control cells, the cells lacking 
PARP12 showed a defect in the re-formation of the Golgi `ribbon'. To 
understand if this effect is connected to the enzymatic activity of PARP 12 and 
not to a structural role of the protein per se, I analysed the Golgi reassembly in 
the presence of PJ34, a known inhibitor of ADP-ribosylation. PJ34 is best 
known as a PARP1 inhibitor, but, as reported in section 4.2.2, at micromolar 
concentrations it also inhibits PARP12 activity (IC50 for PARP1,0.04 AM; IC5o 
for PARP 12,5 AM). 
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Figure 4.22: Abrogation of PARP12 expression by RNA interference affects the re- 
formation of the Golgi complex upon BFA wash-out 
HeLa cells were transfected with a non-targeting or an anti-PARP I2 siRNA. After 72 h, 
the cells were treated with 2.5 µg/ml BFA for 30 min at 37 °C' and then incubated for 90 
min at 37 °C in complete BFA-free media to allow re-formation of the Golgi complex. 
The cells were then fixed and labelled with the DNA-specific dye Hoechst, an anti- 
PARP12 antibody (to check for the interference), and with an anti-giantin antibody (to 
monitor for Golgi complex reassembly). Scale bar 10 ttM. (A) Representative images are 
shown. (B) The graph indicates the percentage of cells showing a partial or complete 
recovery of the Golgi complex structure after BFA wash-out. The data are means t 
standard deviations, from two different experiments. 
r]: 
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Based on these data, after the complete disassembly of the Golgi complex with 
BFA, I allowed the reformation of the Golgi structure in BFA-free medium in 
presence of I µM PJ34 (a concentration that inhibits PARPI) and 100 µM 
PJ34. While the PARP1-inhibitory concentration of PJ34 did not affect the re- 
formation of the Golgi complex (Figure 4.23a), the higher concentration caused 
a defect in the recovery of the Golgi structure (Figure 4.23b), as observed in 
cells silenced for PARP12. As a control, the incubation of cells with only 100 
µM PJ34 did not affect Golgi morphology (Figure 4.23c). Surprisingly, 
inhibition of ADP-ribosylation by PJ34 treatment causes an alteration in 
endogenous PARP 12 localisation, and the apperance in cytoplasmic structures. 
Together, these data thus suggest a role for PARP12 catalysed ADP- 
ribosylation in the control of Golgi complex reassembly. However, it is not 
possible to exclude other effects of the inhibitor PJ34 on other PARPs, such as 
PARP5, at this stage. In this context, the development of a specific PARP12 
inhibitor would be of great value. 
In addition, an important and unexpected finding that emerges from 
these data is the requirement of ADP-ribosylation to maintain PARP 12 
localisation on the Golgi complex. This finding could support the recent data 
by Chang and co-workers, demonstrating that PARP12 is part of a complex 
formed by PARP5, PARP13 and PARP15. Thus the idea is that this complex, 
and possibly ADP-ribosylation, is required for PARP12 localisation (as also 
mentioned in the previous section). 
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Figure 4.23: Golgi structure re-formation after BFA wash-out Is affected when 
ADP-ribosylatlon Is Inhibited by PJ34 
HeLa cells were treated with 2.5 pg/ml BFA for 30 min at 37 °C and then incubated for 
90 min at 37 °C in complete BFA-free media in the presence of 1 pM (A) or 100 µM 
PJ34 (B), to allow Golgi complex re-formation. As the control, cells not treated with 
BFA were incubated with 100 pM PJ34 for 90 min (C). The cells were then fixed and 
labelled with the DNA-specific dye Hoechst, with an anti-PARPI2 antibody and with an 
anti-giantin antibody (to monitor for Golgi complex re-assembly). (D) The graph 
indicates the percentage of cells showing a partial or complete recovery of the Golgi 
complex structure after BFA wash-out. The data are means ± standard deviations, from 
two different experiments. Scale bar 10 µM. 
Note that the presence of 100 ItM PJ34 alters Golgi complex re-formation (B), while the 
re-formation process is normal at tower concentrations of PJ34 (1 µM) (A). 
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4.8 Discussion II 
In this Results chapter, I have provided evidence that PARP12 is a Golgi- 
localised mART and that it can modify Rab 1 A. Rab 1A was identified using the 
macro-domain-based pull-down assay, and then validated through other 
approaches. This method also allows me to identify 24 other new putative 
PARP12 substrates that still need to be validated. Among these, one of 
particular interest is the small GTPase Ran. Here I have also provided evidence 
that PARP 12 localisation can vary according to the cell cycle, and as Ran has a 
well-known role in regulation of the cell cycle (Clarke and Zhang, 2008) this 
observation is particulary intrigueing. 
The choice of RablA as the first target to analyse was based on a 
"hypothesis driven approach": Rabs are indeed known substrates of ADP- 
ribosylation by toxins (Deng and Barbieri, 2008a), and thus I reasoned that 
similar mechanisms might be used by mammalian cells to regulate their 
functions. Moreover, this idea was further supported by the subcellular 
localisation of these two proteins, both of which were present on the Golgi 
complex, where RablA controls ER-to-Golgi and intra-Golgi transport. 
Through the different experiments I have reported here, I found that as also 
demonstrated for Rab 1 A, PARP 12 appears to be important in guaranteeing the 
correct structure of the Golgi complex. This conclusion arises from the 
following observations: 
I. PARP 12 over-expression causes Golgi disassembly (Figure 4.18b); 
2. Abolishing Rab1A expression causes Golgi disassembly (Figure 4.19); 
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3. Over-expressed PARP 12 is not localised to the Golgi complex (Figure 
4.18a); 
4. Endogenous PARP12 is not localised to the Golgi after abolishing Rab 1A 
expression (Figure 4.19). 
A possible explanation for this effect is that ADP-ribosylation impairs Rab 1A 
functions, thus leading to Golgi fragmentation. On the other hand, the mis- 
localisation of PARP12 after its over-expression can be explained by the need 
of a protein-complex (maybe containing PARP5, the other Golgi-localised 
PARP, and RablA) that should recruit PARP12; when PARP12 is over- 
expressed, the endogenous levels of proteins forming the complex are not 
enough to recruit all the over-expressed PARP12, that thus displaces from the 
Golgi complex. Similarly, abrogation of RablA expression causes a 
displacement of endogenous PARP12 from the Golgi complex. Moreover, the 
finding that ADP-ribosylation inhibition by PJ34 treatment affects endogenous 
PARP12 localisation indicates that ADP-ribosylation events are required to 
tether PARP12 to the Golgi complex. 
I also reported here that abolishment of PARP 12 expression, as well as 
inhibition of ADP-ribosylation, are connected to a defect in Golgi complex re- 
formation after BFA has been washed out. This supports the idea that PARP12 
catalysed ADP-ribosylation is required for the Golgi complex re-formation 
process. 
My findings pinpoint to further research to understand these new 
aspects of the Golgi morphology that appear to be regulated by mono-ADP- 
ribosylation. 
251 
Discussion 
CHAPTER 5: final discussion 
Although the mono-ADP-ribosylation has been known for some time mainly as 
the mechanism of action of some bacterial toxins, this post-translational 
modification (PTM) is now emerging as an important mechanism also used by 
mammalian cells to control a vast array of cellular processes (Hottiger et al., 
2011). Here I have provided new evidence of how this PTM can be used to 
regulate protein function, by describing the new ADP-ribosylation mechanism 
of BFA-dependent ADP-ribosylation of CtBPIBARS, and the new 
intracellular function of mono-ADP-ribosylation that is catalysed by the mono- 
ART PARP12. 
5.1 BFA-dependent ADP-ribosylation of CtBP1/BARS regulates its 
functions 
CtBP1BARS is a dual-function protein that is involved in two widely diverse 
biological processes, namely intracellular membrane trafficking and gene 
transcription. After its discovery as a BFA target, CtBP 1 BARS was 
demonstrated to be an essential component of the machinery controlling Golgi 
tubule fission (De Matteis et al., 1994; Spano et al., 1999; Weigert et at., 1999). 
Membrane fission is an essential event for the cell. Indeed, it is used in 
intracellular membrane trafficking for the transport of proteins and lipids from 
donor to acceptor membranes. Following the initial generation of membranous 
carriers through a process of membrane budding and fission, they are 
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transported to their acceptor membranes, with which they undergo fusion 
(Wilson et al., 2010). Membrane fission also has an important role during cell 
division, when the Golgi complex undergoes extensive fragmentation. This 
process is thought to facilitate the equal partitioning of Golgi membranes 
between the two daughter cells (Sutterlin et al., 2002). By promoting Golgi 
tubule fission, CtBP1BARS is an essential component of both these aspects, 
and is indeed involved in the control of intracellular transport (Bonazzi et at., 
2005) (Valente C. et al., submitted) as well as mitotic fragmentation of the 
Golgi complex (Colanzi et al., 2007; Hidalgo Carcedo et al., 2004). 
In addition to these important roles, CtBP1/BARS has been shown to be a 
member of the CtBP family, as it has very high amino acid sequence identity 
with mammalian CtBPI and CtBP2, and it is indeed a splice variant of CtBP1 
(Spano et al., 1999). 
CtBP 1 and CtBP2 are transcriptional corepressors that repress gene 
expression by interacting with DNA-binding transcription factors and 
recruiting histone methyltransferases, histone deacetylases, polycomb group 
proteins, and other chromatin remodeling proteins to targeted promoters 
(Chinnadurai, 2007). The targets of repression of CtBP include epithelial and 
proapoptotic genes, which is consistent with its known roles in promoting cell 
survival and migration (Chinnadurai, 2009). 
CtBP1BARS can control these two entirely different cellular functions 
through a change in its intracellular localisation (cytoplasmic/nuclear), an event 
that is mediated through the binding to different proteins as well as through 
different PTMs. A further level of regulation is the CtBP1BARS binding with 
cofactors, namely NAD(H), and acyl-CoAs. Here, NAD(H) stabilises the 
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dimeric conformation of CtBPs, and thus the co-repressor function, and acyl- 
CoAs promote the monomeric conformation, and thus the fissioning role 
(Corda et al., 2006). 
The description of this new BFA-dependent ADP-ribosylation reaction 
adds a further level of regulation to this dual functional protein, thus 
contributing to the unravelling of the main mechanisms by which the CtBP 
functions can be interchanged. Previous findings from our laboratory showed 
that BFA-dependent ADP-ribosylation could inhibit CtBP1BARS fissiogenic 
activity, but the mechanism was unknown (Weigert et al., 1999). 
The data described in Chapter 3 demonstrated that this mechanism 
involves ADP-ribosyl cyclases, such as CD38, for the formation of an ADP- 
ribosylated adduct, BAC (figures 3.3,3.4), which covalently binds to the 
CtBP1BARS Rossman fold (similarly to NAD(H)/AcylCoA) (Colanzi et al., 
manuscript in preparation). Importantly, BAC binding inhibits the 
CtBP1BARS interactions with its protein partners that are involved in the 
membrane fissioning functions, such as 14-3-3y and PAK1 (Figure 3.9). In 
addition, BAC binding to CtBP1BARS can shift CtBP1BARS conformation 
from monomer to dimer/tetramer (Colanzi et al., in preparation), thus 
favouring the conformation required for its co-repressor activity, while 
inhibiting its fissiogenic function. 
In the nucleus, the CtBP dimers regulate the formation of protein 
complexes that are involved in the inhibition of transcription, by binding to the 
Pro-X-Asp-Leu-Ser (PXDLS) motifs in DNA-binding proteins and by 
regulating the expression of epithelial genes, such as keratin-8 and E-cadherin, 
and apoptosis genes such as Bik, Noxa, Puma and PERP. Additionally, the 
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CtBPs target multiple growth inhibitory tumour suppressors for repression, 
including PTEN, pl6INK4a and pl5INK4b, thus promoting cell survival 
(Chinnadurai, 2009). Indeed, data obtained from mouse embryo fibroblasts 
(MEFs) derived from CtBP1- and CtBP2-knock-out mice show that these cells 
have up-regulated epithelial and pro-apoptotic genes (Grooteclaes et al., 2003). 
My data demonstrate that the co-repressor activity of CtBP1BARS can 
be regulated - and in this specific case increased - in a promoter-dependent 
context. Indeed, among the genes analysed (BAX, NOXA, P21, E-cadherin and 
BCL6), I found that BAC binding to CtBP1BARS modulates CtBPI/BARS 
co-repression function at the E-cadherin and p21 promoters (Figures 3.10, 
3.11). It is possible that this event (BAC binding) could enhance the 
CtBP1BARS interactions with specific repressors, or affect its interactions 
with other chromatin-regulating enzymes (such as the HDACs). Even if the 
molecular mechanism associated to its increased co-repressor activity has not 
been addressed in the present study and further work is required to elucidate 
this point, from the results obtained during my project, a new mechanism for 
the regulation of CtBP co-repressor activity emerged: BAC binding to 
CtBP1BARS stabilises a dimeric/tetrameric conformation of CtBPs, that 
cannot function in fissioning processes (because of a lack of binding with its 
fissioning partners), while it enhances the co-repressor function of 
CtBP 1BARS. Figure 5.1 shows the proposed working model. 
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Figure 5.1: working model. BAC increases CtBP co-repressor activity 
CtBP proteins can be regulated by cofactors. NAD(H) promotes a dimeric 
conformation, active in transcriptional co-repression. AcylCoA favours a 
monomeric conformation, required for membrane fission. 
Similarly to NAD(H), BAC binding to CtBP favours the dimeric conformation. This 
change in the oligomerisation status is associated to a promoter-dependent increased 
co-repressor activity. 
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As mentioned above, I tested a small subset of all the genes that might be 
regulated by CtBP1, and therefore a wider analysis of the CtBP target genes 
could help in our understanding whether and how other genes are affected by 
BAC binding to CtBP1BARS. 
The CtBPs are among the very few transcription factors that harbour an 
intrinsic enzymatic functional domain, which thus represents a `druggable' 
target. A growing body of evidence suggests that CtBP has a role in human 
cancer through the promotion of multiple pro-oncogenic activities, including 
epithelial to mesenchymal transition (EMT), cell migration/invasion, and cell 
survival. Loss of function of the CtBPs leads to enhanced expression of 
epithelial phenotype-related proteins, such as E-cadherin, occludin and keratin- 
8, and this counteracts EMT and tumour malignancy (Chinnadurai, 2009). 
Consideration of the numerous pro-oncogenic properties of CtBP suggest 
it is a potential therapeutic target in cancer. Therefore, the possibility of 
regulating CtBP co-repressor activity using small molecules is of undisputed 
value. Even if the analysis of the genes tested does not support the use of BAC 
as a tool to counteract the pro-oncogenic properties of CtBPs, a wider analysis 
of different genes could help in better understanding whether the effects of 
BAC binding can be exploited as a pharmacological tool. 
The requirement for the presence of CD38 to allow BAC to enter the 
intracellular space (figure 3.7) restricts the range of the possible use of BAC. 
However, this aspect can still be considered positive, as some tumours, such as 
diffuse large B-cell lymphomas, express high levels of CD38 (Malavasi et al., 
2011); thus BAC could selectively target these kind of tumours. 
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Importantly, a striking result that emerges from my data is the reversibility of 
BAC binding to CtBP1BARS. It is important to highlight that BAC binding to 
CtBPIBARS occurs through the BFA molecule, and thus an intracellular 
enzyme that can catalyse the removal of BFA should exist. These data lead us 
to think that, indeed, a molecule similar to BAC is also present in cells. 
Moreover, it is likely that the toxins exploit mechanisms similar to endogenous 
ones in their modulation of protein functions. So, based on the existence of an 
endogenous enzyme that can remove BAC from CtBPI/BARS, it will be very 
interesting to investigate whether similar endogenous mechanisms can regulate 
CtBP functions. It is thus tempting to speculate that an endogenous `BAC-like' 
molecule will represents a further mechanisms that is highly specific for the 
regulation of the different CtBP functions. 
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5.2 The mono-ADP-ribosyltransferase PARP12 is involved in the 
control of the structure of the Golgi complex 
ADP-ribosylation is an ubiquitous protein modification that controls many 
cellular processes, including transcription, DNA repair and bacterial toxicity. 
Mono-ADP-ribosylation is only recently emerging as an important post- 
translational modification that is used by mammalian cells to control a vast 
array of cellular processes (Hoftiger et al., 2011). While more evidence exists 
regarding the roles of poly-ADP-ribosylation in different cellular processes, 
our present knowledge of mono-ADP-ribosylation catalysed by the new 
members of the PARP family is less advanced, and thus their characterisation 
will help in our understanding of their roles. 
Here I have provided evidence that PARP12 is a mono-ART. Similar to 
PARP 10, PARP12 lacks the polymerise activity, while showing robust mono- 
ART activity. In agreement with the sequence alignment data reported by 
Lusher and co-workers (Kleine et at., 2008), 1 have shown here that the 
residues of the catalytic triad of PARP 12 are indeed indispensable for its ADP- 
ribosylation activity, thus demonstrating that PARP12 is an additional member 
of the new sub-family of mono-ARTs. 
More importantly, my data provide the initial evidence for a previously 
uncharacterised function that can be ascribed to mono-ADP-ribosylation: a role 
in the control of the morphology of the Golgi complex. The identification of 
PARP12 substrates, as well as the analysis of PARP12 sub-cellular 
localisation, has been instrumental for gaining of insights into a function for 
PARP12. Indeed, I have shown here that PARP12 is a new Golgi localised 
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protein (Figure 4.18). Interestingly, the Golgi complex has been demonstrated 
to be an important compartment for NAD+ synthesis (Dolle et at., 2010), and 
thus this NAD+ pool can be used to catalyse the ADP-ribosylation reaction also 
at the level of this organelle. In line with these findings, I have shown that, 
indeed, Rab I A, can be ADP-ribosylated by PARP 12. 
The Rab proteins are key players in the control of crucial steps in 
vesicular transport (Stenmark, 2009). A role for these proteins has been 
reported in vesicle budding (e. g., Rab9 functions in the recycling of mannose- 
6-phosphate receptors from late endosomes to the trans-Golgi network), in 
vesicle motility (as in the case of Rabl1), and also in vesicle fusion (as 
reported for Rab5) (Carroll et at., 2001; Hales et al., 2002; McLauchlan et al., 
1998). 
Rabl is involved in the regulation of the earliest stages of protein 
trafficking through the secretory pathway: from the ER to the Golgi complex 
(Allan et al., 2000; Moyer et al., 2001; Tisdale et al., 1992). Protein transport 
between the ER and the Golgi complex occurs via an intermediate 
compartment (IC), which is also known as vesicular tubular clusters (VTCs), 
the ER-Golgi intermediate compartment (ERGIC), or simply the IC. Carrier 
exit from the ER is initiated at specific domains in the ER network known as 
ER exit sites (ERES), via COPII-coated transport carriers. These COPII 
vesicular carriers deliver cargos from the ERES to the stationary ERGIC 
clusters, and then COPI-coated vesicles bud from this compartment to deliver 
material to the cis-Golgi compartment. COPI vesicles are also responsible for 
retrograde transport to the ER from the ERGIC and the Golgi complex 
(Lorente-Rodriguez and Barlowe, 2011). Rabl is involved in both COPI 
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(Alvarez et al., 2003; Monetta et al., 2007) and COPII-mediated events (Allan 
et al., 2000; Moyer et al., 2001). When active and bound to GTP, Rab proteins 
recruit effectors, which function in downstream events that lead to membrane 
fusion. In particular, the activated membrane-bound Rab 1 recruits the tethering 
protein p 115, and possibly other golgins, thus coordinating fusion events 
(Allan et al., 2000). Besides this fundamental role, Rabl has also been shown 
to be required for the maintenance of Golgi complex morphology. In particular, 
it has been reported that microinjection of inactive RablA mutants (i. e. in the 
GDP-bound form) as well over-expression of a Rab 1-GAP protein, result in 
fragmentation of the Golgi complex (Haas et al., 2007; Wilson et al., 1994). 
Data reported here show that the over-expression of PARP12 leads to a 
loss of the classical ribbon-like organisation of the Golgi complex and PARP 12 
localisation in cytoplasmic foci (Figure 4.18). Strikingly, as well as PARP12 
over-expression, abrogation of RablA expression causes Golgi fragmentation 
and displacement of PARP12 from the Golgi complex, from where it instead 
appears in cytoplasmic structures (Figure 4.19). Thus, an intriguing possibility 
is that PARP12 over-expression causes Golgi fragmentation through the ADP- 
ribosylation of Rab1A. 
Although the Rab GTPases mainly function as regulatory switches that 
spatio-temporally coordinate the recruitment of various regulators of 
membrane trafficking, their outputs also impinge on other regulatory circuits, 
such as phosphorylation (Stenmark, 2009). These post-translational 
modifications might alter either the function of the Rab GTPase itself or that of 
its interacting partners, thereby adding another layer of control to their 
activities. In this way, phosphoregulation of Rab functions contributes to the 
261 
Discussion 
dramatic changes in membrane trafficking that occur during, for example, 
mitosis. RabI is indeed phosphorylated by Cdkl, which might contribute to the 
inhibition of vesicle tethering and fusion (Preisinger et al., 2005). This event 
leads to persistent budding of COPI vesicles without fusion, thus generating a 
disassembly of the Golgi (Lowe et al., 1998a). 
Considering that RablA is one of the substrates I found for PARP12, my 
data suggest the existence of a new link between ADP-ribosylation and Rab 1A 
functions. It is tempting to speculate that ADP-ribosylated Rab1A might mimic 
the same effects as inactive RablA (i. e. in the GDP-bound state) or can impair 
Rab lA interaction with specific partners that are important for its functions, 
thus explaining the fragmentation of the Golgi complex after PARP12 over- 
expression. Moreover, I have also reported that Rab 1A over-expression inhibits 
PARP 12 catalytic activity, suggesting that these two proteins are able to 
regulate each other. One possible explanation is that RablA can interact with 
PARP 12 at its catalytic site, thus blocking its enzymatic function. However, 
data obtained so far cannot explain this finding at the molecular level, and 
remains to be explored. 
A crucial point that still needs further analysis is that the over-expressed 
PARP12 localises in cytoplasmic foci and not on the Golgi complex, as is seen 
for the endogenous protein. My data show that as with over-expression, the 
Golgi localisation of PARP 12 is also lost after RabIA interference and after the 
use of the PJ34 ADP-ribosylation inhibitor (Figures 4.19,4.23). Based on these 
data, it can be assumed that PARP12 localisation on the Golgi complex is 
reliant on ADP-ribose formation (even produced by other PARPs), while the 
fragmentation effect on the Golgi structure is dependent on Rab lA ADP- 
262 
Discussion 
ribosylation by PARP12. This would explain the fragmentation of the Golgi 
structure after PARP 12 over-expression (due to Rab 1A ADP-ribosylation, and 
thus possibly its inactivation), an effect that is comparable to RablA 
interference. 
Regarding PARP12 localisation, recently Chang P. and co-workers 
(Leung et al., 2011) demonstrated that PARP5, the other PARP that is located 
to the Golgi complex, interacts with PARP12. My data show that inhibition of 
ADP-ribosylation by the ADP-ribosylation PJ34 inhibitor causes a 
displacement of PARP12 from the Golgi complex, thus suggesting that ADP- 
ribosylation is required to target PARP 12 at this organelle. Based on this 
evidence, it will be interesting to determine whether PARP12localisation at the 
Golgi complex is dependent on the ADP-ribosylation catalysed by PARP5. 
Leung, A. K. et al. also reported data on PARP 12 localisation after over- 
expression. Similarly to my findings, they showed the over-expressed PARP12 
localisation as cytoplasmic foci, that they identify as stress granules using 
specific markers, such as the eukaryotic initiation factor eIF3. Here, PARP12 is 
part of a complex of PARPs, which includes PARP5, PARP 13 and PARP 15. 
The authors proposed that the accessibility of Argonaute/miRNA complex to 
its target mRNA is affected by an increased ADP-ribosylation of multiple 
proteins that bind to the target, resulting in the relief of miRNA silencing. The 
production of pADPR is dependent on this `PARP complex' activity. However, 
they had no comment regarding endogenous PARP 12. 
Thus, an interesting aspect to be investigated is how these foci are 
formed, performing live-cell imaging to follow the over-expression of PARP 12 
with time. It is possible that PARP12 is a multi-functional protein, that 
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harbours different roles according to its localisation and the cellular conditions. 
However, it cannot be excluded that the PARP12 localisation in stress granules 
is a consequence of its over-expression. If this is the case, it is possible that the 
endogenous levels of PARPS, and potentially the basal levels of ADP 
ribosylation, are not sufficient to recruit over-expressed PARP12, thus 
displacing it from the Golgi complex. 
In addition, my data also indicate a clear role for PARP12 and for ADP- 
ribosylation in the re-formation of the Golgi complex. Interestingly, I observed 
a defect in Golgi reassembly after BFA was washed out both after abrogation 
of PARP 12 expression by RNA interference and after treatment with the ADP- 
ribosylation inhibitor PJ34. These results suggest a role for PARP 12, and thus 
for ADP-ribosylation, during Golgi complex re-formation. This new finding 
could have interesting implications in the study of Golgi biogenesis during 
different cellular events, such as the cell cycle. During mitosis, COPI vesicles 
continue to form (Xiang et al., 2007), but the vesicles cannot fuse with their 
target membranes because of the disruption of vesicle tethering complex (Lowe 
et al., 1998b; Misteli and Warren, 1994; Nakamura et al., 1997). For example, 
phosphorylation of GM130 by Cdkl in early mitosis prevents p115 from 
binding, thereby blocking vesicle tethering and subsequent fusion (Levine et 
al., 1996; Lowe et al., 1998b). My data show that the removal of PARP12 
expression, as well as the inhibition of ADP-ribosylation, causes a defect in 
Golgi re-formation after BFA was washed out (Figure 4.23). 
It is tempting to speculate that PARP12-catalysed ADP-ribosylation 
might contribute to the regulation of tethering/fusion events. When this 
situation is altered (by PARP12 siRNA, or by PJ34 treatment), this regulatory 
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mechanism is lost, thus leading to an imbalance between the tethering and 
fusion processes. However, structural studies are needed to understand the 
specific step(s) controlled by ADP-ribosylation, and the molecular mechanism 
through which this effect is achieved. 
In addition, it will be also interesting to investigate whether anterograde 
transport (event in which Rab1A is involved) is impaired by PARP12 catalysed 
ADP-ribosylation activity. A possible explanation is that if ADP-ribosylation 
regulates Rab 1A functions, this trafficking step should be affected. However, 
future studies are needed to determine this. 
In conclusion, my work has highlighted a possible regulatory role of 
mono-ADP-ribosylation at the level of the Golgi complex. Seen from a more 
general perspective, the substrates identified for PARP 12 suggest that this 
enzyme, and thus the mono-ADP-ribosylation catalysed by PARP12, might be 
involved in multiple cellular functions, ranging from regulation of small- 
GTPases to the control of RNA. Consistent with my findings, the recent 
findings of Chang P. and co-workers (Leung et al., 2011) indeed demonstrate a 
role of ADP-ribosylation associated to RNA control. The study of the 
substrates identified for PARP12 might thus add other important contributions 
to the understanding of the role of mono-ADP-ribosylation in cells. 
265 
References 
References 
cAarhus, R., R. M. Graeff, D. M. Dickey, T. F. Walseth, and H. C. Lee. 1995. 
ADP-ribosyl cyclase and CD38 catalyze the synthesis of a calcium-mobilizing 
metabolite from NADP. JBiol Chem. 270: 30327-30333. 
Aguiar, R. C., K. Takeyama, C. He, K. Kreinbrink, and M. A. Shipp. 2005. B- 
aggressive lymphoma family proteins have unique domains that modulate 
transcription and exhibit poly(ADP-ribose) polymerase activity. J Bio! Chem. 
280: 33756-33765. 
eAguiar, R. C., Y. Yakushijin, S. Kharbanda, R. Salgia, J. A. Fletcher, and M. A. 
Shipp. 2000. BAL is a novel risk-related gene in diffuse large B-cell 
lymphomas that enhances cellular migration. Blood. 96: 4328-4334. 
o Ahel, D., Z. Horejsi, N. Wiechens, S. E. Polo, E. Garcia-Wilson, I. Ahel, H. 
Flynn, M. Skehel, S. C. West, S. P. Jackson, T. Owen-Hughes, and S. J. Boulton. 
2009. Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin 
remodeling enzyme ALC I. Science. 325: 1240-1243. 
a Ahel, I., D. Abel, T. Matsusaka, A. J. Clark, J. Pines, S. J. Boulton, and S. C. 
West. 2008. Poly(ADP-ribose)-binding zinc finger motifs in DNA 
repair/checkpoint proteins. Nature. 451: 81-85. 
aAksoy, P., C. Escande, T. A. White, M. Thompson, S. Soares, J. C. Benech, and 
E. N. Chini. 2006. Regulation of SIRT 1 mediated NAD dependent 
deacetylation: a novel role for the multifunctional enzyme CD38. Biochem 
Biophys Res Commun. 349: 353-359. 
Aktories, K., A. E. Lang, C. Schwan, and H. G. Mannherz. 2011. Actin as target 
for modification by bacterial protein toxins. FEBSJ. 
266 
References 
" Aktories, K., and A. Wegner. 1989. ADP-ribosylation of actin by clostridial 
toxins. JCell Biol. 109: 1385-1387. 
'0 Alessio, M., S. Roggero, A. Funaro, L. B. De Monte, L. Pena i, M. Geuna, and 
F. Malavasi. 1990. CD38 molecule: structural and biochemical analysis on 
human T lymphocytes, thymocytes, and plasma cells. Jlmmunol. 145: 878-884. 
Alkhatib, H. M., D. F. Chen, B. Cherney, K. Bhatia, V. Notario, C. Gin, G. 
Stein, E. Slattery, R. G. Roeder, and M. E. Smulson. 1987. Cloning and 
expression of cDNA for human poly(ADP-ribose) polymerase. Proc Natl Acad 
Sci USA. 84: 1224-1228. 
" Allan, B. B., B. D. Moyer, and W. E. Balch. 2000. Rabl recruitment of p115 into 
a cis-SNARE complex: programming budding COPII vesicles for fusion. 
Science. 289: 444-448. 
" Allured, V. S., R. J. Collier, S. F. Carroll, and D. B. McKay. 1986. Structure of 
exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution. Proc Nail 
Acad Sci USA. 83: 1320-1324. 
" Alvarez, C., R. Garcia-Mata, E. Brandon, and E. Sztul. 2003. COPI recruitment 
is modulated by a Rab I b-dependent mechanism. Mol Biol Cell. 14: 2116-2127. 
" Alvarez-Gonzalez, R., and F. R. Althaus. 1989. Poly(ADP-ribose) catabolism in 
mammalian cells exposed to DNA-damaging agents. Mutat Res. 218: 67-74. 
" Alvarez-Gonzalez, R., and M. K. Jacobson. 1987. Characterization of polymers 
of adenosine diphosphate ribose generated in vitro and in vivo. Biochemistry. 
26: 3218-3224. 
o Ame, J. C., V. Rolli, V. Schreiber, C. Niedergang, F. Apiou, P. Decker, S. 
Muller, T. Hoger, J. Menissier-de Murcia, and G. de Murcia. 1999. PARP-2, A 
267 
References 
novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase. J 
Biol Chem. 274: 17860-17868. 
0 Andrabi, S. A., N. S. Kim, S. W. Yu, H. Wang, D. W. Koh, M. Sasaki, J. A. 
Klaus, T. Otsuka, Z. Zhang, R. C. Koehler, P. D. Hum, G. G. Poirier, V. L. 
Dawson, and T. M. Dawson. 2006. Poly(ADP-ribose) (PAR) polymer is a death 
signal. Proc Natl Acad Sci USA. 103: 18308-18313. 
" Audebert, M., B. Salles, and P. Calsou. 2004. Involvement of poly(ADP- 
ribose) polymerase-1 and XRCC 1 /DNA ligase III in an alternative route for 
DNA double-strand breaks rejoining. JBiol Chem. 279: 55117-55126. 
" Audebert, M., B. Salles, and P. Calsou. 2008. Effect of double-strand break 
DNA sequence on the PARP-1 NHEJ pathway. Biochem Biophys Res 
Commun. 369: 982-988. 
" Audebert, M., B. Salles, M. Weinfeld, and P. Calsou. 2006. Involvement of 
polynucleotide kinase in a poly(ADP-ribose) polymerase- l -dependent DNA 
double-strand breaks rejoining pathway. JMo1 Biol. 356: 257-265. 
o Augustin, A., C. Spenlehauer, H. Dumond, J. Menissier-De Murcia, M. Piel, 
A. C. Schmit, F. Apiou, J. L. Vonesch, M. Kock, M. Bornens, and G. De 
Murcia. 2003. PARP-3 localizes preferentially to the daughter centriole and 
interferes with the Gi/S cell cycle progression. JCell Sc!. 116: 1551-1562. 
a Barbieri, J. T., and J. Sun. 2004. Pseudomonas aeruginosa ExoS and ExoT. Rev 
Physiol Biochem Pharmacol. 152: 79-92. 
o Barford, D., A. K. Das, and M. P. Egloff. 1998. The structure and mechanism of 
protein phosphatases: insights into catalysis and regulation. Annu Rev Biophys 
Biomol Struct. 27: 133-164. 
268 
References 
" Barlowe, C. 2000. Traffic COPs of the early secretory pathway. Traffic. 1: 371- 
377. 
" Barnes, C. J., R. K. Vadlamudi, S. K. Mishra, R. H. Jacobson, F. Li, and R. 
Kumar. 2003. Functional inactivation of a transcriptional corepressor by a 
signaling kinase. Nat Struct Biol. 10: 622-628. 
4, Barth, H., K. Aktories, M. R. Popoff, and B. G. Stiles. 2004. Binary bacterial 
toxins: biochemistry, biology, and applications of common Clostridium and 
Bacillus proteins. Microbiol Mol Biol Rev. 68: 373-402, table of contents. 
- Bazan, J. F., and F. Koch-Nolte. 1997. Sequence and structural links between 
distant ADP-ribosyltransferase families. Adv Exp Med Biol. 419: 99-107. 
- Benchoua, A., C. Couriaud, C. Guegan, L. Tartier, P. Couvert, G. Friocourt, J. 
Chelly, J. Menissier-de Murcia, and B. Onteniente. 2002. Active caspase-8 
translocates into the nucleus of apoptotic cells to inactivate poly(ADP-ribose) 
polymerase-2. JBiol Chem. 277: 34217-34222. 
o Bergman, L. M., C. N. Birts, M. Darley, B. Gabrielli, and J. P. Blaydes. 2009. 
CtBPs promote cell survival through the maintenance of mitotic fidelity. Mol 
Cell Biol. 29: 4539-4551. 
' Boehler, C., L. R. Gauthier, O. Mortusewicz, D. S. Biard, J. M. Saliou, A. 
Bresson, S. Sanglier-Cianferani, S. Smith, V. Schreiber, F. Boussin, and F. 
Dantzer. 2011. Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in 
cellular response to DNA damage and mitotic progression. Proc Nall Acad Sci 
USA. 108: 2783-2788. 
^. Bonazzi, M., S. Spano, G. Turacchio, C. Cericola, C. Valente, A. Colanzi, H. S. 
Kweon, V. W. Hsu, E. V. Polishchuck, R. S. Polishchuck, M. Sallese, T. 
269 
References 
Pulvirenti, D. Corda, and A. Luini. 2005. CtBP3/BARS drives membrane 
fission in dynamin-independent transport pathways. Nat Cell Biol. 7: 570-580. 
a. Bortell, R., T. Kanaitsuka, L. A. Stevens, J. Moss, J. P. Mordes, A. A. Rossini, 
and D. L. Greiner. 1999. The RT6 (Art2) family of ADP-ribosyltransferases in 
rat and mouse. Mol Cell Biochem. 193: 61-68. 
Boyd, J. M., T. Subramanian, U. Schaeper, M. La Regina, S. Bayley, and G. 
Chinnadurai. 1993. A region in the C-terminus of adenovirus 2/5 Ela protein is 
required for association with a cellular phosphoprotein and important for the 
negative modulation of T24-ras mediated transformation, tumorigenesis and 
metastasis. EMBO J. 12: 469-478. 
Braren, R., G. Glowacki, M. Nissen, F. Haag, and F. Koch-Nolte. 1998. 
Molecular characterization and expression of the gene for mouse 
NAD+: arginine ecto-mono(ADP-ribosyl)transferase, Artl. Biochem J. 336 ( Pt 
3): 561-568. 
Burnett, G., and E. P. Kennedy. 1954. The enzymatic phosphorylation of 
proteins. JBiol Chem. 211: 969-980. 
" Caiafa, P., and M. Zampieri. 2005. DNA methylation and chromatin structure: 
the puzzling CpG islands. J Cell Biochem. 94: 257-265. 
o Carroll, K. S., J. Hanna, I. Simon, J. Krise, P. Barbero, and S. R. Pfeffer. 2001. 
Role of Rab9 GTPase in facilitating receptor recruitment by TIP47. Science. 
292: 1373-1376. 
" Ceresa, B. P. 2006. Regulation of EGFR endocytic trafficking by rab proteins. 
Histol Histopathol. 21: 987-993. 
270 
References 
" Chambon, P., J. D. Weill, and P. Mandel. 1963. Nicotinamide mononucleotide 
activation of new DNA-dependent polyadenylic acid synthesizing nuclear 
enzyme. Biochem Biophys Res Commun. 11: 39-43. 
" Chang, P., M. Coughlin, and T. J. Mitchison. 2005. Tankyrase-1 polymerization 
of poly(ADP-ribose) is required for spindle structure and function. Nat Cell 
Biol. 7: 1133-1139. 
Chang, P., M. K. Jacobson, and T. J. Mitchison. 2004. Poly(ADP-ribose) is 
required for spindle assembly and structure. Nature. 432: 645-649. 
o Chi, N. W., and H. F. Lodish. 2000. Tankyrase is a golgi-associated mitogen- 
activated protein kinase substrate that interacts with IRAP in GLUT4 vesicles. 
JBiol Chem. 275: 38437-38444. 
Chinnadurai, G. 2003. CtBP family proteins: more than transcriptional 
corepressors. Bioessays. 25: 9-12. 
" Chinnadurai, G. 2007. Transcriptional regulation by C-terminal binding 
proteins. Int J Biochem Cell Biol. 39: 1593-1607. 
" Chinnadurai, G. 2009. The transcriptional corepressor CtBP: a foe of multiple 
tumor suppressors. Cancer Res. 69: 731-734. 
o Chou, H. Y., H. T. Chou, and S. C. Lee. 2006. CDK-dependent activation of 
poly(ADP-ribose) polymerase member 10 (PARP 10). JBiol Chem. 281: 15201- 
15207. 
O Ciccarone, V. C., D. A. Polayes, and V. A. Luckow. 1998. Generation of 
Recombinant Baculovirus DNA in E. coli Using a Baculovirus Shuttle Vector. 
Methods Mol Med. 13: 213-235. 
O Clarke, P. R., and C. Zhang. 2008. Spatial and temporal coordination of mitosis 
by Ran GTPase. Nat Rev Mol Cell Biol. 9: 464-477. 
271 
References 
Coburn, J., R. T. Wyatt, B. H. Iglewski, and D. M. Gill. 1989. Several GTP- 
binding proteins, including p2lc-H-ras, are preferred substrates of 
Pseudomonas aeruginosa exoenzyme S. JBiol Chem. 264: 9004-9008. 
¢ Cohen-Armon, M., L. Visochek, D. Rozensal, A. Kalal, I. Geistrikh, R. Klein, 
S. Bendetz-Nezer, Z. Yao, and R. Seger. 2007. DNA-independent PARP-1 
activation by phosphorylated ERK2 increases Elk I activity: a link to histone 
acetylation. Mol Cell. 25: 297-308. 
Colanzi, A., C. Hidalgo Carcedo, A. Persico, C. Cericola, G. Turacchio, M. 
Bonazzi, A. Luini, and D. Corda. 2007. The Golgi mitotic checkpoint is 
controlled by BARS-dependent fission of the Golgi ribbon into separate stacks 
in G2. EMBO J. 26: 2465-2476. 
Collier, R. J. 1975. Diphtheria toxin: mode of action and structure. Bacteriol 
Rev. 39: 54-85. 
" Cook, B. D., J. N. Dynek, W. Chang, G. Shostak, and S. Smith. 2002. Role for 
the related poly(ADP-Ribose) polymerases tankyrase 1 and 2 at human 
telomeres. Mol Cell Biol. 22: 332-342. 
" Corda, D., A. Colanzi, and A. Luini. 2006. The multiple activities of 
CtBP/BARS proteins: the Golgi view. Trends Cell Biol. 16: 167-173. 
" Corda, D., and M. Di Girolamo. 2003. Functional aspects of protein mono- 
ADP-ribosylation. EMBOJ. 22: 1953-1958. 
" D'Amours, D., S. Desnoyers, I. D'Silva, and G. G. Poirier. 1999. Poly(ADP- 
ribosyl)ation reactions in the regulation of nuclear functions. Biochem J. 342 
Pt 2): 249-268. 
272 
References 
o Dammer, E. B., and M. B. Sewer. 2008. Phosphorylation of CtBPI by cAMP- 
dependent protein kinase modulates induction of CYP17 by stimulating 
partnering of CtBP1 and 2. JBiol Chem. 283: 6925-6934. 
Dani, N., A. Stilla, A. Marchegiani, A. Tamburro, S. Till, A. G. Ladurner, D. 
Corda, and M. Di Girolamo. 2009. Combining affinity purification by ADP- 
ribose-binding macro domains with mass spectrometry to define the 
mammalian ADP-ribosyl proteome. Proc Natl Acad Sci USA. 106: 4243-4248. 
+ Dantzer, F., M. J. Giraud-Panis, I. Jaco, J. C. Ame, I. Schultz, M. Blasco, C. E. 
Koering, E. Gilson, J. Menissier-de Murcia, G. de Murcia, and V. Schreiber. 
2004. Functional interaction between poly(ADP-Ribose) polymerase 2 (PARP- 
2) and TRF2: PARP activity negatively regulates TRF2. Mol Cell Biol. 
24: 1595-1607. 
" David, K. K., S. A. Andrabi, T. M. Dawson, and V. L. Dawson. 2009. 
Parthanatos, a messenger of death. Front Biosci. 14: 1116-1128. 
" De Matteis, M. A., M. Di Girolamo, A. Colanzi, M. Pallas, G. Di Tullio, L. J. 
McDonald, J. Moss, G. Santini, S. Bannykh, D. Corda, and et al. 1994. 
Stimulation of endogenous ADP-ribosylation by brefeldin A. Proc Nat! Acad 
Sci USA. 91: 1114-1118. 
" Deng, Q., and J. T. Barbieri. 2008a. Modulation of host cell endocytosis by the 
type III cytotoxin, Pseudomonas ExoS. Traffic. 9: 1948-1957. 
" Deng, Q., and J. T. Barbieri. 2008b. Molecular mechanisms of the cytotoxicity 
of ADP-ribosylating toxins. Annu Rev Microbiol. 62: 271-288. 
" Deng, Q., J. Sun, and J. T. Barbieri. 2005. Uncoupling Crk signal transduction 
by Pseudomonas exoenzyme T. JBiol Chem. 280: 35953-35960. 
273 
References 
Di Girolamo, M., N. Dani, A. Stilla, and D. Corda. 2005. Physiological 
relevance of the endogenous mono(ADP-ribosyl)ation of cellular proteins. 
FEBS J. 272: 4565-4575. 
a Di Virgilio, F., P. Chiozzi, D. Ferrari, S. Falzoni, J. M. Sanz, A. Morelli, M. 
Torboli, G. Bolognesi, and O. R. Baricordi. 2001. Nucleotide receptors: an 
emerging family of regulatory molecules in blood cells. Blood. 97: 587-600. 
Dolle, C., M. Niere, E. Lohndal, and M. Ziegler. 2010. Visualization of 
subcellular NAD pools and intra-organellar protein localization by poly-ADP- 
ribose formation. Cell Mol Life Sci. 67: 433-443. 
o Domenighini, M., C. Magagnoli, M. Pizza, and R. Rappuoli. 1994. Common 
features of the NAD-binding and catalytic site of ADP-ribosylating toxins. Mol 
Microbiol. 14: 41-50. 
Domenighini, M., and R. Rappuoli. 1996. Three conserved consensus 
sequences identify the NAD-binding site of ADP-ribosylating enzymes, 
expressed by eukaryotes, bacteria and T-even bacteriophages. Mol Microbiol. 
21: 667-674. 
$ Doms, R. W., G. Russ, and J. W. Yewdell. 1989. Brefeldin A redistributes 
resident and itinerant Golgi proteins to the endoplasmic reticulum. J Cell Biol. 
109: 61-72. 
a Donaldson, J. G., and C. L. Jackson. 2000. Regulators and effectors of the ARF 
GTPases. Curr Opin Cell Biol. 12: 475-482. 
Donaldson, J. G., R. A. Kahn, J. Lippincott-Schwartz, and R. D. Klausner. 1991. 
Binding of ARF and beta-COP to Golgi membranes: possible regulation by a 
trimeric G protein. Science. 254: 1197-1199. 
274 
References 
aº Donaldson, J. G., J. Lippincott-Schwartz, G. S. Bloom, T. E. Kreis, and R. D. 
Klausner. 1990. Dissociation of a 110-kD peripheral membrane protein from 
the Golgi apparatus is an early event in brefeldin A action. J Cell Biol. 
111: 2295-2306. 
4, Dynek, IN., and S. Smith. 2004. Resolution of sister telomere association is 
required for progression through mitosis. Science. 304: 97-100. 
El-Khamisy, S. F., M. Masutani, H. Suzuki, and K. W. Caldecott. 2003. A 
requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at 
sites of oxidative DNA damage. Nucleic Acids Res. 31: 5526-5533. 
Finkel, T., C. X. Deng, and R. Mostoslavsky. 2009. Recent progress in the 
biology and physiology of sirtuins. Nature. 460: 587-591. 
" Fjeld, C. C., W. T. Birdsong, and R. H. Goodman. 2003. Differential binding of 
NAD+ and NADH allows the transcriptional corepressor carboxyl-terminal 
binding protein to serve as a metabolic sensor. Proc Nat! Acad Sci USA. 
100: 9202-9207. 
o Flint, A. J., T. Tiganis, D. Barford, and N. K. Tonks. 1997. Development of 
"substrate-trapping" mutants to identify physiological substrates of protein 
tyrosine phosphatases. Proc Natl Acad Sci USA. 94: 1680-1685. 
d Folkers, U., V. Kirik, U. Schobinger, S. Falk, S. Krishnakumar, M. A. Pollock, 
D. G. Oppenheimer, I. Day, A. S. Reddy, G. Jurgens, and M. Hulskamp. 2002. 
The cell morphogenesis gene ANGUSTIFOLIA encodes a CtBP/BARS-like 
protein and is involved in the control of the microtubule cytoskeleton. EMBO 
J. 21: 1280-1288. 
Fong, P. C., D. S. Boss, T. A. Yap, A. Tutt, P. Wu, M. Mergui-Roelvink, P. 
Mortimer, H. Swaisland, A. Lau, M. J. O'Connor, A. Ashworth, J. Carmichael, 
275 
References 
S. B. Kaye, J. H. Schellens, and J. S. de Bono. 2009. Inhibition of poly(ADP- 
ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 
361: 123-134. 
Fowell, D., and D. Mason. 1993. Evidence that the T cell repertoire of normal 
rats contains cells with the potential to cause diabetes. Characterization of the 
CD4+ T cell subset that inhibits this autoimmune potential. J Exp Med. 
177: 627-636. 
o Fraylick, J. E., E. A. Rucks, D. M. Greene, T. S. Vincent, and J. C. Olson. 2002. 
Eukaryotic cell determination of ExoS ADP-ribosyltransferase substrate 
specificity. Biochem Biophys Res Commun. 291: 91-100. 
o Fujiwara, T., K. Oda, S. Yokota, A. Takatsuki, and Y. Ikehara. 1988. Brefeldin 
A causes disassembly of the Golgi complex and accumulation of secretory 
proteins in the endoplasmic reticulum. JBiol Chem. 263: 18545-18552. 
s Funaro, A., A. L. Horenstein, L. Calosso, M. Morra, R. P. Tarocco, L. Franco, 
A. De Flora, and F. Malavasi. 1996. Identification and characterization of an 
active soluble form of human CD38 in normal and pathological fluids. Int 
Immunol. 8: 1643-1650. 
Gagne, J. P., M. Isabelle, K. S. Lo, S. Bourassa, M. J. Hendzel, V. L. Dawson, 
T. M. Dawson, and G. G. Poirier. 2008. Proteome-wide identification of 
poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein 
complexes. Nucleic Acids Res. 36: 6959-6976. 
Gamble, M. J., and R. P. Fisher. 2007. SET and PARPI remove DEK from 
chromatin to permit access by the transcription machinery. Nat Struct Mol Biol. 
14: 548-555. 
276 
References 
" Ganesan, A. K., D. W. Frank, R. P. Misra, G. Schmidt, and J. T. Barbieri. 1998. 
Pseudomonas aeruginosa exoenzyme S ADP-ribosylates Ras at multiple sites. J 
Biol Chem. 273: 7332-7337. 
" Ganz, T. 2003. Defensins: antimicrobial peptides of innate immunity. Nat Rev 
Immunol. 3: 710-720. 
" Gao, G., X. Guo, and S. P. Goff. 2002. Inhibition of retroviral RNA production 
by ZAP, a CCCH-type zinc finger protein. Science. 297: 1703-1706. 
Garriga-Canut, M., B. Schoenike, R. Qazi, K. Bergendahl, T. J. Daley, R. M. 
Pfender, J. F. Morrison, J. Ockuly, C. Stafstrom, T. Sutula, and A. Roopra. 
2006.2-Deoxy-D-glucose reduces epilepsy progression by NRSF-CtBP- 
dependent metabolic regulation of chromatin structure. Nat Neurosei. 9: 1382- 
1387. 
$ Gelman, L., P. Deterre, H. Gouy, L. Boumsell, P. Debre, and G. Bismuth. 
1993. The lymphocyte surface antigen CD38 acts as a nicotinamide adenine 
dinucleotide glycohydrolase in human T lymphocytes. Eur J Immunol. 
23: 3361-3364. 
a Gerasimenko, J. V., M. Sherwood, A. V. Tepikin, O. H. Petersen, and O. V. 
Gerasimenko. 2006. NAADP, cADPR and IP3 all release Ca2+ from the 
endoplasmic reticulum and an acidic store in the secretory granule area. J Cell 
Sci. 119: 226-238. 
Gill, D. M. 1976. The arrangement of subunits in cholera toxin. Biochemistry. 
15: 1242-1248. 
Gill, D. M., A. M. Pappenheimer, Jr., R. Brown, and J. T. Kurnick. 1969. Studies 
on the mode of action of diphtheria toxin. VII. Toxin-stimulated hydrolysis of 
277 
References 
nicotinamide adenine dinucleotide in mammalian cell extracts. J Exp Med. 
129: 1-21. 
o Glowacki, G., R. Braren, M. Cetkovic-Cvrlje, E. H. Leiter, F. Haag, and F. 
Koch-Nolte. 2001. Structure, chromosomal localization, and expression of the 
gene for mouse ecto-mono(ADP-ribosyl)transferase ARTS. Gene. 275: 267- 
277. 
Glowacki, G., R. Braren, K. Firner, M. Nissen, M. Kuhl, P. Reche, F. Bazan, 
M. Cetkovic-Cvrlje, E. Leiter, F. Haag, and F. Koch-Nolte. 2002. The family 
of toxin-related ecto-ADP-ribosyltransferases in humans and the mouse. 
Protein Sci. 11: 1657-1670. 
Goenka, S., and M. Boothby. 2006. Selective potentiation of Stat-dependent 
gene expression by collaborator of Stat6 (CoaSt6), a transcriptional cofactor. 
Proc Natl Acad Sci USA. 103: 4210-4215. 
" Goenka, S., S. H. Cho, and M. Boothby. 2007. Collaborator of Stat6 (CoaSt6)- 
associated poly(ADP-ribose) polymerase activity modulates Stat6-dependent 
gene transcription. JBiol Chem. 282: 18732-18739. 
o Gomez, M., J. Wu, V. Schreiber, J. Dunlap, F. Dantzer, Y. Wang, and Y. Liu. 
2006. PARP1 Is a TRF2-associated poly(ADP-ribose)polymerase and protects 
eroded telomeres. Mol Biol Cell. 17: 1686-1696. 
" Gottschalk, A. J., G. Timinszky, S. E. Kong, J. Jin, Y. Cai, S. K. Swanson, M. P. 
Washburn, L. Florens, A. G. Ladurner, J. W. Conaway, and R. C. Conaway. 
2009. Poly(ADP-ribosyl)ation directs recruitment and activation of an ATP- 
dependent chromatin remodeler. Proc Natl Acad Sci USA. 106: 13770-13774. 
278 
References 
" Grahnert, A., M. Friedrich, M. Pfister, F. Haag, F. Koch-Nolte, and S. 
Hauschildt. 2002. Mono-ADP-ribosyltransferases in human monocytes: 
regulation by lipopolysaccharide. Biochem J. 362: 717-723. 
" Grooteclaes, M., Q. Deveraux, J. Hildebrand, Q. Zhang, R. H. Goodman, and 
S. M. Frisch. 2003. C-terminal-binding protein corepresses epithelial and 
proapoptotic gene expression programs. Proc Natl Acad Sci USA. 100: 4568- 
4573. 
o Guastafierro, T., B. Cecchinelli, M. Zampieri, A. Reale, G. Riggio, 0. 
Sthandier, G. Zupi, L. Calabrese, and P. Caiafa. 2008. CCCTC-binding factor 
activates PARP-1 affecting DNA methylation machinery. J Bio! Chem. 
283: 21873-21880. 
" Guo, X., J. Ma, J. Sun, and G. Gao. 2007. The zinc-finger antiviral protein 
recruits the RNA processing exosome to degrade the target mRNA. Proc Natl 
Acad Sci USA. 104: 151-156. 
" Haag, F., V. Andresen, S. Karsten, F. Koch-Nolte, and H. Thiele. 1995. Both 
allelic forms of the rat T cell differentiation marker RT6 display nicotinamide 
adenine dinucleotide (NAD)-glycohydrolase activity, yet only RT6.2 is capable 
of automodification upon incubation with NAD. Eur J Immunol. 25: 2355- 
2361. 
o Haas, A. K., S. Yoshimura, D. J. Stephens, C. Preisinger, E. Fuchs, and F. A. 
Barr. 2007. Analysis of GTPase-activating proteins: Rabi and Rab43 are key 
Rabs required to maintain a functional Golgi complex in human cells. J Cell 
Sci. 120: 2997-3010. 
¢ Haigis, M. C., and L. P. Guarente. 2006. Mammalian sirtuins--emerging roles in 
physiology, aging, and calorie restriction. Genes Dev. 20: 2913-2921. 
279 
References 
Haigis, M. C., R. Mostoslavsky, K. M. Haigis, K. Fahie, D. C. Christodoulou, 
A. J. Murphy, D. M. Valenzuela, G. D. Yancopoulos, M. Karow, G. Blander, C. 
Wolberger, T. A. Prolla, R. Weindruch, F. W. Alt, and L. Guarente. 2006. 
SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie 
restriction in pancreatic beta cells. Cell. 126: 941-954. 
a Haince, J. F., S. Kozlov, V. L. Dawson, T. M. Dawson, M. J. Hendzel, M. F. 
Lavin, and G. G. Poirier. 2007. Ataxia telangiectasia mutated (ATM) signaling 
network is modulated by a novel poly(ADP-ribose)-dependent pathway in the 
early response to DNA-damaging agents. JBiol Chem. 282: 16441-16453. 
¢ Haince, J. F., D. McDonald, A. Rodrigue, U. Dery, J. Y. Masson, M. J. Hendzel, 
and G. G. Poirier. 2008. PARP 1-dependent kinetics of recruitment of MRE 11 
and NBS1 proteins to multiple DNA damage sites. J Biol Chem. 283: 1197- 
1208. 
o Hakme, A., H. K. Wong, F. Dantzer, and V. Schreiber. 2008. The expanding 
field of poly(ADP-ribosyl)ation reactions. 'Protein Modifications: Beyond the 
Usual Suspects' Review Series. EMBO Rep. 9: 1094-1100. 
o Hales, C. M., J. P. Vaerman, and J. R. Goldenring. 2002. RabII family 
interacting protein 2 associates with Myosin Vb and regulates plasma 
membrane recycling. JBiol Chem. 277: 50415-50421. 
a Hallows, W. C., B. N. Albaugh, and J. M. Denu. 2008. Where in the cell is 
SIRT3? --functional localization of an NAD+-dependent protein deacetylase. 
Biochem J. 411: a 11-13. 
e Hamada, F., and M. Bienz. 2004. The APC tumor suppressor binds to C- 
terminal binding protein to divert nuclear beta-catenin from TCF. Dev Cell. 
7: 677-685. 
280 
References 
" Han, S., and J. A. Tainer. 2002. The ARTT motif and a unified structural 
understanding of substrate recognition in ADP-ribosylating bacterial toxins and 
eukaryotic ADP-ribosyltransferases. Int JMed Microbiol. 291: 523-529. 
" Hans, F., and S. Dimitrov. 2001. Histone H3 phosphorylation and cell division. 
Oncogene. 20: 3021-3027. 
" Happel, N., and D. Doenecke. 2009. Histone H1 and its isoforms: contribution 
to chromatin structure and function. Gene. 431: 1-12. 
" Hara, N., M. Tsuchiya, and M. Shimoyama. 1996. Glutamic acid 207 in rodent 
T-cell RT6 antigens is essential for arginine-specific ADP-ribosylation. J Biol 
Chem. 271: 29552-29555. 
+ Hassa, P. O., M. Covic, S. Hasan, R. Imhof, and M. O. Hoftiger. 2001. The 
enzymatic and DNA binding activity of PARP-1 are not required for NF-kappa 
B coactivator function. JBiol Chem. 276: 45588-45597. 
Hassa, P. O., S. S. Haenni, C. Buerki, N. I. Meier, W. S. Lane, H. Owen, M. 
Gersbach, R. Imhof, and M. O. Hottiger. 2005. Acetylation of poly(ADP- 
ribose) polymerase-1 by p300/CREB-binding protein regulates coactivation of 
NF-kappaB-dependent transcription. JBiol Chem. 280: 40450-40464. 
a Hassa, P. O., S. S. Haenni, M. Elser, and M. O. Hotiger, 2006. Nuclear ADP- 
ribosylation reactions in mammalian cells: where are we today and where are 
we going? Microbiol Mol Biol Rev. 70: 789-829. 
Hay, R. T. 2005. SUMO: a history of modification. Mol Cell. 18: 1-12. 
Helleday, T., H. E. Bryant, and N. Schultz. 2005. Poly(ADP-ribose) polymerise 
(PARP-1) in homologous recombination and as a target for cancer therapy. 
Cell Cycle. 4: 1176-1178. 
281 
References 
a Hidalgo Carcedo, C., M. Bonazzi, S. Spano, G. Turacchio, A. Colanzi, A. 
Luini, and D. Corda. 2004. Mitotic Golgi partitioning is driven by the 
membrane-fissioning protein CtBP3/BARS. Science. 305: 93-96. 
Hirata, Y., N. Kimura, K. Sato, Y. Ohsugi, S. Takasawa, H. Okamoto, J. 
Ishikawa, T. Kaisho, K. Ishihara, and T. Hirano. 1994. ADP ribosyl cyclase 
activity of a novel bone marrow stromal cell surface molecule, BST-1. FEBS 
Lett. 356: 244-248. 
o Honjo, T., Y. Nishizuka, and O. Hayaishi. 1968. Diphtheria toxin-dependent 
adenosine diphosphate ribosylation of aminoacyl transferase II and inhibition 
of protein synthesis. JBiol Chem. 243: 3553-3555. 
a Hoftiger, M. O., M. Boothby, F. Koch-Nolte, B. Luscher, N. M. Martin, R. 
Plummer, Z. Q. Wang, and M. Ziegler. 2011. Progress in the function and 
regulation of ADP-Ribosylation. Sci Signal. 4: mr5. 
o Hoftiger, M. O., P. O. Hassa, B. Luscher, H. Schuler, and F. Koch-Nolte. 2010. 
Toward a unified nomenclature for mammalian ADP-ribosyltransferases. 
Trends Biochem Sci. 35: 208-219. 
Houtkooper, R. H., C. Canto, R. J. Wanders, and J. Auwerx. 2010. The secret 
life of NAD+: an old metabolite controlling new metabolic signaling pathways. 
Endocr Rev. 31: 194-223. 
Howard, M., J. C. Grimaldi, J. F. Bazan, F. E. Lund, L. Santos-Argumedo, R. M. 
Parkhouse, T. F. Walseth, and H. C. Lee. 1993. Formation and hydrolysis of 
cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. Science. 262: 1056- 
1059. 
Hsiao, S. J., and S. Smith. 2008. Tankyrase function at telomeres, spindle poles, 
and beyond. Biochimie. 90: 83-92. 
282 
References 
o Huang, Q., Y. T. Wu, H. L. Tan, C. N. Ong, and H. M. Shen. 2009. A novel 
function of poly(ADP-ribose) polymerase-1 in modulation of autophagy and 
necrosis under oxidative stress. Cell Death Differ. 16: 264-277. 
e Imai, S., C. M. Armstrong, M. Kaeberlein, and L. Guarente. 2000. 
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent 
histone deacetylase. Nature. 403: 795-800. 
Itoh, M., K. Ishihara, H. Tomizawa, H. Tanaka, Y. Kobune, J. Ishikawa, T. 
Kaisho, and T. Hirano. 1994. Molecular cloning of murine BST-1 having 
homology with CD38 and Aplysia ADP-ribosyl cyclase. Biochem Biophys Res 
Commun. 203: 1309-1317. 
Jager, D., K. Werdan, and U. Muller-Werdan. 2011. Endogenous ADP- 
ribosylation of elongation factor-2 by interleukin-lbeta. Mol Cell Biochem. 
348: 125-128. 
o Jeffery, C. J. 2004. Molecular mechanisms for multitasking: recent crystal 
structures of moonlighting proteins. Curr Opin Struct Biol. 14: 663-668. 
Jin, L., W. Wei, Y. Jiang, H. Peng, J. Cai, C. Mao, H. Dai, W. Choy, J. E. 
Bemis, M. R. Jirousek, J. C. Milne, C. H. Westphal, and R. B. Perni. 2009. 
Crystal structures of human SIRT3 displaying substrate-induced 
conformational changes. JBiol Chem. 284: 24394-24405. 
o Johansson, M. 1999. A human poly(ADP-ribose) polymerase gene family 
(ADPRTL): cDNA cloning of two novel poly(ADP-ribose) polymerase 
homologues. Genomics. 57: 442-445. 
Jones, E. M., and A. Baird. 1997. Cell-surface ADP-ribosylation of fibroblast 
growth factor-2 by an arginine-specific ADP-ribosyltransferase. Biochem J. 
323 (Pt 1): 173-177. 
283 
References 
o Ju, B. G., V. V. Lunyak, V. Perissi, I. Garcia-Bassets, D. W. Rose, C. K. Glass, 
and M. G. Rosenfeld. 2006. A topoisomerase Ilbeta-mediated dsDNA break 
required for regulated transcription. Science. 312: 1798-1802. 
o Ju, B. G., and M. G. Rosenfeld. 2006. A breaking strategy for topoisomerase 
11beta/PARP-1-dependent regulated transcription. Cell Cycle. 5: 2557-2560. 
Ju, B. G., D. Solum, E. J. Song, K. J. Lee, D. W. Rose, C. K. Glass, and M. G. 
Rosenfeld. 2004. Activating the PARP-1 sensor component of the groucho/ 
TLE 1 corepressor complex mediates a CaMKinase Ildelta-dependent 
neurogenic gene activation pathway. Cell. 119: 815-829. 
a Juszczynski, P., J. L. Kutok, C. Li, J. Mitra, R. C. Aguiar, and M. A. Shipp. 
2006. BALI and BBAP are regulated by a gamma interferon-responsive 
bidirectional promoter and are overexpressed in diffuse large B-cell 
lymphomas with a prominent inflammatory infiltrate. Mol Cell Biol. 26: 5348- 
5359. 
+ Kahl, S., M. Nissen, R. Girisch, T. Duffy, E. H. Leiter, F. Haag, and F. Koch- 
Nolte. 2000. Metalloprotease-mediated shedding of enzymatically active 
mouse ecto-ADP-ribosyltransferase ART2.2 upon T cell activation. Jlmmunol. 
165: 4463-4469. 
a Kaminker, P. G., S. H. Kim, R. D. Taylor, Y. Zebarjadian, W. D. Funk, G. B. 
Morin, P. Yaswen, and J. Campisi. 2001. TANK2, a new TRFI-associated 
poly(ADP-ribose) polymerase, causes rapid induction of cell death upon 
overexpression. JBiol Chem. 276: 35891-35899. 
¢ Karras, G. I., G. Kustatscher, H. R. Buhecha, M. D. Allen, C. Pugieux, F. Sait, 
M. Bycroft, and A. G. Ladurner. 2005. The macro domain is an ADP-ribose 
binding module. EMBO J. 24: 1911-1920. 
284 
References 
o Kassis, S., J. Hagmann, P. H. Fishman, P. P. Chang, and J. Moss. 1982. 
Mechanism of action of cholera toxin on intact cells. Generation of Al peptide 
and activation of adenylate cyclase. JBiol Chem. 257: 12148-12152. 
o Katsanis, N., and E. M. Fisher. 1998. A novel C-terminal binding protein 
(CTBP2) is closely related to CTBP1, an adenovirus E1A-binding protein, and 
maps to human chromosome 21g21.3. Genomics. 47: 294-299. 
Kaufmann, S. H., S. Desnoyers, Y. Ottaviano, N. E. Davidson, and G. G. Poirier. 
1993. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early 
marker of chemotherapy-induced apoptosis. Cancer Res. 53: 3976-3985. 
a Kefalas, P., B. Saxty, M. Yadollahi-Farsani, and J. MacDermot. 1999. 
Chemotaxin-dependent translocation of immunoreactive ADP- 
ribosyltransferase- l to the surface of human neutrophil polymorphs. Eur J 
Biochem. 259: 866-871. 
o Kennedy, B. K., N. R. Austriaco, Jr., J. Zhang, and L. Guarente. 1995. Mutation 
in the silencing gene SIR4 can delay aging in S. cerevisiae. Cell. 80: 485-496. 
$ Kerns, J. A., M. Emerman, and H. S. Malik. 2008. Positive selection and 
increased antiviral activity associated with the PARP-containing isoform of 
human zinc-finger antiviral protein. PLoS Genet. 4: e21. 
Kickhoefer, V. A., A. C. Siva, N. L. Kedersha, E. M. Inman, C. Ruland, M. 
Streuli, and L. H. Rome. 1999. The 193-kD vault protein, VPARP, is a novel 
poly(ADP-ribose) polymerase. J Cell Biol. 146: 917-928. 
o Kim, J. H., E. J. Cho, S. T. Kim, and H. D. Youn. 2005. CtBP represses p300- 
mediated transcriptional activation by direct association with its bromodomain. 
Nat Struct Mol Biol. 12: 423-428. 
285 
References 
" Kim, M. Y., S. Mauro, N. Gevry, J. T. Lis, and W. L. Kraus. 2004. NAD+- 
dependent modulation of chromatin structure and transcription by nucleosome 
binding properties of PARP-1. Cell. 119: 803-814. 
" Kleine, H., E. Poreba, K. Lesniewicz, P. O. Hassa, M. O. Hoftiger, D. W. 
Litchfield, B. H. Shilton, and B. Luscher. 2008. Substrate-assisted catalysis by 
PARP 10 limits its activity to mono-ADP-ribosylation. Mol Cell. 32: 57-69. 
Koch-Nolte, F., T. Duffy, M. Nissen, S. Kahl, N. Killeen, V. Ablamunits, F. 
Haag, and E. H. Leiter. 1999. A new monoclonal antibody detects a 
developmentally regulated mouse ecto-ADP-ribosyltransferase on T cells: 
subset distribution, inbred strain variation, and modulation upon T cell 
activation. Jlmmunol. 163: 6014-6022. 
+Koch-Nolte, F., and F. Haag. 1997. Mono(ADP-ribosyl)transferases and 
related enzymes in animal tissues. Emerging gene families. Adv Exp Med Biol. 
419: 1-13. 
Koch-Nolte, F., F. Haag, R. Braren, M. Kuhl, J. Hoovers, S. Balasubramanian, 
F. Bazan, and H. G. Thiele. 1997. Two novel human members of an emerging 
mammalian gene family related to mono-ADP-ribosylating bacterial toxins. 
Genomics. 39: 370-376. 
Koch-Nolte, F., S. Kernstock, C. Mueller-Dieckmann, M. S. Weiss, and F. 
Haag. 2008. Mammalian ADP-ribosyltransferases and ADP-ribosylhydrolases. 
Front Biosci. 13: 6716-6729. 
Koch-Nolte, F., J. Klein, C. Hohmann, M. Kuhl, F. Haag, H. R. Gaskins, E. 
Leiter, and H. G. Thiele. 1995. Defects in the structure and expression of the 
genes for the T cell marker Rt6 in NZW and (NZB x NZW)F1 mice. Int 
Immunol. 7: 883-890. 
286 
References 
$ Koehler, C., L. Carlier, D. Veggi, E. Balducci, F. Di Marcello, M. Ferrer- 
Navarro, M. Pizza, X. Daura, M. Soriani, R. Boelens, and A. M. Bonvin. 2011. 
Structural and biochemical characterization of NarE, an iron-containing ADP- 
ribosyltransferase from Neisseria meningitidis. JBiol Chem. 286: 14842-1485 1. 
$ Kraus, W. L. 2008. Transcriptional control by PARP-1: chromatin modulation, 
enhancer-binding, coregulation, and insulation. Curr Opin Cell Biol. 20: 294- 
302. 
d Kraus, W. L., and J. T. Lis. 2003. PARP goes transcription. Cell. 113: 677-683. 
o Krishnakumar, R., M. J. Gamble, K. M. Frizzell, J. G. Berrocal, M. Kininis, and 
W. L. Kraus. 2008. Reciprocal binding of PARP-1 and histone H1 at promoters 
specifies transcriptional outcomes. Science. 319: 819-821. 
o Krishnakumar, R., and W. L. Kraus. 2010a. The PARP side of the nucleus: 
molecular actions, physiological outcomes, and clinical targets. Mol Cell. 39: 8- 
24. 
Krishnakumar, R., and W. L. Kraus. 2010b. PARP-1 regulates chromatin 
structure and transcription through a KDM5B-dependent pathway. Mol Cell. 
39: 736-749. 
o Krueger, K. M., and J. T. Barbieri. 1995. The family of bacterial ADP- 
ribosylating exotoxins. Clin Microbiol Rev. 8: 34-47. 
Kuimov, A. N., D. V. Kuprash, V. N. Petrov, K. K. Vdovichenko, M. J. Scanlan, 
C. V. Jongeneel, M. A. Lagarkova, and S. A. Nedospasov. 2001. Cloning and 
characterization of TNKL, a member of tankyrase gene family. Genes Immun. 
2: 52-55. 
Kumar, V., J. E. Carlson, K. A. Ohgi, T. A. Edwards, D. W. Rose, C. R. 
Escalante, M. G. Rosenfeld, and A. K. Aggarwal. 2002. Transcription 
287 
References 
corepressor CtBP is an NAD(+)-regulated dehydrogenase. Mol Cell. 10: 857- 
869. 
0 Kurosaki, T., H. Ushiro, Y. Mitsuuchi, S. Suzuki, M. Matsuda, Y. Matsuda, N. 
Katunuma, K. Kangawa, H. Matsuo, T. Hirose, and et at. 1987. Primary 
structure of human poly(ADP-ribose) synthetase as deduced from cDNA 
sequence. JBiol Chem. 262: 15990-15997. 
o Landry, J., J. T. Slama, and R. Sternglanz. 2000. Role of NAD(+) in the 
deacetylase activity of the SIR2-like proteins. Biochem Biophys Res Commun. 
278: 685-690. 
'0 Langelier, M. F., D. D. Ruhl, J. L. Planck, W. L. Kraus, and J. M. Pascal. 2010. 
The Zn3 domain of human poly(ADP-ribose) polymerase-1 (PARP-1) 
functions in both DNA-dependent poly(ADP-ribose) synthesis activity and 
chromatin compaction. JBiol Chem. 285: 18877-18887. 
¢ Langelier, M. F., K. M. Servent, E. E. Rogers, and J. M. Pascal. 2008. A third 
zinc-binding domain of human poly(ADP-ribose) polymerise-1 coordinates 
DNA-dependent enzyme activation. JBiol Chem. 283: 4105-4114. 
Lee, H. C., and R. Aarhus. 1991. ADP-ribosyl cyclase: an enzyme that cyclizes 
NAD+ into a calcium-mobilizing metabolite. Cell Regul. 2: 203-209. 
" Lencer, W. I., T. R. Hirst, and R. K. Holmes. 1999. Membrane traffic and the 
cellular uptake of cholera toxin. Biochim Biophys Acta. 1450: 177-190. 
" Leung, A. K., S. Vyas, J. E. Rood, A. Bhutkar, P. A. Sharp, and P. Chang. 2011. 
Poly(ADP-ribose) regulates stress responses and microRNA activity in the 
cytoplasm. Mol Cell. 42: 489-499. 
288 
References 
o Levine, T. P., C. Rabouille, R. H. Kieckbusch, and G. Warren. 1996. Binding of 
the vesicle docking protein p115 to Golgi membranes is inhibited under mitotic 
conditions. JBiol Chem. 271: 17304-17311. 
o Liberali, P., E. Kakkonen, G. Turacchio, C. Valente, A. Spaar, G. Perinetti, 
R. A. Bockmann, D. Corda, A. Colanzi, V. Marjomaki, and A. Luini. 2008. The 
closure of Pakl-dependent macropinosomes requires the phosphorylation of 
CtBP 1 BARS. EMBO J. 27: 970-98 1. 
Liew, C. K., M. Crossley, J. P. Mackay, and H. R. Nicholas. 2007. Solution 
structure of the THAP domain from Caenorhabditis elegans C-terminal binding 
protein (CtBP). JMol Biol. 366: 382-390. 
o Lin, X., B. Sun, M. Liang, Y. Y. Liang, A. Gast, J. Hildebrand, F. C. Brunicardi, 
F. Melchior, and X. H. Feng. 2003. Opposed regulation of corepressor CtBP by 
SUMOylation and PDZ binding. Mol Cell. 11: 1389-1396. 
Lippincott-Schwartz, J., L. Yuan, C. Tipper, M. Amherdt, L. Orci, and R. D. 
Klausner. 1991. Brefeldin A's effects on endosomes, lysosomes, and the TGN 
suggest a general mechanism for regulating organelle structure and membrane 
traffic. Cell. 67: 601-616. 
o Lippincott-Schwartz, J., L. C. Yuan, J. S. Bonifacino, and R. D. Klausner. 1989. 
Rapid redistribution of Golgi proteins into the ER in cells treated with brefeldin 
A: evidence for membrane cycling from Golgi to ER. Cell. 56: 801-813. 
Liu, Q., R. Graeff, I. A. Kriksunov, H. Jiang, B. Zhang, N. Oppenheimer, H. 
Lin, B. V. Potter, H. C. Lee, and Q. Hao. 2009. Structural basis for enzymatic 
evolution from a dedicated ADP-ribosyl cyclase to a multifunctional NAD 
hydrolase. JBiol Chem. 284: 27637-27645. 
289 
References 
+ Liu, Q., I. A. Kriksunov, R. Graeff, C. Munshi, H. C. Lee, and Q. Hao. 2005. 
Crystal structure of human CD38 extracellular domain. Structure. 13: 1331- 
1339. 
e Liu, Q., I. A. Kriksunov, H. Jiang, R. Graeff, H. Lin, H. C. Lee, and Q. Hao. 
2008. Covalent and noncovalent intermediates of an NAD utilizing enzyme, 
human CD38. Chem Biol. 15: 1068-1078. 
" Liu, Y., B. E. Snow, V. A. Kickhoefer, N. Erdmann, W. Zhou, A. Wakeham, M. 
Gomez, L. H. Rome, and L. Harrington. 2004. Vault poly(ADP-ribose) 
polymerase is associated with mammalian telomerase and is dispensable for 
telomerase function and vault structure in vivo. Mol Cell Biol. 24: 5314-5323. 
a Lonskaya, I., V. N. Potaman, L. S. Shlyakhtenko, E. A. Oussatcheva, Y. L. 
Lyubchenko, and V. A. Soldatenkov. 2005. Regulation of poly(ADP-ribose) 
polymerase-1 by DNA structure-specific binding. J Biol Chem. 280: 17076- 
17083. 
" Lorente-Rodriguez, A., and C. Barlowe. 2011. Entry and Exit Mechanisms at 
the cis-Face of the Golgi Complex. Cold Spring Harb Perspect Biol. 3. 
o Loseva, 0., A. S. Jemth, H. E. Bryant, H. Schuler, L. Lehtio, T. Karlberg, and T. 
Helleday. 2010. PARP-3 is a mono-ADP-ribosylase that activates PARP-1 in 
the absence of DNA. JBiol Chem. 285: 8054-8060. 
$ Lowe, M., N. Nakamura, and G. Warren. 1998a. Golgi division and membrane 
traffic. Trends Cell Biol. 8: 40-44. 
Lowe, M., C. Rabouille, N. Nakamura, R. Watson, M. Jackman, E. Jamsa, D. 
Rahman, D. J. Pappin, and G. Warren. 1998b. Cdc2 kinase directly 
phosphorylates the cis-Golgi matrix protein GM 130 and is required for Golgi 
fragmentation in mitosis. Cell. 94: 783-793. 
290 
References 
" Lupi, R., D. Corda, and M. Di Girolamo. 2000. Endogenous ADP-ribosylation 
of the G protein beta subunit prevents the inhibition of type 1 adenylyl cyclase. 
J Biol Chem. 275: 9418-9424. 
" Lyons, R. J., R. Deane, D. K. Lynch, Z. S. Ye, G. M. Sanderson, H. J. Eyre, G. R. 
Sutherland, and R. J. Daly. 2001. Identification of a novel human tankyrase 
through its interaction with the adaptor protein G614. J Biol Chem. 
276: 17172-17180. 
o Ma, Q., K. T. Baldwin, A. J. Renzelli, A. McDaniel, and L. Dong. 2001. TCDD- 
inducible poly(ADP-ribose) polymerase: a novel response to 2,3,7,8- 
tetrachlorodibenzo-p-dioxin. Biochem Biophys Res Commun. 289: 499-506. 
o Malanga, M., J. M. Pleschke, H. E. Kleczkowska, and F. R. Althaus. 1998. 
Poly(ADP-ribose) binds to specific domains of p53 and alters its DNA binding 
functions. JBiol Chem. 273: 11839-11843. 
a Malavasi, F., S. Deaglio, R. Damle, G. Cutrona, M. Ferrarini, and N. 
Chiorazzi. 2011. CD38 and chronic lymphocytic leukemia: a decade later. 
Blood. 
d Malavasi, F., S. Deaglio, A. Funaro, E. Ferrero, A. L. Horenstein, E. Ortolan, T. 
Vaisitti, and S. Aydin. 2008. Evolution and function of the ADP ribosyl 
cyclase/CD38 gene family in physiology and pathology. Physiol Rev. 88: 841- 
886. 
Mani-Telang, P., and D. N. Arnosti. 2007. Developmental expression and 
phylogenetic conservation of alternatively spliced forms of the C-terminal 
binding protein corepressor. Dev Genes Evol. 217: 127-135. 
Mann, M., and O. N. Jensen. 2003. Proteomic analysis of post-translational 
modifications. Nat Biotechnol. 21: 255-261. 
291 
References 
o Mao, Z., C. Hine, X. Tian, M. Van Meter, M. Au, A. Vaidya, A. Seluanov, and 
V. Gorbunova. 2011. SIRT6 promotes DNA repair under stress by activating 
PARP 1. Science. 332: 1443-1446. 
o Maresso, A. W., M. R. Baldwin, and J. T. Barbieri. 2004. Ezrin/radixin/moesin 
proteins are high affinity targets for ADP-ribosylation by Pseudomonas 
aeruginosa ExoS. JBiol Chem. 279: 38402-38408. 
Masson, M., C. Niedergang, V. Schreiber, S. Muller, J. Menissier-de Murcia, 
and G. de Murcia. 1998. XRCC 1 is specifically associated with poly(ADP- 
ribose) polymerase and negatively regulates its activity following DNA 
damage. Mol Cell Biol. 18: 3563-3571. 
McLauchlan, H., J. Newell, N. Morrice, A. Osborne, M. West, and E. Smythe. 
1998. A novel role for RabS-GDI in ligand sequestration into clathrin-coated 
pits. Curr Biol. 8: 34-45. 
o Mehrotra, P., J. P. Riley, R. Patel, F. Li, L. Voss, and S. Goenka. 2011. PARP- 
14 functions as a transcriptional switch for Stat6-dependent gene activation. J 
Biol Chem. 286: 1767-1776. 
4 Mendez, L. M., J. M. Polo, J. J. Yu, M. Krupski, B. B. Ding, A. Melnick, and 
B. H. Ye. 2008. CtBP is an essential corepressor for BCL6 autoregulation. Mol 
Cell Biol. 28: 2175-2186. 
Mendoza-Alvarez, H., and R. Alvarez-Gonzalez. 1993. Poly(ADP-ribose) 
polymerase is a catalytic dimer and the automodification reaction is 
intermolecular. JBiol Chem. 268: 22575-22580. 
O Menissier de Murcia, J., M. Ricoul, L. Tartier, C. Niedergang, A. Huber, F. 
Dantzer, V. Schreiber, J. C. Ame, A. Dierich, M. LeMeur, L. Sabatier, P. 
Chambon, and G. de Murcia. 2003. Functional interaction between PARP-1 
292 
References 
and PARP-2 in chromosome stability and embryonic development in mouse. 
EMBO J. 22: 2255-2263. 
o Messner, S., M. Altmeyer, H. Zhao, A. Pozivil, B. Roschitzki, P. Gehrig, D. 
Rutishauser, D. Huang, A. Caflisch, and M. O. Hottiger. 2010. PARP1 ADP- 
ribosylates lysine residues of the core histone tails. Nucleic Acids Res. 
38: 6350-6362. 
o Michan, S., and D. Sinclair. 2007. Sirtuins in mammals: insights into their 
biological function. Biochem J. 404: 1-13. 
a Michishita, E., J. Y. Park, J. M. Burneskis, J. C. Barrett, and I. Horikawa. 2005. 
Evolutionarily conserved and nonconserved cellular localizations and functions 
of human SIRT proteins. Mol Biol Cell. 16: 4623-4635. 
" Mirnezami, A. H., S. J. Campbell, M. Darley, J. N. Primrose, P. W. Johnson, and 
J. P. Blaydes. 2003. Hdm2 recruits a hypoxia-sensitive corepressor to 
negatively regulate p53-dependent transcription. Curr Biol. 13: 1234-1239. 
" Misteli, T., and G. Warren. 1994. COP-coated vesicles are involved in the 
mitotic fragmentation of Golgi stacks in a cell-free system. J Cell Blot. 
125: 269-282. 
" Monetta, P., I. Slavin, N. Romero, and C. Alvarez. 2007. Rab Ib interacts with 
GBF 1 and modulates both ARF 1 dynamics and COPI association. Mol Bio! 
Cell. 18: 2400-2410. 
" Moyer, B. D., B. B. Allan, and W. E. Balch. 2001. Rabi interaction with a 
GM 130 effector complex regulates COPII vesicle cis--Golgi tethering. T riffic. 
2: 268-276. 
293 
References 
" Moynihan, M. R., and A. M. Pappenheimer, Jr. 1981. Kinetics of 
adenosinediphosphoribosylation of elongation factor 2 in cells exposed to 
diphtheria toxin. Infect Immun. 32: 575-582. 
" Mroz, E. A., A. H. Baird, W. A. Michaud, and J. W. Rocco. 2008. COOH- 
terminal binding protein regulates expression of the p 16INK4A tumor 
suppressor and senescence in primary human cells. Cancer Res. 68: 6049-6053. 
+ Muramatsu, Y., H. Tahara, T. Ono, T. Tsuruo, and H. Seimiya. 2008. Telomere 
elongation by a mutant tankyrase 1 without TRF1 poly(ADP-ribosyl)ation. Exp 
Cell Res. 314: 1115-1124. 
" Nadauld, L. D., R. Phelps, B. C. Moore, A. Eisinger, I. T. Sandoval, S. 
Chidester, P. W. Peterson, E. J. Manos, B. Sklow, R. W. Burt, and D. A. Jones. 
2006. Adenomatous polyposis coli control of C-terminal binding protein-1 
stability regulates expression of intestinal retinol dehydrogenases. J Biol Chem. 
281: 37828-37835. 
" Nakamura, N., M. Lowe, T. P. Levine, C. Rabouille, and G. Warren. 1997. The 
vesicle docking protein p 115 binds GM 130, a cis-Golgi matrix protein, in a 
mitotically regulated manner. Cell. 89: 445-455. 
" Nardini, M., S. Spano, C. Cericola, A. Pesce, A. Massaro, E. Millo, A. Luini, 
D. Corda, and M. Bolognesi. 2003. CtBP/BARS: a dual-function protein 
involved in transcription co-repression and Golgi membrane fission. EMBO J. 
22: 3122-3130. 
" Nardini, M., D. Svergun, P. V. Konarev, S. Spano, M. Fasano, C. Bracco, A. 
Pesce, A. Donadini, C. Cericola, F. Secundo, A. Luini, D. Corda, and M. 
Bolognesi. 2006. The C-terminal domain of the transcriptional corepressor 
CtBP is intrinsically unstructured. Protein Sci. 15: 1042-1050. 
294 
References 
" Nardini, M., C. Valente, S. Ricagno, A. Luini, D. Corda, and M. Bolognesi. 
2009. CtBP1/BARS G1y172-->Glu mutant structure: impairing NAD(H)- 
binding and dimerization. Biochem Biophys Res Commun. 381: 70-74. 
" Nguewa, P. A., M. A. Fuertes, B. Valladares, C. Alonso, and J. M. Perez. 2005. 
Poly(ADP-ribose) polymerises: homology, structural domains and functions. 
Novel therapeutical applications. Prog Biophys Mol Biol. 88: 143-172. 
Nibu, Y., H. Zhang, E. Bajor, S. Barolo, S. Small, and M. Levine. 1998. dCtBP 
mediates transcriptional repression by Knirps, Kruppel and Snail in the 
Drosophila embryo. EMBO J. 17: 7009-7020. 
Obritsch, M. D., D. N. Fish, R. MacLaren, and R. Jung. 2005. Nosocomial 
infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology 
and treatment options. Pharmacotherapy. 25: 1353-1364. 
" Oka, S., J. Kato, and J. Moss. 2006. Identification and characterization of a 
mammalian 39-kDa poly(ADP-ribose) glycohydrolase. J Biol Chem. 281: 705- 
713. 
o Okazaki, I. J., H. J. Kim, N. G. McElvaney, E. Lesma, and J. Moss. 1996. 
Molecular characterization of a glycosylphosphatidylinositol-linked ADP- 
ribosyltransferase from lymphocytes. Blood. 88: 915-921. 
" Okazaki, I. J., and J. Moss. 1998. Glycosylphosphatidylinositol-anchored and 
secretory isoforms of mono-ADP-ribosyltransferases. J Biol Chem. 273: 23617- 
23620. 
" Okazaki, I. J., and J. Moss. 1999. Characterization of 
glycosylphosphatidylinositiol-anchored, secreted, and intracellular vertebrate 
mono-ADP-ribosyltransferases. Annu Rev Nutr. 19: 485-509. 
295 
References 
Okazaki, I. J., A. Zolkiewska, M. S. Nightingale, and J. Moss. 1994. 
Immunological and structural conservation of mammalian skeletal muscle 
glycosylphosphatidylinositol-linked ADP-ribosyltransferases. Biochemistry. 
33: 12828-12836. 
4 Ortolan, E., P. Vacca, A. Capobianco, E. Armando, F. Crivellin, A. Horenstein, 
and F. Malavasi. 2002. CD 157, the Janus of CD38 but with a unique 
personality. Cell Biochem Funct. 20: 309-322. 
Otto, H., P. A. Reche, F. Bazan, K. Dittmar, F. Haag, and F. Koch-Nolte. 2005. 
In silico characterization of the family of PARP-like poly(ADP- 
ribosyl)transferases (pARTs). BMC Genomics. 6: 139. 
Pan, P. W., J. L. Feldman, M. K. Devries, A. Dong, A. M. Edwards, and J. M. 
Denu. 2011. Structure and biochemical functions of SIRT6. J Biol Chem. 
286: 14575-14587. 
o Panzeter, P. L., and F. R. Althaus. 1990. High resolution size analysis of ADP- 
ribose polymers using modified DNA sequencing gels. Nucleic Acids Res. 
18: 2194. 
o Paone, G., L. A. Stevens, R. L. Levine, C. Bourgeois, W. K. Steagall, B. R. 
Gochuico, and J. Moss. 2006. ADP-ribosyltransferase-specific modification of 
human neutrophil peptide-1. JBiol Chem. 281: 17054-17060. 
a Paone, G., A. Wada, L. A. Stevens, A. Matin, T. Hirayama, R. L. Levine, and J. 
Moss. 2002. ADP ribosylation of human neutrophil peptide-1 regulates its 
biological properties. Proc Nail Acad Sci USA. 99: 8231-8235. 
Pavri, R., B. Lewis, T. K. Kim, F. J. Dilworth, H. Erdjument-Bromage, P. 
Tempst, G. de Murcia, R. Evans, P. Chambon, and D. Reinberg. 2005. PARP-1 
296 
References 
determines specificity in a retinoid signaling pathway via direct modulation of 
mediator. Mol Cell. 18: 83-96. 
Pena, C., J. M. Garcia, V. Garcia, J. Silva, G. Dominguez, R. Rodriguez, C. 
Maximiano, A. Garcia de Herreros, A. Munoz, and F. Bonilla. 2006. The 
expression levels of the transcriptional regulators p300 and CtBP modulate the 
correlations between SNAIL, ZEB 1, E-cadherin and vitamin D receptor in 
human colon carcinomas. Int J Cancer. 119: 2098-2104. 
a Peng, G., and S. Y. Lin. 2011. Exploiting the homologous recombination DNA 
repair network for targeted cancer therapy. World J Clin Oncol. 2: 73-79. 
Peyroche, A., B. Antonny, S. Robineau, J. Acker, J. Cherfils, and C. L. Jackson. 
1999. Brefeldin A acts to stabilize an abortive ARF-GDP-Sec7 domain protein 
complex: involvement of specific residues of the Sec7 domain. Mol Cell. 
3: 275-285. 
$ Phan, R. T., and R. Dalla-Favera. 2004. The BCL6 proto-oncogene suppresses 
p53 expression in germinal-centre B cells. Nature. 432: 635-639. 
Pleschke, J. M., H. E. Kleczkowska, M. Strohm, and F. R. Althaus. 2000. 
Poly(ADP-ribose) binds to specific domains in DNA damage checkpoint 
proteins. JBiol Chem. 275: 40974-40980. 
Poirier, G. G., G. de Murcia, J. Jongstra-Bilen, C. Niedergang, and P. Mandel. 
1982. Poly(ADP-ribosyl)ation of polynucleosomes causes relaxation of 
chromatin structure. Proc Natl Acad Sci USA. 79: 3423-3427. 
Preisinger, C., R. Korner, M. Wind, W. D. Lehmann, R. Kopajtich, and F. A. 
Barr. 2005. Plkl docking to GRASP65 phosphorylated by Cdkl suggests a 
mechanism for Golgi checkpoint signalling. EMBO J. 24: 753-765. 
297 
References 
o Quinlan, K. G., M. Nardini, A. Verger, P. Francescato, P. Yaswen, D. Corda, 
M. Bolognesi, and M. Crossley. 2006a. Specific recognition of ZNF217 and 
other zinc finger proteins at a surface groove of C-terminal binding proteins. 
Mol Cell Biol. 26: 8159-8172. 
0 Quinlan, K. G., A. Verger, A. Kwok, S. H. Lee, J. Perdomo, M. Nardini, M. 
Bolognesi, and M. Crossley. 2006b. Role of the C-terminal binding protein 
PXDLS motif binding cleft in protein interactions and transcriptional 
repression. Mol Cell Biol. 26: 8202-8213. 
" Raval-Fernandes, S., V. A. Kickhoefer, C. Kitchen, and L. H. Rome. 2005. 
Increased susceptibility of vault poly(ADP-ribose) polymerase-deficient mice 
to carcinogen-induced tumorigenesis. Cancer Res. 65: 8846-8852. 
" Reale, A., G. D. Matteis, G. Galleazzi, M. Zampieri, and P. Caiafa. 2005. 
Modulation of DNMT1 activity by ADP-ribose polymers. Oncogene. 24: 13-19. 
" Rechsteiner, M., D. Hillyard, and B. M. Olivera. 1976. Turnover at 
nicotinamide adenine dinucleotide in cultures of human cells. J Cell Physiol. 
88: 207-217. 
$ Reeder, R. H., K. Ueda, T. Honjo, Y. Nishizuka, and O. Hayaishi. 1967. Studies 
on the polymer of adenosine diphosphate ribose. 11. Characterization of the 
polymer. JBiol Chem. 242: 3172-3179. 
0 Riefler, G. M., and B. L. Firestein. 2001. Binding of neuronal nitric-oxide 
synthase (nNOS) to carboxyl-terminal-binding protein (CtBP) changes the 
localization of CtBP from the nucleus to the cytosol: a novel function for 
targeting by the PDZ domain of nNOS. JBiol Chem. 276: 48262-48268. 
298 
References 
" Rine, J., J. N. Strathern, J. B. Hicks, and I. Herskowitz. 1979. A suppressor of 
mating-type locus mutations in Saccharomyces cerevisiae: evidence for and 
identification of cryptic mating-type loci. Genetics. 93: 877-901. 
" Rippmann, J. F., K. Damm, and A. Schnapp. 2002. Functional characterization 
of the poly(ADP-ribose) polymerise activity of tankyrase 1, a potential 
regulator of telomere length. JMol Biol. 323: 217-224. 
a Rouleau, M., D. McDonald, P. Gagne, M. E. Ouellet, A. Droit, J. M. Hunter, S. 
Dutertre, C. Prigent, M. J. Hendzel, and G. G. Poirier. 2007. PARP-3 associates 
with polycomb group bodies and with components of the DNA damage repair 
machinery. J Cell Biochem. 100: 385-401. 
4 Sandkvist, M., M. Bagdasarian, and S. P. Howard. 2000. Characterization of the 
multimeric Eps complex required for cholera toxin secretion. Int J Med 
Microbiol. 290: 345-350. 
" Santella, L. 2005. NAADP: a new second messenger comes of age. Mol Interv. 
5: 70-72. 
4, Satoh, M. S., and T. Lindahl. 1992. Role of poly(ADP-ribose) formation in 
DNA repair. Nature. 356: 356-358. 
o Sauve, A. A., I. Celic, J. Avalos, H. Deng, J. D. Boeke, and V. L. Schramm. 
2001. Chemistry of gene silencing: the mechanism of NAD+-dependent 
deacetylation reactions. Biochemistry. 40: 15456-15463. 
a Sauve, A. A., C. Wolberger, V. L. Schramm, and J. D. Boeke. 2006. The 
biochemistry of sirtuins. Annu Rev Biochem. 75: 435-465. 
0 Saxena, A., L. H. Wong, P. Kalitsis, E. Earle, L. G. Shaffer, and K. H. Choo. 
2002. Poly(ADP-ribose) polymerase 2 localizes to mammalian active 
299 
References 
centromeres and interacts with PARP-1, Cenpa, Cenpb and Bub3, but not 
Cenpc. Hum Mol Genet. 11: 2319-2329. 
aSaxty, B. A., M. Yadollahi-Farsani, P. D. Upton, S. R. Johnstone, and J. 
MacDermot. 2001. Inactivation of platelet-derived growth factor-BB following 
modification by ADP-ribosyltransferase. Br JPharmacol. 133: 1219-1226. 
Sbodio, J. I., and N. W. Chi. 2002. Identification of a tankyrase-binding motif 
shared by IRAP, TAB 182, and human TRF 1 but not mouse TRF 1. NuMA 
contains this RXXPDG motif and is a novel tankyrase partner. J Biol Chem. 
277: 31887-31892. 
ýr Schaeper, U., J. M. Boyd, S. Verma, E. Uhlmann, T. Subramanian, and G. 
Chinnadurai. 1995. Molecular cloning and characterization of a cellular 
phosphoprotein that interacts with a conserved C-terminal domain of 
adenovirus E1A involved in negative modulation of oncogenic transformation. 
Proc Natl Acad Sci USA. 92: 10467-10471. 
Scher, M. B., A. Vaquero, and D. Reinberg. 2007. SirT3 is a nuclear NAD+- 
dependent histone deacetylase that translocates to the mitochondria upon 
cellular stress. Genes Dev. 21: 920-928. 
+ Scheuplein, F., S. Adriouch, G. Glowacki, F. Haag, M. Seman, and F. Koch- 
Nolte. 2003. Triggering of T-cell apoptosis by toxin-related ecto-ADP- 
ribosyltransferase ART2. Ann N YAcad Sci. 1010: 296-299. 
a Schmitz, F., A. Konigstorfer, and T. C. Sudhof. 2000. RIBEYE, a component of 
synaptic ribbons: a protein's journey through evolution provides insight into 
synaptic ribbon function. Neuron. 28: 857-872. 
o Schreiber, V., F. Dantzer, J. C. Ame, and G. de Murcia. 2006. Poly(ADP- 
ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol. 7: 517-528. 
300 
References 
o Schwer, B., J. Bunkenborg, R. O. Verdin, J. S. Andersen, and E. Verdin. 2006. 
Reversible lysine acetylation controls the activity of the mitochondria] enzyme 
acetyl-CoA synthetase 2. Proc Nat! Acad Sci USA. 103: 10224-10229. 
Schwer, B., B. J. North, R. A. Frye, M. Ott, and E. Verdin. 2002. The human 
silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial 
nicotinamide adenine dinucleotide-dependent deacetylase. J Cell Biol. 
158: 647-657. 
Sciaky, N., J. Presley, C. Smith, K. J. Zaal, N. Cole, J. E. Moreira, M. Terasaki, 
E. Siggia, and J. Lippincott-Schwartz. 1997. Golgi tubule traffic and the effects 
of brefeldin A visualized in living cells. J Cell Biol. 139: 1137-1155. 
" Seman, M., S. Adriouch, F. Haag, and F. Koch-Nolte. 2004. Ecto-ADP- 
ribosyltransferases (ARTs): emerging actors in cell communication and 
signaling. Curr Med Chem. 11: 857-872. 
Seman, M., S. Adriouch, F. Scheuplein, C. Krebs, D. Freese, G. Glowacki, P. 
Deterre, F. Haag, and F. Koch-Nolte. 2003. NAD-induced T cell death: ADP- 
ribosylation of cell surface proteins by ART2 activates the cytolytic P2X7 
purinoceptor. Immunity. 19: 571-582. 
Shah, G. M., D. Poirier, C. Duchaine, G. Brochu, S. Desnoyers, J. Lagueux, A. 
Verreault, J. C. Hoflack, J. B. Kirkland, and G. G. Poirier. 1995. Methods for 
biochemical study of poly(ADP-ribose) metabolism in vitro and in vivo. Anal 
Biochem. 227: 1-13. 
a Shall, S., and G. de Murcia. 2000. Poly(ADP-ribose) polymerise-1: what have 
we learned from the deficient mouse model? Mutat Res. 460: 1-15. 
301 
References 
" Shi, Y., J. Sawada, G. Sui, B. Affar el, J. R. Whetstine, F. Lan, H. Ogawa, M. P. 
Luke, and Y. Nakatani. 2003. Coordinated histone modifications mediated by a 
CtBP co-repressor complex. Nature. 422: 735-738. 
" Sierra, J., T. Yoshida, C. A. Joazeiro, and K. A. Jones. 2006. The APC tumor 
suppressor counteracts beta-catenin activation and H3K4 methylation at Wnt 
target genes. Genes Dev. 20: 586-600. 
$ Sims, R. J., 3rd, and D. Reinberg. 2008. Is there a code embedded in proteins 
that is based on post-translational modifications? Nat Rev Mol Cell Biol. 9: 815- 
820. 
'w Sixma, T. K., S. E. Pronk, K. H. Kalk, E. S. Wartna, B. A. van Zanten, B. Witholt, 
and W. G. Hol. 1991. Crystal structure of a cholera toxin-related heat-labile 
enterotoxin from E. coli. Nature. 351: 371-377. 
" Smith, S., and T. de Lange. 1999. Cell cycle dependent localization of the 
telomeric PARP, tankyrase, to nuclear pore complexes and centrosomes. J Cell 
Sci. 112 ( Pt 21): 3649-3656. 
a Smith, S., and T. de Lange. 2000. Tankyrase promotes telomere elongation in 
human cells. Curr Biol. 10: 1299-1302. 
" Smith, S., I. Giriat, A. Schmitt, and T. de Lange. 1998. Tankyrase, a 
poly(ADP-ribose) polymerase at human telomeres. Science. 282: 1484-1487. 
¢ Spano, S., M. G. Silletta, A. Colanzi, S. Alberti, G. Fiucci, C. Valente, A. 
Fusella, M. Salmona, A. Mironov, A. Luini, and D. Corda. 1999. Molecular 
cloning and functional characterization of brefeldin A-ADP-ribosylated 
substrate. A novel protein involved in the maintenance of the Golgi structure. J 
Biol Chem. 274: 17705-17710. 
302 
References 
" States, D. J., T. F. Walseth, and H. C. Lee. 1992. Similarities in amino acid 
sequences of Aplysia ADP-ribosyl cyclase and human lymphocyte antigen 
CD38. Trends Biochem Sci. 17: 495. 
" Stein, P. E., A. Boodhoo, G. D. Armstrong, S. A. Cockle, M. H. Klein, and R. J. 
Read. 1994. The crystal structure of pertussis toxin. Structure. 2: 45-57. 
" Stenmark, H. 2009. Rab GTPases as coordinators of vesicle traffic. Nat Rev 
Mol Cell Biol. 10: 513-525. 
" Stevens, L. A., C. Bourgeois, R. Borteil, and J. Moss. 2003. Regulatory role of 
arginine 204 in the catalytic activity of rat alloantigens ART2a and ART2b. J 
Biol Chem. 278: 19591-19596. 
o Streatfield, S. J., M. Sandkvist, T. K. Sixma, M. Bagdasarian, W. G. Hol, and 
T. R. Hirst. 1992. Intermolecular interactions between the A and B subunits of 
heat-labile enterotoxin from Escherichia coli promote holotoxin assembly and 
stability in vivo. Proc Natl Acad Sci USA. 89: 12140-12144. 
" Sugimura, T., S. Fujimura, S. Hasegawa, and Y. Kawamura. 1967. 
Polymerization of the adenosine 5'-diphosphate ribose moiety of NAD by rat 
liver nuclear enzyme. Biochim Biophys Acta. 138: 438-441. 
" Sun, J., and J. T. Barbieri. 2003. Pseudomonas aeruginosa ExoT ADP- 
ribosylates CTIO regulator of kinase (Crk) proteins. J Biol Chem. 278: 32794- 
32800. 
" Sutterlin, C., P. Hsu, A. Mallabiabarrena, and V. Malhotra. 2002. 
Fragmentation and dispersal of the pericentriolar Golgi complex is required for 
entry into mitosis in mammalian cells. Cell. 109: 359-369. 
" Swanson, J. A., and C. Watts. 1995. Macropinocytosis. Trends Cell Biol. 5: 424- 
428. 
303 
References 
" Takada, T., K. Iida, and J. Moss. 1995. Conservation of a common motif in 
enzymes catalyzing ADP-ribose transfer. Identification of domains in 
mammalian transferases. JBiol Chem. 270: 541-544. 
" Takeyama, K., R. C. Aguiar, L. Gu, C. He, G. J. Freeman, J. L. Kutok, J. C. 
Aster, and M. A. Shipp. 2003. The BAL-binding protein BBAP and related 
Deltex family members exhibit ubiquitin-protein isopeptide ligase activity. J 
Biol Chem. 278: 21930-21937. 
" Tanner, K. G., J. Landry, R. Sternglanz, and J. M. Denu. 2000. Silent 
information regulator 2 family of NAD- dependent histone/protein deacetylases 
generates a unique product, 1-O-acetyl-ADP-ribose. Proc Nall Acad Sci USA. 
97: 14178-14182. 
" Tanno, M., J. Sakamoto, T. Miura, K. Shimamoto, and Y. Horio. 2007. 
Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase 
SIRT1. JBiol Chem. 282: 6823-6832. 
o Tao, Z., P. Gao, and H. W. Liu. 2009. Identification of the ADP-ribosylation 
sites in the PARP-1 automodification domain: analysis and implications. JAm 
Chem Soc. 131: 14258-14260. 
o Timinszky, G., S. Till, P. O. Hassa, M. Hothorn, G. Kustatscher, B. Nijmeijer, 
J. Colombelli, M. Altmeyer, E. H. Stelzer, K. Scheffzek, M. O. Hottiger, and 
A. G. Ladurner. 2009. A macrodomain-containing histone rearranges chromatin 
upon sensing PARP 1 activation. Nat Struct Mol Biol. 16: 923-929. 
o Tisdale, E. J., J. R. Bourne, R. Khosravi-Far, C. J. Der, and W. E. Balch. 1992. 
GTP-binding mutants of rab i and rab2 are potent inhibitors of vesicular 
transport from the endoplasmic reticulum to the Golgi complex. J Cell Biol. 
119: 749-761. 
304 
References 
" Tsuchiya, M., S. R. Price, S. C. Tsai, J. Moss, and M. Vaughan. 1991. Molecular 
identification of ADP-ribosylation factor mRNAs and their expression in 
mammalian cells. J Biol Chem. 266: 2772-2777. 
'0 Uchida, K., S. Hanai, K. Ishikawa, Y. Ozawa, M. Uchida, T. Sugimura, and M. 
Miwa. 1993. Cloning of cDNA encoding Drosophila poly(ADP-ribose) 
polymerise: leucine zipper in the auto-modification domain. Proc Nall Acad 
Sci USA. 90: 3481-3485. 
. Vaisitti, T., V. Audrito, S. Serra, C. Bologna, D. Brusa, F. Malavasi, and S. 
Deaglio. 2011. NAD+-metabolizing ecto-enzymes shape tumor-host 
interactions: the chronic lymphocytic leukemia model. FEBS Lett. 585: 1514- 
1520. 
+ Valente, C., S. Spano, A. Luini, and D. Corda. 2005. Purification and 
functional properties of the membrane fissioning protein CtBP3/BARS. 
Methods Enzymol. 404: 296-316. 
o van der Bliek, A. M. 2005. A sixth sense for RabS. Nat Cell Biol. 7: 548-550. 
o Vassilev, L. T., C. Tovar, S. Chen, D. Knezevic, X. Zhao, H. Sun, D. C. 
Heimbrook, and L. Chen. 2006. Selective small-molecule inhibitor reveals 
critical mitotic functions of human CDK1. Proc Nat! Acad Sc! USA. 
103: 10660-10665. 
" Venkitaraman, A. R. 2002. Cancer susceptibility and the functions of BRCA 1 
and BRCA2. Cell. 108: 171-182. 
" Verger, A., K. G. Quinlan, L. A. Crofts, S. Spano, D. Corda, E. P. Kable, F. 
Braet, and M. Crossley. 2006. Mechanisms directing the nuclear localization of 
the CtBP family proteins. Mol Cell Biol. 26: 4882-4894. 
305 
References 
" Wacker, D. A., D. D. Ruhl, E. H. Balagamwala, K. M. Hope, T. Zhang, and W. L. 
Kraus. 2007. The DNA binding and catalytic domains of poly(ADP-ribose) 
polymerase 1 cooperate in the regulation of chromatin structure and 
transcription. Mol Cell Biol. 27: 7475-7485. 
Warren, G., T. Levine, and T. Misteli. 1995. Mitotic disassembly of the 
mammalian Golgi apparatus. Trends Cell Biol. 5: 413-416. 
" Weigert, R., M. G. Silletta, S. Spano, G. Turacchio, C. Cericola, A. Colanzi, S. 
Senatore, R. Mancini, E. V. Polishchuk, M. Salmona, F. Facchiano, K. N. 
Burger, A. Mironov, A. Luini, and D. Corda. 1999. CtBP/BARS induces 
fission of Golgi membranes by acylating lysophosphatidic acid. Nature. 
402: 429-433. 
Wilde, C., and K. Aktories. 2001. The Rho-ADP-ribosylating C3 exoenzyme 
from Clostridium botulinum and related C3-like transferases. Toxicon. 
39: 1647-1660. 
" Williams, G. T., K. M. Lau, J. M. Coote, and A. P. Johnstone. 1985. NAD 
metabolism and mitogen stimulation of human lymphocytes. Exp Cell Res. 
160: 419-426. 
" Wilson, B. S., C. Nuoffer, J. L. Meinkoth, M. McCaffery, J. R. Feramisco, W. E. 
Balch, and M. G. Farquhar. 1994. A Rabl mutant affecting guanine nucleotide 
exchange promotes disassembly of the Golgi apparatus. J Cell Biol. 125: 557- 
571. 
" Wilson, C., R. Venditti, L. R. Rega, A. Colanzi, G. D'Angelo, and M. A. De 
Matteis. 2010. The Golgi apparatus: an organelle with multiple complex 
functions. Biochem J. 433: 1-9. 
306 
References 
" Xiang, Y., J. Seemann, B. Bisel, S. Punthambaker, and Y. Wang. 2007. Active 
ADP-ribosylation factor-i (ARF1) is required for mitotic Golgi fragmentation. 
JBiol Chem. 282: 21829-21837. 
" Yamamoto-Katayama, S., M. Ariyoshi, K. Ishihara, T. Hirano, H. Jingami, and 
K. Morikawa. 2002. Crystallographic studies on human BST-1/CD157 with 
ADP-ribosyl cyclase and NAD glycohydrolase activities. J Mol Biol. 316: 711- 
723. 
" Yang, J. S., S. Y. Lee, S. Spano, H. Gad, L. Zhang, Z. Nie, M. Bonazzi, D. 
Corda, A. Luini, and V. W. Hsu. 2005. A role for BARS at the fission step of 
COPI vesicle formation from Golgi membrane. EMBO J. 24: 4133-4143. 
'0 Ye, B. H., G. Cattoretti, Q. Shen, J. Zhang, N. Hawe, R. de Waard, C. Leung, 
M. Nouri-Shirazi, A. Orazi, R. S. Chaganti, P. Rothman, A. M. Stall, P. F. 
Pandolfi, and R. Dalla-Favera. 1997. The BCL-6 proto-oncogene controls 
germinal-centre formation and Th2-type inflammation. Nat Genet. 16: 161-170. 
a Ye, J. Z., and T. de Lange. 2004. TIN2 is a tankyrase 1 PARP modulator in the 
TRF 1 telomere length control complex. Nat Genet. 36: 618-623. 
" Yeh, T. Y., J. I. Sbodio, Z. Y. Tsun, B. Luo, and N. W. Chi. 2007. Insulin- 
stimulated exocytosis of GLUT4 is enhanced by IRAP and its partner 
tankyrase. Biochem J. 402: 279-290. 
" Ying, W. 2006. NAD+ and NADH in cellular functions and cell death. Front 
Biosci. 11: 3129-3148. 
o Yu, M., S. Schreek, C. Cerni, C. Schamberger, K. Lesniewicz, E. Poreba, J. 
Vervoorts, G. Walsemann, J. Grotzinger, E. Kremmer, Y. Mehrsein, J. 
Mertsching, R. Kraft, M. Austen, J. Luscher-Firzlaff, and B. Luscher. 2005. 
307 
References 
PARP-10, a novel Myc-interacting protein with poly(ADP-ribose) polymerise 
activity, inhibits transformation. Oncogene. 24: 1982-1993. 
a Zampieri, M., C. Passananti, R. Calabrese, M. Perilli, N. Corbi, F. De Cave, T. 
Guastafierro, M. G. Bacalini, A. Reale, G. Amicosante, L. Calabrese, J. 
Zlatanova, and P. Caiafa. 2009. Parp 1 localizes within the Dnmt 1 promoter and 
protects its unmethylated state by its enzymatic activity. PLoS One. 4: e4717. 
Zhang, C. L., T. A. McKinsey, J. R. Lu, and E. N. Olson. 2001. Association of 
COOH-terminal-binding protein (CtBP) and MEF2-interacting transcription 
repressor (MITR) contributes to transcriptional repression of the MEF2 
transcription factor. JBiol Chem. 276: 35-39. 
o Zhang, Q., D. W. Piston, and R. H. Goodman. 2002. Regulation of corepressor 
function by nuclear NADH. Science. 295: 1895-1897. 
" Zhang, Q., S. Y. Wang, A. C. Nottke, J. V. Rocheleau, D. W. Piston, and R. H. 
Goodman. 2006. Redox sensor CtBP mediates hypoxia-induced tumor cell 
migration. Proc Nail Acad Sci USA. 103: 9029-9033. 
" Zhang, R. G., D. L. Scott, M. L. Westbrook, S. Nance, B. D. Spangler, G. G. 
Shipley, and E. M. Westbrook. 1995. The three-dimensional crystal structure of 
cholera toxin. JMo1 Biol. 251: 563-573. 
a Zhang, Y., C. W. Burke, K. D. Ryman, and W. B. Klimstra. 2007. Identification 
and characterization of interferon-induced proteins that inhibit alphavirus 
replication. J Virol. 81: 11246-11255. 
$ Zheng, C. L., T. Sumizawa, X. F. Che, S. Tsuyama, T. Furukawa, M. Haraguchi, 
H. Gao, T. Gotanda, H. C. Jueng, F. Murata, and S. Akiyama. 2005. 
Characterization of MVP and VPARP assembly into vault ribonucleoprotein 
complexes. Biochem Biophys Res Commun. 326: 100-107. 
308 
References 
Zlatanova, J., and P. Caiafa. 2009. CTCF and its protein partners: divide and 
rule? J Cell Sci. 122: 1275-1284. 
Zocchi, E., L. Franco, L. Guida, U. Benatti, A. Bargellesi, F. Malavasi, H. C. 
Lee, and A. De Flora. 1993. A single protein immunologically identified as 
CD38 displays NAD+ glycohydrolase, ADP-ribosyl cyclase and cyclic ADP- 
ribose hydrolase activities at the outer surface of human erythrocytes. Biochem 
Biophys Res Commun. 196: 1459-1465. 
a Zolkiewska, A. 2005. Ecto-ADP-ribose transferases: cell-surface response to 
local tissue injury. Physiology (Bethesda). 20: 374-381. 
r Zolkiewska, A., and J. Moss. 1993. Integrin alpha 7 as substrate for a 
glycosylphosphatidylinositol-anchored ADP-ribosyltransferase on the surface 
of skeletal muscle cells. JBio1 Chem. 268: 25273-25276. 
" Zolkiewska, A., and J. Moss. 1997. The alpha 7 integrin as a target protein for 
cell surface mono-ADP-ribosylation in muscle cells. Adv Erp Med Biol. 
419: 297-303. 
o Zolkiewska, A., M. S. Nightingale, and J. Moss. 1992. Molecular 
characterization of NAD: arginine ADP-ribosyltransferase from rabbit skeletal 
muscle. Proc Natl Acad Sci USA. 89: 11352-11356. 
309 
Ackowledgements 
Acknowledgements 
I would like to thank my Supervisors Drs. Daniela Corda, Alberto Luini and 
Daniela Rhodes for their support and helpful discussions during the course of 
these investigations, and for their help in writing this thesis. 
Special thanks go to Drs. Antonino Colanzi and Stefania Mariggib for all of 
their precious suggestions and help, and for the incredible strength that they 
have given me. 
Thanks are also due to all of my colleagues in our Laboratory, for the excellent 
working atmosphere they have brought in our Laboratory. Special thanks go to 
Carmen, Giuliana and Raman. 
Thanks also to my flatmates Romina and Rossella for their scientific and 
friendly `discussions'. 
I would also like to thank Dr. Chris Berrie for his precious help with my 
English. 
I want to thank the PhD Programme Coordination Team, of Sandro Banfi and 
Barbara Zimbardi, for their assistance and management throughout my studies. 
I would like to thank Roberta and Anna for their friendship. 
A great thank you also goes to my family, because they have always supported 
me during these years. 
My final thanks go to Gerardo, for his attempt to understand the 
incomprehensible life of a scientific researcher. 
310 
